U.S. patent application number 12/371729 was filed with the patent office on 2009-08-27 for modulators for amyloid beta.
Invention is credited to Karlheinz Baumann, Alexander Flohr, Erwin Goetschi, Helmut Jacobsen, Synese Jolidon, Thomas Luebbers.
Application Number | 20090215759 12/371729 |
Document ID | / |
Family ID | 40481869 |
Filed Date | 2009-08-27 |
United States Patent
Application |
20090215759 |
Kind Code |
A1 |
Baumann; Karlheinz ; et
al. |
August 27, 2009 |
MODULATORS FOR AMYLOID BETA
Abstract
The invention relates to compounds of formula ##STR00001##
wherein the substituents are as described in claim 1. Compounds of
formula I are modulators for amyloid beta and thus, they may be
useful for the treatment or prevention of a disease associated with
the deposition of .beta.-amyloid in the brain, in particular
Alzheimer's disease, and other diseases such as cerebral amyloid
angiopathy, hereditary cerebral hemorrhage with amyloidosis,
Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica
and Down syndrome.
Inventors: |
Baumann; Karlheinz;
(Efringen-Kirchen, DE) ; Flohr; Alexander;
(Loerrach, DE) ; Goetschi; Erwin; (Reinach BL,
CH) ; Jacobsen; Helmut; (Schopfheim, DE) ;
Jolidon; Synese; (Blauen, CH) ; Luebbers; Thomas;
(Loerrach, DE) |
Correspondence
Address: |
HOFFMANN-LA ROCHE INC.;PATENT LAW DEPARTMENT
340 KINGSLAND STREET
NUTLEY
NJ
07110
US
|
Family ID: |
40481869 |
Appl. No.: |
12/371729 |
Filed: |
February 16, 2009 |
Current U.S.
Class: |
514/227.8 ;
514/230.5; 514/235.8; 514/252.19; 514/255.05; 514/266.23; 514/275;
514/341; 544/105; 544/122; 544/284; 544/295; 544/331; 544/58.2;
546/272.7; 548/264.8 |
Current CPC
Class: |
C07D 401/12 20130101;
C07D 403/12 20130101; C07D 409/14 20130101; C07D 417/12 20130101;
C07D 403/14 20130101; A61P 25/28 20180101; A61P 25/00 20180101;
C07D 413/12 20130101; C07D 405/14 20130101; C07D 417/14 20130101;
C07D 401/14 20130101; C07D 413/14 20130101 |
Class at
Publication: |
514/227.8 ;
544/331; 514/275; 546/272.7; 514/341; 548/264.8; 544/122;
514/235.8; 544/58.2; 544/295; 514/252.19; 514/255.05; 544/105;
514/230.5; 544/284; 514/266.23 |
International
Class: |
A61K 31/541 20060101
A61K031/541; C07D 403/12 20060101 C07D403/12; A61K 31/506 20060101
A61K031/506; C07D 403/14 20060101 C07D403/14; C07D 417/12 20060101
C07D417/12; C07D 413/12 20060101 C07D413/12; C07D 413/14 20060101
C07D413/14; C07D 401/12 20060101 C07D401/12; A61K 31/454 20060101
A61K031/454; C07D 405/14 20060101 C07D405/14; A61K 31/5377 20060101
A61K031/5377; A61K 31/496 20060101 A61K031/496; A61K 31/497
20060101 A61K031/497; A61K 31/536 20060101 A61K031/536; A61K 31/517
20060101 A61K031/517; C07D 401/14 20060101 C07D401/14; A61P 25/28
20060101 A61P025/28 |
Foreign Application Data
Date |
Code |
Application Number |
Feb 22, 2008 |
EP |
08151825.0 |
Claims
1. A compound of general formula I ##STR00278## wherein R.sup.1 is
hydrogen, lower alkyl or lower alkyl substituted by hydroxy;
R.sup.2 is hydrogen, lower alkoxy, lower alkyl, cyano or halogen;
R.sup.3 is lower alkyl, lower alkenyl, lower alkyl substituted by
fluoro, (CH.sub.2).sub.2O-lower alkyl,
(CH.sub.2).sub.2NR.sup.8.sub.2, or is 4H-benzo[1,4]oxazin-3-one,
cycloalkyl optionally substituted by hydroxy, or is
heterocycloalkyl, which heterocycloalkyl is optionally substituted
by hydroxy or S(O).sub.2-lower alkyl, or is (CH.sub.2).sub.m-aryl
or is a five- or six-membered heteroaryl group, wherein the rings
in the heteroaryl group are optionally substituted by one or more
R' for any definition of L, or when L is a bond, the rings in the
heteroaryl group are optionally substituted by one or more halogen,
hydroxy, --C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH.sub.2, or
when L is --CR.sup.6R.sup.7--, the rings in the heteroaryl group
are optionally substituted by one or more lower alkoxy, hydroxy,
--C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH.sub.2 or when L is
NR.sup.8, the rings in the heteroaryl group are optionally
substituted by one or more CH.sub.2--C(O)O-lower alkyl for L being
NR.sup.8, or when L is C(O), the rings in the heteroaryl group are
optionally substituted by one or more lower alkoxy, hydroxy or
NR.sup.8.sub.2 for L being C(O); R' is halogen, lower alkyl, lower
alkoxy, cyano, lower alkyl substituted by fluoro, lower alkoxy
substituted by fluoro, SF.sub.5, or is a five-membered heteroaryl
group, which is optionally substituted by lower alkyl; Ar is a
five-membered heteroaryl group or is pyridinyl; Z is CH or N; X-Y
is N--CR.sup.4.dbd.CR.sup.5, CH--CR.sup.4.dbd.N,
CH--CR.sup.4.dbd.CR.sup.5 or N--NH; and wherein R.sup.4 and R.sup.5
form together with the corresponding carbon atoms to which they are
attached optionally form an additional ring with
--(CH.sub.2).sub.n, with the proviso that if X-Y is
CH--CR.sup.4.dbd.CR.sup.5 or CH--CR.sup.4.dbd.N, then Z is N; or
R.sup.4 and R.sup.5 are each independently hydrogen, halogen, lower
alkyl, lower alkoxy, C(O)O-lower alkyl, lower alkyl substituted by
one or more groups selected from fluoro, hydroxy, cyano and
cycloalkyl, or are cyano, phenyl, benzyl or a five- or six-membered
heteroaryl group wherein the rings of the heteroaryl group are
optionally substituted by one or more R', or are cycloalkyl or
heterocycloalkyl, each of which optionally substituted by lower
alkyl and hydroxy, with the proviso that R.sup.4 also optionally is
hydroxy or NR.sup.8.sub.2; L is a bond, --CR.sup.6R.sup.7--, --O--,
--NR.sup.8-- or --C(O)--; R.sup.6 and R.sup.7 are each
independently hydrogen, lower alkyl, cycloalkyl, phenyl or R.sup.6
and R.sup.7 together with the carbon atom to which they are
attached form a C.sub.3-6-cycloalkyl group, with the proviso that
R.sup.6 also optionally is hydroxy or lower alkoxy; R.sup.8 is
hydrogen or lower alkyl; m is 0 or 1; and n is 3 or 4; or a
pharmaceutically active acid addition salt thereof.
2. The compound of claim 1 having formula I-A, ##STR00279## wherein
R.sup.1 is hydrogen, lower alkyl or lower alkyl substituted by
hydroxy; R.sup.2 is hydrogen, lower alkoxy, lower alkyl, cyano or
halogen; R.sup.3 is lower alkyl, lower alkenyl, lower alkyl
substituted by fluoro, (CH.sub.2).sub.2O-lower alkyl,
(CH.sub.2).sub.2NR.sup.8.sub.2, or is 4H-benzo[1,4]oxazin-3-one,
cycloalkyl optionally substituted by hydroxy, or is
heterocycloalkyl, which heterocycloalkyl is optionally substituted
by hydroxy or S(O).sub.2-lower alkyl, or is (CH.sub.2).sub.m-aryl
or is a five- or six-membered heteroaryl group, wherein the rings
of the heteroaryl group are optionally substituted by one or more
R' for any definition of L, or when L is a bond, the rings of the
heteroaryl group are optionally substituted by one or more halogen,
hydroxy, --C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH.sub.2, or
when L is --CR.sup.6R.sup.7--, the rings of the heteroaryl group
are optionally substituted by one or more lower alkoxy, hydroxy,
--C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH.sub.2 or when L is
NR.sup.8, the rings of the heteroaryl group are optionally
substituted by one or more CH.sub.2--C(O)O-lower alkyl for L being
NR.sup.8, or when L is C(O), the rings of the heteroaryl group are
optionally substituted by one or more lower alkoxy, hydroxy or
NR.sup.8.sub.2 for L being C(O); R' is halogen, lower alkyl, lower
alkoxy, cyano, lower alkyl substituted by fluoro, lower alkoxy
substituted by fluoro, SF.sub.5, or is a five-membered heteroaryl
group, which is optionally substituted by lower alkyl; Ar is a
five-membered heteroaryl group or is pyridinyl; R.sup.4 and R.sup.5
are each independently hydrogen, halogen, lower alkyl, lower
alkoxy, C(O)O-lower alkyl, lower alkyl substituted by one or more
groups selected from fluoro, hydroxy, cyano and cycloalkyl, or are
cyano, phenyl, benzyl or a five- or six membered heteroaryl group,
wherein the rings in the heteroaryl group are optionally
substituted by one or more R', or are cycloalkyl or
heterocycloalkyl, each of which is optionally substituted by lower
alkyl and hydroxy, with the proviso that R.sup.4 also optionally is
hydroxy or NR.sup.8.sub.2, or wherein R.sup.4 and R.sup.5 together
with the corresponding carbon atoms to which they are attached
optionally form an additional ring with --(CH.sub.2).sub.n; L is a
bond, --CR.sup.6R.sup.7--, --O--, --NR.sup.8-- or --C(O)--; R.sup.6
and R.sup.7 are each independently hydrogen, lower alkyl,
cycloalkyl, phenyl or R.sup.6 and R.sup.7 together with the carbon
atom to which they are attached form a C.sub.3-6-cycloalkyl group,
with the proviso that R.sup.6 also optionally is hydroxy or lower
alkoxy; R.sup.8 is hydrogen or lower alkyl; m is 0 or 1; and n is 3
or 4; or a pharmaceutically active acid addition salt thereof.
3. The compound of claim 2 having formula I-A-1 ##STR00280##
wherein R.sup.2 is hydrogen, lower alkoxy, lower alkyl, cyano or
halogen; R.sup.3 is lower alkyl, lower alkenyl, lower alkyl
substituted by fluoro, (CH.sub.2).sub.2O-lower alkyl,
(CH.sub.2).sub.2NR.sup.8.sub.2, or is 4H-benzo[1,4]oxazin-3-one,
cycloalkyl optionally substituted by hydroxy, or is
heterocycloalkyl, which heterocycloalkyl is optionally substituted
by hydroxy or S(O).sub.2-lower alkyl, or is (CH.sub.2).sub.m-aryl
or is a five- or six-membered heteroaryl group, wherein the rings
in the heteroaryl group are optionally substituted by one or more
R' for any definition of L, or when L is a bond, the rings in the
heteroaryl group are optionally substituted by one or more halogen,
hydroxy, --C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH.sub.2, or
when L is --CR.sup.6R.sup.7--, the rings in the heteroaryl group
are optionally substituted by one or more lower alkoxy, hydroxy,
--C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH.sub.2 or when L is
NR.sup.8, the rings in the heteroaryl group are optionally
substituted by one or more CH.sub.2--C(O)O-lower alkyl, or when L
is C(O), the rings in the heteroaryl group are optionally
substituted by one or more lower alkoxy, hydroxy or NR.sup.8.sub.2;
R' is halogen, lower alkyl, lower alkoxy, cyano, lower alkyl
substituted by fluoro, lower alkoxy substituted by fluoro,
SF.sub.5, or is a five-membered heteroaryl group, which is
optionally substituted by lower alkyl; R.sup.4 and R.sup.5 are each
independently hydrogen, halogen, lower alkyl, lower alkoxy,
C(O)O-lower alkyl, lower alkyl substituted by one or more groups
selected from fluoro, hydroxy, cyano and cycloalkyl, or are cyano,
phenyl, benzyl or a five- or six-membered heteroaryl group, wherein
the rings of the heteroaryl group are optionally substituted by one
or more R', or are cycloalkyl or heterocycloalkyl, each of which is
optionally substituted by lower alkyl and hydroxy, with the proviso
that R.sup.4 also optionally is hydroxy or NR.sup.8.sub.2, or
wherein R.sup.4 and R.sup.5 together with the corresponding carbon
atoms to which they are attached form an additional ring with
--(CH.sub.2).sub.n; L is a bond, --CR.sup.6R.sup.7--, --O--,
--NR.sup.8-- or --C(O)--; R.sup.6 and R.sup.7 are each
independently hydrogen, lower alkyl, cycloalkyl, phenyl or R.sup.6
and R.sup.7 together with the carbon atom to which they are
attached form a C.sub.3-6-cycloalkyl group, with the proviso that
R.sup.6 also optionally is hydroxy or lower alkoxy; R.sup.8 is
hydrogen or lower alkyl; m is 0 or 1; and n is 3 or 4; or a
pharmaceutically active acid addition salt thereof.
4. The compound of claim 3, selected from the group consisting of
(4-benzyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-a-
mine;
[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-(3,4,5-trifluoro-be-
nzyl)-pyrimidin-2-yl]-amine;
[4-(3-chloro-benzyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl-
)-phenyl]-amine;
[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[5-methyl-4-(1-phenyl-ethyl-
)-pyrimidin-2-yl]-amine;
[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(3,4,5-trifluor-
o-phenoxy)-pyrimidin-2-yl]-amine;
[4-(3,4-difluoro-phenoxy)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-
-imidazol-1-yl)-phenyl]-amine;
[4-(4-chloro-phenoxy)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imi-
dazol-1-yl)-phenyl]-amine;
[4-(2,6-dichloro-phenoxy)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-
-1-yl)-phenyl]-amine;
[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(2-trifluoromet-
hyl-phenoxy)-pyrimidin-2-yl]-amine; and
[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(3-trifluoromet-
hoxy-phenoxy)-pyrimidin-2-yl]-amine.
5. The compound of claim 3, selected from the group consisting of
[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(3-trifluoromet-
hyl-phenoxy)-pyrimidin-2-yl]-amine;
[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(3,3,4,4,4-pent-
afluoro-butoxy)-pyrimidin-2-yl]-amine;
{4-[1-(4-chloro-phenyl)-1-methyl-ethyl]-5-methyl-pyrimidin-2-yl}-[3-metho-
xy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine;
{4-[1-(4-chloro-phenyl)-1-methyl-ethyl]-pyrimidin-2-yl}-[3-methoxy-4-(4-m-
ethyl-imidazol-1-yl)-phenyl]-amine;
{4-[1-(4-chloro-phenyl)-1-methyl-ethyl]-pyrimidin-2-yl}-[3-fluoro-4-(4-me-
thyl-imidazol-1-yl)-phenyl]-amine; ethyl
4-(4-chloro-phenyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]--
pyrimidine-5-carboxylate;
[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-(4-trifluoromethyl-pheny-
l)-pyrimidin-2-yl]-amine;
(4-benzyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)--
phenyl]-amine;
(4-ethoxy-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)--
phenyl]-amine; and
N4-(2,2,3,3,4,4,4-heptafluoro-butyl)-N2-[3-methoxy-4-(4-methyl-imidazol-1-
-yl)-phenyl]-6-methyl-pyrimidine-2,4-diamine.
6. The compound of claim 3, selected from the group consisting of
[4-(4-chloro-phenyl)-5-(4-methoxy-benzyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-
-methyl-imidazol-1-yl)-phenyl]-amine;
[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-methoxy-6-methyl-pyrimid-
in-2-yl)-amine;
(4-isopropoxy-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1--
yl)-phenyl]-amine;
[4-(4-Fluoro-phenoxy)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imi-
dazol-1-yl)-phenyl]-amine;
[4-(4-tert-butyl-phenoxy)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-
-imidazol-1-yl)-phenyl]-amine;
2-{6-ethoxy-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidi-
n-4-yl}-propan-2-ol;
N4-(3-chloro-phenyl)-N2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-6-m-
ethyl-pyrimidine-2,4-diamine;
N4-(4-chloro-phenyl)-N2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-6-m-
ethyl-pyrimidine-2,4-diamine;
N4,N4-diethyl-N2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-6-methyl-p-
yrimidine-2,4-diamine; and
1-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimidi-
n-4-yl}-piperidin-4-ol.
7. The compound of claim 3, selected from the group consisting of
[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-methyl-6-pyrrolidin-1-yl-
-pyrimidin-2-yl)-amine;
[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-methyl-6-piperidin-1-yl--
pyrimidin-2-yl)-amine;
2-({2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimid-
in-4-yl}-methyl-amino)-ethanol;
2-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-piperidin-1-yl--
pyrimidin-4-yl}-propan-2-ol;
2-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-pyrrolidin-1-yl-
-pyrimidin-4-yl}-propan-2-ol;
[4-butyl-6-(4-chloro-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imida-
zol-1-yl)-phenyl]-amine;
[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-phenyl-pyrimidin-2-yl)-a-
mine;
5-(4,6-dimethyl-pyrimidin-2-ylamino)-2-(4-methyl-imidazol-1-yl)-benz-
onitrile;
5-[4-(4-chloro-phenyl)-pyrimidin-2-ylamino]-2-(4-methyl-imidazol-
-1-yl)-benzonitrile; and
[5-ethyl-4-(4-trifluoromethyl-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-met-
hyl-imidazol-1-yl)-phenyl]-amine.
8. The compound of claim 3, selected from the group consisting of
[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-(3,4,5-trifluoro-phenyl)-
-pyrimidin-2-yl]-amine;
[4-(2,5-dichloro-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol--
1-yl)-phenyl]-amine;
[4-(3,4-dichloro-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol--
1-yl)-phenyl]-amine;
[4-(2,4-dichloro-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol--
1-yl)-phenyl]-amine;
[4-(4-chloro-3-methyl-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imid-
azol-1-yl)-phenyl]-amine;
[4-(4-chloro-phenyl)-5-propyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imid-
azol-1-yl)-phenyl]-amine;
[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(5-methoxy-4-phenyl-pyrimid-
in-2-yl)-amine;
(4-cyclopropyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phen-
yl]-amine; ethyl
4-benzyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidine--
5-carboxylate; and
[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-(4-methyl-pent-3-enyl)-5-
-phenyl-pyrimidin-2-yl]-amine.
9. The compound of claim 3, selected from the group consisting of
6-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-4-
H-benzo[1,4]oxazin-3-one;
[4-(2-chloro-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl-
)-phenyl]-amine;
(4-isobutyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl-
)-phenyl]-amine;
(4,6-diethyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl-
]-amine;
[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-methyl-6-phenyl--
pyrimidin-2-yl)-amine;
(4-furan-2-yl-6-trifluoromethyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-im-
idazol-1-yl)-phenyl]-amine;
[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-phenyl-5,6,7,8-tetrahydr-
o-quinazolin-2-yl)-amine;
(4,6-dimethyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-pheny-
l]-amine;
(4,6-bis-trifluoromethyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl--
imidazol-1-yl)-phenyl]-amine; and
(4-isopropyl-6-trifluoromethyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imi-
dazol-1-yl)-phenyl]-amine.
10. The compound of claim 3, selected from the group consisting of
(4,6-diisopropyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-ph-
enyl]-amine;
[4-(2-chloro-phenyl)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imid-
azol-1-yl)-phenyl]-amine; ethyl
2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-thiophen-2-yl-pyri-
midine-4-carboxylate; ethyl
6-Isopropyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidi-
ne-4-carboxylate; ethyl
6-cyclopropyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimi-
dine-4-carboxylate; ethyl
2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-pyridin-2-yl-pyrim-
idine-4-carboxylate; ethyl
2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromethyl-
-phenyl)-pyrimidine-4-carboxylate; ethyl
6-(4-chloro-benzyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]--
pyrimidine-4-carboxylate;
2-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimidi-
n-4-yl}-propan-2-ol; and
2-{6-ethyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-
-4-yl}-propan-2-ol.
11. The compound of claim 3, selected from the group consisting of
2-{6-isopropyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrim-
idin-4-yl}-propan-2-ol;
2-{6-cyclopropyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyr-
imidin-4-yl}-propan-2-ol;
2-{6-tert-butyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyri-
midin-4-yl}-propan-2-ol;
2-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-thiophen-2-yl-p-
yrimidin-4-yl}-propan-2-ol;
2-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-pyridin-2-yl-py-
rimidin-4-yl}-propan-2-ol;
2-{6-(4-chloro-benzyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamin-
o]-pyrimidin-4-yl}-propan-2-ol;
2-[2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromet-
hyl-phenyl)-pyrimidin-4-yl]-propan-2-ol;
1-[2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromet-
hyl-phenyl)-pyrimidin-4-yl]-ethanone;
3-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-p-
entan-3-ol; and
2-[2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(3,4,5-trifluor-
o-phenyl)-pyrimidin-4-yl]-propan-2-ol.
12. The compound of claim 3, selected from the group consisting of
2-{6-(2,4-dichloro-phenyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl-
amino]-pyrimidin-4-yl}-propan-2-ol;
2-{6-(4-chloro-phenyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamin-
o]-pyrimidin-4-yl}-propan-2-ol;
2-{6-(2-chloro-phenyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamin-
o]-pyrimidin-4-yl}-propan-2-ol;
2-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-5,6,7,8-tetrahydr-
o-quinazolin-4-yl}-propan-2-ol;
2-{2-[3-fluoro-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-isopropyl-pyrimi-
din-4-yl}-propan-2-ol;
2-[2-[3-fluoro-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluorometh-
yl-phenyl)-pyrimidin-4-yl]-propan-2-ol;
2-{6-dimethylamino-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-p-
yrimidin-4-yl}-propan-2-ol;
1-{6-(1-hydroxy-1-methyl-ethyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-p-
henylamino]-pyrimidin-4-yl}-4-methyl-piperidin-4-ol;
1-[2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromet-
hyl-phenyl)-pyrimidin-4-yl]-cyclopentanol;
5-[4-(1-hydroxy-1-methyl-ethyl)-6-(4-trifluoromethyl-phenyl)-pyrimidin-2--
ylamino]-2-(4-methyl-imidazol-1-yl)-benzonitrile; and
2-[2-[3-methyl-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluorometh-
yl-phenyl)-pyrimidin-4-yl]-propan-2-ol.
13. The compound of claim 2, wherein R.sup.1--Ar is
2-methyl-imidazol-1-yl, 3-methyl-[1,2,4]triazol-1-yl, thiazol-5-yl,
2-methyl-thiazol-5-yl, 2-methyl-oxazol-5-yl, 2-methyl-pyridin-4-yl,
1-methyl-1H-pyrazol-4-yl, 3-methyl-[1,2,4]triazol-1-yl,
[1,2,4]triazol-1-yl, 5-methyl-[1,2,4]triazol-1-yl,
1,3,4]oxadiazol-2-yl, 4-pyridin-4-yl, 2-methyl-pyridin-4-yl,
3-methyl-[1,2,4]thiadiazol-5-yl, or oxazol-5-yl.
14. The compound of claim 13, selected from the group consisting of
(4-benzyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(3-methyl-[1,2,4]triazol--
1-yl)-phenyl]-amine;
(4-benzyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(2-methyl-thiazol-5-yl)-p-
henyl]-amine;
(4-benzyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(2-methyl-oxazol-5-yl)-ph-
enyl]-amine;
2-[2-[3-methoxy-4-(2-methyl-thiazol-5-yl)-phenylamino]-6-(4-trifluorometh-
yl-phenyl)-pyrimidin-4-yl]-propan-2-ol;
(4,6-dimethyl-pyrimidin-2-yl)-[4-(2-methyl-pyridin-4-yl)-phenyl]-amine;
and
(4-benzyl-6-methyl-pyrimidin-2-yl)-[4-(2-methyl-pyridin-4-yl)-phenyl]-
-amine.
15. The compound of claim 1 having formula I-B ##STR00281## wherein
R.sup.1 is hydrogen, lower alkyl or lower alkyl substituted by
hydroxy; R.sup.2 is hydrogen, lower alkoxy, lower alkyl, cyano or
halogen; R.sup.3 is lower alkyl, lower alkenyl, lower alkyl
substituted by fluoro, (CH.sub.2).sub.2O-lower alkyl,
(CH.sub.2).sub.2NR.sup.8.sub.2, or is 4H-benzo[1,4]oxazin-3-one,
cycloalkyl optionally substituted by hydroxy, or is
heterocycloalkyl, which heterocycloalkyl is optionally substituted
by hydroxy or S(O).sub.2-lower alkyl, or is (CH.sub.2).sub.m-aryl
or is a five- or six-membered heteroaryl group, wherein the rings
of the heteroaryl group are optionally substituted by one or more
R' for any definition of L, or when L is a bond, the rings of the
heteroaryl group are optionally substituted by one or more halogen,
hydroxy, --C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH.sub.2, or
when L is --CR.sup.6R.sup.7--, the rings of the heteroaryl group
are optionally substituted by one or more lower alkoxy, hydroxy,
--C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH.sub.2, or when L
is NR.sup.3, the rings of the heteroaryl group are optionally
substituted by one or more CH.sub.2--C(O)O-lower alkyl, or when L
is C(O), the rings of the heteroaryl group are optionally
substituted by one or more lower alkoxy, hydroxy or NR.sup.8.sub.2;
R' is halogen, lower alkyl, lower alkoxy, cyano, lower alkyl
substituted by fluoro, lower alkoxy substituted by fluoro,
SF.sub.5, or is a five-membered heteroaryl group, which is
optionally substituted by lower alkyl; Ar is a five-membered
heteroaryl group or is pyridinyl; R.sup.4 is hydrogen, halogen,
lower alkyl, lower alkoxy, C(O)O-lower alkyl, lower alkyl
substituted by one or more groups selected from fluoro, hydroxy,
cyano and cycloalkyl, or is cyano, phenyl, benzyl or a five- or
six-membered heteroaryl group, wherein the rings of the heteroaryl
group are optionally substituted by one or more R', or is
cycloalkyl or heterocycloalkyl, each of which is optionally
substituted by lower alkyl and hydroxy, or is hydroxy or
NR.sup.8.sub.2; L is a bond, --CR.sup.6R.sup.7--, --O--,
--NR.sup.8-- or --C(O)--; R.sup.6 and R.sup.7 are each
independently hydrogen, lower alkyl, cycloalkyl, or phenyl or
R.sup.6 and R.sup.7 together with the carbon atom to which they are
attached form a C.sub.3-6-cycloalkyl group, with the proviso that
R.sup.6 also optionally is hydroxy or lower alkoxy; R.sup.8 is
hydrogen or lower alkyl; and m is 0 or 1; or a pharmaceutically
active acid addition salt thereof.
16. The compound of claim 15, selected from the group consisting of
(6-benzyl-2-chloro-pyrimidin-4-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)--
phenyl]-amine and
{6-[1-(4-chloro-phenyl)-cyclobutyl]-2-methyl-pyrimidin-4-yl}-[3-methoxy-4-
-(4-methyl-imidazol-1-yl)-phenyl]-amine.
17. The compound of claim 1 having formula I-C ##STR00282## wherein
R.sup.1 is hydrogen, lower alkyl or lower alkyl substituted by
hydroxy; R.sup.2 is hydrogen, lower alkoxy, lower alkyl, cyano or
halogen; R.sup.3 is lower alkyl, lower alkenyl, lower alkyl
substituted by fluoro, (CH.sub.2).sub.2O-lower alkyl,
(CH.sub.2).sub.2NR.sup.8.sub.2, or is 4H-benzo[1,4]oxazin-3-one,
cycloalkyl optionally substituted by hydroxy, or is
heterocycloalkyl, which heterocycloalkyl is optionally substituted
by hydroxy or S(O).sub.2-lower alkyl, or is (CH.sub.2).sub.m-aryl
or is a five- or six-membered heteroaryl group, wherein the rings
in the heteroaryl group are optionally substituted by one or more
R' for any definition of L, or when L is a bond, the rings in the
heteroaryl group are optionally substituted by one or more halogen,
hydroxy, --C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH.sub.2, or
when L is --CR.sup.6R.sup.7--, the rings in the heteroaryl group
are optionally substituted by one or moreis lower alkoxy, hydroxy,
--C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH.sub.2, or when L
is NR.sup.3, the rings in the heteroaryl group are optionally
substituted by one or more CH.sub.2--C(O)O-lower alkyl, or when L
is C(O), the rings in the heteroaryl group are optionally
substituted by one or more lower alkoxy, hydroxy or NR.sup.8.sub.2;
R' is halogen, lower alkyl, lower alkoxy, cyano, lower alkyl
substituted by fluoro, lower alkoxy substituted by fluoro,
SF.sub.5, or is a five-membered heteroaryl group, which is
optionally substituted by lower alkyl; Ar is a five-membered
heteroaryl group or is pyridinyl; R.sup.4 is hydrogen, halogen,
lower alkyl, lower alkoxy, C(O)O-lower alkyl, lower alkyl
substituted by one or more groups selected from fluoro, hydroxy,
cyano and cycloalkyl, or are cyano, phenyl, benzyl or a five- or
six membered heteroaryl group, wherein the rings of the heteroaryl
group are optionally substituted by one or more R', or are
cycloalkyl or heterocycloalkyl, each of which is optionally
substituted by lower alkyl and hydroxy or is hydroxy or NR.sub.12;
L is a bond, --CR.sup.6R.sup.7--, --O--, --NR.sup.8-- or --C(O)--;
R.sup.6 and R.sup.7 are each independently hydrogen, lower alkyl,
cycloalkyl, or phenyl or R.sup.6 and R.sup.7 together with the
carbon atom to which they are attached form a C.sub.3-6-cycloalkyl
group, with the proviso that R.sup.6 also optionally is hydroxy or
lower alkoxy; R.sup.8 is hydrogen or lower alkyl; and m is 0 or 1;
or a pharmaceutically active acid addition salt thereof.
18. The compound of claim 17, which is
(2-benzyl-6-chloro-pyrimidin-4-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)--
phenyl]-amine.
19. The compound of claim 1 having formula I-D ##STR00283## wherein
R.sup.1 is hydrogen, lower alkyl or lower alkyl substituted by
hydroxy; R.sup.2 is hydrogen, lower alkoxy, lower alkyl, cyano or
halogen; R.sup.3 is lower alkyl, lower alkenyl, lower alkyl
substituted by fluoro, (CH.sub.2).sub.2O-lower alkyl,
(CH.sub.2).sub.2NR.sup.8.sub.2, or is 4H-benzo[1,4]oxazin-3-one,
cycloalkyl optionally substituted by hydroxy, or is
heterocycloalkyl, which heterocycloalkyl is optionally substituted
by hydroxy or S(O).sub.2-lower alkyl, or is (CH.sub.2).sub.m-aryl
or is a five- or six-membered heteroaryl group, wherein the rings
in the heteroaryl group are optionally substituted by one or more
R' for any definition of L, or when L is a bond, the rings in the
heteroaryl group are optionally substituted by one or more halogen,
hydroxy, --C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH.sub.2, or
when L is --CR.sup.6R.sup.7--, the rings in the heteroaryl group
are optionally substituted by one or more lower alkoxy, hydroxy,
--C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH.sub.2, or when L
is NR.sup.3, the rings in the heteroaryl group are optionally
substituted by one or more CH.sub.2--C(O)O-lower alkyl, or when L
is C(O), the rings in the heteroaryl group are optionally
substituted by one or more lower alkoxy, hydroxy or NR.sup.8.sub.2;
R' is halogen, lower alkyl, lower alkoxy, cyano, lower alkyl
substituted by fluoro, lower alkoxy substituted by fluoro,
SF.sub.5, or is a five-membered heteroaryl group, which is
optionally substituted by lower alkyl; Ar is a five-membered
heteroaryl group or is pyridinyl; R.sup.4 and R.sup.5 are each
independently hydrogen, halogen, lower alkyl, lower alkoxy,
C(O)O-lower alkyl, lower alkyl substituted by one or more groups
selected from fluoro, hydroxy, cyano and cycloalkyl, or are cyano,
phenyl, benzyl or a five- or six-membered heteroaryl group, wherein
the rings in the heteroaryl group are optionally substituted by one
or more R', or are cycloalkyl or heterocycloalkyl, each of which is
optionally substituted by lower alkyl and hydroxy', with the
proviso that R.sup.4 also optionally is hydroxy or NR.sup.8.sub.2,
or wherein R.sup.4 and R.sup.5 together with the corresponding
carbon atoms to which they are attached form an additional ring
with --(CH.sub.2).sub.n; L is a bond, --CR.sup.6R.sup.7--, --O--,
--NR.sup.8-- or --C(O)--; R.sup.6 and R.sup.7 are each
independently hydrogen, lower alkyl, cycloalkyl, or phenyl or
R.sup.6 and R.sup.7 together with the carbon atom to which they are
attached form a C.sub.3-6-cycloalkyl group, with the proviso that
R.sup.6 also optionally is hydroxy or lower alkoxy; R.sup.8 is
hydrogen or lower alkyl; m is 0 or 1; and n is 3 or 4; or a
pharmaceutically active acid addition salt thereof.
20. The compound of claim 19, selected from the group consisting of
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N'-phenyl-pyridine-2,6-di-
amine;
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N'-(4-trifluorometh-
oxy-phenyl)-pyridine-2,6-diamine;
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N'-(3-trifluoromethoxy-ph-
enyl)-pyridine-2,6-diamine;
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N'-(4-pentafluorosulfanyl-
-phenyl)-pyridine-2,6-diamine;
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N'-(4-trifluoromethyl-phe-
nyl)-pyridine-2,6-diamine;
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N'-(4-trifluoromethoxy-ph-
enyl)-4-trifluoromethyl-pyridine-2,6-diamine;
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N'-(3-trifluoromethoxy-ph-
enyl)-4-trifluoromethyl-pyridine-2,6-diamine;
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-4-trifluoromethyl-N'-(4-t-
rifluoromethyl-phenyl)-pyridine-2,6-diamine; and
[2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluorometho-
xy-phenylamino)-pyridin-4-yl]-methanol.
21. The compound of claim 1 having formula I-E ##STR00284## wherein
R.sup.1 is hydrogen, lower alkyl or lower alkyl substituted by
hydroxy; R.sup.2 is hydrogen, lower alkoxy, lower alkyl, cyano or
halogen; R.sup.3 is lower alkyl, lower alkenyl, lower alkyl
substituted by fluoro, (CH.sub.2).sub.2O-lower alkyl,
(CH.sub.2).sub.2NR.sup.8.sub.2, or is 4H-benzo[1,4]oxazin-3-one,
cycloalkyl optionally substituted by hydroxy, or is
heterocycloalkyl, which heterocycloalkyl is optionally substituted
by hydroxy or S(O).sub.2-lower alkyl, or is (CH.sub.2).sub.m-aryl
or is a five- or six-membered heteroaryl group, wherein the rings
in the heteroaryl group are optionally substituted by one or more
R' for any definition of L, or when L is a bond, the rings in the
heteroaryl group are optionally substituted by one or more halogen,
hydroxy, --C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH.sub.2, or
when L is --CR.sup.6R.sup.7--, the rings in the heteroaryl group
are optionally substituted by one or more lower alkoxy, hydroxy,
--C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH.sub.2, or when L
is NR.sup.8, the rings in the heteroaryl group are optionally
substituted by one or more CH.sub.2--C(O)O-lower alkyl, or when L
is C(O), the rings in the heteroaryl group are optionally
substituted by one or more lower alkoxy, hydroxy or NR.sup.8.sub.2;
R' is halogen, lower alkyl, lower alkoxy, cyano, lower alkyl
substituted by fluoro, lower alkoxy substituted by fluoro,
SF.sub.5, or is a five-membered heteroaryl group, which is
optionally substituted by lower alkyl; Ar is a five-membered
heteroaryl group or is pyridinyl; L is a bond, --CR.sup.6R.sup.7--,
--O--, --NR.sup.8-- or --C(O)--; R.sup.6 and R.sup.7 are each
independently from each other hydrogen, lower alkyl, cycloalkyl, or
phenyl or R.sup.6 and R.sup.7 together with the carbon atom to
which they are attached form a C.sub.3-6-cycloalkyl group, with the
proviso that R.sup.6 also optionally is hydroxy or lower alkoxy;
R.sup.8 is hydrogen or lower alkyl; and m is 0 or 1; or a
pharmaceutically active acid addition salt thereof.
22. The compound of claim 21, selected from the group consisting of
[5-(4-chloro-benzyl)-4H-[1,2,4]triazol-3-yl]-[3-methoxy-4-(4-methyl-imida-
zol-1-yl)-phenyl]-amine and
[5-(4-fluoro-benzyl)-4H-[1,2,4]triazol-3-yl]-[3-methoxy-4-(4-methyl-imida-
zol-1-yl)-phenyl]-amine.
23. A pharmaceutical composition comprising a therapeutically
effective amount of a compound of formula I ##STR00285## wherein
R.sup.1 is hydrogen, lower alkyl or lower alkyl substituted by
hydroxy; R.sup.2 is hydrogen, lower alkoxy, lower alkyl, cyano or
halogen; R.sup.3 is lower alkyl, lower alkenyl, lower alkyl
substituted by fluoro, (CH.sub.2).sub.2O-lower alkyl,
(CH.sub.2).sub.2NR.sup.8.sub.2, or is 4H-benzo[1,4]oxazin-3-one,
cycloalkyl optionally substituted by hydroxy, or is
heterocycloalkyl, which heterocycloalkyl is optionally substituted
by hydroxy or S(O).sub.2-lower alkyl, or is (CH.sub.2).sub.m-aryl
or is a five- or six-membered heteroaryl group, wherein the rings
in the heteroaryl group are optionally substituted by one or more
R' for any definition of L, or when L is a bond, the rings in the
heteroaryl group are optionally substituted by one or more halogen,
hydroxy, --C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH.sub.2, or
when L is --CR.sup.6R.sup.7--, the rings in the heteroaryl group
are optionally substituted by one or more lower alkoxy, hydroxy,
--C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH.sub.2 or when L is
NR.sup.8, the rings in the heteroaryl group are optionally
substituted by one or more CH.sub.2--C(O)O-lower alkyl for L being
NR.sup.8, or when L is C(O), the rings in the heteroaryl group are
optionally substituted by one or more lower alkoxy, hydroxy or
NR.sup.8.sub.2 for L being C(O); R' is halogen, lower alkyl, lower
alkoxy, cyano, lower alkyl substituted by fluoro, lower alkoxy
substituted by fluoro, SF.sub.5, or is a five-membered heteroaryl
group, which is optionally substituted by lower alkyl; Ar is a
five-membered heteroaryl group or is pyridinyl; Z is CH or N; X-Y
is N--CR.sup.4.dbd.CR.sup.5CH--CR.sup.4.dbd.N,
CH--CR.sup.4.dbd.CR.sup.5 or N--NH; and wherein R.sup.4 and R.sup.5
form together with the corresponding carbon atoms to which they are
attached optionally form an additional ring with
--(CH.sub.2).sub.n, with the proviso that if X-Y is
CH--CR.sup.4.dbd.CR.sup.5 or CH--CR.sup.4.dbd.N, then Z is N; or
R.sup.4 and R.sup.5 are each independently hydrogen, halogen, lower
alkyl, lower alkoxy, C(O)O-lower alkyl, lower alkyl substituted by
one or more groups selected from fluoro, hydroxy, cyano and
cycloalkyl, or are cyano, phenyl, benzyl or a five- or six-membered
heteroaryl group wherein the rings of the heteroaryl group are
optionally substituted by one or more R', or are cycloalkyl or
heterocycloalkyl, each of which optionally substituted by lower
alkyl and hydroxy, with the proviso that R.sup.4 also optionally is
hydroxy or NR.sup.8.sub.2; L is a bond, --CR.sup.6R.sup.7--, --O--,
--NR.sup.8-- or --C(O)--; R.sup.6 and R.sup.7 are each
independently hydrogen, lower alkyl, cycloalkyl, phenyl or R.sup.6
and R.sup.7 together with the carbon atom to which they are
attached form a C.sub.3-6-cycloalkyl group, with the proviso that
R.sup.6 also optionally is hydroxy or lower alkoxy; R.sup.8 is
hydrogen or lower alkyl; m is 0 or 1; and n is 3 or 4; or a
pharmaceutically active acid addition salt thereof and a
pharmaceutically acceptable carrier.
Description
PRIORITY TO RELATED APPLICATION(S)
[0001] This application claims the benefit of European Patent
Application No. 08151825.0, filed Feb. 22, 2008, which is hereby
incorporated by reference in its entirety.
BACKGROUND OF THE INVENTION
[0002] Alzheimer's disease (AD) is the most common cause of
dementia in later life. Pathologically, AD is characterized by the
deposition of amyloid in extracellular plaques and intracellular
neurofibrillary tangles in the brain. The amyloid plaques are
mainly composed of amyloid peptides (A.beta. peptides) which
originate from the .beta.-Amyloid Precursor Protein (APP) by a
series of proteolytic cleavage steps. Several forms of APP have
been identified of which the most abundant are proteins of 695, 751
and 770 amino acids length. They all arise from a single gene
through differential splicing. The A.beta. peptides are derived
from the same domain of the APP.
[0003] A.beta. peptides are produced from APP through the
sequential action of two proteolytic enzymes termed .beta.- and
.gamma.-secretase. .beta.-Secretase cleaves first in the
extracellular domain of APP just outside of the trans-membrane
domain (TM) to produce a C-terminal fragment of APP containing the
TM- and cytoplasmatic domain (CTF.beta.). CTF.beta. is the
substrate for .gamma.-secretase which cleaves at several adjacent
positions within the TM to produce the A.beta. peptides and the
cytoplasmic fragment. Various proteolytic cleavages mediated by
.gamma.-secretase result in A.beta. peptides of different chain
length, e.g. A.beta.38, A.beta.40 and A.beta.42. The latter one is
regarded to be the more pathogenic amyloid peptide because of its
strong tendency to form neurotoxic aggregates.
[0004] The .beta.-secretase is a typical aspartyl protease. The
.gamma.-secretase is a proteolytic activity consisting of several
proteins, its exact composition is incompletely understood.
However, the presenilins are essential components of this activity
and may represent a new group of atypical aspartyl proteases which
cleave within the TM of their substrates and which are themselves
polytopic membrane proteins. Other essential components of
.gamma.-secretase may be nicastrin and the products of the aph1 and
pen-2 genes. Proven substrates for .gamma.-secretase are the APP
and the proteins of the Notch receptor family, however,
.gamma.-secretase has loose substrate specificity and may cleave
further membrane proteins unrelated to APP and Notch.
[0005] The .gamma.-secretase activity is absolutely required for
the production of A.beta. peptides. This has been shown both by
genetic means, i.e., ablation of the presenilin genes and by
low-molecular-weight inhibitory compounds. Since according to the
amyloid hypothesis for AD the production and deposition of A.beta.
is the ultimate cause for the disease, it is thought that selective
and potent inhibitors of .gamma.-secretase will be useful for the
prevention and treatment of AD.
[0006] An alternative mode of treatment is the modulation of the
.gamma.-secretase activity which results in a selective reduction
of the A.beta.42 production. This will result in to an increase of
shorter A.beta. isoforms, such as A.beta.38, A.beta.37 or others,
which have reduced capability for aggregation and plaque formation,
and hence less neurotoxic. Compounds which show this effect on
modulating .gamma.-secretase activity include certain non-steroidal
anti-inflammatory drugs (NSAIDs) and related analogues (Weggen et
al. Nature, 414 (2001) 212-16).
[0007] Numerous documents describe the current knowledge on
.gamma.-secretase modulation, for example the following
publications: [0008] Morihara et al, J. Neurochem., 83 (2002)
1009-12 [0009] Jantzen et al, J. Neuroscience, 22 (2002) 226-54
[0010] Takahashi et al, J. Biol. Chem., 278 (2003) 18644-70 [0011]
Beher et al, J. Biol. Chem. 279 (2004) 43419-26 [0012] Lleo et al,
Nature Med. 10 (2004) 1065-6 [0013] Kukar et al, Nature Med. 11
(2005) 545-50 [0014] Perretto et al, J. Med. Chem. 48 (2005)
5705-20 [0015] Clarke et al, J. Biol. Chem. 281 (2006) 31279-89
[0016] Stock et al, Bioorg. Med. Chem. Lett. 16 (2006) 2219-2223
[0017] Narlawar et al, J. Med. Chem. 49 (2006) 7588-91
SUMMARY OF THE INVENTION
[0018] The invention provides a compound of formula
##STR00002##
wherein [0019] R.sup.1 is hydrogen, lower alkyl or lower alkyl
substituted by hydroxy; [0020] R.sup.2 is hydrogen, lower alkoxy,
lower alkyl, cyano or halogen; [0021] R.sup.3 is lower alkyl, lower
alkenyl, lower alkyl substituted by fluoro, (CH.sub.2).sub.2O-lower
alkyl, (CH.sub.2).sub.2NR.sup.8.sub.2, or is
4H-benzo[1,4]oxazin-3-one, cycloalkyl optionally substituted by
hydroxy, or is heterocycloalkyl, which heterocycloalkyl is
optionally substituted by hydroxy or S(O).sub.2-lower alkyl, or is
(CH.sub.2).sub.m-aryl or is a five- or six-membered heteroaryl
group [0022] wherein the rings in the heteroaryl group are
optionally substituted by one or more R' for any definition of L,
or [0023] when L is a bond, the rings in the heteroaryl are
optionally substituted by one or more halogen, hydroxy,
--C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH.sub.2, or [0024]
when L is --CR.sup.6R.sup.7--, the rings in the heteroaryl are
optionally substituted by one or more lower alkoxy, hydroxy,
--C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH.sub.2, or [0025]
when L is NR.sup.8, the rings in the heteroaryl are optionally
substituted by one or more CH.sub.2--C(O)O-lower alkyl, or [0026]
when L is C(O), the rings in the heteroaryl are optionally
substituted by one or more lower alkoxy, hydroxy or NR.sup.8.sub.2;
[0027] R' is halogen, lower alkyl, lower alkoxy, cyano, lower alkyl
substituted by fluoro, lower alkoxy substituted by fluoro,
SF.sub.5, or is a five-membered heteroaryl group, which is
optionally substituted by lower alkyl; [0028] Ar is a five-membered
heteroaryl group or is pyridinyl; [0029] Z is CH or N; [0030] X-Y
is N--CR.sup.4.dbd.CR.sup.5, CH--CR.sup.4.dbd.N,
CH--CR.sup.4.dbd.CR.sup.5 or N--NH; and wherein R.sup.4 and R.sup.5
together with the corresponding carbon atoms to which they are
attached optionally form an additional ring with
--(CH.sub.2).sub.n, with the proviso that if X-Y is
CH--CR.sup.4.dbd.CR.sup.5 or CH--CR.sup.4.dbd.N, then Z is N; or
[0031] R.sup.4 and R.sup.5 are each independently hydrogen,
halogen, lower alkyl, lower alkoxy, C(O)O-lower alkyl, lower alkyl
substituted by one or more groups selected from fluoro, hydroxy,
cyano and cycloalkyl, [0032] or are cyano, phenyl, benzyl or a
five- or six-membered heteroaryl group wherein the rings in the
heteroaryl group are optionally substituted by one or more R', or
are cycloalkyl or heterocycloalkyl, each of which is optionally
substituted by lower alkyl and hydroxy, with the proviso that
R.sup.4 also is optionally hydroxy or NR.sup.8.sub.2; [0033] L is a
bond, --CR.sup.6R.sup.7--, --O--, --NR.sup.8-- or --C(O)--; [0034]
R.sup.6 and R.sup.7 are each independently hydrogen, lower alkyl,
cycloalkyl, or phenyl or R.sup.6 and R.sup.7 together with the
carbon atom to which they are attached form a C.sub.3-6-cycloalkyl
group, with the proviso that R.sup.6 also is optionally hydroxy or
lower alkoxy; [0035] R.sup.8 is hydrogen or lower alkyl; [0036] m 0
or 1; and [0037] n is 3 or 4; or a pharmaceutically active acid
addition salt thereof.
[0038] The invention also provides all forms of optically pure
enantiomers, racemates or diastereomeric mixtures for compounds of
formula I.
[0039] The invention further provides pharmaceutical compositions
containing compounds of formula I and methods for the preparation
of such compounds and compositions.
[0040] The present compounds of formula I are modulators for
amyloid beta and, thus, they may be useful for the treatment or
prevention of a disease associated with the deposition of
.beta.-amyloid in the brain, in particular Alzheimer's disease, and
other diseases such as cerebral amyloid angiopathy, hereditary
cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D),
multi-infarct dementia, dementia pugilistica and Down syndrome.
DETAILED DESCRIPTION OF THE INVENTION
[0041] The following definitions of general terms used herein apply
irrespective of whether the terms in question appear alone or in
combination. It must be noted that, as used in the specification
and the appended claims, the singular forms "a", "an," and "the"
include plural forms unless the context clearly dictates
otherwise.
[0042] As used herein, the term "lower alkyl" denotes a saturated
straight- or branched-chain hydrocarbon group containing from 1 to
7 carbon atoms, for example, methyl, ethyl, propyl, isopropyl,
n-butyl, i-butyl, 2-butyl, t-butyl and the like. Preferred alkyl
groups are groups with 1-4 carbon atoms.
[0043] As used herein "halogen" denotes fluorine, chlorine,
bromine, and iodine.
[0044] As used herein, the term "cycloalkyl" denotes a saturated
carbon ring system, containing from 3 to 6 carbon atoms, for
example cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
[0045] As used herein, the term "lower alkoxy" denotes a group
containing an alkyl group as defined above which is attached via an
oxygen atom.
[0046] As used herein, the term "lower alkyl substituted by
halogen" denotes an alkyl group as defined above, wherein at least
one hydrogen atom is replaced by halogen. As used herein, the term
"lower alkyl substituted by fluoro" denotes an alkyl group as
defined above, wherein at least one hydrogen atom is replaced by
fluoro, for example CF.sub.3, CHF.sub.2, CH.sub.2F,
CH.sub.2CF.sub.3, CH.sub.2CH.sub.2CF.sub.3,
CH.sub.2CF.sub.2CF.sub.3, CH.sub.2CF.sub.2CF.sub.2CF.sub.3,
CH.sub.2CH.sub.2CF.sub.2CF.sub.3 and the like.
[0047] As used herein, the term "lower alkoxy substituted by
fluoro" denotes an alkoxy group as defined above, wherein at least
one hydrogen atom is replaced by fluoro, for example OCF.sub.3,
OCHF.sub.2, OCH.sub.2F, OCH.sub.2CF.sub.3,
OCH.sub.2CH.sub.2CF.sub.3, OCH.sub.2CF.sub.2CF.sub.3,
OCH.sub.2CF.sub.2CF.sub.2CF.sub.3,
OCH.sub.2CH.sub.2CF.sub.2CF.sub.3 and the like.
[0048] The term "lower alkenyl" denotes a straight- or
branched-chain carbon group containing from 2-7, preferably from
2-4, carbon atoms, wherein at least one bond is a double bond.
[0049] As used herein, the term "five-membered heteroaryl group"
denotes an heterocyclic group, containing at least two heteroatoms,
selected from the group consisting of N, O and S, wherein at least
one of the rings in the heterocyclic group is aromatic, for example
oxazol-5-yl, [1,2,4]triazol-1-yl, [1,2,4]triazol-3-yl,
[1,2,3]triazol-1-yl, imidazol-1-yl, thiazol-5-yl, thiazol-2-yl,
furan-2-yl, thiophen-2-yl, pyrazol-4-yl, pyrazol-3-yl,
pyrazol-1-yl, [1,2,4]-oxadiazol-5-yl, [1,3,4]-oxadiazol-2-yl or
[1,2,4]thiadiazol-5-yl. Preferred are the imidazol-1-yl,
pyrazol-4-yl, [1,2,4]triazol-1-yl or oxazol-5-yl groups.
[0050] The term "six-membered heteroaryl group" denotes a
heterocyclic group, containing at least one heteroatom, selected
from the group consisting of N, O and S, wherein at least one ring
in the heterocyclic group is aromatic, for example pyridinyl,
pyrazinyl, pyrimidinyl or pyridazinyl.
[0051] The term "aryl" denotes an aromatic mono or bicyclic carbon
ring system, for example phenyl or naphthyl.
[0052] The term "heterocycloalkyl" denotes a non-aromatic ring
system, containing at least one heteroatom, selected from the group
consisting of N, O and S, for example tetrahydro-pyran-4-yl,
piperidin-4-yl, pyrrolidin-1-yl, morpholinyl,
1,1-dioxo-6-thiomorpholin-4-yl, oxetan-3-yl or piperazin-1-yl.
[0053] "Pharmaceutically acceptable," such as pharmaceutically
acceptable carrier, excipient, etc., means pharmacologically
acceptable and substantially non-toxic to the subject to which the
particular compound is administered.
[0054] The term "pharmaceutically acceptable acid addition salts"
embraces salts with inorganic and organic acids, such as
hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid,
citric acid, formic acid, fumaric acid, maleic acid, acetic acid,
succinic acid, tartaric acid, methane-sulfonic acid,
p-toluenesulfonic acid and the like.
[0055] "Therapeutically effective amount" means an amount that is
effective to prevent, alleviate or ameliorate symptoms of disease
or prolong the survival of the subject being treated.
[0056] One embodiment of the invention provides compounds of
formula
##STR00003##
wherein [0057] R.sup.1 is hydrogen, lower alkyl, lower alkyl
substituted by halogen or by hydroxy, or is lower alkoxy or lower
alkoxy substituted by halogen; [0058] R.sup.2 is hydrogen, lower
alkoxy, lower alkyl, cyano or halogen; [0059] R.sup.3 is lower
alkyl, lower alkyl substituted by fluoro or is aryl or a five- or
six membered heteroaryl group [0060] wherein the rings in the
heteroaryl group are optionally substituted by one or more R' for
any definition of L, or [0061] when L is a bond, the rings in the
heteroaryl group are optionally substituted by one or more halogen,
or [0062] when L is a bond or --CR.sup.6R.sup.7--, the rings in the
heteroaryl group are optionally substituted by one or more hydroxy,
C(O)O-lower alkyl or C(O)NH.sub.2; [0063] R' is halogen, lower
alkyl, lower alkoxy, cyano, lower alkyl substituted by fluoro,
lower alkoxy substituted by fluoro or is a five-membered heteroaryl
group; [0064] Ar is a five-membered heteroaryl group; [0065] Z is
CH or N; [0066] X-Y is N--CR.sup.4.dbd.CR.sup.5, N--CR.sup.4.dbd.N,
CH--CR.dbd.N, CH--CR.sup.4.dbd.CR.sup.5 or N--NH; with the proviso
that if X-Y is CH--CR.sup.4.dbd.CR.sup.5 or CH--CR.sup.4.dbd.N,
then Z is N; [0067] R.sup.4 and R.sup.5 are each independently
hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy, C(O)O-lower
alkyl, lower alkyl substituted by fluoro, or are cyano, phenyl,
benzyl or a five- or six-membered heteroaryl group, wherein the
rings in the five- or six-membered heteroaryl group are optionally
substituted by one or more R'; [0068] L is a bond,
--CR.sup.6R.sup.7--, --O--, --NR.sup.8-- or --C(O)--; [0069]
R.sup.6 and R.sup.7 are each independently hydrogen, lower alkyl,
lower alkoxy, hydroxy, phenyl or R.sup.6 and R.sup.7 together with
the carbon atom to which they are attached form a
C.sub.3-6-cycloalkyl group; and [0070] R.sup.8 is hydrogen or lower
alkyl; or pharmaceutically active acid addition salts.
[0071] Preferred are compounds of formula I-A
##STR00004##
wherein [0072] R.sup.1 is hydrogen, lower alkyl or lower alkyl
substituted by hydroxy; [0073] R.sup.2 is hydrogen, lower alkoxy,
lower alkyl, cyano or halogen; [0074] R.sup.3 is lower alkyl, lower
alkenyl, lower alkyl substituted by fluoro, (CH.sub.2).sub.2O-lower
alkyl, (CH.sub.2).sub.2NR.sup.8.sub.2, or is
4H-benzo[1,4]oxazin-3-one, cycloalkyl optionally substituted by
hydroxy, or is heterocycloalkyl, which heterocycloalkyl is
optionally substituted by hydroxy or S(O).sub.2-lower alkyl, or is
(CH.sub.2).sub.m-aryl or is a five- or six-membered heteroaryl
group [0075] wherein the rings in the heteroaryl group is
optionally substituted by one or more R' for any definition of L,
or [0076] when L is a bond, the rings in the heteroaryl group are
optionally substituted by one or more halogen, hydroxy,
--C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH.sub.2, or [0077]
when L is --CR.sup.6R.sup.7--, the rings in the heteroaryl group
are optionally substituted by one or more lower alkoxy, hydroxy,
--C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH.sub.2, or [0078]
when L is NR.sup.8, the rings in the heteroaryl group are
optionally substituted by one or more CH.sub.2--C(O)O-lower alkyl,
or [0079] when L is C(O), the rings in the heteroaryl group is
lower alkoxy, hydroxy or NR.sup.8.sub.2; [0080] R' is halogen,
lower alkyl, lower alkoxy, cyano, lower alkyl substituted by
fluoro, lower alkoxy substituted by fluoro, SF.sub.5, or is a
five-membered heteroaryl group optionally substituted by lower
alkyl; [0081] Ar is a five-membered heteroaryl group or is
pyridinyl; [0082] R.sup.4 and R.sup.5 are each independently
hydrogen, halogen, lower alkyl, lower alkoxy, C(O)O-lower alkyl,
lower alkyl substituted by one or more groups selected from fluoro,
hydroxy, cyano and cycloalkyl, or are cyano, phenyl, benzyl or a
five- or six membered heteroaryl group, wherein the rings in the
heteroaryl group are optionally substituted by one or more R', or
are cycloalkyl or heterocycloalkyl, each of which is optionally
substituted by lower alkyl and hydroxy, with the proviso that
R.sup.4 also is optionally hydroxy or NR.sup.8.sub.2, or wherein
R.sup.4 and R.sup.5 together with the corresponding carbon atoms to
which they are attached optionally form an additional ring with
--(CH.sub.2).sub.n; [0083] L is a bond, --CR.sup.6R.sup.7--, --O--,
--NR.sup.8-- or --C(O)--; [0084] R.sup.6 and R.sup.7 are each
independently hydrogen, lower alkyl, cycloalkyl, or phenyl or
R.sup.6 and R.sup.7 together with the carbon atom to which they are
attached form a C.sub.3-6-cycloalkyl group, with the proviso that
R.sup.6 also is optionally hydroxy or lower alkoxy; [0085] R.sup.8
is hydrogen or lower alkyl; [0086] m is 0 or 1; and [0087] n is 3
or 4; or pharmaceutically active acid addition salts thereof.
[0088] Preferred compounds from formula I-A are those of formula
I-A-1
##STR00005##
wherein [0089] R.sup.2 is hydrogen, lower alkoxy, lower alkyl,
cyano or halogen; [0090] R.sup.3 is lower alkyl, lower alkenyl,
lower alkyl substituted by fluoro, (CH.sub.2).sub.2O-lower alkyl,
(CH.sub.2).sub.2NR.sup.8.sub.2, or is 4H-benzo[1,4]oxazin-3-one,
cycloalkyl optionally substituted by hydroxy, or is
heterocycloalkyl, which heterocycloalkyl is optionally substituted
by hydroxy or S(O).sub.2-lower alkyl, or is (CH.sub.2).sub.m-aryl
or is a five- or six-membered heteroaryl group, wherein the rings
in the heteroaryl group are optionally substituted by one or more
R' for any definition of L, or [0091] when L is a bond, the rings
of the heteroaryl group are optionally substituted by one or more
halogen, hydroxy, --C(O)O-lower alkyl, OC(O)-lower alkyl or
C(O)NH.sub.2, or [0092] when L is --CR.sup.6R.sup.7--, the rings of
the heteroaryl group are optionally substituted by one or more
lower alkoxy, hydroxy, --C(O)O-lower alkyl, OC(O)-lower alkyl or
C(O)NH.sub.2, or [0093] when L is NR.sup.3, the rings of the
heteroaryl group are optionally substituted by one or more
CH.sub.2--C(O)O-lower alkyl, or [0094] when L is C(O), the rings of
the heteroaryl group are optionally substituted by one or more
lower alkoxy, hydroxy or NR.sup.8.sub.2; [0095] R' is halogen,
lower alkyl, lower alkoxy, cyano, lower alkyl substituted by
fluoro, lower alkoxy substituted by fluoro, SF.sub.5, or is a
five-membered heteroaryl group, which is optionally substituted by
lower alkyl; [0096] R.sup.4 and R.sup.5 are each independently
hydrogen, halogen, lower alkyl, lower alkoxy, C(O)O-lower alkyl,
lower alkyl substituted by one or more groups selected from fluoro,
hydroxy, cyano and cycloalkyl, or are cyano, phenyl, benzyl or a
five- or six-membered heteroaryl group wherein the rings in the
heteroaryl group are optionally substituted by one or more R', or
are cycloalkyl or heterocycloalkyl, each of which is optionally
substituted by lower alkyl and hydroxy, with the proviso that
R.sup.4 also is optionally hydroxy or NR.sup.8.sub.2, or wherein
R.sup.4 and R.sup.5 together with the corresponding carbon atoms to
which they are attached optionally form an additional ring with
--(CH.sub.2).sub.n; [0097] L is a bond, --CR.sup.6R.sup.7--, --O--,
--NR.sup.8-- or --C(O)--; [0098] R.sup.6 and R.sup.7 are each
independently hydrogen, lower alkyl, cycloalkyl, phenyl or R.sup.6
and R.sup.7 together with the carbon atom to which they are
attached form a C.sub.3-6-cycloalkyl group, with the proviso that
R.sup.6 also is optionally hydroxy or lower alkoxy; [0099] R.sup.8
is hydrogen or lower alkyl; [0100] m is 0 or 1; and [0101] n is 3
or 4; or pharmaceutically active acid addition salts thereof.
[0102] Preferred compounds from this group are the following
compounds: [0103]
(4-benzyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-ph-
enyl]-amine; [0104]
[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-(3,4,5-trifluoro-benzyl)-
-pyrimidin-2-yl]-amine; [0105]
[4-(3-chloro-benzyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl-
)-phenyl]-amine; [0106]
[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[5-methyl-4-(1-phenyl-ethyl-
)-pyrimidin-2-yl]-amine; [0107]
[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(3,4,5-trifluor-
o-phenoxy)-pyrimidin-2-yl]-amine; [0108]
[4-(3,4-difluoro-phenoxy)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-
-imidazol-1-yl)-phenyl]-amine; [0109]
[4-(4-chloro-phenoxy)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imi-
dazol-1-yl)-phenyl]-amine; [0110]
[4-(2,6-dichloro-phenoxy)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-
-1-yl)-phenyl]-amine; [0111]
[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(2-trifluoromet-
hyl-phenoxy)-pyrimidin-2-yl]-amine; [0112]
[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(3-trifluoromet-
hoxy-phenoxy)-pyrimidin-2-yl]-amine; [0113]
[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(3-trifluoromet-
hyl-phenoxy)-pyrimidin-2-yl]-amine; [0114]
[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(3,3,4,4,4-pent-
afluoro-butoxy)-pyrimidin-2-yl]-amine; [0115]
{4-[1-(4-chloro-phenyl)-1-methyl-ethyl]-5-methyl-pyrimidin-2-yl}-[3-metho-
xy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine; [0116]
{4-[1-(4-chloro-phenyl)-1-methyl-ethyl]-pyrimidin-2-yl}-[3-methoxy-4-(4-m-
ethyl-imidazol-1-yl)-phenyl]-amine; [0117]
{4-[1-(4-chloro-phenyl)-1-methyl-ethyl]-pyrimidin-2-yl}-[3-fluoro-4-(4-me-
thyl-imidazol-1-yl)-phenyl]-amine; [0118] ethyl
4-(4-chloro-phenyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]--
pyrimidine-5-carboxylate; [0119]
[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-(4-trifluoromethyl-pheny-
l)-pyrimidin-2-yl]-amine; [0120]
(4-benzyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)--
phenyl]-amine; [0121]
(4-ethoxy-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)--
phenyl]-amine; [0122]
N4-(2,2,3,3,4,4,4-heptafluoro-butyl)-N2-[3-methoxy-4-(4-methyl-imidazol-1-
-yl)-phenyl]-6-methyl-pyrimidine-2,4-diamine; [0123]
[4-(4-chloro-phenyl)-5-(4-methoxy-benzyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-
-methyl-imidazol-1-yl)-phenyl]-amine; [0124]
[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-methoxy-6-methyl-pyrimid-
in-2-yl)-amine; [0125]
(4-isopropoxy-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1--
yl)-phenyl]-amine; [0126]
[4-(4-Fluoro-phenoxy)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imi-
dazol-1-yl)-phenyl]-amine; [0127]
[4-(4-tert-butyl-phenoxy)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-
-imidazol-1-yl)-phenyl]-amine; [0128]
2-{6-ethoxy-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidi-
n-4-yl}-propan-2-ol; [0129]
N4-(3-chloro-phenyl)-N2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-6-m-
ethyl-pyrimidine-2,4-diamine; [0130]
N4-(4-chloro-phenyl)-N2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-6-m-
ethyl-pyrimidine-2,4-diamine; [0131]
N4,N4-diethyl-N2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-6-methyl-p-
yrimidine-2,4-diamine; [0132]
1-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimidi-
n-4-yl}-piperidin-4-ol; [0133]
[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-methyl-6-pyrrolidin-1-yl-
-pyrimidin-2-yl)-amine; [0134]
[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-methyl-6-piperidin-1-yl--
pyrimidin-2-yl)-amine; [0135]
2-({2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimid-
in-4-yl}-methyl-amino)-ethanol; [0136]
2-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-piperidin-1-yl--
pyrimidin-4-yl}-propan-2-ol; [0137]
2-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-pyrrolidin-1-yl-
-pyrimidin-4-yl}-propan-2-ol; [0138]
[4-butyl-6-(4-chloro-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imida-
zol-1-yl)-phenyl]-amine; [0139]
[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-phenyl-pyrimidin-2-yl)-a-
mine; [0140]
5-(4,6-dimethyl-pyrimidin-2-ylamino)-2-(4-methyl-imidazol-1-yl)-benzonitr-
ile; [0141]
5-[4-(4-chloro-phenyl)-pyrimidin-2-ylamino]-2-(4-methyl-imidazol-1-yl)-be-
nzonitrile; [0142]
[5-ethyl-4-(4-trifluoromethyl-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-met-
hyl-imidazol-1-yl)-phenyl]-amine; [0143]
[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-(3,4,5-trifluoro-phenyl)-
-pyrimidin-2-yl]-amine; [0144]
[4-(2,5-dichloro-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol--
1-yl)-phenyl]-amine; [0145]
[4-(3,4-dichloro-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol--
1-yl)-phenyl]-amine; [0146]
[4-(2,4-dichloro-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol--
1-yl)-phenyl]-amine; [0147]
[4-(4-chloro-3-methyl-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imid-
azol-1-yl)-phenyl]-amine; [0148]
[4-(4-chloro-phenyl)-5-propyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imid-
azol-1-yl)-phenyl]-amine; [0149]
[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(5-methoxy-4-phenyl-pyrimid-
in-2-yl)-amine; [0150]
(4-cyclopropyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phen-
yl]-amine; [0151] ethyl
4-benzyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidine--
5-carboxylate; [0152]
[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-(4-methyl-pent-3-enyl)-5-
-phenyl-pyrimidin-2-yl]-amine; [0153]
6-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-4-
H-benzo[1,4]oxazin-3-one; [0154]
[4-(2-chloro-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl-
)-phenyl]-amine; [0155]
(4-isobutyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl-
)-phenyl]-amine; [0156]
(4,6-diethyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl-
]-amine; [0157]
[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-methyl-6-phenyl-pyrimidi-
n-2-yl)-amine; [0158]
(4-furan-2-yl-6-trifluoromethyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-im-
idazol-1-yl)-phenyl]-amine; [0159]
[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-phenyl-5,6,7,8-tetrahydr-
o-quinazolin-2-yl)-amine; [0160]
(4,6-dimethyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-pheny-
l]-amine; [0161]
(4,6-bis-trifluoromethyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol--
1-yl)-phenyl]-amine; [0162]
(4-isopropyl-6-trifluoromethyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imi-
dazol-1-yl)-phenyl]-amine; [0163]
(4,6-diisopropyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-ph-
enyl]-amine; [0164]
[4-(2-chloro-phenyl)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imid-
azol-1-yl)-phenyl]-amine; [0165] ethyl
2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-thiophen-2-yl-pyri-
midine-4-carboxylate; [0166] ethyl
6-Isopropyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidi-
ne-4-carboxylate; [0167] ethyl
6-cyclopropyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimi-
dine-4-carboxylate; [0168] ethyl
2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-pyridin-2-yl-pyrim-
idine-4-carboxylate; [0169] ethyl
2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromethyl-
-phenyl)-pyrimidine-4-carboxylate; [0170] ethyl
6-(4-chloro-benzyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]--
pyrimidine-4-carboxylate; [0171]
2-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimidi-
n-4-yl}-propan-2-ol; [0172]
2-{6-ethyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-
-4-yl}-propan-2-ol; [0173]
2-{6-isopropyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrim-
idin-4-yl}-propan-2-ol; [0174]
2-{6-cyclopropyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyr-
imidin-4-yl}-propan-2-ol; [0175]
2-{6-tert-butyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyri-
midin-4-yl}-propan-2-ol; [0176]
2-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-thiophen-2-yl-p-
yrimidin-4-yl}-propan-2-ol; [0177]
2-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-pyridin-2-yl-py-
rimidin-4-yl}-propan-2-ol; [0178]
2-{6-(4-chloro-benzyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamin-
o]-pyrimidin-4-yl}-propan-2-ol; [0179]
2-[2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromet-
hyl-phenyl)-pyrimidin-4-yl]-propan-2-ol; [0180]
1-[2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromet-
hyl-phenyl)-pyrimidin-4-yl]-ethanone; [0181]
3-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-p-
entan-3-ol; [0182]
2-[2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(3,4,5-trifluor-
o-phenyl)-pyrimidin-4-yl]-propan-2-ol; [0183]
2-{6-(2,4-dichloro-phenyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl-
amino]-pyrimidin-4-yl}-propan-2-ol; [0184]
2-{6-(4-chloro-phenyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamin-
o]-pyrimidin-4-yl}-propan-2-ol; [0185]
2-{6-(2-chloro-phenyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamin-
o]-pyrimidin-4-yl}-propan-2-ol; [0186]
2-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-5,6,7,8-tetrahydr-
o-quinazolin-4-yl}-propan-2-ol; [0187]
2-{2-[3-fluoro-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-isopropyl-pyrimi-
din-4-yl}-propan-2-ol; [0188]
2-[2-[3-fluoro-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluorometh-
yl-phenyl)-pyrimidin-4-yl]-propan-2-ol; [0189]
2-{6-dimethylamino-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-p-
yrimidin-4-yl}-propan-2-ol; [0190]
1-{6-(1-hydroxy-1-methyl-ethyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-p-
henylamino]-pyrimidin-4-yl}-4-methyl-piperidin-4-ol; [0191]
1-[2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromet-
hyl-phenyl)-pyrimidin-4-yl]-cyclopentanol; [0192]
5-[4-(1-hydroxy-1-methyl-ethyl)-6-(4-trifluoromethyl-phenyl)-pyrimidin-2--
ylamino]-2-(4-methyl-imidazol-1-yl)-benzonitrile; and [0193]
2-[2-[3-methyl-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluorometh-
yl-phenyl)-pyrimidin-4-yl]-propan-2-ol.
[0194] Preferred compounds of formula I-A are further those,
wherein R.sup.1--Ar is 2-methyl-imidazol-1-yl,
3-methyl-[1,2,4]triazol-1-yl, thiazol-5-yl, 2-methyl-thiazol-5-yl,
2-methyl-oxazol-5-yl, 2-methyl-pyridin-4-yl,
1-methyl-1H-pyrazol-4-yl, 3-methyl-[1,2,4]triazol-1-yl,
[1,2,4]triazol-1-yl, 5-methyl-[1,2,4]triazol-1-yl,
1,3,4]oxadiazol-2-yl, 4-pyridin-4-yl, 2-methyl-pyridin-4-yl,
3-methyl-[1,2,4]thiadiazol-5-yl, or oxazol-5-yl, for example the
following compounds [0195]
(4-benzyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(3-methyl-[1,2,4]triazol--
1-yl)-phenyl]-amine; [0196]
(4-benzyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(2-methyl-thiazol-5-yl)-p-
henyl]-amine; [0197]
(4-benzyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(2-methyl-oxazol-5-yl)-ph-
enyl]-amine; [0198]
2-[2-[3-methoxy-4-(2-methyl-thiazol-5-yl)-phenylamino]-6-(4-trifluorometh-
yl-phenyl)-pyrimidin-4-yl]-propan-2-ol; [0199]
(4,6-dimethyl-pyrimidin-2-yl)-[4-(2-methyl-pyridin-4-yl)-phenyl]-amine;
and [0200]
(4-benzyl-6-methyl-pyrimidin-2-yl)-[4-(2-methyl-pyridin-4-yl)-phenyl]-ami-
ne.
[0201] Preferred are further compounds of formula
##STR00006##
wherein [0202] R.sup.1 is hydrogen, lower alkyl or lower alkyl
substituted by hydroxy; [0203] R.sup.2 is hydrogen, lower alkoxy,
lower alkyl, cyano or halogen; [0204] R.sup.3 is lower alkyl, lower
alkenyl, lower alkyl substituted by fluoro, (CH.sub.2).sub.2O-lower
alkyl, (CH.sub.2).sub.2NR.sup.8.sub.2, or is
4H-benzo[1,4]oxazin-3-one, cycloalkyl optionally substituted by
hydroxy, or is heterocycloalkyl, which heterocycloalkyl is
optionally substituted by hydroxy or S(O).sub.2-lower alkyl, or is
(CH.sub.2).sub.m-aryl or is a five- or six-membered heteroaryl
group, hwerein the rings in the heteroaryl group are optionally
substituted by one or more R' for any definition of L, or [0205]
when L is a bond, the rings in the heteroaryl group are optionally
substituted by one or more halogen, hydroxy, --C(O)O-lower alkyl,
OC(O)-lower alkyl or C(O)NH.sub.2, or [0206] when L is
--CR.sup.6R.sup.7--, the rings in the heteroaryl group are
optionally substituted by one or more lower alkoxy, hydroxy,
--C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH.sub.2, or [0207]
when L is NR.sup.8, the rings in the heteroaryl group are
optionally substituted by one or more CH.sub.2--C(O)O-lower alkyl,
or [0208] when L is C(O), the rings in the heteroaryl group are
optionally substituted by one or more lower alkoxy, hydroxy or
NR.sup.8.sub.2; [0209] R' is halogen, lower alkyl, lower alkoxy,
cyano, lower alkyl substituted by fluoro, lower alkoxy substituted
by fluoro, SF.sub.5, or is a five-membered heteroaryl group, which
is optionally substituted by lower alkyl; [0210] Ar is a
five-membered heteroaryl group or is pyridinyl; [0211] R.sup.4 is
hydrogen, halogen, lower alkyl, lower alkoxy, C(O)O-lower alkyl,
lower alkyl substituted by one or more groups selected from fluoro,
hydroxy, cyano or cycloalkyl, or is cyano, phenyl, benzyl or a
five- or six membered heteroaryl group in which the rings of the
heteroaryl group are optionally substituted by one or more R', or
is cycloalkyl or heterocycloalkyl, each of which is optionally
substituted by lower alkyl and hydroxy, or is hydroxy or
NR.sup.8.sub.2; [0212] L is a bond, --CR.sup.6R.sup.7--, --O--,
--NR.sup.8-- or --C(O)--; [0213] R.sup.6 and R.sup.7 are each
independently hydrogen, lower alkyl, cycloalkyl, phenyl or R.sup.6
and R.sup.7 together with the carbon atom to which they are
attached form a C.sub.3-6-cycloalkyl group, with the proviso that
R.sup.6 also is optionally hydroxy or lower alkoxy; [0214] R.sup.8
is hydrogen or lower alkyl; [0215] m is 0 or 1; and [0216] n is 3
or 4; or pharmaceutically active acid addition salts.
[0217] Preferred compounds from formula I-B are for example the
following compounds
(6-benzyl-2-chloro-pyrimidin-4-yl)-[3-methoxy-4-(4-methyl-imida-
zol-1-yl)-phenyl]-amine and
{6-[1-(4-chloro-phenyl)-cyclobutyl]-2-methyl-pyrimidin-4-yl}-[3-methoxy-4-
-(4-methyl-imidazol-1-yl)-phenyl]-amine.
[0218] Preferred are further compounds of formula
##STR00007##
wherein [0219] R.sup.1 is hydrogen, lower alkyl or lower alkyl
substituted by hydroxy; [0220] R.sup.2 is hydrogen, lower alkoxy,
lower alkyl, cyano or halogen; [0221] R.sup.3 is lower alkyl, lower
alkenyl, lower alkyl substituted by fluoro, (CH.sub.2).sub.2O-lower
alkyl, (CH.sub.2).sub.2NR.sup.8.sub.2, or is
4H-benzo[1,4]oxazin-3-one, cycloalkyl optionally substituted by
hydroxy, or is heterocycloalkyl, which heterocycloalkyl is
optionally substituted by hydroxy or S(O).sub.2-lower alkyl, or is
(CH.sub.2).sub.m-aryl or is a five- or six-membered heteroaryl
group, wherein the rings of the heteroaryl group are optionally
substituted by one or more R' for any definition of L, or [0222]
when L is a bond, the rings of the heteroaryl group are optionally
substituted by one or more halogen, hydroxy, --C(O)O-lower alkyl,
OC(O)-lower alkyl or C(O)NH.sub.2, or [0223] when L is
--CR.sup.6R.sup.7--, the rings of the heteroaryl group are
optionally substituted by one or more lower alkoxy, hydroxy,
--C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH.sub.2, or [0224]
when L is NR.sup.8, the rings of the heteroaryl group are
optionally substituted by one or more CH.sub.2--C(O)O-lower alkyl
for L being NR.sup.8, or [0225] when L is C(O), the rings of the
heteroaryl group are optionally substituted by one or more lower
alkoxy, hydroxy or NR.sup.8.sub.2 for L being C(O); [0226] R' is
halogen, lower alkyl, lower alkoxy, cyano, lower alkyl substituted
by fluoro, lower alkoxy substituted by fluoro, SF.sub.5, or is a
five-membered heteroaryl group, which is optionally substituted by
lower alkyl; [0227] Ar is a five-membered heteroaryl group or is
pyridinyl; [0228] R.sup.4 is hydrogen, halogen, lower alkyl, lower
alkoxy, C(O)O-lower alkyl, lower alkyl substituted by one or more
groups selected from fluoro, hydroxy, cyano or cycloalkyl, or are
cyano, phenyl, benzyl or a five- or six-membered heteroaryl group,
wherein the rings in the heteroaryl group are optionally
substituted by one or more R', or are cycloalkyl or
heterocycloalkyl, each of which is optionally substituted by lower
alkyl and hydroxy or is hydroxy or NR.sup.8.sub.2; [0229] L is a
bond, --CR.sup.6R.sup.7--, --O--, --NR.sup.8-- or --C(O)--; [0230]
R.sup.6 and R.sup.7 are each independently hydrogen, lower alkyl,
cycloalkyl, phenyl or R.sup.6 and R.sup.7 form together with the
carbon atom to which they are attached form a C.sub.3-6-cycloalkyl
group, with the proviso that R.sup.6 also is hydroxy or lower
alkoxy; [0231] R.sup.8 is hydrogen or lower alkyl; [0232] m is 0 or
1; and [0233] n is 3 or 4; or pharmaceutically active acid addition
salts, for example the compound
(2-benzyl-6-chloro-pyrimidin-4-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)--
phenyl]-amine.
[0234] Preferred are further compounds of formula
##STR00008##
wherein [0235] R.sup.1 is hydrogen, lower alkyl or lower alkyl
substituted by hydroxy; [0236] R.sup.2 is hydrogen, lower alkoxy,
lower alkyl, cyano or halogen; [0237] R.sup.3 is lower alkyl, lower
alkenyl, lower alkyl substituted by fluoro, (CH.sub.2).sub.2O-lower
alkyl, (CH.sub.2).sub.2NR.sup.8.sub.2, or is
4H-benzo[1,4]oxazin-3-one, cycloalkyl optionally substituted by
hydroxy, or is heterocycloalkyl, which heterocycloalkyl is
optionally substituted by hydroxy or S(O).sub.2-lower alkyl, or is
(CH.sub.2).sub.m-aryl or is a five- or six-membered heteroaryl
group, wherein the rings of the heteroaryl group are optionally
substituted by one or more R' for any definition of L, or [0238]
when L is a bond, the rings of the heteroaryl group are optionally
substituted by one or more halogen, hydroxy, --C(O)O-lower alkyl,
OC(O)-lower alkyl or C(O)NH.sub.2, or [0239] when L is
--CR.sup.6R.sup.7--, the rings of the heteroaryl group are
optionally substituted by one or more lower alkoxy, hydroxy,
--C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH.sub.2, or [0240]
when L is NR.sup.8, is CH.sub.2--C(O)O-lower alkyl, or [0241] when
L is C(O), is lower alkoxy, hydroxy or NR.sup.8.sub.2; [0242] R' is
halogen, lower alkyl, lower alkoxy, cyano, lower alkyl substituted
by fluoro, lower alkoxy substituted by fluoro, SF.sub.5, or is a
five-membered heteroaryl group, which is optionally substituted by
lower alkyl; [0243] Ar is a five-membered heteroaryl group or is
pyridinyl; [0244] R.sup.4 and R.sup.5 are each independently
hydrogen, halogen, lower alkyl, lower alkoxy, C(O)O-lower alkyl,
lower alkyl substituted by one or more groups selected from fluoro,
hydroxy, cyano and cycloalkyl, or are cyano, phenyl, benzyl or a
five- or six-membered heteroaryl group, wherein the rings of the
heteroaryl group are optionally substituted by one or more R', or
are cycloalkyl or heterocycloalkyl, each of which is optionally
substituted by lower alkyl and hydroxy', with the proviso that
R.sup.4 also is optionally hydroxy or NR.sup.8.sub.2, or wherein
R.sup.4 and R.sup.5 together with the corresponding carbon atoms to
which they are attached optionally form an additional ring with
--(CH.sub.2).sub.n; [0245] L is a bond, --CR.sup.6R.sup.7--, --O--,
--NR.sup.8-- or --C(O)--; [0246] R.sup.6 and R.sup.7 are each
independently hydrogen, lower alkyl, cycloalkyl, phenyl or R.sup.6
and R.sup.7 together with the carbon atom to which they are
attached form a C.sub.3-6-cycloalkyl group, with the proviso that
R.sup.6 also optionally is hydroxy or lower alkoxy; [0247] R.sup.8
is hydrogen or lower alkyl; [0248] m is 0 or 1; and [0249] n is 3
ro 4; or pharmaceutically active acid addition salts thereof.
[0250] Preferred compounds from this group are for example the
following compounds [0251]
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N'-phenyl-pyridine-2,6-di-
amine; [0252]
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N'-(4-trifluoromethoxy-ph-
enyl)-pyridine-2,6-diamine; [0253]
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N'-(3-trifluoromethoxy-ph-
enyl)-pyridine-2,6-diamine; [0254]
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N'-(4-pentafluorosulfanyl-
-phenyl)-pyridine-2,6-diamine; [0255]
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N'-(4-trifluoromethyl-phe-
nyl)-pyridine-2,6-diamine; [0256]
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N'-(4-trifluoromethoxy-ph-
enyl)-4-trifluoromethyl-pyridine-2,6-diamine; [0257]
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N'-(3-trifluoromethoxy-ph-
enyl)-4-trifluoromethyl-pyridine-2,6-diamine; [0258]
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-4-trifluoromethyl-N'-(4-t-
rifluoromethyl-phenyl)-pyridine-2,6-diamine; and [0259]
[2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluorometho-
xy-phenylamino)-pyridin-4-yl]-methanol.
[0260] Preferred are further compounds of formula
##STR00009##
wherein [0261] R.sup.1 is hydrogen, lower alkyl or lower alkyl
substituted by hydroxy; [0262] R.sup.2 is hydrogen, lower alkoxy,
lower alkyl, cyano or halogen; [0263] R.sup.3 is lower alkyl, lower
alkenyl, lower alkyl substituted by fluoro, (CH.sub.2).sub.2O-lower
alkyl, (CH.sub.2).sub.2NR.sup.8.sub.2, or is
4H-benzo[1,4]oxazin-3-one, cycloalkyl optionally substituted by
hydroxy, or is heterocycloalkyl, which heterocycloalkyl is
optionally substituted by hydroxy or S(O).sub.2-lower alkyl, or is
(CH.sub.2).sub.m-aryl or is a five- or six-membered heteroaryl
group, [0264] wherein the rings in the heteroaryl group are
optionally substituted by one or more R' for any definition of L,
or [0265] when L is a bond, the rings in the heteroaryl group are
optionally substituted by one or more halogen, hydroxy,
--C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH.sub.2, or [0266]
when L is --CR.sup.6R.sup.7--, the rings in the heteroaryl group
are optionally substituted by one or more lower alkoxy, hydroxy,
--C(O)O-lower alkyl, OC(O)-lower alkyl or C(O)NH.sub.2 or [0267]
when L is NR.sup.8, the rings in the heteroaryl group are
optionally substituted by one or more CH.sub.2--C(O)O-lower alkyl,
or [0268] when L is C(O), the rings in the heteroaryl group are
optionally substituted by one or more lower alkoxy, hydroxy or
NR.sup.8.sub.2; [0269] R' is halogen, lower alkyl, lower alkoxy,
cyano, lower alkyl substituted by fluoro, lower alkoxy substituted
by fluoro, SF.sub.5, or is a five-membered heteroaryl group, which
is optionally substituted by lower alkyl; [0270] Ar is a
five-membered heteroaryl group or is pyridinyl; [0271] L is a bond,
--CR.sup.6R.sup.7--, --O--, --NR.sup.8-- or --C(O)--; [0272]
R.sup.6R.sup.7 are each independently hydrogen, lower alkyl,
cycloalkyl, or phenyl or R.sup.6 and R.sup.7 together with the
carbon atom to which they are attached form a C.sub.3-6-cycloalkyl
group, with the proviso that R.sup.6 also optionally is hydroxy or
lower alkoxy; [0273] R.sup.8 is hydrogen or lower alkyl; and [0274]
m is 0 or 1; or pharmaceutically active acid addition salts
thereof.
[0275] Preferred compounds from this group are the following
compounds [0276]
[5-(4-chloro-benzyl)-4H-[1,2,4]triazol-3-yl]-[3-methoxy-4-(4-methy-
l-imidazol-1-yl)-phenyl]-amine and [0277]
[5-(4-fluoro-benzyl)-4H-[1,2,4]triazol-3-yl]-[3-methoxy-4-(4-methyl-imida-
zol-1-yl)-phenyl]-amine.
[0278] The present compounds of formula I and their
pharmaceutically acceptable salts can be prepared by methods known
in the art, for example, by processes described below, which
processes comprise
a) reacting a compound of formula
##STR00010## [0279] with a compound of formula
[0279] ##STR00011## [0280] or, alternatively, reacting a
compound
[0280] ##STR00012## [0281] with a compound of formula
[0281] ##STR00013## [0282] to obtain a compound of formula
##STR00014##
[0282] wherein the substituents have the meaning as described
above, or, alternatively, reacting a compound of formula
##STR00015##
with a compound of formula
##STR00016##
wherein R is C.sub.1-4-alkyl, to obtain a compound of formula
##STR00017##
which may be further converted to a compound I-A, or b) reacting a
compound of formula II
##STR00018##
with a compound of formula
##STR00019##
to obtain a compound of formula
##STR00020##
wherein the substituents have the meaning as described above, or c)
reacting a compound of formula
##STR00021##
with a compound of formula
##STR00022##
to obtain a compound of formula
##STR00023##
wherein the substituents have the meaning as described above, or d)
reacting a compound of formula
##STR00024##
with a compound of formula
##STR00025##
or, alternatively, a compound of formula
##STR00026##
with a compound of formula
HL-R.sup.3 XII
to obtain a compound of formula
##STR00027##
wherein the substituents have the meaning as described above, or e)
reacting a compound of formula
##STR00028##
with a compound of formula
##STR00029##
to obtain a compound of formula
##STR00030##
wherein the substituents have the meaning as described above, and
if desired, converting the compounds obtained into pharmaceutically
acceptable acid addition salts.
[0283] The detailed description can be found below and in Examples
1-238.
[0284] The preparation of compounds of formula I of the present
invention can be carried out in sequential or convergent synthetic
routes. Syntheses of the compounds of the invention are shown in
the following schemes 1 to 7. The skills required for carrying out
the reaction and purification of the resulting products are known
to those skilled in the art. The substituents and indices used in
the following description of the processes have the significance
given herein before unless indicated to the contrary.
[0285] In more detail, the compounds of formula I can be
manufactured by the methods given below, by the methods given in
the examples or by analogous methods. Appropriate reaction
conditions for the individual reaction steps are known to a person
skilled in the art. The reaction sequence is not limited to the one
displayed in the schemes, however, depending on the starting
materials and their respective reactivity the sequence of reaction
steps can be freely altered. Starting materials are either
commercially available or can be prepared by methods analogous to
the methods given below, by methods described in the examples, or
by methods known in the art.
[0286] An aniline II, a guanidine IV or a thiourea XIII can be
prepared as described in Scheme 1. Nucleophilic substitution at
room temperature or elevated temperature (e.g reflux or under
pressure using a microwave oven) under neutral conditions or in the
presence of a base (like e.g. potassium carbonate), neat or in a
polar solvent (like e.g. THF or DMSO etc.) of a substituted
4-nitro-phenyl halide XVI (hal=F, Cl, Br, I) with a compound
R.sup.1ArH, (like 4-methyl-imidazole) yields a nitro derivative XV.
The nitro derivative XV can be also obtained by a Suzuki or Stille
coupling of a 4-nitro-phenyl halide XVI (hal=Cl, Br, I) and a
corresponding aryl boronic acid or aryl tin derivative R.sup.1ArM
under palladium(0) catalysis in the presence of a base in a polar
or apolar solvent and ambient or high temperature or by Suzuki
coupling of a 4-nitro-phenyl boronic acid XVIII with a halide
R.sup.1Arhal (hal=Cl, Br, I). Alternatively, a nitro derivative XV
can be prepared from a suitable precursor, such as e.g. a carbonyl
derivative XVIII (R.dbd.H, NH.sub.2, alkoxy or C.sub.1-4-alkyl), by
applying standard reaction sequences for the formation of the
substituent ArR.sup.1. A nitro compound XV can be reduced to an
aniline II using generally known procedures, e.g. hydrogenation in
the presence of a catalyst (like e.g. 10% palladium on carbon) in a
solvent (like e.g. ethanol or ethyl acetate) or, by using a metal
(like e.g. iron) or a metal salt (like e.g. stannous chloride) in a
polar solvent (like e.g. acetic acid or tetrahydrofuran).
Alternatively, aniline II can be prepared by introducing a
substituent ArR.sup.1 into a N-protected aniline derivative XIX
(PG=protecting group) using generally known procedures, e.g.
displacement reactions under catalytic conditions (like e.g.
palladium(0) or copper(II) catalysis) or, by forming a group
ArR.sup.1 in a N-protected carbonyl derivative XX, respectively,
and subsequently cleaving off the protecting group. The aniline
derivative II can be also prepared directly in a Suzuki reaction of
the boronic acid derivative XXI with a corresponding aryl halide
R.sup.1Arhal (hal=Cl, Br, I) under palladium(0) catalysis in the
presence of a base in a polar or apolar solvent and ambient or high
temperature. A guanidine IV can be prepared from an aniline II by
reaction with cyanamide under acidic conditions (e.g. hydrochloric
acid or nitric acid) in a protic solvent (like ethanol) or, by
treatment with a carboxamidine derivative, like
3,5-dimethyl-pyrazole-1-carboxamidine, 2-methyl-isothiourea or
sulfphoguanidine, in a polar or apolar solvent, optionally in the
presence of base. A thiourea XIII can be prepared by either
reacting an aniline II with a thiophosgene derivative (like e.g.
1,1'-thiocarbonyldi-2(1H)-pyridone) followed by aminolysis with
ammonia or, by treatment of II with an acyl isothiocyanate (like
e.g. benzoyl isothiocyanate) and subsequent hydrolysis of the
intermediate formed.
##STR00031##
[0287] Heterocyclic anilines II like an oxadiazole derivative IIa
(Scheme 2) may be prepared from a corresponding ester XVIIIa by
conversion to a acylated carboxylic acid hydrazide and subsequent
cyclization to an oxadiazole XVa followed by reduction of the
latter using generally known methods as described above. Treatment
of an aldehyde XVIIIb with TosMIC (tosylmethyl isocyanide) yields
an oxazole XVb. A ketone XIIIc can be converted into a substituted
oxazole XVc by treatment with iodobenzene diacetate,
trifluoromethanesulfonic acid and a nitrile R.sup.1CN. A
thiadiazoles XVd can be prepared from a thioamide XXII in the
presence of N,N-dimethylacetamide dimethyl acetal and
hydroxyl-amine-O-sulfonic acid. A thioamide XXII can be obtained by
treatment of a corresponding amide XVIIId with Lawesson's reagent
according to known procedures. Reduction of nitro derivatives XVa-d
provides the respective anilines IIa-d.
##STR00032## ##STR00033##
[0288] Heterocyclic anilines like the pyridine derivatives IIe
(Scheme 3) may be prepared by Suzuki coupling of a boronic acid XXI
with a halide XXIII, or by Suzuki coupling of a halide XVI (hal=Cl,
Br, I) to a pyridine boronic acid or ester (like e.g. the pinacol
ester) XXIV and subsequent reduction of the nitro compound XVe.
Aryl boronic acids and esters XXIV used as starting materials are
either commercially available or readily prepared by methods known
to one skilled in the art of organic synthesis, e.g. by treatment
of the corresponding aryl bromides R.sup.1ArBr with
bis(pinacolato)diboron in the presence of a palladium catalyst.
[0289] Heterocyclic anilines like the pyrazole derivative IIf can
be prepared by Suzuki coupling of a 4-nitro-phenyl-boronic acid
XVII, or an ester thereof (like e.g.
2-(2-methoxy-4-nitro-phenyl)-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane),
with a halide XXV (like e.g. 1-methyl-4-iodo-1H-pyrazole) under
palladium(II) catalysis in the presence of a base in a polar or
apolar medium under heating.
[0290] Heterocyclic anilines like the thiazole derivative IIg can
be prepared from a halide XVI (hal=Cl, Br, I) by palladium(0) (like
e.g. palladium tetrakis-triphenylphosphine) catalyzed Heck reaction
with an alkyl substituted thiazole XXVI in the presence of a base
(like e.g. potassium acetate) in a polar solvent (like e.g.
N,N-dimethylacetamide) under heating (e.g. to reflux or in a
microwave oven) and subsequent reduction of the nitro group.
##STR00034## ##STR00035##
[0291] Compounds of formula I-A (Scheme 4) can be prepared by
firstly converting a ketone XXIX to an enamine V or a diketone VI,
respectively, followed by condensating these intermediates with a
guanidine IV (Scheme 2). A ketone XXVIII can be prepared by
generally known methods, e.g. by treating a nitrile XXVII in an
inert solvent (like toluene) with a solution of a Grignard reagent
(like methylmagnesium chloride in tetrahydrofuran) at temperatures
from 20 to 100.degree. C.). Preparation of an enamine V can be
achieved by reaction of XXVIII with an aminal of DMF (like
N,N-diemethylformamide dimethyl acetal or Bredereck's reagent
(tert.-butoxy-bis(dimethylamino)methane)). A diketone VI can be
prepared from a ketone XXVIII by known methods, e.g. by reaction
with a carboxylic acid ester in the presence of a strong base (like
sodium hydride, potassium tert.-butoxide, lithium diisopropylamide)
in a polar or apolar solvent (like ethanol, tetrahydrofuran or
toluene). Condensation of the guanidine IV with an enamine V or a
ketone VI in a polar or unpolar solvent, optionally in the presence
of base (like triethylamine), at temperatures from 20 to
150.degree. C., optionally using an microwave oven at 100 to
250.degree. C., yields the pyrimidine I-A. Alternatively, compounds
of structure I-A can be prepared by reacting a keto-ester VII with
a guanidine IV and subsequently converting the resulting pyrimidine
XXIX to a compound I-A by further reactions on the hydroxy
substituent of the pyrimidine ring, e.g by preparing a
corresponding chloro-pyrimidine which can be converted to a
compound I-A carrying a specific group R.sup.4. A keto-ester VII
can be prepared from a ketone XXVIII by known methods, e.g. by
reaction with a dialkyl carbonate (like diethyl carbonate) in the
presence of a strong base (like sodium hydride) in an aprotic
solvent (like tetrahydrofuran or N,N-dimethylformamide).
##STR00036##
[0292] Further route for the preparation of compounds of formula
I-A consists in reacting a 2-chloro-pyrimidine III with an aniline
II (Scheme 5). In an analogous manner, compounds of formula I-B and
I-C can be prepared by reacting an aniline II with a
chloro-pyridine VIII or IX, respectively. The intermediates III,
VIII and IX can be prepared by generally known methods. A
trichloro-pyrimidine XXX can first be reduced to a
dichloro-derivative XXXI, e.g. by treatment with zink in aquous
ammonia at 0.degree. C., and subsequently, the 4-chloro substituent
of XXXI is replaced by a group HL-R.sup.3 using a nucleophilic
substitution reaction (like reaction with a Grignard reagent, e.g.
benzylmagnesium chloride in tetrahydrofuran at -80 to +20.degree.
C.) or, by a metal catalyst assisted displacement reaction (e.g.
using palladium acetate, 2-(dicyclohexylphosphino-biphenyl,
tetrahydrofuran, microwave oven, 30 min, 200.degree. C.).
Alternatively, one of the reactive chloro atoms of XXX is first
replaced by a group Q-R.sup.3, followed by replacement of a second
chloro-substituent in the intermediate XXXII by a group R.sup.4, to
afford III. A chloro-pyrimidine VIII is prepared by replacement of
one chloro atom by a group HL-R.sup.3, analogously as described for
the preparation of III. In analogous manner, a chloro-pyrimidine IX
is prepared by replacement of one chloro atom of a compound XXXIV
by a group R.sup.4. The coupling of intermediates III, VIII, and
IX, respectively, with an aniline II is accomplished by applying a
metal catalyst assisted displacement reaction (e.g. using palladium
acetate, 2-(dicyclohexylphosphino-biphenyl, potassium carbonate,
dioxane, microwave oven, 30 min, 200.degree. C.).
##STR00037##
[0293] The preparation of a compound of formula I-D (Scheme 6) can
be achieved by reacting a 1,6-dichloro-pyridine XXX with a compound
HL-R.sup.3 (XII) followed by coupling of the resulting intermediate
X with an aniline II. Alternatively, a compound XXX is at first
coupled to an aniline II and the resulting chloro-pyridine XI is
then reacted with XII. The chloro displacement reactions used in
these syntheses can be achieved by thermal nucleophilic
displacement reactions, preferably in the presence of a suitable
catalyst (like an Pd(0) compound).
##STR00038##
[0294] For the preparation of a compound I-E (Scheme 7), a thiourea
XIII is converted to a reactive derivative, such as a thio-amidino
ether hydroiodide XXXVI which can be obtained by the treatment of
XIII with methyl iodide in acetone at 20.degree. C. Condensation of
XXXVI with a carboxylic acid hydrazide XIV, e.g. by heating the two
components in a polar solvent (like ethanol), affords compounds
I-E.
##STR00039##
[0295] The compounds were investigated in accordance with the test
given hereinafter.
Cellular Assay
[0296] Human neuroglioma H4 cells overexpressing human APP were
plated at 30,000 cells/well/200 .mu.l in 96-well plates in IMDM
media containing 10% FCS, 0.2 mg/l Hygromycin B and incubated for 2
h at 37.degree. C., 5% CO.sub.2 prior to adding test compounds.
[0297] Compounds for testing were dissolved in 100% Me.sub.2SO
yielding in a 10 mM stock solution. Typically 12 .mu.l of these
solutions were further diluted in 1000 .mu.l of IMDM media (w/o
FCS). Sub sequential 1:1 dilutions gave a ten point dose response
curve. 100 .mu.l of each dilution was added to the cells in 96-well
plates. Appropriate controls using vehicle only and reference
compound were applied to this assay. The final concentration of
Me.sub.2SO was 0.4%.
[0298] After incubation for 22 hrs at 37.degree. C., 5% CO.sub.2,
50 .mu.l supernatant was transferred into round-bottom 96-well
polypropylene plates for detection of A.beta.42. 50 .mu.l assay
buffer (50 mM Tris/Cl, pH 7.4, 60 mM NaCl, 0.5% BSA, 1% TWEEN 20)
was added to the wells followed by the addition of 100 .mu.l of
detection antibody (ruthenylated A.beta.42-specific antibody BAP15
0.0625 .mu.g/mL in assay buffer). 50 .mu.l of a premix of capture
antibody (biotinylated 6E10 antibody, 1 .mu.g/mL) and
Steptavidin-coated magnetic beads (Dynal M-280, 0.125 mg/mL) were
preincubated for 1 hr at room temperature before adding the assay
plates. Assay plates were incubated on a shaker for 3 hrs at room
temperature and finally read in the Bioveris M8 Analyser according
to the manufacturer's instructions (Bioveris).
[0299] Toxicity of compounds was monitored by a cell viability test
of the compound-treated cells using a calorimetric assay (CellTiter
96.TM. AQ assay, Promega) according to the manufacturer's
instructions. Briefly, after removal of 50 .mu.l cell culture
supernatant for detection of A.beta.42, 20 .mu.l of 1.times.MTS/PES
solution was added to the cells and incubated for 30 min at
37.degree. C., 5% CO.sub.2. Optical density was then recorded at
490 nm.
[0300] IC.sub.50 values for inhibition of A.beta.42 secretion were
calculated by nonlinear regression fit analysis using XLfit 4.0
software (IDBS).
[0301] The preferred compounds show an IC.sub.50<0.5 (nM). In
the list below are described some data to the .gamma.-secretase
inhibition:
TABLE-US-00001 Example No./ IC.sub.50 in vitro Formula (nM) 1/I-A
0.22 2/I-A 0.21 3/I-A 0.24 5/I-A 0.20 9/I-A 0.19 11/I-A 0.23 12/I-A
0.38 13/I-A 0.43 16/I-A 0.21 17/I-A 0.30 18/I-A 0.23 19/I-A 0.46
20/I-A 0.44 21/I-A 0.47 22/I-A 0.49 28/IA 0.49 38/I-A 0.32 43/I-A
0.15 46/I-A 0.27 47/I-A 0.19 61/I-A 0.50 62/I-B 0.98 64/I-B 0.67
65/I-C 2.51 70/I-D 0.26 72/I-E 0.10 73/I-E 0.22 75/I-A 0.31 76/I-A
0.49 81/I-A 0.34 82/I-A 0.48 88/I-A 0.39 90/I-A 0.17 91/I-A 0.07
92/I-A 0.45 94/I-A 0.32 95/I-A 0.42 97/I-A 0.2 104/I-A 0.42 105/I-A
0.44 106/I-A 0.12 108/I-A 0.28 109/I-A 0.32 112/I-A 0.32 113/I-A
0.22 115/I-A 0.4 116/I-A 0.36 117/I-A 0.15 118/I-A 0.27 119/I-A
0.11 120/I-A 0.16 121/I-A 0.25 122/I-A 0.46 131/I-A 0.32 134/I-A
0.38 136/I-A 0.29 137/I-A 0.43 140/I-A 0.18 145/I-A 0.39 146/I-A
0.3 147/I-A 0.25 149/I-A 0.26 150/I-A 0.23 152/I-A 0.22 153/I-A
0.21 154/I-A 0.43 155/I-A 0.13 156/I-A 0.41 157/I-A 0.13 159/I-A
0.12 161/I-A 0.28 162/I-A 0.17 163/I-A 0.36 164/I-A 0.21 165/I-A
0.23 166/I-A 0.28 167/I-A 0.07 168/I-A 0.06 169/I-A 0.17 170/I-A
0.32 172/I-A 0.45 173/I-A 0.09 174/I-A 0.1 175/I-A 0.1 176/I-A 0.47
179/I-A 0.08 180/I-A 0.14 181/I-A 0.09 182/I-A 0.26 183/I-A 0.43
187/I-D 0.22 188/I-D 0.24 189/I-D 0.31 192/I-D 0.27 196/I-D 0.28
197/I-D 0.45 198/I-D 0.31 202/I-D 0.33 205/I-A 0.49 209/I-A 0.43
218/I-A 0.36 220/I-A 0.37 221/I-A 0.34 223/I-A 0.34 226/I-A 0.13
228/I-A 0.18 233/I-A 0.29 234/I-A 0.22 235/I-A 0.28 236/I-A 0.45
237/I-A 0.5
[0302] The present invention also provides pharmaceutical
compositions containing compounds of the invention, for example,
compounds of formula I or pharmaceutically acceptable salts thereof
and a pharmaceutically acceptable carrier. Such pharmaceutical
compositions can be in the form of tablets, coated tablets,
dragees, hard and soft gelatin capsules, solutions, emulsions or
suspensions. The pharmaceutical compositions also can be in the
form of suppositories or injectable solutions.
[0303] The pharmaceutical compositions of the invention, in
addition to one or more compounds of the invention, contain a
pharmaceutically acceptable carrier. Suitable pharmaceutically
acceptable carriers include pharmaceutically inert, inorganic or
organic carriers. Lactose, corn starch or derivatives thereof,
talc, stearic acids or its salts and the like can be used, for
example, as such carriers for tablets, coated tablets, dragees and
hard gelatine capsules. Suitable carriers for soft gelatine
capsules are, for example, vegetable oils, waxes, fats, semi-solid
and liquid polyols and the like. Depending on the nature of the
active substance no carriers are, however, usually required in the
case of soft gelatine capsules. Suitable carriers for the
production of solutions and syrups are, for example, water,
polyols, glycerol, vegetable oil and the like. Suitable carriers
for suppositories are, for example, natural or hardened oils,
waxes, fats, semi-liquid or liquid polyols and the like.
[0304] The pharmaceutical composition can, moreover, contain
preservatives, solubilizers, stabilizers, wetting agents,
emulsifiers, sweeteners, colorants, flavorants, salts for varying
the osmotic pressure, buffers, masking agents or antioxidants. They
can also contain still other therapeutically valuable
substances.
[0305] The present invention also provides a method for the
manufacture of pharmaceutical compositions. Such process comprises
bringing one or more compounds of formula I and/or pharmaceutically
acceptable acid addition salts thereof and, if desired, one or more
other therapeutically valuable substances into a galenical
administration form together with one or more therapeutically inert
carriers.
[0306] In accordance with the invention compounds of formula I as
well as their pharmaceutically acceptable salts are useful in the
control or prevention of illnesses based on the inhibition of the
.gamma.-secretase, such as of Alzheimer's disease.
[0307] The dosage at which compounds of the invention can be
administered can vary within wide limits and will, of course, have
to be adjusted to the individual requirements in each particular
case. In the case of oral administration the dosage for adults can
vary from about 0.01 mg to about 1000 mg per day of a compound of
general formula I or of the corresponding amount of a
pharmaceutically acceptable salt thereof. The daily dosage may be
administered as single dose or in divided doses and, in addition,
the upper limit can also be exceeded when this is found to be
indicated.
TABLE-US-00002 Tablet Formulation (Wet Granulation) mg/tablet Item
Ingredients 5 mg 25 mg 100 mg 500 mg 1. Compound of formula I 5 25
100 500 2. Lactose Anhydrous DTG 125 105 30 150 3. Sta-Rx 1500 6 6
6 30 4. Microcrystalline Cellulose 30 30 30 150 5. Magnesium
Stearate 1 1 1 1 Total 167 167 167 831
Manufacturing Procedure
[0308] 1. Mix items 1, 2, 3 and 4 and granulate with purified
water. 2. Dry the granules at 50.degree. C. 3. Pass the granules
through suitable milling equipment. 4. Add item 5 and mix for three
minutes; compress on a suitable press.
TABLE-US-00003 Capsule Formulation mg/capsule Item Ingredients 5 mg
25 mg 100 mg 500 mg 1. Compound of formula I 5 25 100 500 2.
Hydrous Lactose 159 123 148 -- 3. Corn Starch 25 35 40 70 4. Talc
10 15 10 25 5. Magnesium Stearate 1 2 2 5 Total 200 200 300 600
Manufacturing Procedure
[0309] 1. Mix items 1, 2 and 3 in a suitable mixer for 30 minutes.
2. Add items 4 and 5 and mix for 3 minutes. 3. Fill into a suitable
capsule.
EXAMPLE 1
(4-Benzyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-am-
ine
##STR00040##
[0310] a) 1-(2-Methoxy-4-nitro-phenyl)-4-methyl-1H-imidazole
[0311] A solution of 2-chloro-5-nitroanisole (187 mg, 1 mmol), of
4-methyl-1H-imidazole (335 mg, 4 mmol) and of potassium hydroxide
(99 mg, 1.5 mmol) in DMSO (0.86 mL) was stirred for 5 h at
80.degree. C. under an atmosphere of nitrogen. After cooling to
20.degree. C. the reaction was poured onto ice-water. A
precipitation was formed and the suspension was stirred for 15 min.
The solid was filtered off, washed with water, dissolved in
dichloromethane, dried over sodium sulfate, filtered and the
solvent was evaporated under reduced pressure to yield a yellow
solid. The crude product was purified on silica gel using
dichloromethane/methanol (19:1 v/v) as eluent to yield the title
compound (106 mg, 45%) as a pale-yellow solid. Alternatively the
product can be also crystallized from the crude material from
diethyl ether.
[0312] MS ISP (m/e): 234.3 (100) [(M+H).sup.+].
[0313] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=7.97 (d,
1H), 7.96 (s, 1H), 7.83 (s, 1H), 7.42 (d, 1H), 7.00 (s, 1H), 4.00
(s, 3H), 2.31 (s, 3H).
b) 3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine
[0314] 1-(2-Methoxy-4-nitro-phenyl)-4-methyl-1H-imidazole (2.52 g,
10.8 mmol) dissolved in ethanol (110 mL) was stirred under an
atmosphere of hydrogen at 20.degree. C. for 3.5 h in the presence
of 10% palladium on charcoal (0.25 g). The catalyst was filtered
off and washed with ethanol. The solvent of the filtrate was
evaporated under reduced pressure. The crude product was purified
on silica gel using dichloromethane/methanol (19:1 v/v) as eluent.
The fraction containing the product was suspended in diethyl ether,
stirred for 15 min, filtered and dried to yield the title compound
(1.72 g, 78%) as a yellow solid.
[0315] MS ISP (m/e): 204.3 (100) [(M+H).sup.+].
[0316] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=7.48 (s,
1H), 6.91 (d, 1H), 6.88 (s, 1H), 6.35 (s, 1H), 6.17 (d, 1H), 3.68
(s, 3H), 2.11 (s, 3H).
c) 6-Benzyl-2,4-dichloro-pyrimidine
[0317] To a solution of 2,4,6-trichloropyrimidine (936 mg, 5.0
mmol) in tetrahydrofuran (50 mL) was added at -78.degree. C. under
an atmosphere of nitrogen and stirring drop wise 1 M
benzylmagnesium chloride solution in diethyl ether (5 mL, 5.0
mmol). The reaction was let to warm up to 20.degree. C. over 16 h.
The solvent was removed under reduced pressure and the residue was
dissolved in water. The aqueous layer was extracted twice with
dichloromethane. The combined organic layers were washed once with
brine, dried over sodium sulfate, filtered and the solvent was
removed under reduced pressure. The residue was purified by column
chromatography on silica gel using heptane and then heptane/ethyl
acetate (9:1 v/v) as eluent to yield the title compound (778 mg,
65%) as a pale-yellow viscous oil.
[0318] MS ISP (m/e): 238.9/241.0 (100/70) [(M+H).sup.+].
[0319] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=7.73 (s,
1H), 7.26-7.34 (m, 5H), 4.12 (s, 2H).
d) 4-Benzyl-2-chloro-pyrimidine
[0320] To an emulsion of 6-benzyl-2,4-dichloro-pyrimidine (239 mg,
1 mmol) in 25% aqueous ammonia solution (1 mL) was added after
stirring for 10 min at 0.degree. C. zinc powder (82 mg, 1.25 mmol).
The reaction was stirred at 20.degree. C. for 16 h. The yellow
suspension was diluted with ethyl acetate an insoluble material was
filtered off. The layers were separated and the aqueous layer was
extracted with ethyl acetate. The combined organic layers were
washed with brine, dried over sodium sulfate and evaporated under
reduced pressure to yield the crude title compound (210 mg, 92%) as
a yellow oil.
[0321] MS EI (m/e): 203.1/204.2 (100/50) [M.sup.+].
[0322] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=8.66 (d,
1H), 7.73 (d, 1H), 7.25-7.45 (m, 5H), 4.11 (s, 2H).
e)
(4-Benzyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-
-amine
[0323] Palladium acetate (2.7 mg, 0.012 mmol) and
2-(dicyclohexylphosphino)-biphenyl (8.7 mg, 0.024 mmol) were
dissolved under an atmosphere of nitrogen in dioxane (1 mL) and
stirred for 10 min at 20.degree. C. This solution was added at
20.degree. C. under an atmosphere of nitrogen to a microwave flask
containing 3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (61 mg,
0.3 mmol), 4-benzyl-2-chloro-pyrimidine (68 mg, 0.3 mmol) and
potassium carbonate (829 mg, 6.0 mmol). The mixture was diluted
with dioxane (1.7 mL) and heated for 30 min to 200.degree. C. in a
microwave oven. The reaction was poured onto water and extracted
twice with ethyl acetate. The combined organic solutions were
washed with brine, dried over sodium sulfate, filtered and the
residue was purified by column chromatography on silica gel using
dichloromethane/methanol (19:1 v/v) as eluent to yield the title
compound (50 mg, 45%) as a yellow solid.
[0324] MS ISP (m/e): 372.2 (100) [(M+H).sup.+].
[0325] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=9.77 (s,
1H), 8.41 (d, 1H), 7.83 (s, 1H), 7.65 (s, 1H), 7.18-7.39 (m, 7H),
7.02 (s, 1H), 6.79 (d, 1H), 4.00 (s, 2H), 3.73 (s, 3H), 2.14 (s,
3H).
EXAMPLE 2
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-(3,4,5-trifluoro-benzyl)--
pyrimidin-2-yl]-amine
##STR00041##
[0326] a) 2,4-Dichloro-6-(3,4,5-trifluoro-benzyl)-pyrimidine
[0327] To a suspension of magnesium (0.24 g, 10.0 mmol) in diethyl
ether (15 mL) 3,4,5-trifluorobenzylbromide (1.69 g, 9.0 mmol) was
added drop wise. The reaction was started with little iodine and
heated to reflux for 2 h. To a solution of
2,4,6-trichloropyrimidine (2.32 g, 10.0 mmol) in tetrahydrofuran
(90 mL) was added the above prepared Grignard solution at
-78.degree. C. under an atmosphere of nitrogen. The reaction was
continued as described in example 1d) to yield the title compound
(0.39 g, 15%) as a pale-yellow solid. .sup.1H NMR (DMSO-D.sub.6,
300 MHz): .delta. (ppm)=7.74 (s, 1H), 7.32 (m, 2H), 4.14 (s,
2H).
b) 2-Chloro-4-(3,4,5-trifluoro-benzyl)-pyrimidine
[0328] The title compound was prepared from
2,4-dichloro-6-(3,4,5-trifluoro-benzyl)-pyrimidine in analogous
manner as described in example 1d). It was obtained in 54% yield as
a yellow oil.
[0329] MS ISN (m/e): 257.0/258.9 (100/30) [(M-H).sup.-].
[0330] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=8.69 (d,
1H), 7.47 (d, 1H), 7.31 (m, 2H), 4.14 (s, 2H).
c)
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-(3,4,5-trifluoro-benzy-
l)-pyrimidin-2-yl]-amine
[0331] The title compound was prepared in analogous manner as
described in example 1e) from
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and
4-(3,4,5-trifluoro-benzyl)-2-chloro-pyrimidine. It was obtained as
a pale-brown solid in 54% yield.
[0332] MS ISP (m/e): 426.2 (100) [(M+H).sup.+].
[0333] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=9.77 (s,
1H), 8.45 (d, 1H), 7.76 (s, 1H), 7.65 (s, 1H), 7.40 (d, 1H), 7.32
(t, 2H), 7.19 (d, 1H), 7.02 (s, 1H), 6.81 (d, 1H), 4.02 (s, 2H),
3.76 (s, 3H), 2.14 (s, 3H).
EXAMPLE 3
[4-(3-Chloro-benzyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-
-phenyl]-amine
##STR00042##
[0334] a) 2,4-Dichloro-6-(3-chloro-benzyl)-pyrimidine
[0335] The title compound was prepared in analogous manner as
described in example 2a) from 3-chloro-benzylbromide and
2,4,6-trichloropyrimidine. It was obtained as a pale-yellow oil in
26% yield.
[0336] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=7.77 (s,
1H), 7.27-7.43 (m, 4H), 4.14 (s, 2H).
b) 2-Chloro-4-(3-chloro-benzyl)-pyrimidine
[0337] The title compound was prepared in analogous manner as
described in example 1d) from
2,4-dichloro-6-(3-chloro-benzyl)-pyrimidine. It was obtained in 31%
yield as a yellow oil. .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta.
(ppm)=8.68 (d, 1H), 7.49 (d, 1H), 7.26-7.42 (m, 4H), 4.14 (s,
2H).
c)
[4-(3-Chloro-benzyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1--
yl)-phenyl]-amine
[0338] The title compound was prepared in analogous manner as
described in example 1e) from
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and
2-chloro-4-(3-chloro-benzyl)-pyrimidine. It was obtained as a
yellow solid in 55% yield.
[0339] MS ISP (m/e): 406.3/408.3 (100/29) [(M+H).sup.+].
[0340] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=9.78 (s,
1H), 8.43 (d, 1H), 7.79 (s, 1H), 7.65 (s, 1H), 7.27-7.42 (m, 5H),
7.18 (d, 1H), 7.02 (s, 1H), 6.83 (d, 1H), 4.02 (s, 2H), 3.74 (s,
3H), 2.14 (s, 3H).
EXAMPLE 4
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-(1-phenyl-cyclohexyl)-pyr-
imidin-2-yl]-amine
##STR00043##
[0341] a) 3-Dimethylamino-1-(1-phenyl-cyclohexyl)-propenone
[0342] Acetyl-1-phenylcyclohexane (101 mg, 0.5 mmol) was heated in
dimethyl formamide dimethyl acetale (0.8 mL) for 16 h to
110.degree. C. under an atmosphere of nitrogen. The reaction was
evaporated to dryness under reduced pressure and was twice
evaporated with toluene to yield the crude title compound (126 mg,
98%) as a yellow semi-solid which was used without further
purification in the next step.
[0343] MS ISP (m/e): 331.4 (79) [(M+H).sup.+], 275.1 (100)
[(M-isubutene+H).sup.+].
b) N-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine
dinitrate
[0344] To a solution of
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (5.08 g, 25.0
mmol) in ethanol (25 mL) was added at 20.degree. C. cyanamide (3.15
g, 75 mmol) dissolved in water (3.2 mL) and then 37% aqueous
hydrochloric acid solution (4.9 g, 50 mmol). The solution was
heated for 3 h to reflux. Additional cyanamide (2.1 g) in water
(2.1 mL) and 37% aq hydrochloric acid solution (2.8 mL) were added
and the mixture was heated to reflux for another 2 h. At 20.degree.
C. 65% aqueous nitric acid (3.5 mL, 50 mmol) was added. The
reaction was stirred for 30 minute at 20.degree. C. and the formed
precipitate was filtered off, washed with ethanol and diethyl
ether. (Caution: the filtrate may contain the ethyl ester of nitric
acid). The solid was dried under reduced pressure at 20.degree. C.
to yield the title compound (5.42 g, 58%) as a white solid.
[0345] MS ISP (m/e): 246.1 (100) [(M+H).sup.+].
[0346] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=10.17 (s,
1H), 9.34 (s, 1H), 8.40 (br s, 2H), 7.67 (br s, 4H), 7.63 (d, 1H),
7.21 (s, 1H), 6.99 (d, 1H), 3.88 (s, 3H), 2.35 (s, 3H).
[0347] c)
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-(1-phenyl-cyclo-
hexyl)-pyrimidin-2-yl]-amine
[0348] N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine
dinitrate (74 mg, 0.20 mmol), crude
3-dimethylamino-1-(1-phenyl-yclohexyl)-propenone (124 mg, 0.48
mmol) and triethylamine (41 mg, 0.40 mmol) in ethanol (2 mL) were
heated to reflux under an atmosphere of nitrogen for 16 h. The
reaction was transferred with 1-methyl-2-pyrrolidone (3 mL) into a
microwave tube and additional triethylamine (41 mg) was added. The
reaction was heated to 200.degree. C. for 30 min, which yields only
traces of product. Therefore the reaction was heated to 250.degree.
C. in the microwave oven, but decomposition of the starting
material occurred. The reaction was poured onto water, extracted
twice with diethyl ether. The combined organic layers were washed
with water and brine, dried over sodium sulfate, filtered and the
solvent was removed under reduced pressure. The residue was
purified by column chromatography on silica gel using
dichloromethane/methanol (19:1 v/v) as eluent to yield the title
compound (6 mg, 7%) as a pale-brown solid.
[0349] MS ISP (m/e): 440.3 [(M+H).sup.+].
[0350] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=8.27 (d,
1H), 7.79 (s, 1H), 7.64 (s, 1H), 7.15-7.39 (m, 6H), 7.03 (d, 1H),
6.88 (s, 1H), 6.62 (d, 1H), 3.86 (s, 3H), 2.55 (m, 2H), 2.30 (s,
3H), 2.40 (m, 2H), 1.20-1.70 (m, 6H).
EXAMPLE 5
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[5-methyl-4-(1-phenyl-ethyl)-
-pyrimidin-2-yl]-amine
##STR00044##
[0351] a) 1-Dimethylamino-2-methyl-4-phenyl-pent-1-en-3-one
[0352] A mixture of 2-phenyl-3-pentanone (106 mg, 0.54 mmol) and of
tert.-butoxy-bis(dimethylamino)methane (146 mg, 0.75 mmol, 90%) was
stirred at 110.degree. C. for 16 h. The reaction was evaporated to
dryness, treated twice with toluene and the solvent was evaporated
under reduced pressure to give the crude title compound (138 mg,
97%) as a dark brown solid which was used directly in the next step
without further purification.
[0353] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=7.15-7.31
(m, 6H), 4.21 (q, 1H), 3.00 (s, 6H), 1.94 (s, 3H), 1.41 (d,
3H).
[0354] b)
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[5-methyl-4-(1-phe-
nyl-ethyl)-pyrimidin-2-yl]-amine
[0355] The title compound was prepared in analogous manner
described in example 4c) from
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine
dinitrate, 1-dimethylamino-2-methyl-4-phenyl-pent-1-en-3-one and
triethylamine using 1-methyl-2-pyrrolidinone as the solvent. The
reaction was performed in a microwave at 200.degree. C. for 30 min.
The title compound was isolated as a pale-yellow solid in 39%
yield.
[0356] MS ISP (m/e): 400.3 (100) [(M+H).sup.+].
[0357] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=9.64 (s,
1H), 8.22 (s, 1H), 7.90 (s, 1H), 7.66 (s, 1H), 7.42 (d, 1H),
7.15-7.32 (m, 6H), 7.03 (s, 1H), 4.38 (q, 1H), 3.78 (s, 3H), 2.14
(s, 3H), 2.07 (s, 3H), 1.63 (d, 3H).
EXAMPLE 6
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-{4-[1-(3-methoxy-phenyl)-1-m-
ethyl-ethyl]-pyrimidin-2-yl}-amine
##STR00045##
[0358] a)
1-Dimethylamino-4-(3-methoxy-phenyl)-4-methyl-pent-1-en-3-one
[0359] The title compound was prepared from
3-(3-methoxy-phenyl)-3-methyl-butan-2-one in analogous manner as
described in example 5a) as a yellow viscous oil in 99% yield and
was used without further purification in the next step.
[0360] MS ISP (m/e): 248.2 (100) [(M+H).sup.+].
[0361] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=7.54 (d,
1H), 7.21 (t, 1H), 6.91 (d, 1H), 6.88 (s, 1H), 6.73 (d, 1H), 4.75
(d, 1H), 3.80 (s, 3H), 2.50-3.15 (br s, 6H), 1.48 (s, 3H).
b)
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-{4-[1-(3-methoxy-phenyl)--
1-methyl-ethyl]-pyrimidin-2-yl}-amine
[0362] The title compound was prepared in analogous manner as
described in example 4c) from
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine
dinitrate,
1-dimethylamino-4-(3-methoxy-phenyl)-4-methyl-pent-1-en-3-one and
triethylamine using 1-methyl-pyrrolidinone as the solvent. The
reaction was performed in a microwave at 200.degree. C. for 2.5 h.
The title compound was isolated as a brown viscous oil in 44%
yield.
[0363] MS ISP (m/e): 430.3 (100) [(M+H).sup.+].
[0364] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=9.74 (s,
1H), 8.41 (d, 1H), 7.85 (s, 1H), 7.64 (s, 1H), 7.29 (d, 1H), 7.23
(t, 1H), 7.19 (d, 1H), 7.02 (s, 1H), 6.80-6.82 (m, 3H), 6.73 (d,
1H), 3.71 (s, 6H), 2.14 (s, 3H), 1.68 (s, 6H).
EXAMPLE 7
{4-[1-(4-Chloro-phenyl)-cyclopropyl]-pyrimidin-2-yl}-[3-methoxy-4-(4-methy-
l-imidazol-1-yl)-phenyl]-amine
##STR00046##
[0365] a) 1-[1-(4-Chloro-phenyl)-cyclopropyl]-ethanone
[0366] To a solution of
1-(4-chlorophenyl)-1-cyclopropanecarbonitrile (181 mg, 1.0 mmol) in
toluene (5 mL) was added drop wise at 20.degree. C. under an
atmosphere of nitrogen a 3 M solution of methylmagnesium chloride
in tetrahydrofuran (0.5 mL, 1.5 mmol). The reaction was heated for
16 h to 80.degree. C. In an ice bath 6 N aqueous hydrochloric acid
solution (1.08 mL) was added carefully and the reaction was heated
to reflux for 2 h. The reaction was diluted with toluene, extracted
once with water, once with brine, dried over sodium sulfate,
filtered and the solvent was evaporated under reduced pressure. The
residue was purified by column chromatography on silica gel using
heptane/ethyl acetate (9:1 v/v) as eluent to yield the title
compound (67 mg, 34%) as a yellow oil.
[0367] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=7.31 (m,
4H), 2.00 (s, 3H), 1.61 (q, 2H), 1.15 (q, 2H).
b)
1-[1-(4-Chloro-phenyl)-cyclopropyl]-3-dimethylamino-propenone
[0368] The title compound was prepared from
1-[1-(4-chloro-phenyl)-cyclopropyl]-ethanone in analogous manner as
described in example 5a) as a pale-yellow viscous oil in 99% yield
and was used without further purification in the next step.
[0369] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=7.52 (d,
1H), 7.26-7.33 (m, 4H), 6.73 (d, 1H), 4.71 (d, 1H), 3.00 (br s,
3H), 2.65 (br s, 3H), 1.59 (m, 2H), 1.00 (m, 2H).
c)
{4-[1-(4-Chloro-phenyl)-cyclopropyl]-pyrimidin-2-yl}-[3-methoxy-4-(4-me-
thyl-imidazol-1-yl)-phenyl]-amine
[0370] The title compound was prepared in analogous manner as
described in example 4c) from
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine
dinitrate,
1-[1-(4-chloro-phenyl)-cyclopropyl]-3-dimethylamino-propenone and
triethylamine using 1-methyl-2-pyrrolidine as the solvent. The
reaction was performed in a microwave at 200.degree. C. for 2.5 h.
The title compound was isolated as a brown viscous oil in 22%
yield.
[0371] MS ISP (m/e): 432.3/434.3 (100/39) [(M+H).sup.+].
[0372] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=9.73 (s,
1H), 8.25 (d, 1H), 7.84 (s, 1H), 7.66 (s, 1H), 7.47 (d, 2H), 7.43
(d, 2H), 7.26 (d, 1H), 7.20 (d, 1H), 7.04 (s, 1H), 6.18 (d, 1H),
3.82 (s, 3H), 2.14 (s, 3H), 1.75 (m, 2H), 1.38 (m, 1H).
EXAMPLE 8
(4-Chloro-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-p-
henyl]-amine
##STR00047##
[0373] a)
2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-py-
rimidin-4-ol
[0374] To a solution of sodium ethoxide (724 mg, 13 mmol) in
methanol (60 mL) was added at 20.degree. C. under an atmosphere of
nitrogen N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine
dinitrate (2.10 g, 5.7 mmol) and ethyl acetoacetate (2.43 g, 18.7
mmol). The reaction was heated to reflux for 40 h. After cooling it
was poured onto water and set to pH 7 with 1N aqueous hydrochloric
acid solution. The precipitate was filtered off, washed with water
and diethyl ether, and dried in high vacuum for 16 h at 45.degree.
C. to yield the title compound (146 g, 83%) as a white solid.
[0375] MS ISP (m/e): 312.2 (100) [(M+H).sup.+].
[0376] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=7.83 (br
s, 1H), 7.67 (s, 1H), 7.25 (s, 2H), 7.04 (s, 1H), 5.77 (s, 1H),
3.80 (s, 3H), 2.17 (s, 3H), 2.14 (s, 3H).
b)
(4-Chloro-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl-
)-phenyl]-amine
[0377] A solution of
2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimidin-4-
-ol (1.45 g (46.6 mmol) in phosphorous oxychloride (4.7 mL) was
heated to reflux for 2 h. The excess of phosphorous oxychloride was
evaporated under reduce pressure and the residue was treated
carefully with ice and then, under ice cooling, with 25% aqueous
ammonia. The precipitate formed was filtered off, washed with water
and then with diethyl ether and dried to give the title compound
(1.53 g, 100%) as a pale-brown solid.
[0378] MS ISP (m/e): 330.1/332.2 (100/25) [(M+H).sup.+].
[0379] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=10.16 (s,
1H), 7.81 (s, 1H), 7.67 (s, 1H), 7.36 (d, 1H), 7.27 (d, 1H), 7.05
(s, 1H), 6.95 (s, 1H), 3.80 (s, 3H), 2.40 (s, 3H), 2.14 (s,
3H).
EXAMPLE 9
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(3,4,5-trifluoro-
-phenoxy)-pyrimidin-2-yl]-amine
##STR00048##
[0381] To a solution of 3,4,5-trifluorophenol (33 mg, 0.22 mmol) in
1-methyl-2-pyrrolidone (2 mL) was added at 20.degree. C. under an
atmosphere of nitrogen a 55% dispersion of sodium hydride in oil
(10 mg, 0.22 mmol). The reaction was stirred for 30 min and then,
(4-chloro-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)--
phenyl]-amine (66 mg, 0.2 mmol) was added. The mixture was heated
in a microwave oven to 200.degree. C. for 30 min and then poured
onto 1 N aqueous sodium hydroxide solution. The mixture was stirred
for 15 min, and the precipitate formed was filtered off, washed
with water and dried to yield the title compound (72 mg, 8%) as a
pale-brown solid.
[0382] MS ISP (m/e): 442.2 (100) [(M+H).sup.+].
[0383] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=9.74 (s,
1H), 7.63 (s, 1H), 7.60 (s, 1H), 7.46 (dd, 2H), 7.25 (d, 1H), 7.11
(d, 1H), 7.00 (s, 1H), 6.46 (s, 1H), 3.64 (s, 3H), 2.38 (s, 3H),
2.14 (s, 3H).
EXAMPLE 10
[4-(2,6-Dichloro-phenoxy)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol--
1-yl)-phenyl]-amine
##STR00049##
[0384] a) 4-Chloro-6-(2,6-dichloro-phenoxy)-pyrimidine
[0385] 4,6-Dichloropyrimidine (149 mg, 1.0 mmol),
2,6-dichlorophenol (179 mg, 1.1 mmol), potassium carbonate (166 mg,
1.2 mmol), and sodium iodide (7.5 mg, 0.05 mmol) were stirred in
acetonitrile (3 mL) at 20.degree. C. under an atmosphere of
nitrogen for 64 h. The reaction was poured onto 1N aqueous sodium
hydroxide solution and extracted twice with diethyl ether. The
combined organic layers were washed with brine, dried over sodium
sulfate, filtered and the solvent was evaporated under reduced
pressure to give the title compound (195 mg, 71%) as a white
solid.
[0386] MS EI (m/e): 274.9/276.9/278.9 (100/95/50) [M.sup.+].
[0387] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=8.69 (s,
1H), 7.78 (s, 1H), 7.66 (d, 2H), 7.42 (dd, 1H).
b)
[4-(2,6-Dichloro-phenoxy)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidaz-
ol-1-yl)-phenyl]-amine
[0388] The title compound was prepared in analogous manner as
described in example 1e) from
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and
4-chloro-6-(2,6-dichloro-phenoxy)-pyrimidine. It was obtained as a
yellow solid in 29% yield.
[0389] MS ISP (m/e): 442.1/444.1 (100/60) [(M+H).sup.+].
[0390] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=9.79 (s,
1H), 8.48 (d, 1H), 7.66 (d, 2H), 7.61 (s, 1H), 7.42 (dd, 1H), 7.31
(s, 1H), 7.11 (d, 1H), 6.99 (s, 1H), 6.96 (d, 1H), 6.71 (d, 1H),
3.64 (s, 3H), 2.13 (s, 3H).
EXAMPLE 11
[4-(3,4-Difluoro-phenoxy)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl--
imidazol-1-yl)-phenyl]-amine
##STR00050##
[0392] The title compound was prepared in analogous manners as
described in example 9) from 3,4-difluorophenol and
(4-chloro-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)--
phenyl]-amine. It was obtained in 81% yield as a pale-brown
solid.
[0393] MS ISP (m/e): 424.2 (100) [(M+H).sup.+].
[0394] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=9.73 (s,
1H), 7.50-7.62 (m, 4H), 7.23 (d, 1H), 7.14 (m, 1H), 7.08 (d, 1H),
6.99 (s, 1H), 6.43 (s, 1H), 3.60 (s, 3H), 2.37 (s, 3H), 2.13 (s,
3H).
EXAMPLE 12
[4-(4-Chloro-phenoxy)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imid-
azol-1-yl)-phenyl]-amine
##STR00051##
[0396] The title compound was prepared in analogous manners as
described in example 9) from 4-chlorophenol and
(4-chloro-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)--
phenyl]-amine. It was obtained in 73% yield as a pale-brown
solid.
[0397] MS ISP (m/e): 422.1/424.2 (100/35) [(M+H).sup.+].
[0398] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=9.72 (s,
1H), 7.61 (s, 1H), 7.58 (s, 1H), 7.52 (d, 2H), 7.28 (d, 2H), 7.18
(d, 1H), 7.07 (d, 1H), 6.99 (s, 1H), 6.43 (s, 1H), 3.54 (s, 3H),
2.37 (s, 3H), 2.13 (s, 3H).
EXAMPLE 13
[4-(4-Dichloro-phenoxy)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1--
yl)-phenyl]-amine
##STR00052##
[0400] The title compound was prepared in analogous manner as
described in example 1e) from
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and
2-chloro-4-(4-chloro-phenoxy)-pyrimidine. It was obtained as a
yellow solid in 58% yield.
[0401] MS ISP (m/e): 408.3/410.2 (100/34) [(M+H).sup.+].
[0402] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=9.74 (s,
1H), 8.42 (d, 1H), 7.62 (s, 1H), 7.53 (d, 2H), 7.48 (s, 1H), 7.31
(d, 2H), 7.23 (d, 1H), 7.07 (d, 1H), 6.99 (s, 1H), 6.54 (d, 1H),
3.56 (s, 3H), 2.13 (s, 3H).
EXAMPLE 14
3-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimidin-
-4-yloxy}-benzonitrile
##STR00053##
[0404] The title compound was prepared in analogous manners as
described in example 9) from 3-hydroxy-benzonitrile and
(4-chloro-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)--
phenyl]-amine. It was obtained in 75% yield as a pale-brown solid.
MS ISP (m/e): 413.4 (100) [(M+H).sup.+]
[0405] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=9.74 (s,
1H), 7.86 (s, 1H), 7.78 (d, 1H), 7.61-7.71 (m, 3H), 7.51 (br s,
1H), 7.17 (br d, 1H), 7.05 (d, 1H), 6.99 (s, 1H), 6.49 (s, 1H),
3.56 (s, 3H), 2.38 (s, 3H), 2.13 (s, 3H).
EXAMPLE 15
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(pyridin-3-yloxy-
)-pyrimidin-2-yl]-amine
##STR00054##
[0407] The title compound was prepared in analogous manners as
described in example 9 from 3-hydroxy-pyridine and
(4-chloro-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)--
phenyl]-amine. It was obtained in 53% yield as a pale-yellow solid
after purification by column chromatography on silica gel using
dichloromethane/methanol (19:1 v/v) as eluent.
[0408] MS ISP (m/e): 389.3 (100) [(M+H).sup.+].
[0409] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=9.72 (s,
1H), 8.54 (d, 1H), 8.48 (dd, 1H), 7.73 (dd, 1H), 7.48 (s, 1H),
7.49-7.55 (m, 2H), 7.17 (br d, 1H), 7.07 (d, 1H), 6.98 (s, 1H),
6.48 (s, 1H), 3.53 (s, 3H), 2.39 (s, 3H), 2.13 (s, 3H).
EXAMPLE 16
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(2-trifluorometh-
yl-phenoxy)-pyrimidin-2-yl]-amine
##STR00055##
[0411] The title compound was prepared in analogous manners as
described in example 9 from 2-trifluoromethyl-phenol and
(4-chloro-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)--
phenyl]-amine. The reaction was heated for 3.5 h to 200.degree. C.
in a microwave oven. Several times the phenol (overall 4.4
equivalents) and additional sodium hydride had to be added in order
to obtain complete conversion. The title compound was obtained,
after purification by column chromatography on silica gel using
dichloromethane/methanol (19:1 v/v) as eluent, as a white solid in
15% yield.
[0412] MS ISP (m/e): 456.2 (100) [(M+H).sup.+].
[0413] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=9.75 (s,
1H), 8.82 (m, 2H), 7.60 (s, 1H), 7.51 (m, 3H), 7.12 (br d, 1H),
7.01 (d, 1H), 6.96 (s, 1H), 6.53 (s, 1H), 3.53 (s, 3H), 2.39 (s,
3H), 2.13 (s, 3H).
EXAMPLE 17
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(3-trifluorometh-
oxy-phenoxy)-pyrimidin-2-yl]-amine
##STR00056##
[0415] The title compound was prepared in analogous manners as
described in example 9 from 3-trifluoromethoxy-phenol and
(4-chloro-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)--
phenyl]-amine. It was obtained in 95% yield as a pale-brown solid.
MS ISP (m/e): 472.0 (100) [(M+H).sup.+].
[0416] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=9.77 (s,
1H), 751-7.63 (m, 3H), 7.28-7.36 (m, 3H), 7.18 (br d, 1H), 7.3 (d,
1H), 6.96 (s, 1H), 6.48 (s, 1H), 3.52 (s, 3H), 2.38 (s, 3H), 2.12
(s, 3H).
EXAMPLE 18
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(3-trifluorometh-
yl-phenoxy)-pyrimidin-2-yl]-amine
##STR00057##
[0418] The title compound was prepared in analogous manners as
described in example 9 from 3-trifluoromethyl-phenol and
(4-chloro-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)--
phenyl]-amine. It was obtained in 62% yield as a pale-yellow
viscous oil.
[0419] MS ISP (m/e): 456.2 (100) [(M+H).sup.+].
[0420] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=9.74 (s,
1H), 7.66-7.72 (m, 3H), 7.59 (s, 1H), 7.58 (d, 1H), 7.51 (br s,
1H), 7.13 (br d, 1H), 7.01 (d, 1H), 6.96 (s, 1H), 6.49 (s, 1H),
3.50 (s, 3H), 2.39 (s, 3H), 2.13 (s, 3H).
EXAMPLE 19
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(3,3,4,4,4-penta-
fluoro-butoxy)-pyrimidin-2-yl]-amine
##STR00058##
[0422] Sodium (6.9 mg, 0.3 mmol) was dissolved under stirring and
heating under an atmosphere of argon in
3,3,4,4,4-pentafluorobutan-1-ol (676 mg, 4.0 mmol). To this
solution
(4-chloro-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)--
phenyl]-amine (66 mg, 0.20 mmol) was added and the reaction mixture
was stirred for 16 h at 20.degree. C. and then heated to
100.degree. C. for 4 h. The reaction mixture was poured onto water
and was acidified with 1N aqueous hydrochloric acid solution. It
was extracted twice with diethyl ether. The aqueous layer was set
to basic pH with 1N aqueous sodium hydroxide solution and extracted
three times with diethyl ether. The combined organic layers were
washed with brine, dried over sodium sulfate and evaporated under
reduced pressure. The residue was purified by column chromatography
on silica gel using dichloromethane/methanol (19:1 v/v) as eluent
to yield the title compound (59 mg, 64%) as a pale-yellow
solid.
[0423] MS ISP (m/e): 458.1 (100) [(M+H).sup.+].
[0424] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=9.71 (s,
1H), 7.89 (s, 1H), 7.65 (s, 1H), 7.33 (d, 1H), 7.20 (d, 1H), 7.02
(s, 1H), 6.23 (s, 1H), 4.63 (t, 2H), 3.79 (s, 3H), 2.80 (tt, 2H),
2.31 (s, 3H), 2.14 (s, 3H).
EXAMPLE 20
{4-[1-(4-Chloro-phenyl)-1-methyl-ethyl]-5-methyl-pyrimidin-2-yl}-[3-methox-
y-4-(4-methyl-imidazol-1-yl)-phenyl]-amine
##STR00059##
[0425] a) 3-(4-Chlorophenyl)-3-methyl-2-pentanone
[0426] To a solution of 2-(4-chlorophenyl)-2-methylpropionitrile
(243 mg, 1.4 mmol) in benzene (1.4 mL) was added slowly at
50.degree. C. under an atmosphere of nitrogen and with stirring to
a 2.8 M solution of ethylmagnesium chloride in tetrahydrofuran
(1.45 ml, 4.1 mmol). The reaction mixture was heated to reflux for
2 h, and thereafter, cooled and poured onto 10% aqueous ammonium
chloride solution (4 mL). The organic layer was separated and
treated with 2 N aqueous hydrochloric acid solution (1 mL). The
reaction was heated to reflux for 1 h. After cooling the reaction
mixture was diluted with water and extracted twice with benzene.
The organic layer was washed with brine, dried over sodium sulfate
and evaporated under reduced pressure. The residue was purified by
column chromatography on silica gel using heptane/ethyl acetate
(9:1 v/v) as eluent to give the title compound (64 mg, 20%) as a
pale-yellow oil.
[0427] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=7.41 (d,
2H), 7.27 (d, 2H), 2.25 (q, 2H), 1.41 (s, 6H), 0.83 (t, 3H).
b)
4-(4-Chloro-phenyl)-1-dimethylamino-2,4-dimethyl-pent-1-en-3-one
[0428] The title compound was prepared from
3-(4-chlorophenyl)-3-methyl-2-pentanone in analogous manner as
described in example 5a) as a brown viscous oil in 97% yield and
was used without further purification in the next step.
[0429] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=7.27 (d,
2H), 7.17 (d, 2H), 6.81 (s, 1H), 2.83 (s, 6H), 1.79 (s, 3H), 1.47
(s, 6H).
c)
{4-[1-(4-Chloro-phenyl)-1-methyl-ethyl]-5-methyl-pyrimidin-2-yl}-[3-met-
hoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine
[0430] The title compound was prepared in analogous manner as
described in example 4c) from
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine
dinitrate,
4-(4-chloro-phenyl)-1-dimethylamino-2,4-dimethyl-pent-1-en-3-one
and triethylamine using 1-methyl-2-pyrrolidone as the solvent. The
reaction was performed in a microwave oven at 200.degree. C. for
2.5 h. The title compound was isolated as a yellow solid in 52%
yield.
[0431] MS ISP (m/e): 448.1/450.1 (100/34) [(M+H).sup.+].
[0432] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=9.66 (s,
1H), 8.16 (s, 1H), 7.84 (s, 1H), 7.65 (s, 1H), 7.44 (d, 1H), 7.38
(d, 2H), 7.23 (d, 1H), 7.20 (d, 2H), 7.03 (s, 1H), 3.79 (s, 3H),
2.14 (s, 3H), 1.67 (s, 6H), 1.57 (s, 3H).
EXAMPLE 21
{4-[1-(4-Chloro-phenyl)-1-methyl-ethyl]-pyrimidin-2-yl}-[3-methoxy-4-(4-me-
thyl-imidazol-1-yl)-phenyl]-amine
##STR00060##
[0433] a)
4-(4-Chloro-phenyl)-1-dimethylamino-4-methyl-pent-1-en-3-one
[0434] The title compound was prepared from
3-(4-chlorophenyl)-3-methyl-2-butanone in analogous manner as
described in example 5a) as a pale-yellow solid in 73% yield and
was used without further purification in the next step.
[0435] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=7.55 (d,
1H), 7.26 (m, 4H), 4.70 (d, 1H), 3.00 (br s, 3H), 2.70 (br s, 3H),
1.47 (s, 6H).
b)
{4-[1-(4-Chloro-phenyl)-1-methyl-ethyl]-pyrimidin-2-yl}-[3-methoxy-4-(4-
-methyl-imidazol-1-yl)-phenyl]-amine
[0436] The title compound was prepared in analogous manner as
described in example 4c) from
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate
and 4-(4-chloro-phenyl)-1-dimethylamino-4-methyl-pent-1-en-3-one,
and triethylamine using 1-methyl-2-pyrrolidone as solvent. The
reaction was performed in a microwave oven at 200.degree. C. for 2
h. The title compound was isolated as a brown solid in 20%
yield.
[0437] MS ISP (m/e): 434.3/436.1 (100/40) [(M+H).sup.+].
[0438] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=8.31 (d,
1H), 7.72 (s, 1H), 7.63 (s, 1H), 7.27 (d, 2H), 7.21 (d, 1H), 7.15
(d, 1H), 7.01 (d, 1H), 6.87 (s, 1H), 6.57 (d, 1H), 3.77 (s, 3H),
2.30 (s, 3H), 1.71 (s, 6H).
EXAMPLE 22
{4-[1-(4-Chloro-phenyl)-1-methyl-ethyl]-pyrimidin-2-yl}-[3-fluoro-4-(4-met-
hyl-imidazol-1-yl)-phenyl]-amine
##STR00061##
[0439] a) 1-(2-Fluoro-4-nitro-phenyl)-4-methyl-1H-imidazole
[0440] 3,4-Difluoro-4-nitro-benzene (7.97 g (50 mmol),
4-methyl-1H-imidazole (4.51 g (55 mmol) and
N,N-diisopropylethylamine (16.16 g (125 mmol) were dissolved in
acetonitrile (80 mL) and the reaction was heated to reflux for 24 h
under an atmosphere of nitrogen. The solvent was evaporated under
reduced pressure and the residue was crystallized from a mixture of
ethyl acetate and heptane to yield the title compound (4.66 g, 42%)
as a pale-yellow solid.
[0441] MS ISP (m/e): 222.1 (100) [(M+H).sup.+].
[0442] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=8.42 (d,
1H), 8.21 (d, 1H), 8.11 (s, 1H), 7.95 (t, 1H), 7.43 (s, 1H), 2.19
(s, 3H).
b) 3-Fluoro-4-(4-methyl-imidazol-1-yl)-phenylamine
[0443] 1-(2-Fluoro-4-nitro-phenyl)-4-methyl-1H-imidazole (4.66 g,
21.1 mmol) was dissolved in a mixture of methanol (25 mL) and
tetrahydrofuran (100 mL). The solution was cooled to 0.degree. C.
under an atmosphere of nitrogen. Ammonium formate (6.64 g, 105
mmol) and 10% palladium on charcoal (0.24 g) was added and the
mixture was stirred at 20.degree. C. for 18 h. The mixture was
filtered through celite and the celite was washed with methanol.
The filtrate was evaporated under reduced pressure and the residue
was partitioned between ethyl acetate and 10% aqueous sodium
bicarbonate solution. The organic layer was separated, washed with
brine, dried over sodium sulfate and evaporated under reduced
pressure to yield the title compound (3.89 g, 97%) as a yellow
solid.
[0444] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=7.62 (s,
1H), 7.12 (t, 1H), 7.01 (s, 1H), 6.41-6.51 (m, 2H), 5.64 (br s,
2H), 2.13 (s, 3H).
c) N-[3-fluoro-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine
Nitrate
[0445] A suspension of
3-fluoro-4-(4-methyl-imidazol-1-yl)-phenylamine (500 mg, 2.62
mmol), of 50% aqueous cyanamide solution (249 mg, 2.96 mmol) and of
65% aqueous nitric acid (253 mg, 2.62 mmol) in ethanol (2.6 mL) was
heated for 5 days to reflux under an atmosphere of nitrogen. Twice
the same amounts of cyanamide and nitric acid were added to the
reaction mixture after 2 and 4 days, respectively. The mixture was
cooled and let stand at 20.degree. C. for 1 d. The precipitated
solid was filtered off (Caution: the filtrate may contain the ethyl
ester of nitric acid) and washed with ethanol to yield the title
compound (280 mg, 36%) as an off-white solid.
[0446] MS ISP (m/e): 234.1 (100) [(M+H).sup.+].
[0447] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=9.82 (br
s, 1H), 7.90 (s, 1H), 7.67 (t, 1H), 7.56 (s, 4H), 7.43 (d, 1H),
7.25 (s, 1H), 7.21 (d, 1H), 2.18 (s, 1H).
d)
{4-[1-(4-Chloro-phenyl)-1-methyl-ethyl]-5-methyl-pyrimidin-2-yl}-[3-met-
hoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine
[0448] The title compound was prepared in analogous manner as
described in example 4c) from
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine
dinitrate,
4-(4-chloro-phenyl)-1-dimethylamino-4-methyl-pent-1-en-3-one, and
triethylamine using 1-methyl-2-pyrrolidone as solvent. The reaction
was performed in a microwave at 200.degree. C. for 2.5 h. The title
compound was isolated as a yellow solid in 52% yield.
[0449] MS ISP (m/e): 448.1/450.1 (100/34) [(M+H).sup.+].
[0450] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=9.66 (s,
1H), 8.16 (s, 1H), 7.84 (s, 1H), 7.65 (s, 1H), 7.44 (d, 1H), 7.38
(d, 2H), 7.23 (d, 1H), 7.20 (d, 2H), 7.03 (s, 1H), 3.79 (s, 3H),
2.14 (s, 3H), 1.67 (s, 6H), 1.57 (s, 3H).
EXAMPLE 23
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-{4-[1-methyl-1-(3,4,5-triflu-
oro-phenyl)-ethyl]-pyrimidin-2-yl}-amine
##STR00062##
[0451] a) 2-Methyl-2-(3,4,5-trifluoro-phenyl)-propionitrile
[0452] Potassium tert.-butoxide (3.44 g, 30 mmol) was dissolved in
tetrahydrofuran (100 mL) and stirred under am atmosphere of
nitrogen. (3,4,5-trifluorophenyl)-acetonitrile (2.12 g, 12 mmol)
dissolved in tetrahydrofuran (10 mL) was added drop wise at
0.degree. C. The solution turned orange and heat was evolved.
Methyl iodide (1.88 mL, 30 mmol) dissolved in tetrahydrofuran (10
mL) was added drop wise. The solution turned pale brown and was
stirred for 4 h at 20.degree. C. The reaction was poured onto water
and extracted twice with diethyl ether. The combined organic layers
were washed with brine, dried over sodium sulfate, filtered and the
solvent was evaporated und reduce pressure to yield the title
compound (2.30 g, 96%) as a yellow solid.
[0453] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=7.26 (m,
2H), 1.71 (s, 6H).
b) 3-Methyl-3-(3,4,5-trifluoro-phenyl)-butan-2-one
[0454] The title compound was prepared in analogous manner as
described in example 20a) from
2-methyl-2-(3,4,5-trifluoro-phenyl)-propionitrile and 3 M
methylmagnesium chloride solution in tetrahydrofuran in 42% yield
as a pale-yellow oil.
[0455] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=7.24 (m,
2H), 1.97 (s, 3H), 1.42 (s, 6H).
c)
1-Dimethylamino-4-methyl-4-(3,4,5-trifluoro-phenyl)-pent-1-en-3-one
[0456] The title compound was prepared crude in analogous manner as
described in example 5a) from
3-methyl-3-(3,4,5-trifluoro-phenyl)-butan-2-one as a yellow oil and
was used as crude material in the next step.
[0457] MS ISP (m/e): 272.2 (100) [(M+H).sup.+].
[0458] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=7.58 (d,
1H), 6.93 (m, 2H), 4.70 (d, 1H), 3.04 (br s, 3H), 2.69 (br s, 3H),
1.44 (s, 6H).
d)
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-{4-[1-methyl-1-(3,4,5-tri-
fluoro-phenyl)-ethyl]-pyrimidin-2-yl}-amine
[0459] The title compound was prepared in analogous manner as
described in example 4c) from
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate
and
1-dimethylamino-4-methyl-4-(3,4,5-trifluoro-phenyl)-pent-1-en-3-one
as a pale-brown solid in 21% yield.
[0460] MS ISP (m/e): 454.2 (100) [(M+H).sup.+].
[0461] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=9.77 (s,
1H), 8.44 (d, 1H), 7.78 (s, 1H), 7.65 (s, 1H), 7.32 (d, 1H),
7.17-7.28 (m, 4H), 7.02 (s, 1H), 6.75 (d, 1H), 3.74 (s, 3H), 2.14
(s, 3H), 1.69 (s, 6H).
EXAMPLE 24
{4-Chloro-6-[1-(4-chloro-phenyl)-1-methyl-ethyl]-pyrimidin-2-yl}-[3-methox-
y-4-(4-methyl-imidazol-1-yl)-phenyl]-amine
##STR00063##
[0462] a) Ethyl 4-(4-chloro-phenyl)-4-methyl-3-oxo-pentanoate
[0463] To a solution of 3-(4-chlorophenyl)-3-methyl-2-butanone (197
mg, 1 mmol) in diethyl carbonate (1.32 g, 11 mmol) was added at
20.degree. C. under an atmosphere of nitrogen portion wise a
dispersion of 55% sodium hydride in mineral oil (91 mg, 2.1 mmol).
The reaction turned yellow and was heated to 50.degree. C. After
the gas evolution stopped the reaction was stirred at 85.degree. C.
for 30 min. After cooling to 20.degree. C. the reaction was poured
onto ice-water (2 mL) and then acetic acid (0.14 mL) was added. The
reaction was extracted twice with diethyl ether. The combined
organic layers were washed with water and with brine, dried over
sodium sulfate and evaporated under reduced pressure. The residue
was purified by column chromatography on silica gel using
heptene/ethyl acetate (9:1 v/v) as eluent to yield the title
compound as a pale-yellow oil (79 mg, 29%).
[0464] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=7.43 (d,
2H), 7.30 (d, 2H), 3.99 (q, 2H), 3.42 (s, 2H), 1.44 (s, 6H), 1.13
(t, 3H).
b)
6-[1-(4-Chloro-phenyl)-1-methyl-ethyl]-2-[3-methoxy-4-(4-methyl-imidazo-
l-1-yl)-phenylamino]-pyrimidin-4-ol
[0465] Sodium ethoxide (288 mg, 5.18 mmol) was dissolved in
methanol (20 mL). At 20.degree. C. under an atmosphere of nitrogen
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate
(835 mg, 2.25 mmol) and ethyl
4-(4-chloro-phenyl)-4-methyl-3-oxo-pentanoate (700 mg, 2.48 mmol)
dissolved in methanol (2.5 mL) were added. The reaction was heated
for 48 h to reflux. The solvent was evaporated under reduced
pressure and the residue was taken up in water and acidified to pH
6 with 1 N aqueous hydrochloric acid solution. The mixture was
extracted with dichloromethane and the organic layer was washed
with brine, dried over sodium sulfate and evaporated under reduced
pressure to afford a solid residue. The concentrated aqueous layer
was extracted further with boiling tetrahydrofuran. The organic
layer was concentrated and combined with the first residue. The
crude material was purified by column chromatography on silica gel
using dichloromethane/methanol (9:1 v/v) as eluent. The product
fraction was stirred with diethyl ether for 15 min. The precipitate
was collected by filtration to yield the title compound as an
off-white solid (180 mg, 18%).
[0466] MS ISP (m/e): 450.1/452.0 (100/35) [(M+H).sup.+].
[0467] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=7.65-7.69
(m, 2H), 7.33 (dd, 4H), 7.20 (m, 1H), 6.93-7.03 (m, 2H), 5.84 (s,
1H), 3.58 (s, 3H), 2.13 (s, 3H), 1.58 (s, 6H).
c)
{4-Chloro-6-[1-(4-chloro-phenyl)-1-methyl-ethyl]-pyrimidin-2-yl}-[3-met-
hoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine
[0468] The title compound was prepared in analogous manner as
described in example 8b) starting with
6-[1-(4-chloro-phenyl)-1-methyl-ethyl]-2-[3-methoxy-4-(4-methyl-imidazol--
1-yl)-phenylamino]-pyrimidin-4-ol. The crude product was purified
by column chromatography on silica gel using
dichloromethane/methanol (19:1 v/v) as eluent to yield a
pale-yellow foam (92 mg, 49%).
[0469] MS ISP (m/e): 368.0/470.1 (100/59) [(M+H).sup.+].
[0470] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=10.16 (s,
1H), 7.75 (s, 1H), 7.65 (s, 1H), 7.37 (dd, 4H), 7.26 (s, 2H), 7.03
(s, 1H), 6.86 (s, 1H), 3.69 (s, 3H), 2.14 (s, 3H), 1.69 (s,
6H).
EXAMPLE 25
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-trifluoromethyl-pyrimidin-
-2-yl)-amine
##STR00064##
[0472] The title compound was prepared in analogous manner as
described in example 1e) from
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and
2-chloro-4-trifluoromethyl-pyrimidine. The reaction was refluxed
for 16 h. The title compound was obtained as a pale-yellow solid in
43% yield.
[0473] MS ISP (m/e): 350.3 (100) [(M+H).sup.+].
[0474] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=10.41 (s,
1H), 8.86 (d, 1H), 7.84 (s, 1H), 7.69 (s, 1H), 7.37 (d, 1H), 7.32
(d, 1H), 7.29 (d, 1H), 7.06 (s, 1H), 3.80 (s, 3H), 2.15 (s,
3H).
EXAMPLE 26
2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-4-trifluoromethyl-pyr-
imidine-5-carboxylic Acid Methyl Ester
##STR00065##
[0476] The title compound was prepared in analogous manner as
described in example 1e) from
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and methyl
2-chloro-4-trifluoromethyl-pyrimidine-5-carboxylate. The reaction
was heated to reflux for 16 h. The title compound was obtained as a
pale-yellow solid in 20% yield.
[0477] MS ISP (m/e): 408.2 (100) [(M+H).sup.+].
[0478] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=10.92 (s,
1H), 9.10 (d, 1H), 7.88 (br s, 1H), 7.72 (s, 1H), 7.35 (s, 2H),
7.08 (s, 1H), 3.87 (s, 3H), 3.81 (s, 3H), 2.15 (s, 3H).
EXAMPLE 27
Methyl
2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrim-
idine-4-carboxylate
##STR00066##
[0480] The title compound was prepared in analogous manner as
described in example 1e) from
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and methyl
2-chloro-6-methyl-pyrimidine-4-carboxylate. The reaction was heated
to reflux for 16 h. The title compound was obtained as a pale-brown
solid in 18% yield.
[0481] MS ISP (m/e): 354.2 (100) [(M+H).sup.+].
[0482] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=10.19 (s,
1H), 8.26 (br s, 1H), 7.67 (s, 1H), 7.34 (s, 1H), 7.30 (d, 1H),
7.24 (d, 1H), 7.04 (s, 1H), 3.90 (s, 3H), 3.84 (s, 3H), 2.14 (s,
3H).
EXAMPLE 28
Ethyl
4-(4-chloro-phenyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylam-
ino]-pyrimidine-5-carboxylate
##STR00067##
[0483] a) Ethyl
3-dimethylamino-2-(4-chloromethyl-benzoyl)-acrylate
[0484] A mixture of ethyl 3-(4-chloro-phenyl)-3-oxo-propionate (227
mg, 1.0 mmol) and of tert.-butoxy-bis(dimethylamino)methane (271
mg, 1.4 mmol, 90%) was stirred at 110.degree. C. for 2 h. The
reaction was evaporated to dryness, treated twice with toluene and
the solvent was evaporated under reduced pressure to give the crude
title compound (292 mg, 99%) as a brown oil which was used directly
in the next step without further purification.
[0485] MS ISP (m/e): 282.3 [(M+H).sup.+].
b) Ethyl
4-(4-chloro-phenyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-pheny-
lamino]-pyrimidine-5-carboxylate
[0486] A mixture of
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate
(185 mg, 0.5 mmol), crude ethyl
3-dimethylamino-2-(4-chloro-benzoyl)-acrylate (292 mg, 1.0 mmol),
and triethylamine (0.66 mL, 4.7 mmol) in ethanol (2 mL) was heated
at reflux for 15 h. The mixture was cooled and diluted with ethyl
acetate (50 mL). The solution was washed with sat. sodium carbonate
solution (5 mL) and with brine (5 mL), dried over sodium sulfate
and evaporated under reduced pressure. The residual material was
purified by chromatography on silica gel using
dichloromethane/0-20% methanol as eluent to give the title compound
(157 mg, 68%) as a pale-yellow solid. Mp 216-218.degree. C.
[0487] MS ISP (m/e): 464.1 [(M+H).sup.+].
EXAMPLE 29
[4-(4-Chloro-phenyl)-6-trifluoromethyl-pyrimidin-2-yl]-[3-methoxy-4-(4-met-
hyl-imidazol-1-yl)-phenyl]-amine
##STR00068##
[0489] A mixture of
1-(4-chloro-phenyl)-4,4,4-trifluoro-butane-1,3-dione (50 mg, 0.2
mmol), N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine
dinitrate (74 mg, 0.2 mmol), and triethylamine (0.14 mL, 1.0 mmol)
in ethanol (0.5 mL) was heated to 78.degree. C. for 18 h. The
mixture was cooled, diluted with ethyl acetate (30 mL), and then
washed with sat. sodium carbonate solution (5 mL) and with brine (5
mL). The organic layer was dried over sodium sulfate and evaporated
under reduced pressure. The residual material was purified by
column chromatography on silica gel (5 g) using ethyl acetate/0-10%
ethanol as eluent to give the title compound (10 mg, 11%) as
light-yellow solid. Mp 202-204.degree. C.
[0490] MS ISP (m/e): 460.0 [(M+H).sup.+].
EXAMPLE 30
[4-(4-Imidazol-1-yl-phenyl)-6-trifluoromethyl-pyrimidin-2-yl]-[3-methoxy-4-
-(4-methyl-imidazol-1-yl)-phenyl]-amine
##STR00069##
[0492] The title compound was prepared from
4,4,4-trifluoro-1-(4-imidazol-1-yl-phenyl)-butane-1,3-dione (137
mg, 0.49 mmol) and
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate
(180 mg, 0.49 mmol) using in analogous manner the procedure
described in example 29). Obtained as a pale-yellow solid (19 mg,
8%). Mp 248-250.degree. C.
[0493] MS ISP (m/e): 492.1 [(M+H).sup.+].
EXAMPLE 31
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-(4-pyrazol-1-yl-phenyl)-6-
-trifluoromethyl-pyrimidin-2-yl]-amine
##STR00070##
[0494] a)
4,4,4-Trifluoro-1-(4-pyrazol-1-yl-phenyl)-butane-1,3-dione
[0495] A 5.4 N solution of sodium methoxide in methanol (3.0 mL,
16.2 mmol) was added drop wise over 10 min to a solution of ethyl
trifluoro-acetate (1.81 mL, 15.2 mmol) in 2-ethoxy-2-methyl-propane
(20 mL) at 20.degree. C. followed by the addition of a suspension
of 1-(4-pyrazol-1-yl-phenyl)-ethanone (2.57 g, 13.8 mmol) in
2-ethoxy-2-methyl-propane (10 mL). The reaction mixture was stirred
for 22 h at 20.degree. C. and then poured onto ice-water (50 mL).
The mixture was extracted with ethyl acetate and the organic layer
was washed with brine, dried over sodium sulfate and evaporated
under reduced pressure. The remaining solid was recrystallized from
ethyl acetate/heptane to give the title compound (2.47 g, 63%) as
off-white solid. Mp 96.degree. C.
b)
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-(4-pyrazol-1-yl-phenyl-
)-6-trifluoromethyl-pyrimidin-2-yl]-amine
[0496] The title compound was prepared from
4,4,4-trifluoro-1-(4-pyrazol-1-yl-phenyl)-butane-1,3-dione (137 mg,
0.0.49 mmol) and
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate
(180 mg, 0.49 mmol) using in analogous manner the procedure
described in example 29). Obtained as a pale-yellow solid (25 mg,
10%). Mp 252-254.degree. C.
[0497] MS ISP (m/e): 492.0 [(M+H).sup.+].
EXAMPLE 32
Ethyl
2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-4-(4-trifluorom-
ethyl-phenyl)-pyrimidine-5-carboxylate
##STR00071##
[0498] a) Ethyl
3-dimethylamino-2-(4-trifluoromethyl-benzoyl)-acrylate
[0499] Ethyl 3-oxo-3-(4-trifluoromethyl-phenyl)-propionate (130 mg,
0.5 mmol) was reacted with tert.-butoxy-bis-(dimethylamino)-methane
using in analogous manner the procedure described in example 28a)
to give crude title compound (151 mg) as a red oil which was used
directly in the next step.
[0500] MS ISP (m/e): 316.3 [(M+H).sup.+].
b) Ethyl
2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-4-(4-trifluo-
romethyl-phenyl)-pyrimidine-5-carboxylate
[0501] The title compound was prepared from ethyl
3-dimethylamino-2-(4-trifluoromethyl-benzoyl)-acrylate (151 mg,
0.48 mmol) and
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate
(133 mg, 0.36 mmol) using in analogous manner the procedure
described in example 28b). Obtained as a pale-yellow solid (14 mg,
6%).
[0502] MS ISP (m/e): 498.0 [(M+H).sup.+].
EXAMPLE 33
Ethyl
4-(3-cyano-phenyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylami-
no]-pyrimidine-5-carboxylate
##STR00072##
[0503] a) Ethyl 3-dimethylamino-2-(3-cyano-benzoyl)-acrylate
[0504] Ethyl 3-oxo-3-(3-cyano-phenyl)-propionate (109 mg, 0.5 mmol)
was reacted with tert.-butoxy-bis-(dimethylamino)-methane using in
analogous manner the procedure described in example 28a) to give
crude title compound (85 mg) as a yellow oil which was used
directly in the next step.
b) Ethyl
4-(3-cyano-phenyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl-
amino]-pyrimidine-5-carboxylate
[0505] The title compound was prepared from ethyl
3-dimethylamino-2-(3-cyano-benzoyl)-acrylate (85 mg, 0.31 mmol) and
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate
(116 mg, 0.31 mmol) using in analogous manner the procedure
described in example 28b). Obtained as a pale-yellow solid (41 mg,
29%). Mp 195-197.degree. C.
[0506] MS ISP (m/e): 455.1 [(M+H).sup.+].
EXAMPLE 34
Ethyl
{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-5-phenyl-pyrim-
idin-4-yl}-phenyl-acetate
##STR00073##
[0507] a)
Ethyl-5-dimethylamino-3-oxo-2,4-diphenyl-pent-4-enoate
[0508] Ethyl 3-oxo-2,4-diphenyl-butyrate (76 mg, 0.3 mmol) was
reacted with tert.-butoxy-bis-(dimethylamino)-methane using in
analogous manner the procedure described in example 28a) to give
crude title compound (102 mg) as a red oil which was used directly
in the next step.
[0509] MS ISP (m/e): 338.4 [(M+H).sup.+].
b) Ethyl
{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-5-phenyl-py-
rimidin-4-yl}-phenyl-acetate
[0510] The title compound was prepared from
ethyl-5-dimethylamino-3-oxo-2,4-diphenyl-pent-4-enoate (102 mg, 0.3
mmol) and N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine
dinitrate (83 mg, 0.22 mmol) using in analogous manner the
procedure described in example 28b). Obtained as a light-brown
solid (5 mg, 3%). Mp 84-86.degree. C.
[0511] MS ISP (m/e): 520.0 [(M+H).sup.+].
EXAMPLE 35
Ethyl
4-(4-chloro-phenyl)-2-[3-fluoro-4-(4-methyl-imidazol-1-yl)-phenylami-
no]-pyrimidine-5-carboxylate
##STR00074##
[0513] The title compound was prepared from crude ethyl
3-dimethylamino-2-(4-chloro-benzoyl)-acrylate (89 mg, 0.3 mmol) and
N-[3-fluoro-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate
(80 mg, 0.22 mmol) using in analogous manner the procedure
described in example 28b). Obtained as a pale-yellow solid (28 mg,
28%). Mp 232-234.degree. C.
[0514] MS ISP (m/e): 452.1 [(M+H).sup.+].
EXAMPLE 36
Ethyl
4-(4-bromo-2-chloro-phenyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)--
phenylamino]-pyrimidine-5-carboxylate
##STR00075##
[0516] The title compound was prepared from crude ethyl
2-(4-bromo-2-chloro-benzoyl)-3-dimethylamino-acrylate (50 mg, 0.14
mmol) and N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine
dinitrate (43 mg, 0.12 mmol) using in analogous manner the
procedure described in example 28b). Obtained as a yellow solid (50
mg) in 28% yield.
[0517] MS ISP (m/e): 544.1/542.1/546.0/545.1/543.1
(100/85/39/30/26) [(M+H).sup.+].
[0518] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=7.74 (br s,
1H), 7.65 (s, 1H), 7.61 (d, 1H), 7.51 (d, 2H), 7.24 (d, 1H), 7.19
(d, 1H), 7.08 (d, 1H), 6.88 (s, 1H), 4.19 (q, 2H), 3.82 (s, 3H),
2.29 (s, 3H), 1.14 (t, 3H).
EXAMPLE 37
[4-(4-Chloro-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-
-phenyl]-amine
##STR00076##
[0519] a) 1-(4-Chloro-phenyl)-3-dimethylamino-propenone
[0520] 1-(4-Chloro-phenyl)-ethanone (49 mg, 0.3 mmol) was reacted
with tert.-butoxy-bis-(dimethylamino)-methane using in analogous
manner the procedure described in example 28a) to give crude title
compound (87 mg) as a yellow solid which was used directly in the
next step.
[0521] MS ISP (m/e): 210.1 [(M+H).sup.+].
b)
[4-(4-Chloro-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1--
yl)-phenyl]-amine
[0522] The title compound was prepared from crude
1-(4-chloro-phenyl)-3-dimethylamino-propenone (87 mg, 0.3 mmol) and
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate
(83 mg, 0.22 mmol) using in analogous manner the procedure
described in example 28b). Obtained as a pale-yellow solid (29 mg,
33%). Mp 202-204.degree. C.
[0523] MS ISP (m/e): 392.1 [(M+H).sup.+].
EXAMPLE 38
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-(4-trifluoromethyl-phenyl-
)-pyrimidin-2-yl]-amine
##STR00077##
[0524] a)
1-(4-Trifluoromethyl-phenyl)-3-dimethylamino-propenone
[0525] 4-(Trifluoromethyl)-acetophenone (58 mg, 0.3 mmol) was
reacted with tert.-butoxy-bis-(dimethylamino)-methane using in
analogous manner the procedure described in example 28a) to give
crude title compound (81 mg) as a yellow solid which was used
directly in the next step.
[0526] MS ISP (m/e): 244.4 [(M+H).sup.+].
b)
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-(4-trifluoromethyl-phe-
nyl)-pyrimidin-2-yl]-amine
[0527] The title compound was prepared from crude
1-(4-trifluoromethyl-phenyl)-3-dimethylamino-propenone (81 mg, 0.3
mmol) and N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine
dinitrate (83 mg, 0.22 mmol) using in analogous manner the
procedure described in example 28b). Obtained as a pale-yellow
solid (25 mg, 27%).
[0528] MS ISP (m/e): 426.1 [(M+H).sup.+].
EXAMPLE 39
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-pyridin-3-yl-pyrimidin-2--
yl)-amine
##STR00078##
[0529] a) 3-Dimethylamino-1-pyridin-3-yl-propenone
[0530] Pyridin-3-yl-ethanone (62 mg, 0.5 mmol) was reacted with
tert.-butoxy-bis-(dimethylamino)-methane using in analogous manner
the procedure described in example 28a) to give crude title
compound (90 mg) as a yellow solid which was used directly in the
next step.
[0531] MS ISP (m/e): 177.1 [(M+H).sup.+].
b)
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-pyridin-3-yl-pyrimidin-
-2-yl)-amine
[0532] A mixture of
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate
(185 mg, 0.37 mmol), crude 3-dimethylamino-1-pyridin-3-yl-propenone
(90 mg, 0.5 mmol) and triethylamine (0.35 mL, 2.5 mmol) in ethanol
(1 mL) was heated in a sealed tube in a microwave oven to
160.degree. C. for 0.5 h. The mixture was cooled, diluted with
ethyl acetate (30 mL), and then washed with sat. sodium carbonate
solution (5 mL) and with brine (5 mL). The organic layer was dried
over sodium sulfate and evaporated under reduced pressure. The
residual material was purified by chromatography on silica gel
using dichloromethane/0-20% methanol as eluent to give the title
compound (62 mg, 47%) as a pale-yellow solid. Mp 204-206.degree.
C.
[0533] MS ISP (m/e): 359.4 [(M+H).sup.+].
EXAMPLE 40
[4-(4-Chloro-phenyl)-6-trifluoromethyl-pyrimidin-2-yl]-[3-fluoro-4-(4-meth-
yl-imidazol-1-yl)-phenyl]-amine
##STR00079##
[0535] The title compound was prepared from
1-(4-chloro-phenyl)-4,4,4-trifluoro-butane-1,3-dione (125 mg, 0.5
mmol) and N-[3-fluoro-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine
dinitrate (180 mg, 0.5 mmol) using in analogous manner the
procedure described in example 29). Obtained as a pale-yellow solid
(18 mg, 8%). Mp 248-250.degree. C.
[0536] MS ISP (m/e): 447.6 [(M+H).sup.+].
EXAMPLE 41
Ethyl
2-[3-Fluoro-4-(4-methyl-imidazol-1-yl)-phenylamino]-4-(4-trifluorome-
thyl-phenyl)-pyrimidine-5-carboxylate
##STR00080##
[0538] The title compound was prepared from crude ethyl
3-dimethylamino-2-(4-trifluoromethyl-benzoyl)-acrylate (142 mg,
0.45 mmol) and
N-[3-fluoro-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate
(121 mg, 0.34 mmol) using in analogous manner the procedure
described in example 28b). Obtained as a pale-yellow solid (128 mg,
78%). Mp 219-221.degree. C.
[0539] MS ISP (m/e): 486.4 [(M+H).sup.+].
EXAMPLE 42
[3-Fluoro-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-(4-trifluoromethyl-phenyl)-
-pyrimidin-2-yl]-amine
##STR00081##
[0541] The title compound was prepared from crude
1-(4-trifluoromethyl-phenyl)-3-dimethylamino-propenone (114 mg,
0.47 mmol) and
N-[3-fluoro-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate
(126 mg, 0.35 mmol) using in analogous manner the procedure
described in example 39b). Obtained as a pale-yellow solid (99 mg,
68%). Mp 196-197.degree. C.
[0542] MS ISP (m/e): 414.1 [(M+H).sup.+].
EXAMPLE 43
(4-Benzyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-p-
henyl]-amine
##STR00082##
[0543] a) 4-Benzyl-2-chloro-6-methyl-pyrimidine
[0544] 4-Benzyl-2,6-dichloro-pyrimidine (2.5 g, 10.5 mmol) was
dissolved in tetrahydrofuran (40 mL) under an atmosphere of
nitrogen and subsequently treated with dimethylzinc (2M in toluene,
5.76 mL) and tetrakis(triphenylphosphine)palladium(0) (245 mg).
After stirring for 18 h at ambient temperature, ethyl acetate and
water were added, the phases separated and the aqueous layer was
extracted twice with ethyl acetate. The combined organic phases
were dried over magnesium sulfate and evaporated under reduced
pressure. Column chromatography on silica gel using heptane/ethyl
acetate 9:1 v/v) as eluent afforded the title compound (1.89 g,
83%) as colorless oil.
[0545] NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=7.35-7.24 (m, 5H),
6.84 (s, 1H), 4.06 (s, 2H), 2.44 (s, 3H).
[0546] MS ISP (m/e): 219.3 (100) [(M+H).sup.+].
b)
(4-Benzyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl-
)-phenyl]-amine
[0547] Palladium(II) acetate (3.3 mg) and
2-(dicyclohexylphosphino)-biphenyl (11 mg) were stirred in dioxane
(1.5 mL) while nitrogen was bubbled through the solution. In a
second flask, a mixture of 4-benzyl-2-chloro-6-methyl-pyrimidine
(80 mg), 3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (75 mg),
and potassium carbonate (1.03 g) in dioxane (2 mL) was degassed
with nitrogen, and subsequently, the above described catalyst
solution was added. The reaction mixture was heated in a microwave
oven at 200.degree. C. for 30 min. The suspension was filtered,
insoluble material was washed with ethyl acetate, and the combined
solutions are concentrated under reduced pressure. The residual
material was purified by chromatography on silica gel using
dichloromethane/methanol 19:1 v/v) as eluent to afford the title
compound (93 mg, 66%) as a colorless wax.
[0548] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=7.84 (d,
1H), 7.62 (d, 1H), 7.33-7.26 (m, 5H), 7.13 (m, 2H), 7.00 (m, 1H),
6.86 (s, 1H), 6.50 (s, 1H), 3.97 (s, 2H), 3.78 (s, 3H), 2.37 (s,
3H), 2.30 (s, 3H);
[0549] MS ISP (m/e): 386.4 (100) [(M+H).sup.+].
EXAMPLE 44
[3-Fluoro-4-(4-methyl-imidazol-1-yl)-phenyl]-{4-[1-methyl-1-(3,4,5-trifluo-
ro-phenyl)-ethyl]-pyrimidin-2-yl}-amine
##STR00083##
[0551] The title compound was prepared in analogous manner as
described in example 5b) from
N-[3-fluoro-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate
(81 mg, 0.30 mmol) and
1-dimethylamino-4-methyl-4-(3,4,5-trifluoro-phenyl)-pent-1-en-3-one
(98 mg, 0.36 mmol) as a light yellow solid (74 mg) in 56%
yield.
[0552] MS ISP (m/e): 442.2 (100) [(M+H).sup.+].
[0553] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=10.0 (s,
1H), 8.48 (d, 1H), 7.78 (s, 1H), 7.86 (d, 1H), 7.78 (s, 1H), 7.44
(m, 2H), 7.27 (dd, 2H), 7.15 (s, 1H), 6.87 (d, 1H), 2.16 (s, 3H),
1.68 (s, 6H).
EXAMPLE 45
[4-(4-Chloro-phenyl)-5-pyridin-4-yl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-
-imidazol-1-yl)-phenyl]-amine
##STR00084##
[0554] a)
1-(4-Chloro-phenyl)-3-dimethylamino-2-pyridin-4-yl-propenone
[0555] 1-(4-Chloro-phenyl)-2-pyridin-4-yl-ethanone (116 mg, 0.5
mmol) was reacted with tert.-butoxy-bis-(dimethylamino)-methane
using in analogous manner the procedure described in example 28a)
to give crude title compound (165 mg) as a yellow oil which was
used directly in the next step. MS ISP (m/e): 287.0
[(M+H).sup.+].
b)
[4-(4-Chloro-phenyl)-5-pyridin-4-yl-pyrimidin-2-yl]-[3-methoxy-4-(4-met-
hyl-imidazol-1-yl)-phenyl]-amine
[0556] The title compound was prepared from crude
1-(4-chloro-phenyl)-3-dimethylamino-2-pyridin-4-yl-propenone (165
mg, ca. 0.5 mmol) and
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate
(138 mg, 0.37 mmol) using in analogous manner the procedure
described in example 39b). Obtained as yellow solid (9 mg, 5%).
[0557] MS ISP (m/e): 469.4 [(M+H).sup.+].
[0558] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=8.58 (d,
1H), 8.49 (s, 1H), 7.85 (s, 1H), 7.65 (s, 1H), 7.42 (s, 1H), 7.41
and 7.30 (2 d, 4H), 7.18 (d, 1H), 7.12 (s, 1H), 7.11 (d, 2H), 6.89
(s, 1H), 3.86 (s, 3H), 2.31 (s, 3H).
EXAMPLE 46
(4-Ethoxy-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-p-
henyl]-amine
##STR00085##
[0560] A mixture of
(4-chloro-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)--
phenyl]-amine (165 mg, 0.5 mmol) and sodium ethoxide (54 mg, 0.75
mmol) in ethanol (3 ml) was heated for 30 min to 160.degree. C. in
a microwave oven. The reaction mixture was concentrated under
reduced pressure and the residue was partitioned between ethyl
acetate and water. The organic layer was washed with brine, dried
over sodium sulfate and evaporated under reduced pressure. The
residue was stirred with diethyl ether for 30 min to yield the
title compound as a brown solid (139 mg, 82%).
[0561] MS ISP (m/e): 340.1 [(M+H).sup.+];
[0562] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=7.77 (s,
1H), 7.62 (s, 1H), 7.15 (d, 1H), 7.06 (s, 1H), 7.01 (d, 2H), 6.87
(s, 1H), 6.10 (s, 1H), 4.41 (q, 2H), 3.86 (s, 3H), 2.35 (s, 3H),
2.30 (s, 3H), 1.40 (t, 3H).
EXAMPLE 47
N-4-(2,2,3,3,4,4,4-Heptafluoro-butyl)-N-2-[3-methoxy-4-(4-methyl-imidazol--
1-yl)-phenyl]-6-methyl-pyrimidine-2,4-diamine
##STR00086##
[0564] A mixture of
(4-chloro-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)--
phenyl]-amine (66 mg, 0.20 mmol) and 1H,1H-heptafluorobutylamine
(119 mg, 0.60 mmol) in 1-methyl-2-pyrrolidone (2 mL) was heated for
1 h to 200.degree. C. in a microwave oven. The reaction mixture was
poured onto 1 N aqueous sodium hydroxide solution and the mixture
was extracted with diethyl ether. The organic layer was washed with
water and with brine, dried over sodium sulfate and evaporated
under reduced pressure. The residue was purified by column
chromatography on silica gel using dichloromethane/methanol (9:1
v/v) as eluent to yield the title compound as a brown solid (15 mg,
13%).
[0565] MS ISP (m/e): 493.1 [(M+H).sup.+].
[0566] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=7.62 (s,
1H), 7.54 (s, 1H), 7.14 (s, 2H), 6.96 (s, 1H), 6.87 (s, 1H), 5.90
(s, 1H), 4.79 (br t, 1H), 4.32-4.16 (m, 2H), 3.84 (s, 3H), 2.30 (s,
6H).
EXAMPLE 48
(4-Benzyl-pyrimidin-2-yl)-[3-fluoro-4-(4-methyl-imidazol-1-yl)-phenyl]-ami-
ne
##STR00087##
[0568] The title compound was prepared from
3-fluoro-4-(4-methyl-imidazol-1-yl)-phenylamine (94 mg, 0.49 mmol)
and 4-benzyl-2-chloro-pyrimidine (100 mg, 0.49 mmol) in analogous
manner to the procedure described in example 1e). Obtained as a
pale-yellow solid (50 mg, 29 MS ISP (m/e): 360.3 [(M+H).sup.+].
[0569] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=8.33 (d,
1H), 7.94 (dd, 1H), 7.66 (s, 1H), 7.28 (m, 8H), 6.92 (s, 1H), 6.65
(d, 1H), 4.025 (s, 2H), 2.30 (s, 3H).
EXAMPLE 49
(4-Benzyl-6-methyl-pyrimidin-2-yl)-[3-fluoro-4-(2-methyl-imidazol-1-yl)-ph-
enyl]-amine
##STR00088##
[0571] The title compound was prepared from
3-fluoro-4-(2-methyl-imidazol-1-yl)-phenylamine (87 mg, 0.46 mmol)
and 4-benzyl-2-chloro-6-methyl-pyrimidine (100 mg, 0.46 mmol) in
analogous manner to the procedure described in example 1e).
Obtained as a light yellow oil (140 mg, 82%).
[0572] MS ISP (m/e): 374.4 [(M+H).sup.+].
[0573] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=8.00 (dd,
1H), 7.30 (m, 5H), 7.18 (m, 3H), 7.05 (s, 1H), 6.94 (s, 1H), 3.99
(s, 2H), 2.39 (s, 3H), 2.30 (s, 3H).
EXAMPLE 50
(4-Benzyl-6-methyl-pyrimidin-2-yl)-(3-fluoro-4-imidazol-1-yl-phenyl)-amine
##STR00089##
[0575] The title compound was prepared from
3-fluoro-4-imidazol-1-yl-phenylamine (81 mg, 0.46 mmol) and
4-benzyl-2-chloro-6-methyl-pyrimidine (100 mg, 0.46 mmol) in
analogous manner to the procedure described in example 1e).
Obtained as a light yellow wax (40 mg, 24%).
[0576] MS ISP (m/e): 360.4 [(M+H).sup.+].
[0577] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=8.01 (dd,
1H), 7.76 (s, 1H), 7.27 (m, 10H), 6.54 (s, 1H), 3.99 (s, 2H), 2.39
(s, 3H).
EXAMPLE 51
(4-Benzyl-6-methyl-pyrimidin-2-yl)-(3-fluoro-4-[1,2,4]triazol-1-yl-phenyl)-
-amine
##STR00090##
[0579] The title compound was prepared from
3-fluoro-4-[1,2,4]triazol-1-yl-phenylamine (81.4 mg, 0.46 mmol) and
4-benzyl-2-chloro-6-methyl-pyrimidine (100 mg, 0.46 mmol) in
analogous manner to the procedure described in example 1e).
Obtained as a light yellow wax (98 mg, 60%).
[0580] MS ISP (m/e): 361.0 [(M+H).sup.+].
[0581] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=8.57 (d,
1H), 8.11 (s, 1H), 8.11 (dd, 1H), 7.69 (dd, 1H), 7.31 (m, 5H), 7.20
(m, 2H), 6.55 (s, 1H), 3.99 (s, 2H), 2.39 (s, 3H).
EXAMPLE 52
(4-Benzyl-6-methyl-pyrimidin-2-yl)-(3-methoxy-4-thiazol-5-yl-phenyl)-amine
##STR00091##
[0582] a) 5-(2-Methoxy-4-nitro-phenyl)-thiazole
[0583] In a microwave vial, a mixture of 2-bromo-5-nitroanisole
(300 mg, 1.27 mmol), potassium acetate (188 mg, 1.90 mmol) and
tetrakis(triphenylphosphine)palladium(0) (74 mg, 0.634 mmol) in 4
ml dimethyl acetamide was flushed with argon. Thiazole (459 uL,
6.34 mmol) was added, the tube was sealed, and the mixture was
heated for 1 h to 160.degree. C. in a microwave oven. The mixture
was diluted with ethyl acetate and water, the layers were separated
and the aqueous layer was extraceted with ethyl acetate. The
organic phase was dried over magnesium sulfate and evaporated under
reduced pressure. The residual material was subjected to column
chromatography on silica gel using heptane/ethyl acetate (7:3) as
eluent to afford the title compound as yellow solid (177 mg, 59%).
Mp 125-128.degree. C.
[0584] MS ISP (m/e): 237.1 [(M+H).sup.+].
[0585] .sup.1H NMR (CDCl.sub.3, 400 MHz): .delta. (ppm)=8.91 (s,
1H), 8.44 (s, 1H), 7.93 (d, 1H), 7.87 (d, 1H), 7.81 (d, 1H), 4.08
(s, 3H),%). .sup.13C NMR (CDCl.sub.3, 100 MHz): .delta.
(ppm)=155.5, 154.7, 148.0, 143.1, 132.0, 128.7, 126.9, 116.42,
106.7, 56.3.
b) 3-Methoxy-4-thiazol-5-yl-phenylamine
[0586] A suspension of 5-(2-methoxy-4-nitro-phenyl)-thiazole (160
mg, 0.68 mmol and stannous dichloride (655 mg, 3.39 mmol) in
ethanol (10 mL) was stirred at reflux temperature for 75 min. The
yellow solution was evaporated under reduced pressure and the
residue was dissolved in ethyl acetate. This solution is washed
successively with 2N aqueous sodium hydroxide and with brine, dried
over magnesium sulfate and evaporated under reduced pressure. The
residual material was triturated with dichloromethane, insoluble
material was filtered off, and the filtrate was evaporated under
reduced pressure to afford the title compound (128 mg, 92%) as
orange oil.
[0587] MS ISP (m/e): 206.9 [(M+H).sup.+].
[0588] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=8.68 (s,
1H), 8.11 (s, 1H), 7.40 (d, 1H), 6.31-6.36 (m, 2H), 3.89 (s, b,
5H).
c)
(4-Benzyl-6-methyl-pyrimidin-2-yl)-(3-methoxy-4-thiazol-5-yl-phenyl)-am-
ine
[0589] The title compound was prepared from
3-methoxy-4-thiazol-5-yl-phenylamine (118 mg, 0.57 mmol) and
4-benzyl-2-chloro-6-methyl-pyrimidine (125 mg, 0.57 mmol) in
analogous manner to the procedure described in example 1e).
Obtained as a colorless wax (70 mg, 32%).
[0590] MS ISP (m/e): 389.4 [(M+H).sup.+].
[0591] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=8.72 (s,
1H), 8.20 (s, 1H), 7.86 (d, 1H), 7.53 (d, 1H), 7.29-7.34 (m, 5H),
7.16 (s, 1H), 7.01 (dd, 1H), 6.49 (s, 1H), 3.98 (s, 2H), 3.89 (s,
3H), 2.37 (s, 3H).
EXAMPLE 53
(4-Benzyl-6-methyl-pyrimidin-2-yl)-(3-fluoro-4-[1,3,4]oxadiazol-2-yl-pheny-
l)-amine
##STR00092##
[0592] a) Methyl
4-(4-benzyl-6-methyl-pyrimidin-2-ylamino)-2-fluoro-benzoate
[0593] The title compound was prepared from methyl
4-amino-2-fluoro-benzoate (480 mg, 2.84 mmol) and
4-benzyl-2-chloro-6-methyl-pyrimidine (620 mg, 2.84 mmol) in the
same manner as described for example 1e). Obtained as white solid
(840 mg, 84%). Mp 148-151.degree. C.
[0594] MS ISP (m/e): 352.4 [(M+H).sup.+].
[0595] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=7.90 (dd,
1H), 7.85 (d, 1H), 7.31 (m, 6H), 7.12 (d, 1H), 6.55 (s, 1H), 3.99
(s, 2H), 3.91 (s, 3H), 2.39 (s, 3H).
b) 4-(4-Benzyl-6-methyl-pyrimidin-2-ylamino)-2-fluoro-benzoic Acid
Hydrazide
[0596] A mixture of methyl
4-(4-benzyl-6-methyl-pyrimidin-2-ylamino)-2-fluoro-benzoate (420
mg, 1.20 mmol) and hydrazine monohydrate (1.4 mL, 28.8 mmol) in
ethanol (9 mL) was stirred at 90.degree. C. for 6 h. After cooling
to 20.degree. C., a white precipitate was formed which was isolated
by filtration to afford the title compound (345 mg, 82%) as white
solid. Mp 191-193.degree. C.
[0597] MS ISP (m/e): 352.4 [(M+H).sup.+].
[0598] .sup.1H NMR (DMSO-d6, 300 MHz): .delta. (ppm)=10.0 (s, 1H),
9.25 (s broad, 1H), 7.88 (d, 1H), 7.48 (d, 2H) 7.33 (m, 3H), 7.25
(m, 2H), 6.75 (s, 1H), 4.47 (d, 2H), 3.97 (s, 2H), 2.35 (s,
3H).
c)
(4-Benzyl-6-methyl-pyrimidin-2-yl)-(3-fluoro-4-[1,3,4]oxadiazol-2-yl-ph-
enyl)-amine
[0599] A suspension of
4-(4-benzyl-6-methyl-pyrimidin-2-ylamino)-2-fluoro-benzoic acid
hydrazide (98 mg, 0.28 mmol) in trimethyl orthoformate (2.0 ml,
17.9 mmol) was heated in a microwave oven for 2 h to 200.degree. C.
followed by 5.5 h at 230.degree. C. The mixture was evaporated
under reduced pressure and the residue was purified by column
chromatography on silica gel using dichloromethane/methanol (95:5
v/v) as eluent to afford the title compound (60 mg, 60%) as a light
yellow solid. Mp 153-15 6.degree. C.
[0600] MS ISP (m/e): 362.3 [(M+H).sup.+].
[0601] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=8.48 (s,
1H), 8.06 (dd, 1H), 7.96 (dd, 1H), 7.29 (m, 6H), 6.58 (s, 1H), 4.01
(s, 2H), 2.40 (s, 3H).
EXAMPLE 54
Ethyl
4-(2-chloro-4-fluoro-phenyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-
-phenylamino]-pyrimidine-5-carboxylate
##STR00093##
[0602] a) 1-(4-Chloro-phenyl)-3-dimethylamino-propenone
[0603] Ethyl 3-(2-chloro-4-fluoro-phenyl)-3-oxo-propionate (42 mg,
0.17 mmol) was reacted with
tert.-butoxy-bis-(dimethylamino)-methane using in analogous manner
the procedure described in example 28a) to give crude title
compound (51 mg) as a white solid which was used directly in the
next step. Mp 100-101.degree. C.
b) Ethyl
4-(2-chloro-4-fluoro-phenyl)-2-[3-methoxy-4-(4-methyl-imidazol-1--
yl)-phenylamino]-pyrimidine-5-carboxylate
[0604] The title compound was prepared from crude ethyl
2-(2-chloro-4-fluoro-benzoyl)-3-dimethylamino-acrylate (50 mg, 0.17
mmol) and N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine
dinitrate (51 mg, 0.14 mmol) using in analogous manner the
procedure described in example 28b). Obtained as a yellow solid (14
mg, 21%).
[0605] MS ISP (m/e): 482.2/484.2/483.1
(100/39/27)[(M+H).sup.+].
[0606] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=7.73 (s,
2H), 7.65 (s, 1H), 7.62 (d, 1H), 7.52 (d, 2H), 7.24 (s, 1H), 7.20
(d, 1H), 7.08 (d, 1H), 6.88 (s, 1H), 4.19 (q, 2H), 3.82 (s, 3H),
2.30 (s, 3H), 1.15 (s, 3H).
EXAMPLE 55
4-(4-Chloro-phenyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-p-
yrimidine-5-carbonitrile
##STR00094##
[0608] The title compound was prepared from crude
2-(4-chloro-benzoyl)-3-dimethylamino-acrylonitrile (50 mg, 0.21
mmol) and N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine
dinitrate (66 mg, 0.18 mmol) using in analogous manner the
procedure described in example 28b). Obtained as a pale-yellow
solid (10 mg, 14%).
[0609] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=8.75 (s,
2H), 8.05 (s, 1H), 7.97 (s, 1H), 7.70 (d, 2H), 7.40 (d, 2H), 7.24
(d, 1H), 7.15 (d, 1H), 6.90 (s, 1H), 3.86 (s, 3H), 2.31 (s,
3H);
EXAMPLE 56
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-5-(3-methyl-[1,2,4-
]oxadiazol-5-yl)-pyrimidin-2-yl]-amine
##STR00095##
[0610] a)
4-Dimethylamino-3-(3-methyl-[1,2,4]oxadiazol-5-yl)-but-3-en-2-on-
e
[0611] 1-(3-Methyl-[1,2,4]oxadiazol-5-yl)-propan-2-one (224 mg, 1.6
mmol) was reacted with tert.-butoxy-bis-(dimethylamino)-methane
using in analogous manner the procedure described in example 28a)
to give crude title compound (313 mg) as a yellow oil which was
used directly in the next step.
[0612] MS ISP (m/e): 196.1[(M+H).sup.+].
b)
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-5-(3-methyl-[1,-
2,4]oxadiazol-5-yl)-pyrimidin-2-yl]-amine
[0613] The title compound was prepared from crude
4-dimethylamino-3-(3-methyl-[1,2,4]oxadiazol-5-yl)-but-3-en-2-one
(313 mg, 1.6 mmol) and
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate
(297 mg, 0.8 mmol) using in analogous manner the procedure
described in example 39b). Obtained as a pale-yellow solid (142 mg,
47%).
[0614] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=9.08 (s,
1H), 7.77 (s, 1H), 7.66 (s, 1H), 7.48 (s, 1H), 7.22 (d, 1H), 7.13
(dd, 1H), 6.90 (s, 1H), 3.90 (s, 3H), 2.86 (s, 3H), 2.49 (s, 3H),
2.31 (s, 3H); MS ISP (m/e): 378.5 [(M+H).sup.+].
EXAMPLE 57
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-{4-[1-(5-methyl-[1,3,4]oxadi-
azol-2-yl)-cyclopropyl]-pyrimidin-2-yl}-amine
##STR00096##
[0615] a)
1-[1-(5-Methyl-[1,3,4]oxadiazol-2-yl)-cyclopropyl]-ethanone
[0616] A mixture of 1-(5-methyl-[1,3,4]oxadiazol-2-yl)-propan-2-one
(312 mg, 2.2 mmol), 1,2-dibromo-ethane (0.25 mL, 2.85 mmol), and
potassium carbonate (770 mg, 5.6 mmol) in acetone (5 mL) was
stirred at 60.degree. C. for 16 h. Insoluble material was filtered
off and the filtrate was diluted with ethyl acetate (30 mL). The
solution was washed with water and brine, dried over sodium
sulfate, and evaporated under reduced pressure. The residual
material was purified by chromatography on silica gel using
heptane/0-100% ethyl acetate as eluent to afford the title compound
(75 mg, 20%) as pale-yellow oil.
[0617] MS ISP (m/e): 167.3 [(M+H).sup.+].
b)
3-Dimethylamino-1-[1-(5-methyl-[1,3,4]oxadiazol-2-yl)-cyclopropyl]-prop-
enone
[0618] 1-[1-(5-Methyl-[1,3,4]oxadiazol-2-yl)-cyclopropyl]-ethanone
(75 mg, 0.45 mmol) was reacted with
tert.-butoxy-bis-(dimethylamino)-methane using in analogous manner
the procedure described in example 28a) to give crude title
compound (118 mg) as a yellow oil which was used directly in the
next step.
[0619] MS ISP (m/e): 222.3 [(M+H).sup.+].
c)
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-{4-[1-(5-methyl-[1,3,4]ox-
adiazol-2-yl)-cyclopropyl]-pyrimidin-2-yl}-amine
[0620] The title compound was prepared from crude
3-dimethylamino-1-[1-(5-methyl-[1,3,4]oxadiazol-2-yl)-cyclopropyl]-propen-
one (118 mg, ca. 0.45 mmol) and
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate
(149 mg, 0.4 mmol) using in analogous manner the procedure
described in example 39b). Obtained as a pale-yellow solid (31 mg,
17%).
[0621] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=8.34 (d,
1H), 7.64 (s, 1H), 7.60 (d, 1H), 7.21 (s, 1H), 7.17 (d, 1H), 7.02
(dd, 1H), 6.95 (d, 1H), 6.88 (s, 1H), 3.87 (s, 3H), 2.56 (s, 3H),
2.30 (s, 3H), 1.94 (m, 2H), 1.76 (m, 2H); MS ISP (m/e): 404.5
[(M+H).sup.+].
EXAMPLE 58
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-{4-[1-methyl-1-(3-methyl-[1,-
2,4]oxadiazol-5-yl)-ethyl]-pyrimidin-2-yl}-amine
##STR00097##
[0622] a)
3-Methyl-3-(3-methyl-[1,2,4]oxadiazol-5-yl)-butan-2-one
[0623] Methyl iodide (0.375 ml, 6 mmol) was added to a mixture of
1-(3-methyl-[1,2,4]oxadiazol-5-yl)-propan-2-one (0.84 g, 6 mmol)
and potassium carbonate (4.15 g, 30 mmol) in acetoniotrile (8 mL),
and the mixture was stirred at 20.degree. C. for 12 h. Insoluble
material was filtered off and the filtrate was diluted with
dichloromethane. The solution was washed with 1 N hydrochloric acid
and with brine, dried over sodium sulfate, and evaporated under
reduced pressure. The residual oil was subjected to column
chromatography on silica gel. Heptane/0-20% ethyl acetate eluted
successively the title compound
3-methyl-3-(3-methyl-[1,2,4]oxadiazol-5-yl)-butan-2-one (181 mg,
18%), obtained as colorless oil, Rf 0.4 (SiO.sub.2, ethyl
acetate/heptane 1:1), MS ISP (m/e): 169.1 [(M+H).sup.+];
3-(3-Methyl-[1,2,4]oxadiazol-5-yl)-butan-2-one (296 mg, 3 2%),
obtained as colorless oil, Rf 0.2 (SiO.sub.2, ethyl acetate/heptane
1:1), MS ISP (m/e): 155.1 [(M+H).sup.+]; and
3-hydroxy-3-(3-methyl-[1,2,4]oxadiazol-5-yl)-butan-2-one (204 mg,
20%), obtained as colorless oil, Rf 0.1 (SiO.sub.2, ethyl
acetate/heptane 1:1),
[0624] MS ISP (m/e): 171.1 [(M+H).sup.+].
b)
1-Dimethylamino-4-methyl-4-(3-methyl-[1,2,4]oxadiazol-5-yl)-pent-1-en-3-
-one
[0625] 3-Methyl-3-(3-methyl-[1,2,4]oxadiazol-5-yl)-butan-2-one (101
mg, 0.6 mmol) was reacted with
tert.-butoxy-bis-(dimethylamino)-methane using in analogous manner
the procedure described in example 28a) to give crude title
compound (140 mg) as a yellow oil which was used directly in the
next step.
[0626] MS ISP (m/e): 224.4 [(M+H).sup.+].
c)
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-{4-[1-methyl-1-(3-methyl--
[1,2,4]oxadiazol-5-yl)-ethyl]-pyrimidin-2-yl}-amine
[0627] The title compound was prepared from crude
1-dimethylamino-4-methyl-4-(3-methyl-[1,2,4]oxadiazol-5-yl)-pent-1-en-3-o-
ne (140 mg, 0.6 mmol) and
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate
(186 mg, 0.5 mmol) using in analogous manner the procedure
described in example 39b). Obtained as a pale-yellow solid (31 mg,
13%).
[0628] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=8.42 (d,
1H), 7.64 (s, 1H), 7.48 (br s, 1H), 7.15 (d, 1H), 7.02 (dd, 1H),
6.87 (s, 1H), 6.73 (d, 1H), 3.87 (s, 3H), 2.41 (s, 3H), 2.30 (s,
3H), 1.85 (s, 6H);
[0629] MS ISP (m/e): 406.1 [(M+H).sup.+].
[0630] As a by-product
2-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-i-
sobutyramide (20 mg, 9%) was obtained (see example 60)
EXAMPLE 59
1-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-1--
(3-methyl-[1,2,4]oxadiazol-5-yl)-ethanol
##STR00098##
[0631] a)
1-Dimethylamino-4-hydroxy-4-(3-methyl-[1,2,4]oxadiazol-5-yl)-pen-
t-1-en-3-one
[0632] 3-Hydroxy-3-(3-methyl-[1,2,4]oxadiazol-5-yl)-butan-2-one
(see example 58a) (102 mg, 0.6 mmol) was reacted with
tert.-butoxy-bis-(dimethylamino)-methane using in analogous manner
the procedure described in example 28a) to give crude title
compound (138 mg) as a yellow oil which was used directly in the
next step.
[0633] MS ISP (m/e): 226.3[(M+H).sup.+].
b)
1-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-
-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-ethanol
[0634] The title compound was prepared from crude
1-dimethylamino-4-methyl-4-(3-methyl-[1,2,4]oxadiazol-5-yl)-pent-1-en-3-o-
ne (138 mg, 0.6 mmol) and
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate
(185 mg, 0.5 mmol) using in analogous manner the procedure
described in example 39b). Obtained as a pale-yellow solid (32 mg,
16%);
[0635] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=8.51 (d,
1H), 7.59 (s, 1H), 7.66 (s, 1H), 7.46 (s, 1H), 7.19 (d, 1H), 7.05
(d, 1H), 7.03 (dd, 1H), 6.88 (s, 1H), 3.88 (s, 3H), 2.40 (s, 3H),
2.30 (s, 3H), 2.03 (s, 3H); MS ISP (m/e): 408.1 [(M+H).sup.+].
EXAMPLE 60
2-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-is-
obutyramide
##STR00099##
[0637] The title compound was isolated as a by-product in the
preparation of example 58 (see example 58c)). Obtained as a
pale-yellow solid.
[0638] MS ISP (m/e): 367.1 [(M+H).sup.+].
[0639] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=8.45 (d,
1H), 7.70 (s, 1H), 7.64 (s, 1H), 7.40 (s, 1H), 7.19 (d, 1H), 7.08
(dd, 1H), 6.89 (d, 1H), 6.88 (s, 1H), 6.16 and 5.44 (2 br s, 2H),
3.88 (s, 3H), 2.30 (s, 3H), 1.65 (s, 6H).
EXAMPLE 61
[4-(4-Chloro-phenyl)-5-(4-methoxy-benzyl)-pyrimidin-2-yl]-[3-methoxy-4-(4--
methyl-imidazol-1-yl)-phenyl]-amine
##STR00100##
[0640] a)
1-(4-Chloro-phenyl)-3-dimethylamino-2-(4-methoxy-benzyl)-propeno-
ne
[0641] 1-(4-Chloro-phenyl)-3-(4-methoxy-phenyl)-propan-1-one (137
mg, 0.5 mmol) was reacted with
tert.-butoxy-bis-(dimethylamino)-methane using in analogous manner
the procedure described in example 28a) to give crude title
compound (172 mg) as a yellow solid which was used directly in the
next step.
[0642] MS ISP (m/e): 330.4 [(M+H).sup.+].
b)
4-(4-Chloro-phenyl)-5-(4-methoxy-benzyl)-pyrimidin-2-yl]-[3-methoxy-4-(-
4-methyl-imidazol-1-yl)-phenyl]-amine
[0643] The title compound was prepared from crude
1-(4-chloro-phenyl)-3-dimethylamino-2-(4-methoxy-benzyl)-propenone
(172 mg, 0.5 mmol) and
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate
(137 mg, 0.37 mmol) using in analogous manner the procedure
described in example 39b). Obtained as an off-white solid (38 mg,
20%).
[0644] MS ISP (m/e): 512.3 [(M+H).sup.+].
[0645] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=8.32 (s,
1H), 7.84 (s, 1H), 7.62 (s, 1H), 7.49 and 7.41 (2d, 4H), 7.16 (d,
1H), 7.02 (dd, 1H), 6.95 (d, 2H), 6.87 (s, 1H), 6.82 (d, 2H), 3.91
(s, 2H), 3.81 (s, 3H), 3.79 (s, 3H), 2.29 (s, 3H).
EXAMPLE 62
(6-Benzyl-2-chloro-pyrimidin-4-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-p-
henyl]-amine
##STR00101##
[0647] Palladium acetate (2.7 mg, 0.012 mmol) and
2-(dicyclohexylphosphino)-biphenyl (8.5 mg, 0.024 mmol) were
dissolved under an atmosphere of nitrogen under stirring in dioxane
(1 mL). After 10 min stirring this solution was added to a
suspension of 3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (61
mg, 0.3 mmol), 4-benzyl-2,6-dichloropyrimidine (71.7 mg, 0.3 mmol)
and potassium carbonate (829 mg, 6 mmol) in dioxane (1.7 mL). The
reaction was heated to reflux for 16 h. After cooling to 20.degree.
C. the reaction was poured onto water and the mixture was extracted
with ethyl actate. The organic layer was washed with brine, dried
over sodium sulfate, and the solvent was evaporated under reduced
pressure. The residue was purified by column chromatography on
silica gel using dichloromethane/methanol (19:1 v/v) as eluent to
yield the title compound (9.0 mg, 24%) as a yellow solid.
[0648] MS ISP (m/e): 406.3/408.3 (100/50) [(M+H).sup.+].
[0649] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=7.63 (s,
1H), 7.20-7.33 (m, 5H), 7.18 (d, 1H), 7.00 (s, 1H), 6.87 (s, 1H),
6.82 (d, 1H), 6.30 (s, 1H), 3.99 (s, 2H), 3.77 (s, 3H), 2.29 (s,
3H).
EXAMPLE 63
[6-(4-Chloro-phenoxy)-pyrimidin-4-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl-
)-phenyl]-amine
##STR00102##
[0650] a) 4-Chloro-6-(4-chloro-phenoxy)-pyrimidine
[0651] 4,6-Dichloropyrimidine (149 mg, 1 mmol), 4-chlorophenol (135
mg, 1.05 mmol), potassium carbonate (166 mg, 1.2 mmol) and sodium
iodide (7.5 mg, 0.05 mmol) were stirred in acetonitrile (3 mL) at
20.degree. C. under an atmosphere of nitrogen for 16 h. The
reaction was poured onto 1 N aqueous sodium hydroxide solution and
the mixture was extracted with diethyl ether. The organic layer was
washed with brine, dried over sodium sulfate, and the solvent was
evaporated under reduced pressure. The title compound (224 mg, 93%)
was obtained as a pale-yellow solid.
[0652] MS EI (m/e): 240.1/242.0 (100/55) [M.sup.+].
[0653] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=8.06 (s,
1H), 7.53 (d, 2H), 7.45 (s, 1H), 7.31 (d, 2H).
b)
[6-(4-Chloro-phenoxy)-pyrimidin-4-yl]-[3-methoxy-4-(4-methyl-imidazol-1-
-yl)-phenyl]-amine
[0654] The title compound was prepared from
4-chloro-6-(4-chloro-phenoxy)-pyrimidine and
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine in analogous
manner as described in example 62 by heating the reaction mixture
in a microwave oven at 200.degree. C. for 2.5 h. Obtained as a
yellow solid in 18% yield.
[0655] MS ISP (m/e): 408.3/410.2 (100/34) [(M+H).sup.+].
[0656] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=9.79 (s,
1H), 8.40 (s, 1H), 7.68 (s, 1H), 7.51-7.54 (m, 3H), 7.25-7.32 (m,
3H), 7.05 (s, 1H), 6.19 (s, 1H), 3.80 (s, 3H), 2.14 (s, 3H).
EXAMPLE 64
{6-[1-(4-Chloro-phenyl)-cyclobutyl]-2-methyl-pyrimidin-4-yl}-[3-methoxy-4--
(4-methyl-imidazol-1-yl)-phenyl]-amine
##STR00103##
[0657] a) Methyl
3-[1-(4-chlorophenyl)cyclobutyl]-3-oxopropionate
[0658] Sodium hydride (1.86 g of a 60% dispersion in mineral oil,
46.5 mmol) was added to a solution of
1-[1-(4-chlorophenyl)cyclobutyl]ethanone (4.18 g, 20.0 mmol) and of
dimethyl carbonate (8.4 mL, 99.6 mmol) in of dioxane (20 mL). After
the reaction mixture had been refluxed for 4 h, it was chilled in
an ice-water bath and treated drop wise with 1 M aqueous sodium
hydrogen sulfate solution (50 mL). The mixture containing now a
thick precipitate was then partitioned between diethyl ether and
water. The organic phase was washed with sat. sodium hydrogen
carbonate solution and with brine, dried over magnesium sulfate,
and evaporated under reduced pressure. The residual material was
purified by chromatography on silica gel using heptane/0-10% ethyl
acetate as eluent to afford the title compound (4.45 g, 79%) as
pale-yellow oil.
b) 6-[1-(4-Chlorophenyl)cyclobutyl]-2-methylpyrimidin-4-ol
[0659] To a solution of acetamidine hydrochloride (0.617 g, 6.53
mmol) in methanol (10 mL) was added potassium tert.-butoxide (0.80
g, 6.54 mmol) followed by methyl
3-[1-(4-chlorophenyl)cyclobutyl]-3-oxopropionate (1.34 g, 5.02
mmol). The mixture was stirred at 20.degree. C. for 16 h, then
refluxed for 2 h. The reaction mixture was cooled, diluted with
water, made alkaline by the addition of 10 mL of 10% aqueous sodium
hydroxide solution, and then washed with diethyl ether. The aqueous
phase was acidified with concentrated hydrochloric acid, and then
extracted with diethyl ether. This ether extract was washed with
brine, dried over magnesium sulfate, and concentrated under reduced
pressure to give the title compound (1.04 g, 75%) as a solid foam.
Mp 130-140.degree. C.
[0660] MS ISP (m/e): 275 [(M+H).sup.+].
c) 4-Chloro-6-[1-(4-chlorophenyl)cyclobutyl]-2-methylpyrimidine
[0661] To 6-[1-(4-chlorophenyl)cyclobutyl]-2-methylpyrimidin-4-ol
(1.00 g, 3.65 mmol) was added phosphorous oxychloride (10 mL) and
the mixture was refluxed for 1.5 h. After cooling to 20.degree. C.,
the reaction mixture was poured into ice/water (55 mL). After the
addition of dichloromethane, the mixture was neutralized with 32%
aqueous sodium hydroxide solution. The layers were separated and
the organic layer was washed with 0.1 N sodium hydroxide solution
and with water, dried over magnesium sulfate, and evaporated under
reduced pressure. The residual material was purified by
chromatography on silica gel using dichloromethane/methanol (95:5
v/v) as eluent to afford the title compound (0.91 g, 85%) as an
off-white solid. Mp 96-98.degree. C.
[0662] MS ISP (m/e): 293 [(M+H).sup.+].
d)
{6-[1-(4-Chloro-phenyl)-cyclobutyl]-2-methyl-pyrimidin-4-yl}-[3-methoxy-
-4-(4-methyl-imidazol-1-yl)-phenyl]-amine
[0663] The title compound was prepared in analogous manner as
described in example 62 from
4-chloro-6-[1-(4-chloro-phenyl)-cyclobutyl]-2-methyl-pyrimidine and
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine. Obtained as a
pale-yellow solid in 81% yield after column chromatography of the
crude product on silica gel using dichloromethane/methanol (19:1
v/v) as eluent.
[0664] MS ISP (m/e): 460.3/462.2 (100/44) [(M+H).sup.+].
[0665] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=9.57 (s,
1H), 7.75 (s, 1H), 7.66 (s, 1H), 7.40 (d, 2H), 7.35 (d, 2H), 7.24
(s, 2H), 6.36 (s, 1H), 3.79 (s, 3H), 2.78-2.99 (m, 2H), 2.50-2.62
(m, 2H), 2.14 (s, 3H), 1.79-1.99 (m, 2H).
EXAMPLE 65
(2-Benzyl-6-chloro-pyrimidin-4-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-p-
henyl]-amine
##STR00104##
[0667] The title compound was prepared in analogous manner as
described in example 62 from 2-benzyl-4,6-dichloro-pyrimidine and
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine. Obtained as
yellow solid in 48% yield after column chromatography of the crude
product on silica gel using dichloromethane/methanol (98:2 and then
95:5 v/v) as eluent.
[0668] MS ISP (m/e): 406.3/408.4 (100/26) [(M+H).sup.+].
[0669] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=10.01 (s,
1H), 7.68 (s, 1H), 7.64 (s, 1H), 7.32 (d, 4H), 7.18-7.28 (m, 2H),
7.17 (d, 1H), 7.05 (s, 1H), 6.69 (s, 1H), 4.06 (s, 2H), 3.72 (s,
3H), 2.14 (s, 3H).
EXAMPLE 66
Methyl
2-Chloro-6-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-isoni-
cotinate
##STR00105##
[0671] The title compound was prepared in analogous manner as
described in example 1e) from methyl-2,6-dichloroisonicotinate (64
mg, 0.3 mmol) and 3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine
(61 mg, 0.3 mmol). The reaction mixture was heated for 16 h to
reflux. Obtained as a yellow solid (40 mg, 36%) after column
chromatography of the crude product on silica gel using
dichloromethane/methanol (19:1 v/v) as eluent.
[0672] MS ISP (m/e): 373.2/375.2 (100/42) [(M+H).sup.+].
[0673] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=9.94 (s,
1H), 7.69 (s, 1H), 7.64 (s, 1H), 7.36 (s, 1H), 7.31 (d, 1H), 7.28
(d, 1H), 7.16 (s, 1H), 7.06 (s, 1H), 3.90 (s, 3H), 3.82 (s, 3H),
2.15 (s, 3H).
EXAMPLE 67
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(6-methyl-4-trifluoromethyl--
pyridin-2-yl)-amine
##STR00106##
[0675] The title compound was prepared in analogous manner as
described in example 1e) from
2-chlor-6-methyl-4-(trifluormethyl)pyridine (59 mg, 0.3 mmol) and
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (61 mg, 0.3 mmol).
The reaction was heated for 16 h to reflux. Obtained as a
pale-yellow solid (75 mg 69%) after column chromatography of the
crude reaction product on silica gel using dichloromethane/methanol
(19:1 v/v) as eluent.
[0676] MS ISP (m/e): 363.3 (100) [(M+H).sup.+].
[0677] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=9.63 (s,
1H), 7.88 (s, 1H), 7.66 (s, 1H), 7.25 (s, 2H), 7.04 (s, 1H), 6.96
(s, 1H), 6.93 (s, 1H), 3.82 (s, 3H), 2.14 (s, 3H).
EXAMPLE 68
{2-Chloro-6-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyridin-4-y-
l}-methanol
##STR00107##
[0679] The title compound was prepared in analogous manner as
described in example 1e) from 2,6-dichlorpyridin-4-methanol (53 mg,
0.3 mmol) and 3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (61
mg, 0.3 mmol). The reaction was heated for 16 h to reflux. Obtained
as a pale-yellow solid (25 mg, 24%) after column chromatography on
silica gel using dichloromethane/methanol (9:1 v/v) as eluent.
[0680] MS ISP (m/e): 345.2/347.1 (100/39) [(M+H).sup.+].
[0681] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=9.57 (s,
1H), 7.66 (s, 1H), 7.64 (s, 1H), 7.25 (s, 2H), 7.03 (s, 1H), 6.83
(s, 1H), 6.76 (s, 1H), 5.48 (t, 1H), 4.47 (d, 2H), 3.80 (s, 3H),
2.14 (s, 3H).
EXAMPLE 69
[6-(4-Chloro-phenoxy)-pyridin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)--
phenyl]-amine
##STR00108##
[0682] a) 2-Chloro-6-(4-chloro-phenoxy)-pyrimidine
[0683] The title compound was prepared in analogous manner as
described in example 10a) from 4,6-dichlorpyrimidin (149 mg, 1.0
mmol) and 4-chlorphenol (129 mg, 1.05 mmol). Obtained as a
pale-yellow solid (224 mg, 93%).
[0684] MS EI (m/e): 240.1/242.0 (100/55) [M.sup.+].
[0685] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=8.66 (s,
1H), 7.53 (d, 2H), 7.45 (s, 1H), 7.31 (d, 2H).
b)
[6-(4-Chloro-phenoxy)-pyridin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-y-
l)-phenyl]-amine
[0686] The title compound was prepared in analogous manner as
described in example 1e) from
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (61 mg, 0.3 mmol)
and 4-chloro-6-(4-chloro-phenoxy)-pyrimidine (90 mg, 0.3 mmol). The
reaction was heated in a microwave oven to 200.degree. C. for 1 h.
Obtained as a yellow solid (48 mg, 39%) after chromatography of the
crude reaction product on silica gel using dichloromethane/methanol
(9:1 v/v) as eluent.
[0687] MS ISP (m/e): 407.2/409.3 (100/31) [(M+H).sup.+].
[0688] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=9.37 (s,
1H), 7.67 (m, 2H), 7.58 (s, 1H), 7.48 (d, 2H), 7.33 (s, 1H), 7.17
(d, 2H), 6.97 (s, 2H), 6.61 (d, 1H), 6.44 (d, 1H), 3.42 (s, 3H),
2.13 (s, 3H).
EXAMPLE 70
N-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N'-phenyl-pyridine-2,6-dia-
mine
##STR00109##
[0689] a) (6-Chloro-pyridin-2-yl)-phenyl-amine
[0690] A mixture of palladium(II)acetate (303 mg; 1.35 mmol) and
rac-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (842 mg; 1.35 mmol)
in toluene (10 mL) was stirred under argon for 10 min at 20.degree.
C., and then added to a mixture of 2,6-dichloroaniline (2.0 g; 13.5
mmol), aniline (1.51 g; 16.2 mmol), and potassium carbonate (37.4
g; 270 mmol) in 140 ml toluene. The reaction mixture was heated to
reflux for 16 h. The resulting suspension was cooled, filtered, and
the filtrate was concentrated under reduced pressure. Column
chromatography of the residue on silica gel using heptane/ethyl
acetate (4:1 v/v) as eluent gave the title compound (1.5 g, 54%) as
an orange oil.
[0691] MS ISP (m/e): 205.1 (100)/207.1 (30) [(M+H).sup.+].
[0692] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=7.50-7.25
(m, 5H), 7.13 (t, 1H), 6.74 (dd, 2H), 6.58 (s broad, 1H).
b)
N-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N'-phenyl-pyridine-2,6--
diamine
[0693] A mixture of palladium(II)acetate (4 mg; 0.02 mmol) and
(2-biphenyl)dicyclohexylphosphine (14 mg; 0.04 mmol) in dioxane (5
mL) was stirred under argon for 10 min at 20.degree. C.
(6-Chloro-pyridin-2-yl)-phenyl-amine (100 mg; 0.5 mmol),
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (99 mg; 0.5 mmol),
and potassium carbonate (1.35 g; 10 mmol) were added and the
mixture was refluxed under argon for 3 h. After quenching the
reaction by addition of water, the mixture was extracted with ethyl
acetate. The organic phase was dried over sodium sulfate,
concentrated under reduced pressure. The crude product was purified
by column chromatography on silica gel using dichloromethane/0-20%
methanol as eluent to give the title compound (42 mg, 23%) as a
light yellow solid.
[0694] MS ISP (m/e): 372.2 (100) [(M+H).sup.+].
[0695] NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=9.06 (br s, 1H),
8.85 (br s, 1H), 7.65 (d, 1H), 7.55 (d, 2H), 7.47 (d, 1H), 7.41 (t,
1H), 7.23 (t, 3H), 7.14 (d, 1H), 7.02 (s, 1H), 6.87 (t, 1H), 6.27
(dd, 2H), 3.56 (s, 3H), 2.14 (s, 3H).
EXAMPLE 71
(5-Benzyl-4H-[1,2,4]triazol-3-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-ph-
enyl]-amine
##STR00110##
[0696] a)
1-(4-Isothiocyanato-2-methoxy-phenyl)-4-methyl-1H-imidazole
[0697] A solution of
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (203 mg, 1 mmol)
and of 1,1'-thiocarbonyldi-2(1H)-pyridone (263 mg, 1.1 mmol) in
dichloromethane (10 mL) was stirred at 20.degree. C. for 16 h to
yield an orange solution. The solution was concentrated under
reduced pressure to 1/4 Of its volume and subjected to column
chromatography on silica gel using dichloromethane/methanol (95:5
v/v) as eluent to yield the title compound (230 mg, 94%) as a
yellow oil which solidified on standing.
[0698] MS ISP (m/e): 246.3 (100) [(M+H).sup.+].
[0699] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=7.67 (s,
1H), 7.21 (d, 1H), 6.91-6.86 (m, 3H), 3.86 (s, 3H), 2.29 (s,
3H).
b) [3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-thiourea
[0700] 1-(4-Isothiocyanato-2-methoxy-phenyl)-4-methyl-1H-imidazole
(227 mg, 0.93 mmol) was dissolved in tetrahydrofuran (2.3 mL). At
0.degree. C. under stirring ammonia gas was bubbled through the
solution for 5 min. A solid precipitated. The suspension was
stirred at 20.degree. C. for 16 h. The solvent was evaporated under
reduced pressure and the residue was stirred with diethyl ether for
30 min. The solid was filtered off and dried to yield the title
compound (170 mg, 70%) as a pale-yellow solid.
[0701] MS ISP (m/e): 263.3 (100) [(M+H).sup.+].
[0702] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=9.84 (s,
1H), 7.90-7.20 (br s, 2H), 7.71 (s, 1H), 7.46 (s, 1H), 7.28 (d,
1H), 7.07 (s, 1H), 7.03 (d, 1H), 3.79 (s, 3H), 2.15 (s, 3H).
c)
(5-Benzyl-4H-[1,2,4]triazol-3-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-
-phenyl]-amine
[0703] A solution of
[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-thiourea (400 mg,
1.52 mmol) in acetone (25 ml) was treated with iodomethane (0.14
ml, 2.29 mmol) and stirred at 20.degree. C. for 16 h. The reaction
mixture was concentrated and the crude S-methyl-isothiourea
redissolved in ethanol (25 ml). Phenylacetic acid hydrazide (252
mg, 1.52 mmol) was added and the mixture was refluxed for 16 h
under argon. After cooling to 20.degree. C., 2 N sodium hydroxide
solution (5 ml) was added and the mixture was refluxed for 2 h.
After cooling to 20.degree. C., the mixture was brought to pH 7 by
careful addition of 1 N aqueous hydrochloric acid and then
extracted with ethyl acetate. The organic phase was dried over
sodium sulfate and evaporation under reduced pressure to afford a
sticky semisolid which was triturared in diethyl ether (3 mL).
Filtration yielded the title compound (146 mg, 27%) as greyish
solid.
[0704] MS ISP (m/e): 361.5 (100) [(M+H).sup.+].
[0705] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=13.5 (br
s, 1H), 9.31 (br s, 1H), 7.59 (s, 1H), 7.50 (s, 1H), 7.40-7.20 (m,
5H), 7.12 (qa, 2H), 6.97 (s, 1H), 4.00 (s, 2H), 3.74 (s, 3H), 2.13
(s, 3H).
EXAMPLE 72
[5-(4-Chloro-benzyl)-4H-[1,2,4]triazol-3-yl]-[3-methoxy-4-(4-methyl-imidaz-
ol-1-yl)-phenyl]-amine
##STR00111##
[0707] The title compound was prepared in analogy to example 71c)
starting with
[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-thiourea (150 mg,
0.57 mmol) and (4-chloro-phenyl)-acetic acid hydrazide (116 mg,
0.57 mmol). Obtained as a brownish solid (36 mg, 16%) after
chromatography of the crude reaction product on amino-modified
silica gel (Merck HPTLC Silica Gel 60 NH2F254S) using ethyl acetate
as eluent.
[0708] MS ISN (m/e): 393.3 (100) [(M-H).sup.-].
[0709] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=13.2
(very br s, 1H), 9.50 (br s, 1H), 7.59 (s, 1H), 7.50 (s, 1H),
7.40-7.30 (qa, 4H), 7.20-7.10 (m, 2H), 6.97 (s, 1H), 3.99 (s, 2H),
3.73 (s, 3H), 2.13 (s, 3H).
EXAMPLE 73
[5-(4-Fluoro-benzyl)-4H-[1,2,4]triazol-3-yl]-[3-methoxy-4-(4-methyl-imidaz-
ol-1-yl)-phenyl]-amine
##STR00112##
[0711] The title compound was prepared in analogy to example 71c)
starting with
[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-thiourea (200 mg,
0.76 mmol) and (4-fluoro-phenyl)-acetic acid hydrazide (141 mg,
0.76 mmol). Obtained as a greyish solid (21 mg, 7%).
[0712] MS ISP (m/e): 379.3 (100) [(M+H).sup.+].
[0713] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=13.1 (br
s, 1H), 9.32 (br s, 1H), 7.59 (s, 1H), 7.49 (s, 1H), 7.40-7.30 (m,
2H), 7.20-7.10 (m, 3H), 6.98 (s, 1H), 4.00 (s, 2H), 3.74 (s, 3H),
2.13 (s, 3H).
EXAMPLE 74
[5-(4-Fluoro-phenyl)-4H-[1,2,4]triazol-3-yl]-[3-methoxy-4-(4-methyl-imidaz-
ol-1-yl)-phenyl]-amine
##STR00113##
[0715] The title compound was prepared in analogy to example 71c)
starting with
[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-thiourea (250 mg,
0.95 mmol) and 4-fluoro-benzhydrazide (162 mg, 0.95 mmol). Obtained
as a brownish solid (41 mg, 12%).
[0716] MS ISP (m/e): 365.1 (100) [(M+H).sup.+].
[0717] .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=13.85 (br
s, 1H), 9.56 (br s, 1H), 8.01 (t, 2H), 7.63 (s, 2H), 7.50-7.25 (m,
2H), 7.19 (br s, 2H), 7.01 (s, 1H), 3.81 (s, 3H), 2.14 (s, 3H).
EXAMPLE 75
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-methoxy-6-methyl-pyrimidi-
n-2-yl)-amine
##STR00114##
[0719] A mixture of
(4-chloro-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)--
phenyl]-amine (99 mg, 0.3 mmol) and sodium methoxide (25 mg, 0.45
mmol) in methanol (3 mL) was heated for 30 min to 160.degree. C. in
a microwave oven. The reaction mixture was concentrated under
reduced pressure and the residue was partitioned between ethyl
acetate and water. The aqueous layer was extracted twice with ethyl
acetate. The combined organic layers were washed with brine, dried
over sodium sulfate and evaporated under reduced pressure. The
residue was purified by reversed preparative HPLC using
acetonitril/water (0.1% formic acid) to yield the title compound as
a yellow solid (30 mg, 31%). MS ISP (m/e): 326.2 (100)
[(M+H).sup.+].
[0720] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=7.80 (s,
1H), 7.62 (s, 1H), 7.15 (d, 1H), 7.11 (s, 1H), 7.02 (d, 1H), 6.87
(s, 1H), 6.12 (s, 1H), 3.97 (s, 3H), 3.86 (s, 3H), 2.35 (s, 3H),
2.30 (s, 3H).
EXAMPLE 76
(4-Isopropoxy-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-y-
l)-phenyl]-amine
##STR00115##
[0722] Sodium (10 mg, 0.45 mmol) was dissolved under heating and
stirring under an atmosphere of nitrogen in isopropanol (1 mL).
(4-Chloro-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)--
phenyl]-amine (99 mg, 0.3 mmol) was added and the suspension was
heated to reflux over night. The solvent was evaporated under
reduced pressure and the residue was taken up in water and
extracted twice with diethyl ether. The combined organic layers
were washed with brine, dried over sodium sulfate, filtered and
evaporated under reduced pressure to dryness. The residue was
purified by column chromatography on silica gel using
dichloromethane/methanol (19:1 v/v) as eluent. The fraction
containing the product was purified by reversed preparative HPLC
using acetonitril/water (0.1% formic acid) to yield the title
compound as an off-white solid (25 mg, 24%). MS ISP (m/e): 354.2
(100) [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=7.73 (s, 1H), 7.63 (s, 1H), 7.18 (d, 1H), 7.04 (s, 1H), 7.03
(d, 1H), 6.87 (s, 1H), 6.06 (s, 1H), 5.36 (sept, 1H), 3.86 (s, 3H),
2.33 (s, 3H), 2.30 (s, 3H), 1.38 (s, 3H), 1.36 (s, 3H).
EXAMPLE 77
[4-(2-Methoxy-ethoxy)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imid-
azol-1-yl)-phenyl]-amine
##STR00116##
[0724] Sodium (10 mg, 0.45 mmol) was dissolved under an atmosphere
of nitrogen in 2-methoxyethanol (0.95 mL).
(4-Chloro-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)--
phenyl]-amine (99 mg, 0.3 mmol) was added and the suspension was
heated to 100.degree. C. for 2 hours. The solvent was evaporated
under reduced pressure and the residue was taken up in water and
extracted twice with diethyl ether. The combined organic layers
were washed with brine, dried over sodium sulfate, filtered and
evaporated under reduced pressure to dryness. The residue was
purified by column chromatography on silica gel using
dichloromethane/methanol (19:1 v/v) as eluent to yield the title
compound as a yellow solid (41 mg, 37%). MS ISP (m/e): 370.2 (100)
[(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=7.74 (s, 1H), 7.63 (s, 1H), 7.18 (d, 1H), 7.05 (s, 1H), 7.03
(d, 1H), 6.87 (s, 1H), 6.18 (s, 1H), 4.51 (dd, 2H), 3.86 (s, 3H),
3.73 (dd, 2H), 3.45 (s, 3H), 2.35 (s, 3H), 2.30 (s, 3H).
EXAMPLE 78
[4-(2-Dimethylamino-ethoxy)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methy-
l-imidazol-1-yl)-phenyl]-amine
##STR00117##
[0726] Sodium (10 mg, 0.45 mmol) was dissolved under an atmosphere
of nitrogen in 2-dimethylaminoethanol (0.92 mL).
(4-Chloro-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)--
phenyl]-amine (99 mg, 0.3 mmol) was added and the suspension was
heated to 100.degree. C. for 2 hours. The solvent was evaporated
under reduced pressure and the residue was taken up in water and
extracted twice with diethyl ether. The combined organic layers
were washed with brine, dried over sodium sulfate, filtered and
evaporated under reduced pressure to dryness. The residue was
purified by column chromatography on silica gel using
dichloromethane/methanol/saturated aqueous ammonia solution
(19:1:0.2 v/v/v) as eluent to yield the title compound as a brown
viscous oil (37 mg, 33%). MS ISP (m/e): 383.2 (100) [(M+H).sup.+].
.sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=7.74 (s, 1H), 7.62
(s, 1H), 7.15 (d, 1H), 7.07 (s, 1H), 7.05 (d, 1H), 6.87 (s, 1H),
6.16 (s, 1H), 4.45 (t, 2H), 3.86 (s, 3H), 2.71 (t, 2H), 2.36 (s,
3H), 2.34 (s, 6H), 2.30 (s, 3H).
EXAMPLE 79
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(tetrahydro-pyra-
n-4-yloxy)-pyrimidin-2-yl]-amine
##STR00118##
[0728] Sodium (10 mg, 0.45 mmol) was dissolved under stirring and
heating (100.degree. C. for 3 hours) under an atmosphere of
nitrogen in tetrahydro-4H-pyran-4-ol (0.99 mL).
(4-Chloro-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)--
phenyl]-amine (99 mg, 0.3 mmol) was added and the suspension was
heated to 100.degree. C. for 2 hours. The solvent was evaporated
under reduced pressure and the residue was taken up in water and
extracted twice with diethyl ether. The combined organic layers
were washed with brine, dried over sodium sulfate, filtered and
evaporated under reduced pressure to dryness. The residue was
purified by reversed preparative HPLC using acetonitril/water (0.1%
formic acid) to yield the title compound as a white solid (13 mg,
11%). MS ISP (m/e): 396.2 (100) [(M+H).sup.+]. .sup.1H NMR
(CDCl.sub.3, 300 MHz): .delta. (ppm)=7.65 (s, 1H), 7.62 (s, 1H),
7.17 (d, 1H), 7.15 (s, 1H), 7.13 (d, 1H), 6.87 (s, 1H), 6.12 (s,
1H), 5.30 (m, 1H), 3.98 (m, 2H), 3.86 (s, 3H), 3.62 (m, 2H), 2.36
(s, 3H), 2.31 (s, 3H), 2.04 (m, 2H), 1.84 (m, 2H).
EXAMPLE 80
(4-Cyclopentyloxy-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-
-1-yl)-phenyl]-amine
##STR00119##
[0729] a) 2-Chloro-4-cyclopentyloxy-6-methyl-pyrimidine and
4-chloro-2-cyclopentyloxy-6-methyl-pyrimidine
[0730] To a solution of cycpopentanol (86 mg, 1.0 mmol) in
tetrahydrofurane (6 mL) was added at under an atmosphere of
nitrogen potassium tert.-butylate (126 mg, 1.1 mmol).
2,4-Dichloro-6-methylpyrimidine (166 mg, 1.0 mmol) was added to
this solution and the reaction was stirred at for 3 hours. The
solvent was evaporated under reduced pressure and the residue was
taken up in water and extracted twice with diethyl ether. The
combined organic layers were washed with brine, dried over sodium
sulfate, filtered and evaporated under reduced pressure to dryness.
The residue was purified by column chromatography on silica gel
using heptane/ethyl acetate (9:1 v/v) as eluent to yield the title
compound as a colorless oil as a 1:1 mixture of regioisomers (116
mg, 55%). MS ISP (m/e): 213.1/215.5 (14/3) [(M+H).sup.+],
145.0/147.0 (100/41) [(M-cyclopentene+H).sup.+]. .sup.1H NMR
(CDCl.sub.3, 300 MHz): .delta. (ppm)=6.81 (s, 1H), 6.42 (s, 1H),
5.45 (m, 2H), 2.42 (s, 3H), 2.40 (s, 3H), 1.58-2.04 (m, 16H).
b)
(4-Cyclopentyloxy-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imida-
zol-1-yl)-phenyl]-amine
[0731] Palladium acetate (7.1 mg, 0.03 mmol) and
2-(dicyclohexylphosphino)biphenyl (23.1 mg, 0.64 mmol) were
dissolved in dioxane (3.6 mL) and stirred for 10 minutes at. Sodium
tert.-butylate (59 mg, 0.6 mmol),
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (81 mg, 0.4 mmol)
and 1:1 mixture of 2-chloro-4-cyclopentyloxy-6-methyl-pyrimidine
and 4-chloro-2-cyclopentyloxy-6-methyl-pyrimidine (94 mg, 0.44
mmol) were added and the reaction was heated to 200.degree. C. for
30 minutes in a microwave oven. The solvent was evaporated under
reduced pressure and the residue was taken up in water and
extracted twice with ethyl acetate. The combined organic layers
were washed with brine, dried over sodium sulfate, filtered and
evaporated under reduced pressure to dryness. The residue was
purified by column chromatography on silica gel using
methylenechloride/methanol (19:1 v/v) as eluent to yield the title
compound as a white solid (56 mg, 37%). MS ISP (m/e): 380.1 (100)
[(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=7.70 (s, 1H), 7.62 (s, 1H), 7.15 (d, 1H), 7.07 (d, 1H), 7.05
(s, 1H), 6.87 (s, 1H), 6.06 (s, 1H), 5.30 (m, 1H), 3.85 (s, 3H),
2.33 (s, 3H), 2.30 (s, 3H), 1.75-2.00 (m, 6H), 1.60-1.68 (m,
2H).
EXAMPLE 81
[4-(4-Fluoro-phenoxy)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imid-
azol-1-yl)-phenyl]-amine
##STR00120##
[0732] 2-Chloro-4-(4-fluoro-phenoxy)-6-methyl-pyrimidine
[0733] 4-Fluorophenol (103 mg, 0.92 mmol) and
potassium-tert-butylate (113 mg, 1.0 mmol) were dissolved in 7 mL
of tetrahydrofurane. 2,4-dichloro-6-methylpyrimidine (150 mg, 0.92
mmol) was added and the mixture stirred at 20.degree. C. overnight.
Water was added and the mixture extracted with diethyl ether.
Chromatography of the crude reaction product on silica gel using a
heptane/ethyl acetate as an eluent gave the title compound (150 mg,
68%) as a slightly yellow solid. .sup.1H NMR (CDCl.sub.3, 300 MHz):
.delta. (ppm)=7.50-7.40 (m, 2H), 7.28 (t, 1H), 7.14 (d, 2H), 6.57
(s, 1H), 2.47 (s, 3H).
b)
[4-(4-Fluoro-phenoxy)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-i-
midazol-1-yl)-phenyl]-amine
[0734] Palladium acetate (7 mg, 0.03 mmol) and
2-(dicyclohexylphosphino)biphenyl (22 mg, 0.06 mmol) were dissolved
in 2.5 mL of dioxane and stirred at 20.degree. C. under argon for
10 minutes. Sodium tert-butylate (57 mg, 0.59 mmol) was added,
followed by 3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (80
mg, 0.39 mmol) and
2-chloro-4-(4-fluoro-phenoxy)-6-methyl-pyrimidine (115 mg, 0.48
mmol). The resulting mixture was heated in the microwave oven for
20 minutes at 200.degree. C. Dichloromethane was added, insoluble
material filtered off and the resulting solution purified by
chromatography on silica gel using ethyl acetate as a solvent. The
title compound was isolated as a yellow solid (50 mg, 31%). MS ISP
(m/e): 406.3 (100) [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300
MHz): .delta. (ppm)=7.58 (d, 1H), 7.46 (d, 1H), 7.17 (s, 1H),
7.15-7.05 (m, 4H), 7.04 (d, 1H), 6.91 (dxd, 1H), 6.80 (s, 1H), 6.23
(s, 1H), 3.62 (s, 1H), 2.40 (s, 3H), 2.28 (s, 3H).
EXAMPLE 82
[4-(4-tert-Butyl-phenoxy)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl--
imidazol-1-yl)-phenyl]-amine
##STR00121##
[0735] a) 4-(4-tert-Butyl-phenoxy)-2-chloro-6-methyl-pyrimidine
[0736] Prepared in analogy to example 81a) from 4-t-butylphenol and
2,4-dichloro-6-methylpyrimidine in a yield of 51%. .sup.1H NMR
(CDCl.sub.3, 300 MHz): .delta. (ppm)=7.44 (d, 2H), 7.07 (d, 2H),
6.54 (s, 1H), 2.45 (s, 3H), 1.35 (s, 9H).
b)
[4-(4-tert-Butyl-phenoxy)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-meth-
yl-imidazol-1-yl)-phenyl]-amine
[0737] Prepared in analogy to example 81b) from
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and
4-(4-tert-butyl-phenoxy)-2-chloro-6-methyl-pyrimidine in a yield of
39%. MS ISP (m/e): 444.3 (100) [(M+H).sup.+]. .sup.1H NMR
(CDCl.sub.3, 300 MHz): .delta. (ppm)=7.58 d, 1H), 7.55 (d, 1H, 7.42
(d, 2H), 7.18 (s, 1H), 7.08 (d, 2H), 7.03 (d, 1H), 6.91 (dxd, 1H),
6.82 (s, 1H), 6.21 (s, 1H), 3.59 (s, 3H), 2.39 (s, 3H), 2.28 (s,
3H), 1.35 (s, 9H).
EXAMPLE 83
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(4-trifluorometh-
yl-phenoxy)-pyrimidin-2-yl]-amine
##STR00122##
[0738] a)
2-Chloro-4-methyl-6-(4-trifluoromethoxy-phenoxy)-pyrimidine
[0739] Prepared in analogy to example 81a) from
4-trifluoromethylphenol and 2,4-dichloro-6-methylpyrimidine in a
yield of 56%. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=7.70
(d, 2H), 7.28 (d, 2H), 6.70 (s, 1H), 2.52 (s, 3H).
b)
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(4-trifluorom-
ethyl-phenoxy)-pyrimidin-2-yl]-amine
[0740] Prepared in analogy to example 81b) from
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and
2-chloro-4-methyl-6-(4-trifluoromethoxy-phenoxy)-pyrimidine in a
yield of 29%. MS ISP (m/e): 456.2 (100) [(M+H).sup.+]. .sup.1H NMR
(CDCl.sub.3, 300 MHz): .delta. (ppm)=7.70 (d, 2H), 7.58 (d, 1H),
7.46 (s broad, 1H), 7.30 (d, 2H), 7.05 (s broad, 1H), 7.03 (d, 1H),
7.37 (dxd, 1H), 6.82 (s, 1H), 6.32 (s, 1H), 3.55 (s, 3H), 2.43 (s,
3H), 2.28 (s, 3H).
EXAMPLE 84
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(4-trifluorometh-
oxy-phenoxy)-pyrimidin-2-yl]-amine
##STR00123##
[0741] a)
2-Chloro-4-methyl-6-(4-trifluoromethoxy-phenoxy)-pyrimidine
[0742] Prepared in analogy to example 81a) from
4-trifluoromethoxyphenol and 2,4-dichloro-6-methylpyrimidine in a
yield of 60%. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=7.28
(d, 2H), 7.18 (d, 2H), 6.65 (s, 1H), 2.50 (s, 3H).
b)
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(4-trifluorom-
ethoxy-phenoxy)-pyrimidin-2-yl]-amine
[0743] Prepared in analogy to example 81b) from
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and
2-chloro-4-methyl-6-(4-trifluoromethoxy-phenoxy)-pyrimidine in a
yield of 13%. MS ISP (m/e): 472.1 (100) [(M+H).sup.+]. .sup.1H NMR
(CDCl.sub.3, 300 MHz): .delta. (ppm)=7.44 (s, 1H), 7.35-7.15 (m,
5H), 7.01 (s, 2H), 6.86 (s, 1H), 6.30 (s, 1H), 3.63 (s, 3H), 2.43
(s, 3H), 2.39 (s, 3H).
EXAMPLE 85
(4,6-Dimethoxy-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-pheny-
l]-amine
##STR00124##
[0745] Prepared in analogy to example 81b) from
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and
2-chloro-4,6-dimethoxypyrimidine, using potassium carbonate as a
base. The title compound was isolated in a yield of 52%. MS ISP
(m/e): 342.1 (100) [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300
MHz): .delta. (ppm)=7.70-7.55 (m broad, 2H), 7.35-7.20 (m broad,
3H), 7.04 (s broad, 1H), 3.92 (s broad, 6H), 3.81 (s broad, 3H),
2.14 (s broad, 3H).
EXAMPLE 86
[4-(4-Pentafluorothio-phenoxy)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-me-
thyl-imidazol-1-yl)-phenyl]-amine
##STR00125##
[0746] a)
2-Chloro-4-methyl-6-(4-pentafluorothio-phenoxy)-pyrimidine
[0747] Prepared in analogy to example 81a) from
4-pentafluorothiophenol and 2,4-dichloro-6-methylpyrimidine in a
yield of 55%. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=7.83
(d, 2H), 7.26 (d, 2H), 6.73 (s, 1H), 2.53 (s, 3H).
b)
[4-(4-Pentafluorothio-phenoxy)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-
-methyl-imidazol-1-yl)-phenyl]-amine
[0748] Prepared in analogy to example 81b) from
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and
2-chloro-4-methyl-6-(4-pentafluorothio-phenoxy)-pyrimidine in a
yield of 23%. MS ISP (m/e): 514.2 (100) [(M+H).sup.+]. .sup.1H NMR
(CDCl.sub.3, 300 MHz): .delta. (ppm)=7.82 (d, 2H), 7.58 (d, 1H),
7.40 (s, 1H), 7.30-7.20 (m, 2H), 7.06 (s, 1H), 7.03 (s, 1H), 6.87
(dxd, 1H), 6.83 (s, 1H), 6.33 (s, 1H), 3.57 (s, 3H), 2.44 (s, 3H),
2.29 (s, 3H).
EXAMPLE 87
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(oxetan-3-yloxy)-
-pyrimidin-2-yl]-amine
##STR00126##
[0749] a) 2-Chloro-4-methyl-6-(oxetan-3-yloxy)-pyrimidine
[0750] A solution of oxetan-3-ol (173 mg, 2.34 mmol) in 5 mL of
tetrahydrofurane was treated with potassium tert-butylate (288 mg,
2.57 mmol) and stirred for 10 minutes at 20.degree. C.
2,4-Dichloro-6-methylpyrimidine (381 mg, 2.34 mmol) was added and
the resulting mixture stirred for 2 hours at 20.degree. C. Addition
of water and extraction with ethyl acetate, followed by
chromatography on silica gel using heptane/ethyl acetate 7:3 v/v as
a solvent gave the title compound as a yellowish foam (206 mg,
44%). MS ISP (m/e): 201.2 (33) [(M+H).sup.+].
b)
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-6-(oxetan-3-ylo-
xy)-pyrimidin-2-yl]-amine
[0751] Prepared in analogy to example 81b) from
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and
2-chloro-4-methyl-6-(oxetan-3-yloxy)-pyrimidine, using potassium
carbonate as a base. The title compound was isolated in a yield of
27%. MS ISP (m/e): 368.1 (100) [(M+H).sup.+]. .sup.1H NMR
(CDCl.sub.3, 300 MHz): .delta. (ppm)=9.62 (s broad, 1H), 7.67 (d,
2H), 7.41 (dxd, 1H), 7.26 (d, 1H), 7.04 (s, 1H), 6.28 (s, 1H), 5.65
(m, 1H), 4.90 (t, 2H), 4.58 (m, 2H), 3.81 (s, 3H), 2.31 (s, 3H),
2.14 (s, 3H).
EXAMPLE 88
2-{6-Ethoxy-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-
-4-yl}-propan-2-ol
##STR00127##
[0752] a) Ethyl 2-chloro-6-ethoxy-pyrimidine-4-carboxylate
[0753] A mixture of methyl 2,4-dichloropyrimidine-6-carboxylate
(2.07 g, 10.0 mmol) and potassium tert.-butoxide (1.12 g, 10.0
mmol) in ethanol (50 mL) was stirred for 4 h at 60.degree. C. The
mixture was cooled to, insoluble material was removed by
filtration, and the filtrate was evaporated under reduced pressure.
The oily residue was partitioned between ethyl acetate and brine,
and the organic layer was dried over sodium sulfate and evaporated
under reduced pressure to give crude title compound (0.98 g, 43%)
as colorless oil. MS ISP (m/e): 231.1 [(M+H).sup.+]
b) 2-(2-Chloro-6-ethoxy-pyrimidin-4-yl)-propan-2-ol
[0754] To a solution of ethyl
2-chloro-6-ethoxy-pyrimidine-4-carboxylate (460 mg, 2.0 mmol) in
tetrahydrofurane (5 mL) was added at 0.degree. C. over 2 min a 3 M
solution of methyl-magnesiumchloride in tetrahydrofurane (1.67 mL,
5.0 mmol). The reaction mixture was stirred at 0.degree. C. for 15
min followed by 1.5 h at. The mixture was poured on saturated
sodium carbonate solution (10 mL) and the product was extracted
with ethyl acetate (40 mL). The organic layer was washed with brine
(20 mL), dried over sodium sulfate and evaporated under reduced
pressure. The residual material was purified by chromatography on
silica gel using heptane/0-15% ethyl acetate as eluent to afford
the title compound (223 mg, 53%) as colorless oil. MS ISP (m/e):
217.2 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=6.72 (s, 1H), 4.52 (q, 2H), 3.35 (s, 1H), 1.57 (s, 6H), 1.43
(t, 3H).
c)
2-{6-Ethoxy-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimi-
din-4-yl}-propan-2-ol
[0755] A solution of
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (102 mg, 0.5
mmol), 2-(2-chloro-6-ethoxy-pyrimidin-4-yl)-propan-2-ol (108 mg,
0.5 mmol) and 1 N aqueous hydrochloric acid (0.025 mL) in ethanol
(0.8 mL) was heated in a sealed tube in a microwave oven to
170.degree. C. for 45 min. The mixture was cooled, diluted with
ethyl acetate (50 mL), and then washed with water (20 mL) and brine
(20 mL). The organic layer was dried over sodium sulfate and
evaporated under reduced pressure. The residual material was
purified by chromatography on silica gel using
dichloromethane/0-10% ethanol as eluent to give the title compound
(20 mg, 10%) as yellow foam. MS ISP (m/e): 384.3
[(M+H).sup.+].).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.20, 7.78, 7.75 and 7.63 (4 d, 4.times.2H), 7.31 (s, 2H),
7.16 (s, 1H), 3.93 (s, 1H), 2.53 (s, 3H), 1.61 (s, 6H).
EXAMPLE 89
N4-Cyclohexyl-N2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-6-methyl-py-
rimidine-2,4-diamine
##STR00128##
[0757] A solution of
(4-chloro-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)--
phenyl]-amine (66 mg, 0.2 mmol) and cyclohexylamine (60 mg, 0.6
mmol) in N-methylpyrroldione (2 mL) was heated for 30 min to
200.degree. C. in a microwave oven. Additional cyclohexylamine (60
mg, 0.6 mmol) was added and the reaction was heated for 30 min to
200.degree. C. in a microwave oven. The reaction mixture was poured
onto water and the precipitate was filtered off, washed with water,
dissolved in 1N aqueous sodium hydroxide solution and extracted
twice with diethyl ether. The combined organic layers were washed
with water, once with brine, dried over sodium sulfate, filtered
and the solvent was evaporated under reduced pressure to yield the
title compound as a light brown solid (64 mg, 82%). MS ISP (m/e):
393.4 (100) [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz):
.delta. (ppm)=7.60 (br s, 2H), 7.13 (s, 2H), 6.92 (br s, 1H), 6.86
(s, 1H), 5.75 (s, 1H), 4.61 (m, 1H), 3.85 (s, 3H), 3.69 (m, 1H),
2.30 (s, 3H), 2.26 (s, 3H), 2.05 (br d, 2H), 1.60-1.82 (m, 4H),
1.18-1.45 (m, 4H).
EXAMPLE 90
N4-(3-Chloro-phenyl)-N2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-6-me-
thyl-pyrimidine-2,4-diamine
##STR00129##
[0759] Palladium acetate (5.4 mg, 0.024 mmol) and
2-(dicyclohexylphosphino)biphenyl (17.0 mg, 0.048 mmol) were
dissolved in dioxane (2.7 mL) and stirred for 10 minutes at
20.degree. C. Sodium tert.-butylate (44 mg, 0.45 mmol),
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (99 mg, 0.3 mmol)
and 3-chloroaniline (43 mg, 0.33 mmol) were added and the reaction
was heated to 200.degree. C. for 30 minutes in a microwave oven.
The solvent was evaporated under reduced pressure and the residue
was taken up in water and extracted twice with ethyl acetate. The
combined organic layers were washed with brine, dried over sodium
sulfate, filtered and evaporated under reduced pressure to dryness.
The residue was purified by column chromatography on silica gel
using methylenechloride/methanol (19:1 v/v) as eluent to yield the
title compound as a yellow solid (34 mg, 27%). MS ISP (m/e): 421.2
(100) [(M+H).sup.+]. .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta.
(ppm)=9.47 (s, 1H), 9.41 (s, 1H), 7.88 (s, 1H), 7.18-7.68 (m, 10H),
7.02 (m, 2H), 3.70 (s, 3H), 2.26 (s, 3H), 2.14 (s, 3H).
EXAMPLE 91
N4-(4-Chloro-phenyl)-N2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-6-me-
thyl-pyrimidine-2,4-diamine
##STR00130##
[0761] The title compound was prepared from
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (99 mg, 0.3 mmol)
and 4-chloroaniline (43 mg, 0.33 mmol) in analogous manner as
described in example 90. It was obtained in 30% yield as a light
yellow solid. MS ISP (m/e): 421.1/423.2 (100/30) [(M+H).sup.+].
.sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=9.43 (s, 1H),
9.36 (s, 1H), 7.74 (m, 3H), 7.66 (s, 1H), 7.43 (d, 1H), 7.34 (d,
2H), 7.04 (s, 1H), 6.14 (s, 1H), 3.70 (s, 3H), 2.25 (s, 3H), 2.15
(s, 3H).
EXAMPLE 92
N4,N4-Diethyl-N2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-6-methyl-py-
rimidine-2,4-diamine
##STR00131##
[0762] a) (2-Chloro-6-methyl-pyrimidin-4-yl)-diethyl-amine
[0763] To a solution of 2,4-dichloro-6-methylpyrimidine (166 mg,
1.0 mmol) in tetrahydrofurane (5 mL) was added at 20.degree. C.
under stirring diethyl amine (88 mg, 1.2 mmol) and the reaction was
stirred for 3 hours at 20.degree. C. Additional diethylyamine (44
mg, 0.6 mmol) were added and the reaction was stirred at 20.degree.
C. over night. The solvent was evaporated under reduced pressure
and the residue was taken up in water and extracted twice with
diethyl ether. The combined organic layers were washed with brine,
dried over sodium sulfate, filtered and evaporated under reduced
pressure to dryness. The residue was purified by column
chromatography on silica gel using heptane/ethyl acetate (9:1 to
7:3 v/v) as eluent to yield the title compound (90 mg, 45%) as a
yellow viscous. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=6.11 (s, 1H), 3.49 (br s, 4H), 2.33 (s, 3H), 1.19 (t,
6H).
b)
N4,N4-Diethyl-N2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-6-methyl-
-pyrimidine-2,4-diamine
[0764] The title compound was prepared from
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (67 mg, 0.33 mmol)
and (2-chloro-6-methyl-pyrimidin-4-yl)-diethyl-amine (67 mg, 0.33
mmol) in analogous manner as described in example 90. It was
obtained in 65% yield as a light yellow viscous oil. MS ISP (m/e):
367.2 (100) [(M+H).sup.+]. .sup.1H NMR (DMSO-D.sub.6, 300 MHz):
.delta. (ppm)=9.15 (s, 1H), 7.88 (s, 1H), 7.63 (s, 1H), 7.32 (d,
1H), 7.16 (d, 1H), 7.01 (s, 1H), 6.00 (s, 1H), 3.78 (s, 3H), 3.51
(br q, 4H), 2.20 (s, 3H), 2.14 (s, 3H), 1.13 (t, 6H).
EXAMPLE 93
N4-Isobutyl-N2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-6-methyl-pyri-
midine-2,4-diamine
##STR00132##
[0765] a) (2-Chloro-6-methyl-pyrimidin-4-yl)-isobutyl-amine
[0766] To a solution of 2,4-dichloro-6-methylpyrimidine (998 mg,
6.0 mmol) in tetrahydrofurane (30 mL) was added at 0.degree. C.
under stirring isobutylamine (895 mg, 12.0 mmol) and the reaction
was stirred for 6 hours at 0.degree. C. and for 2 hours at
20.degree. C. The solvent was evaporated under reduced pressure and
the residue was taken up in 1N aqueous sodium hydroxide solution
and extracted twice with diethyl ether. The combined organic layers
were washed with brine, dried over sodium sulfate, filtered and
evaporated under reduced pressure to dryness. The residue was
purified by column chromatography on silica gel using heptane/ethyl
acetate (9:1 to 7:3 v/v) as eluent to yield the title compound (655
mg, 55%) as white crystals. MS ISP (m/e): 200.2/202.2 (100/32)
[(M+H).sup.+]. .sup.1H NMR (DMSO-D.sub.6, 300 MHz, rotamers):
.delta. (ppm)=7.75 (br s, 1H), 6.25 (br s, 1H), 2.90-3.12 (br m,
2H), 2.12-2.22 (br s, 3H), 1.79 (sept, 1H), 0.88 (d, 6H).
b)
N4-Isobutyl-N2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-6-methyl-p-
yrimidine-2,4-diamine
[0767] The title compound was prepared from
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (61 mg, 0.30 mmol)
and (2-chloro-6-methyl-pyrimidin-4-yl)-isobutyl-amine (66 mg, 0.33
mmol) in analogous manner as described in example 90. It was
obtained in 89% yield as a yellow solid. MS ISP (m/e): 367.2 (100)
[(M+H).sup.+]. .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta.
(ppm)=9.12 (s, 1H), 7.97 (s, 1H), 7.63 (s, 1H), 7.34 (d, 1H), 7.13
(d, 1H), 7.10 (br s, 1H), 7.01 (s, 1H), 5.87 (s, 1H), 3.78 (s, 3H),
3.16 (br s, 2H), 2.13 (s, 3H), 1.74 (sept, 1H), 0.91 (d, 6H).
EXAMPLE 94
1-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimidin-
-4-yl}-piperidin-4-ol
##STR00133##
[0768] a) 1-(2-Chloro-6-methyl-pyrimidin-4-yl)-piperidin-4-ol
[0769] To a solution of 2,4-dichloro-6-methylpyrimidine (998 mg,
6.0 mmol) in tetrahydrofurane (30 mL) was added under stirring
N,N-diisopropyl ethyl amine (853 mg, 6.6 mmol) and
4-hydroxypiperidine (681 mg, 6.6 mmol) and the reaction was stirred
over night at 20.degree. C. The solvent was evaporated under
reduced pressure and the residue was taken up in water and
extracted twice with diethyl ether. The combined organic layers
were washed with brine, dried over sodium sulfate, filtered and
evaporated under reduced pressure to dryness. The residue was
purified by column chromatography on silica gel using heptane/ethyl
acetate (1:1 v/v) as eluent to yield the title compound (779 mg,
57%) as white crystals. MS ISP (m/e): 228.2/230.2 (100/35)
[(M+H).sup.+]. .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta.
(ppm)=6.73 (s, 1H), 4.78 (d, 1H), 3.95 (br m, 2H), 3.75 (m, 1H),
3.25 (m, 2H), 2.22 (s, 3H), 1.75 (m, 2H), 1.33 (m, 2H).
b)
1-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimi-
din-4-yl}-piperidin-4-ol
[0770] The title compound was prepared from
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (41 mg, 0.20 mmol)
and 1-(2-chloro-6-methyl-pyrimidin-4-yl)-piperidin-4-ol (50 mg,
0.22 mmol) in analogous manner as described in example 90. It was
obtained in 82% yield as a light brown solid. MS ISP (m/e): 395.2
(100) [(M+H).sup.+]; .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta.
(ppm)=9.23 (s, 1H), 7.96 (s, 1H), 7.63 (s, 1H), 7.18 (m, 2H), 7.01
(s, 1H), 6.22 (s, 1H), 4.75 (d, 1H), 4.03 (br m, 2H), 3.78 (s, 3H),
3.75 (m, 1H), 3.23 (m, 2H), 2.20 (s, 3H), 2.14 (s, 3H), 1.76 (m,
2H), 1.32 (m, 2H).
EXAMPLE 95
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-methyl-6-pyrrolidin-1-yl--
pyrimidin-2-yl)-amine
##STR00134##
[0771] a) 2-Chloro-4-methyl-6-pyrrolidin-1-yl-pyrimidine
[0772] To a solution of 2,4-dichloro-6-methylpyrimidine (998 mg,
6.0 mmol) in tetrahydrofurane (30 mL) was added under stirring
N,N-diisopropyl ethyl amine (853 mg, 6.6 mmol) and pyrrolidine (469
mg, 6.6 mmol) and the reaction was stirred over night at 20.degree.
C. The solvent was evaporated under reduced pressure and the
residue was taken up in water and extracted twice with ethyl
acetate. The combined organic layers were washed with brine, dried
over sodium sulfate, filtered and evaporated under reduced pressure
to dryness. The residue was purified by column chromatography on
silica gel using heptane/ethyl acetate (9:1 to 7:3 v/v) as eluent
to yield the title compound (694 mg, 58%) as white crystals. MS ISP
(m/e): 198.1/200.1 (100/40) [(M+H).sup.+]. .sup.1H NMR
(DMSO-D.sub.6, 300 MHz): .delta. (ppm)=6.35 (s, 1H), 3.44 (m, 2H),
3.30 (m, 2H), 2.29 (s, 3H), 1.94 (m, 4H).
[0773] In addition 4-chloro-2-methyl-6-pyrrolidin-1-yl-pyrimidine
(89 mg, 8%) was obtained as colorless oil. MS ISP (m/e):
198.1/200.1 (100/39) [(M+H).sup.+]. .sup.1H NMR (DMSO-D.sub.6, 300
MHz): .delta. (ppm)=6.58 (s, 1H), 3.45 (m, 4H), 2.26 (s, 3H), 1.90
(m, 4H).
b)
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-methyl-6-pyrrolidin-1--
yl-pyrimidin-2-yl)-amine
[0774] The title compound was prepared from
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (61 mg, 0.30 mmol)
and 2-chloro-4-methyl-6-pyrrolidin-1-yl-pyrimidine (65 mg, 0.33
mmol) in analogous manner as described in example 90. It was
obtained in 91% yield as a light brown solid. MS ISP (m/e): 365.2
(100) [(M+H).sup.+]. .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta.
(ppm)=9.21 (s, 1H), 8.10 (s, 1H), 7.62 (s, 1H), 7.27 (d, 1H), 7.15
(d, 1H), 7.00 (s, 1H), 5.86 (s, 1H), 3.79 (s, 3H), 3.45 (br m, 4H),
2.19 (s, 3H), 2.14 (s, 3H), 1.94 (br m, 4H).
EXAMPLE 96
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-methyl-6-morpholin-4-yl-p-
yrimidin-2-yl)-amine
##STR00135##
[0775] a) 4-(2-Chloro-6-methyl-pyrimidin-4-yl)-morpholine
[0776] To a solution of 2,4-dichloro-6-methylpyrimidine (998 mg,
6.0 mmol) in tetrahydrofurane (30 mL) was added at 0.degree. C.
under stirring N,N-diisopropyl ethyl amine (853 mg, 6.6 mmol) and
morpholine (627 mg, 6.6 mmol) and the reaction was stirred over
night at 20.degree. C. The solvent was evaporated under reduced
pressure and the residue was taken up in water and extracted twice
with ethyl acetate. The combined organic layers were washed with
brine, dried over sodium sulfate, filtered and evaporated under
reduced pressure to dryness. The residue was purified by column
chromatography on silica gel using heptane/ethyl acetate (7:3 v/v)
as eluent to yield the title compound (893 mg, 70%) as white
crystals. MS ISP (m/e): 214.1/216.2 (100/34) [(M+H).sup.+]. .sup.1H
NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=6.73 (s, 1H), 3.65 (m,
4H), 3.58 (m, 2H), 2.25 (s, 3H).
[0777] In addition 4-(2-chloro-6-methyl-pyrimidin-4-yl)-morpholine
(304 mg, 24%) was obtained as white crystals. MS ISP (m/e):
214.2/216.2 (100/39) [(M+H).sup.+]. .sup.1H NMR (DMSO-D.sub.6, 300
MHz): .delta. (ppm)=6.68 (s, 1H), 3.65 (m, 8H), 2.28 (s, 3H).
b)
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-methyl-6-morpholin-4-y-
l-pyrimidin-2-yl)-amine
[0778] The title compound was prepared from
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (61 mg, 0.30 mmol)
and 4-(2-chloro-6-methyl-pyrimidin-4-yl)-morpholine (71 mg, 0.33
mmol) in analogous manner as described in example 90. The crude
product was purified by stirring with diethyl ether. It was
obtained in 87% yield as a light brown solid. MS ISP (m/e): 381.3
(100) [(M+H).sup.+]. .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta.
(ppm)=9.27 (s, 1H), 7.90 (s, 1H), 7.63 (s, 1H), 7.23 (d, 1H), 7.16
(d, 1H), 7.01 (s, 1H), 6.21 (s, 1H), 3.77 (s, 3H), 3.68 (m, 4H),
3.57 (m, 4H), 2.22 (s, 3H), 2.14 (s, 3H).
EXAMPLE 97
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-methyl-6-piperidin-1-yl-p-
yrimidin-2-yl)-amine
##STR00136##
[0779] a) 2-Chloro-4-methyl-6-piperidin-1-yl-pyrimidine
[0780] To a solution of 2,4-dichloro-6-methylpyrimidine (998 mg,
6.0 mmol) in tetrahydrofurane (30 mL) was added under stirring
N,N-diisopropyl ethyl amine (853 mg, 6.6 mmol) and piperidine (613
mg, 6.6 mmol) and the reaction was stirred over night at 20.degree.
C. The solvent was evaporated under reduced pressure and the
residue was taken up in water and extracted twice with ethyl
acetate. The combined organic layers were washed with brine, dried
over sodium sulfate, filtered and evaporated under reduced pressure
to dryness. The residue was purified by column chromatography on
silica gel using heptane/ethyl acetate (9:1 to 7:3 v/v) as eluent
to yield the title compound (678 mg, 53%) as light yellow crystals.
MS ISP (m/e): 212.1/214.3 (100/40) [(M+H).sup.+]. .sup.1H NMR
(DMSO-D.sub.6, 300 MHz): .delta. (ppm)=6.70 (s, 1H), 3.58 (m, 4H),
2.22 (s, 3H), 1.61 (m, 2H), 1.51 (m, 4H).
[0781] In addition 4-chloro-2-methyl-6-piperidin-1-yl-pyrimidine
(220 mg, 17%) was obtained as colorless oil. MS ISP (m/e):
212.1/214.1 (100/73) [(M+H).sup.+]. .sup.1H NMR (DMSO-D.sub.6, 300
MHz): .delta. (ppm)=6.57 (s, 1H), 3.70 (m, 4H), 2.23 (s, 3H), 1.61
(m, 2H), 1.50 (m, 4H).
b)
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-methyl-6-piperidin-1-y-
l-pyrimidin-2-yl)-amine
[0782] The title compound was prepared from
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (61 mg, 0.30 mmol)
and 2-chloro-4-methyl-6-piperidin-1-yl-pyrimidine (70 mg, 0.33
mmol) in analogous manner as described in example 90. The crude
product was purified by stirring with diethyl ether. It was
obtained in 78% yield as a light brown solid. MS ISP (m/e): 379.3
(100) [(M+H).sup.+]. .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta.
(ppm)=9.21 (s, 1H), 7.97 (s, 1H), 7.63 (s, 1H), 7.19 (d, 1H), 7.15
(d, 1H), 7.01 (s, 1H), 6.19 (s, 1H), 3.77 (s, 3H), 3.62 (m, 4H),
2.20 (s, 3H), 2.14 (s, 3H), 1.63 (m, 2H), 1.53 (m, 4H).
EXAMPLE 98
[4-(1,1-Dioxo-6-thiomorpholin-4-yl)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4--
(4-methyl-imidazol-1-yl)-phenyl]-amine
##STR00137##
[0783] a) 4-(2-Chloro-6-methyl-pyrimidin-4-yl)-thiomorpholine
1,1-dioxide
[0784] A mixture of 2,4-dichloro-6-methylpyrimidine (579 mg, 3.55
mmol), thiomorpholine-1,1-dioxide (480 mg, 3.55 mmol) and
triethylamine (0.99 mL, 7.10 mmol) in 7 mL isopropanol was refluxed
overnight. Water was added and the mixture of the regioisomers were
extracted with ethyl acetate. Chromatography on on S1--NH2 gel
(Isolute) using cyclo-hexane/ethyl acetate (gradient 30 to 60%
ethyl acetate) gave the title compound as a colourless solid (364
mg, 39%). MS ISP (m/e): 201.2 (33) [(M+H).sup.+]. .sup.1H NMR
(CDCl.sub.3, 300 MHz): .delta. (ppm)=6.39 (s, 1H), 4.20 (t broad,
4H), 3.08 (t broad, 4H), 2.41 (s, 3H).
b)
[4-(1,1-Dioxo-6-thiomorpholin-4-yl)-6-methyl-pyrimidin-2-yl]-[3-methoxy-
-4-(4-methyl-imidazol-1-yl)-phenyl]-amine
[0785] Prepared in analogy to example 81b) from
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and
4-(2-chloro-6-methyl-pyrimidin-4-yl)-thiomorpholine 1,1-dioxide,
using potassium carbonate as a base. The title compound was
isolated as a slightly yellow solid in a yield of 82%. MS ISP
(m/e): 429.3 (100) [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300
MHz): .delta. (ppm)=7.62 (s, 1H), 7.58 (d, 1H), 7.16 (d, 1H), 7.04
(dxd, 1H), 6.99 (s, 1H), 6.87 (s, 1H), 6.07 (s, 1H), 4.18 (t broad,
4H), 3.84 (s, 3H), 3.09 (t broad, 4H), 2.35 (s, 3H), 2.26 (s,
3H).
EXAMPLE 99
({2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimidin--
4-yl}-methyl-amino)-acetic Acid tert-butyl Ester
##STR00138##
[0786] a) [(2-Chloro-6-methyl-pyrimidin-4-yl)-methyl-amino]-acetic
acid tert-butyl ester
[0787] Prepared in analogy to example 98a), using
2,4-dichloro-6-methylpyrimidine and sarcosine tert-butyl ester
hydrochloride. The title compound was isolated as a slightly yellow
oil in a yield of 52%. MS ISP (m/e): 272.2 & 274.0 (25 &
10) [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=6.23 (s broad, 1H), 4.21 (s broad, 2H), 3.10 (s broad, 3H),
2.36 (s, 3H), 1.46 (s, 9H).
b)
({2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimid-
in-4-yl}-methyl-amino)-acetic Acid tert-butyl Ester
[0788] Prepared in analogy to example 81b) from
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and
[(2-chloro-6-methyl-pyrimidin-4-yl)-methyl-amino]-acetic acid
tert-butyl ester, using potassium carbonate as a base. The title
compound was isolated as a slightly yellow foam in a yield of 79%.
MS ISP (m/e): 439.3 (100) [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3,
300 MHz): .delta. (ppm)=7.65 (s broad, 1H), 7.60 (d, 1H), 7.12 (d,
1H), 7.05-6.95 (m, 2H), 6.85 (s, 1H), 5.94 (s, 1H), 3.87 (s, 3H),
3.12 (s broad, 3H), 2.30 (s, 3H), 2.29 (s, 3H), 1.39 (s, 9H).
EXAMPLE 100
1-({2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimidi-
n-4-yl}-methyl-amino)-2-methyl-propan-2-ol
##STR00139##
[0789] a) [(2-Chloro-6-methyl-pyrimidin-4-yl)-methyl-amino]-acetic
Acid Benzyl Ester
[0790] Prepared in analogy to example 98a), using
2,4-dichloro-6-methylpyrimidine and sarcosine-benzylester
hydrochloride. The title compound was isolated as a slightly yellow
oil in a yield of 62%. MS ISP (m/e): 306.1 & 308.2 (100 &
38) [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=7.40-7.35 (m, 5H), 6.23 (s broad, 1H), 5.19 (s, 2H), 4.39 (s
broad, 2H), 3.11 (s broad, 3H), 2.36 (s, 3H).
b)
({2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimid-
in-4-yl}-methyl-amino)-acetic Acid Benzyl Ester
[0791] Prepared in analogy to example 81b) from
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and
[(2-chloro-6-methyl-pyrimidin-4-yl)-methyl-amino]-acetic acid
benzyl ester, using potassium carbonate as a base. The title
compound was isolated as a colorless solid in a yield of 56%. MS
ISP (m/e): 473.3 (100) [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300
MHz): .delta. (ppm)=7.58 (s, 1H), 7.54 (s broad, 1H), 7.35-7.20 (m,
4H), 7.10-6.95 (m, 2H), 6.89 (s broad, 1H), 6.82 (s, 1H), 5.95 (s,
1H), 5.16 (s, 2H), 4.39 (s broad, 2H), 3.80 (s, 3H), 3.14 (s, 3H),
2.31 (s, 3H), 2.30 (s, 3H).
c)
1-({2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrim-
idin-4-yl}-methyl-amino)-2-methyl-propan-2-ol
[0792] A solution of
({2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimidin-
-4-yl}-methyl-amino)-acetic acid benzyl ester (32 mg, 0.07 mmol) in
2 mL of tetrahydrofurane was cooled in an ice-bath and treated with
a 3 molar solution of methyl magnesium chloride in tetrahydrofurane
(0.15 mL, 1.5 mmol). The mixture was stirred for 10 minutes in the
ice-bath and for additional 2 hours at 20.degree. C. Hydrolysis and
extraction with ethyl acetate gave the title compound as a
yellowish sticky gum (27 mg, 100%). MS ISP (m/e): 397.3 (100)
[(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=7.62 (s, 1H), 7.52 (s, 1H), 7.37 (d, 1H), 7.30-7.10 (m, 2H),
6.86 (s, 1H), 5.98 (s, 1H), 3.834 (s, 3H), 3.62 (s, 2H), 3.19 (s,
3H), 2.33 (s, 3H), 2.29 (s, 3H), 1.25 (s, 6H).
EXAMPLE 101
2-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-ylamin-
o}-ethanol
##STR00140##
[0793] a) 2-(2-Chloro-pyrimidin-4-ylamino)-ethanol
[0794] Prepared in analogy to example 98a), using
2,4-dichloro-pyrimidine and ethanolamine.
[0795] The title compound was isolated as a colorless solid in a
yield of 16%. MS ISP (m/e): 174.3 & 172.1 (100 & 40)
[(M+H).sup.+]. .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta.
(ppm)=7.90 (s broad, 1H), 7.84 (d, 1H), 6.48 (d, 1H), 4.77 (t, 1H),
3.52 (qa, 2H), 3.26 (qa broad, 2H).
b)
2-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yla-
mino}-ethanol
[0796] Prepared in analogy to example 81b) from
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and
2-(2-chloro-pyrimidin-4-ylamino)-ethanol, using potassium carbonate
as a base.
[0797] The title compound was isolated as a slightly orange solid
in a yield of 23%. MS ISP (m/e): 341.2 (100) [(M+H).sup.+]. .sup.1H
NMR (DMSO-D.sub.6, 300 MHz): .delta. (ppm)=9.14 (s, 1H), 7.91 (s
broad, 1H), 7.82 (d broad, 1H), 7.63 (s, 1H), 7.33 (d broad, 1H),
7.25 (s broad, 1H), 7.15 (d, 1H), 7.01 (s, 1H), 6.00 (d, 1H), 4.74
(t, 1H), 3.78 (s, 3H), 3.55 (qa, 2H), 3.50-3.35 (m, 2H), 2.14 (s,
3H).
EXAMPLE 102
2-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-ylamin-
o}-2-methyl-propan-1-ol
##STR00141##
[0798] a) 2-(2-Chloro-pyrimidin-4-ylamino)-2-methyl-propan-1-ol
[0799] Prepared in analogy to example 98a), using
2,4-dichloro-pyrimidine and 2-amino-2-methylpropan-1-ol. The title
compound was isolated as a yellowish solid in a yield of 19%. MS
ISP (m/e): 200.3 (100) [(M+H).sup.+]. .sup.1H NMR (DMSO-D.sub.6,
300 MHz): .delta. (ppm)=7.84 (d, 1H), 7.49 (s, 1H), 6.50 (d, 1H),
4.85 (s, 1H), 3.53 (d, 2H), 1.29 (s, 6H).
b)
2-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yla-
mino}-2-methyl-propan-1-ol
[0800] Prepared in analogy to example 81b) from
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and
2-(2-chloro-pyrimidin-4-ylamino)-2-methyl-propan-1-ol, using
potassium carbonate as a base. The title compound was isolated as a
slightly orange solid in a yield of 62%. MS ISP (m/e): 369.2 (100)
[(M+H).sup.+]. .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta.
(ppm)=7.91 (d, 1H), 7.62 (d, 1H), 7.43 (d, 1H), 7.20-7.10 (m, 2H),
6.87 (s, 1H), 6.79 (s, 1H), 5.88 (d, 1H), 4.74 (s, 1H), 3.84 (s,
3H), 3.69 (s, 2H), 2.29 (s, 3H), 1.42 (s, 6H).
EXAMPLE 103
[4-(4-Methanesulfonyl-piperazin-1-yl)-6-methyl-pyrimidin-2-yl]-[3-methoxy--
4-(4-methyl-imidazol-1-yl)-phenyl]-amine
##STR00142##
[0801] a)
4-Chloro-2-(4-methanesulfonyl-piperazin-1-yl)-6-methyl-pyrimidin-
e
[0802] Prepared in analogy to example 98a), using
2,4-dichloro-6-methylpyrimidine and 1-methanesulfonyl-piperazine.
The title compound was isolated as a yellow solid in a yield of
41%. MS ISP (m/e): 291.1 (100) [(M+H).sup.+]. .sup.1H NMR
(DMSO-D.sub.6, 300 MHz): .delta. (ppm)=6.81 (s, 1H), 3.80-3.70 (m,
4H), 3.20-3.15 (m, 4H), 2.90 (s, 3H), 2.26 (s, 3H).
b)
[4-(4-Methanesulfonyl-piperazin-1-yl)-6-methyl-pyrimidin-2-yl]-[3-metho-
xy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine
[0803] Prepared in analogy to example 81b) from
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and
4-chloro-2-(4-methanesulfonyl-piperazin-1-yl)-6-methyl-pyrimidine.
The title compound was isolated as a yellowish solid in a yield of
4%. MS ISP (m/e): 458.3 (100) [(M+H).sup.+]. .sup.1H NMR
(DMSO-D.sub.6, 300 MHz): .delta. (ppm)=9.32 (s, 1H), 7.90 (s, 1H),
7.63 (d, 1H), 7.24 (d, 1H), 7.18 (d, 1H), 7.01 (s, 1H), 6.28 (s,
1H), 3.78 (s, 3H), 3.80-3.70 (m, 4H), 3.19 (t, 4H), 2.91 (s, 3H),
2.23 (s, 3H), 2.14 (s, 3H).
EXAMPLE 104
2-({2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimidi-
n-4-yl}-methyl-amino)-ethanol
##STR00143##
[0804] a)
2-[(2-Chloro-6-methyl-pyrimidin-4-yl)-methyl-amino]-ethanol
[0805] Prepared in analogy to example 98a), using
2,4-dichloro-6-methylpyrimidine and 2-(methylamino)ethanol. The
title compound was isolated as a yellowish oil in a yield of 61%.
MS ISP (m/e): 202.2 (100) [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3,
300 MHz): .delta. (ppm)=6.22 (s, 1H), 3.86 (t, 2H), 3.70-3.60 (m,
2H), 3.11 (s, 3H), 2.70 (s very broad, 1H), 2.34 (s, 3H).
b)
2-({2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenalamino]-6-methyl-pyrim-
idin-4-yl}-methyl-amino)-ethanol
[0806] Prepared in analogy to example 81b) from
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and
2-[(2-chloro-6-methyl-pyrimidin-4-yl)-methyl-amino]-ethanol. The
title compound was isolated as a colorless solid in a yield of 57%.
MS ISP (m/e): 369.2 (100) [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3,
300 MHz): .delta. (ppm)=7.70 (d, 1H), 7.60 (s, 1H), 7.11 (d, 1H),
7.05-6.90 (m, 2H), 6.85 (s, 1H), 5.92 (s, 1H), 3.95-3.80 (m, 2H),
3.84 (s, 3H), 3.80-3.70 (m, 2H), 3.12 (s, 3H), 2.31 (s, 3H), 2.29
(s, 3H).
EXAMPLE 105
2-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-piperidin-1-yl-p-
yrimidin-4-yl}-propan-2-ol
##STR00144##
[0807] a)
2-(2-Chloro-6-piperidin-1-yl-pyrimidin-4-yl)-propan-2-ol
[0808] Using in analogous manner the procedure described in example
88b), but replacing ethyl
2-chloro-6-ethoxy-pyrimidine-4-carboxylate by methyl
2-chloro-6-piperidin-1-yl-pyrimidine-4-carboxylate (511 mg, 2.0
mmol), the title compound was obtained as light yellow solid (144
mg, 26%). MS ISP (m/e): 256.2 [(M+H).sup.+]. .sup.1H NMR
(CDCl.sub.3, 300 MHz): .delta. (ppm)=6.47 (s, 1H), 3.64 (m, 4H),
3.44 (s, 1H), 1.63 (m, 6H), 1.50 (s, 6H).
b)
2-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-piperidin-1-y-
l-pyrimidin-4-yl}-propan-2-ol
[0809] Using in analogous manner the procedure described in example
88c), but replacing
2-(2-chloro-6-ethoxy-pyrimidin-4-yl)-propan-2-ol by
2-(2-chloro-6-piperidin-1-yl-pyrimidin-4-yl)-propan-2-ol (26 mg,
0.1 mmol), the title compound was obtained as light yellow foam (5
mg, 12%). MS ISP (m/e): 423.3 [(M+H).sup.+]. .sup.1H NMR
(CDCl.sub.3, 300 MHz): .delta. (ppm)=7.67 (d, 1H), 7.64 (s, 1H),
7.18 (d, 1H), 7.11 (s, 1H), 7.02 (dd, 1H), 6.88 (s, 1H), 6.27 (s,
1H), 4.43 (q, 2H), 4.10 (br s, 1H), 2.30 (s, 3H), 1.51 (s, 6H),
1.42 (t, 3H).
EXAMPLE 106
2-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-pyrrolidin-1-yl--
pyrimidin-4-yl}-propan-2-ol
##STR00145##
[0810] a) Methyl
2-chloro-6-pyrrolidin-1-yl-pyrimidine-4-carboxylate
[0811] A mixture of methyl 2,4-dichloropyrimidine-6-carboxylate
(1.66 g, 8.0 mmol), pyrrolidine (0.66 mL, 8 mmol) and sodium
carbonate (1.54 g, 14.0 mmol) in methanol (8 mL) was stirred for 1
h at. The mixture was partitioned between ethyl acetate and water,
and the organic layer was subsequently washed with brine, dried
over sodium sulfate and evaporated under reduced pressure to give
crude title compound (0.78 g, 40%) as light yellow solid. MS ISP
(m/e): 242.2 [(M+H).sup.+].
b) 2-(2-Chloro-6-pyrrolidin-1-yl-pyrimidin-4-yl)-propan-2-ol
[0812] Using in analogous manner the procedure described in example
88b), but replacing ethyl
2-chloro-6-ethoxy-pyrimidine-4-carboxylate by methyl
2-chloro-6-pyrrolidin-1-yl-pyrimidine-4-carboxylate (773 mg, 3.2
mmol), the title compound was obtained as light yellow solid (584
mg, 76%). MS ISP (m/e): 242.2 [(M+H).sup.+]. .sup.1H NMR
(CDCl.sub.3, 300 MHz): .delta. (ppm)=6.24 (s, 1H), 3.64 (m, 2H),
3.56 (s, 1H), 3.37 (m, 2H), 2.04 (m, 4H), 1.50 (s, 6H).
c)
2-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-pyrrolidin-1--
yl-pyrimidin-4-yl}-propan-2-ol
[0813] Using in analogous manner the procedure described in example
88c), but replacing
2-(2-chloro-6-ethoxy-pyrimidin-4-yl)-propan-2-ol by
2-(2-chloro-6-pyrrolidin-1-yl-pyrimidin-4-yl)-propan-2-ol (120 mg,
0.5 mmol), the title compound was obtained as light yellow foam (16
mg, 8%). MS ISP (m/e): 409.3 [(M+H).sup.+]. .sup.1H NMR
(CDCl.sub.3, 300 MHz): .delta. (ppm)=7.82 (d, 1H), 7.62 (s, 1H),
7.14 (d, 1H), 7.02 (dd, 1H), 6.98 (s, 1H), 6.87 (s, 1H), 5.86 (s,
1H), 4.46 (br s, 1H), 3.86 (s, 3H), 3.3-3.8 (m, 4H), 2.30 (s, 3H),
2.05 (m, 4H), 1.57 (s, 6H).
EXAMPLE 107
1-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-pi-
peridin-4-ol
##STR00146##
[0815] The title compound was prepared from
1-(2-chloropyrimidin-4-yl)-4-piperidinol (120 mg, 0.534 mmol) and
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (109 mg, 0534
mmol) using in analogous manner the procedure described in example
43b). Obtained after trituration in dichloromethane/methanol (19:1
v/v) as a white solid (117 mg, 57%). MS ISP (m/e): 381.1
[(M+H).sup.+]. .sup.1HNMR (DMSO-D.sub.6, 300 MHz): .delta.
(ppm)=9.24 (s, 1H), 7.97 (d, 1H), 7.84 (d, 1H), 7.63 (s, 1H), 7.26
(dd, 1H), 7.18 (d, 1H), 7.03 (s, 1H), 6.31 (d, 1H), 4.77 (d, 1H),
4.07 (mbroad, 2H), 3.78 (s, 3H), 3.77 (m, 1H), 3.25 (m broad, 2H),
2.14 (s, 3H), 1.78 (m broad, 2H), 1.36 (m broad, 2H). Mp
197-200.degree. C.
EXAMPLE 108
[4-Butyl-6-(4-chloro-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidaz-
ol-1-yl)-phenyl]-amine
##STR00147##
[0817] A suspension of
N-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate
(153 mg, 0.41 mmol), 1-(4-chloro-phenyl)-hept-2-yn-1-one (100 mg,
0.45 mmol, CAS 105363-17-5) and sodium methanolat (120 mg, 1.24
mmol) in acetonitrile (2.0 mL) was heated two times to 120.degree.
C. for 30 minutes in a microwave oven. Water was added and the
reaction was extracted twice with ethyl acetate. The combined
organic layers were dried over sodium sulfate, filtered and the
solvent was evaporated. The residue was purified by column
chromatography on silica gel using dichloromethane/methanol (9:1
v/v) as eluent to yield the title compound as a yellow solid (30
mg, 16%). MS ISP (m/e): 448.3/450.1 (100/37) [(M+H).sup.+]. .sup.1H
NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=8.04 (d, 2H), 7.98 (s,
1H), 7.64 (s, 1H), 7.46 (d, 2H), 7.29 (s, 1H), 7.18 (d, 1H), 7.04
(d, 1H), 6.89 (s, 1H), 3.89 (s, 3H), 2.74 (t, 2H), 2.31 (, 3H),
1.79 (m, 2H), 1.43 (m, 2H), 0.98 (t, 3H).
EXAMPLE 109
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-phenyl-pyrimidin-2-yl)-am-
ine
##STR00148##
[0819] A solution of
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate
(249 mg, 0.67 mmol), 3-(dimethylamino)-1-phenyl-2-propen-1-one (141
mg, 0.80 mmol, CAS 1131-80-2) and triethyl amine (187 uL. 1.34
mmol) in ethanol (4 mL) was heated to 160.degree. C. for 1 hour in
a microwave oven. The solvent was evaporated under reduced pressure
and the residue purified by column chromatography on silica using
methylenechloride and dichloromethane/methanol (19:1 v/v) as eluent
to yield the title compound a a yellow solid (67 mg, 28%). MS ISP
(m/e): 358.2 (100) [(M+H).sup.+]. .sup.1H NMR (DMSO-D.sub.6, 300
MHz): .delta. (ppm)=9.90 (s, 1H), 8.60 (s, 1H), 8.20 (br s, 2H),
7.99 (s, 1H), 7.68 (s, 1H), 7.43-7.56 (m, 5H), 7.26 (t, 1H), 7.06
(s, 1H), 3.84 (s, 3H), 2.15 (s, 3H).
EXAMPLE 110
[5-(3,4-Dichloro-phenyl)-4-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-i-
midazol-1-yl)-phenyl]-amine
##STR00149##
[0820] a)
(E/Z)-3-(3,4-Dichloro-phenyl)-4-dimethylamino-but-3-en-2-one
[0821] A mixture of 1-(3,4-dichlorophenyl)propan-2-one (1.0 g, 4.93
mmol) and N,N-dimethylformamide dimethyl acetal (1.64 mL, 12.3
mmol) was heated overnight at 130.degree. C. The resulting solution
was concentrated, treated with diethyl ether and filtered to yield
the crude title product as a brownish solid. MS ISP (m/e): 258.0
& 260.1 (100 & 68) [(M+H).sup.+].
b)
[5-(3,4-Dichloro-phenyl)-4-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methy-
l-imidazol-1-yl)-phenyl]-amine
[0822] A solution of
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate
(100 mg, 0.27 mmol; see Example 4b),
(E/Z)-3-(3,4-dichloro-phenyl)-4-dimethylamino-but-3-en-2-one (156
mg, 0.60 mmol) and triethylamine (0.19 mL, 1.34 mmol) in 5 mL of
ethanol was refluxed for 28 hours. The mixture was diluted with
water, extracted with ethyl acetate and the product purified by
chromatography on silica gel using ethyl acetate as a solvent. The
product was isolated as a yellow solid (3 mg, 3%). MS ISP (m/e):
440.1 (100) [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz):
.delta. (ppm)=9.65 (s very broad, 1H), 8.38 (s, 1H), 8.20 (s, 1H),
7.50-6.90 (m, 5H), 6.92 (s, 1H), 3.85 (s, 3H), 2.40 (s, 3H), 2.38
(s, 3H).
EXAMPLE 111
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-thiazol-2-yl-pyrimidin-2--
yl)-amine
##STR00150##
[0823] a) (E/Z)-3-Dimethylamino-1-thiazol-2-yl-propenone
[0824] A mixture of 2-acetylthiazole (145 mg, 1.14 mmol) and
tert-butoxy-bis (dimethylamino)methane (0.33 mL, 1.59 mmol) was
heated for 2 hours at 130.degree. C. The mixture was concentrated
in vacuo to give the crude title compound (160 mg; 93%) as a
brownish gum.
[0825] MS ISP (m/e): 183.0 (100).
b)
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-thiazol-2-yl-pyrimidin-
-2-yl)-amine
[0826] A solution of
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate
(75 mg, 0.22 mmol; see Example 4b),
(E/Z)-3-dimethylamino-1-thiazol-2-yl-propenone (160 mg, 0.88 mmol)
and triethylamine (0.12 mL, 0.87 mmol) in 5 mL of ethanol was
heated in the microwave oven for 1.5 hours at 100.degree. C. The
mixture was diluted with water, extracted with ethyl acetate and
the product purified by chromatography on silica gel using a
mixture of heptane/ethyl acetate 2:8 v/v as a solvent. The product
was isolated as a yellow solid (10 mg, 12%). MS ISP (m/e): 365.1
(100) [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.59 (d; 1H), 8.02 (d, 1H), 7.84 (d, 1H), 7.77 (s, 1H), 7.62
(d, 1H), 7.57 (d, 1H), 7.35 (s, 1H), 7.22 (d, 1H), 7.10 (dxd; 1H),
6.91 (s, 1H), 3.97 (s, 3H), 2.34 (s, 3H).
EXAMPLE 112
5-(4,6-Dimethyl-pyrimidin-2-ylamino)-2-(4-methyl-imidazol-1-yl)-benzonitri-
le
##STR00151##
[0827] a) 5-Bromo-2-(4-methyl-imidazol-1-yl)-benzonitrile
[0828] This compound was prepared from 5-bromo-2-fluorobenzonitrile
and 4-methylimidazole, as described in US2006/0004013.
b)
5-(4,6-Dimethyl-pyrimidin-2-ylamino)-2-(4-methyl-imidazol-1-yl)-benzoni-
trile
[0829] A mixture of 5-bromo-2-(4-methyl-imidazol-1-yl)-benzonitrile
(200 mg, 0.76 mmol), 2-amino-4,6-dimethyl-pyrimidine (141 mg, 1.14
mmol), sodium phenoxide (266 mg, 2.29 mmol),
tris(dibenzylideneacetone)dipalladium chloroform complex (21 mg,
0.02 mmol) and
4,5-bis(diphenylphosphino)-9,9-dimethylxanthene=xanthphos (26 mg,
0.04 mmol) in 5 mL of dioxane was heated to 80.degree. C. under
argon for 2 hours. The mixture was diluted with water, extracted
with ethyl acetate and the product purified by chromatography on
silica gel using dichloromethane/methanol 9:1 v/v as an eluent. The
title compound was obtained as a colorless solid (144 mg, 62%). MS
ISP (m/e): 305.1 (100) [(M+H).sup.+]. .sup.1H NMR (DMSO-D.sub.6,
300 MHz): .delta. (ppm)=10.08 (s, 1H), 8.44 (s, 1H), 8.15 (d, 1H),
7.89 (s, 1H), 7.55 (d, 1H), 7.25 (s, 1H), 6.76 (s, 1H), 2.36 (s,
6H), 2.18 (s, 3H).
EXAMPLE 113
5-[4-(4-Chloro-phenyl)-pyrimidin-2-ylamino]-2-(4-methyl-imidazol-1-yl)-ben-
zonitrile
##STR00152##
[0831] Prepared in analogy to example 112b) from
5-bromo-2-(4-methyl-imidazol-1-yl)-benzonitrile and
4-(4-chloro-phenyl)-pyrimidin-2-ylamine. The title compound was
obtained as a colorless solid (Yield=35%). MS ISP (m/e): 387.2
(100) [(M+H).sup.+]. .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta.
(ppm)=10.31 (s, 1H), 8.69 (d, 1H), 8.47 (s, 1H), 8.25-8.15 (m, 3H),
7.97 (s, 1H), 7.55-7.50 (m, 3H), 7.57 (d, 1H), 7.29 (s, 1H), 2.20
(s, 3H).
EXAMPLES 114-138
[0832] Using in analogous manner the procedure described in example
28a), 1-(4-trifluoromethyl-phenyl)-propan,
1-(4-trifluoromethyl-phenyl)-butan-1-one,
1-(3,4,5-trifluoro-phenyl)-ethanone,
1-(2,5-dichloro-phenyl)-ethanone, 1-(3,4-dichloro-phenyl)-ethanone,
1-(2,4-dichloro-phenyl)-ethanone,
1-(4-chloro-3-methyl-phenyl)-ethanone,
1-(4-chloro-phenyl)-pentan-1-one,
1-(4-chloro-phenyl)-2-methoxy-ethanone,
1-(3,5-dimethyl-pyrazin-2-yl)-ethanone, 3-methyl-butan-2-one,
3,3-dimethyl-butan-2-one, 1-methoxy-propan-2-one, acetic acid
2-oxo-propyl ester, 3-hydroxy-butan-2-one,
3-hydroxy-3-methyl-butan-2-one, 1-cyclopentyl-propan-2-one,
1-cyclopropyl-ethanone, 1-cyclopentyl-ethanone,
1-cyclohexyl-propan-1-one, ethyl 3-oxo-4-phenyl-butyrate, ethyl
7-methyl-3-oxo-oct-6-enoate, 6-methyl-1-phenyl-hept-5-en-2-one,
ethyl 2-oxo-propionate, and 6-acetyl-4H-benzo[1,4]oxazin-3-one,
were reacted with tert.-butoxy-bis-(dimethylamino)-methane,
respectively, and the resulting products were subsequently reacted
with N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine
dinitrate operating in analogous manner as described in example
39b) to afford the following compounds:
EXAMPLE 114
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[5-methyl-4-(4-trifluorometh-
yl-phenyl)-pyrimidin-2-yl]-amine
##STR00153##
[0834] Obtained in 42% yield as light yellow solid. MS ISP (m/e):
440.3 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.40 (s, 1H), 7.74-7.80 (m, 5H), 7.62 (s, 1H), 7.23 (s, 1H),
7.17 (d, 1H), 7.06 (dd, 1H), 6.87 (s, 1H), 3.82 (s, 3H), 2.30 (s,
3H), 2.29 (s, 3H).
EXAMPLE 115
[5-Ethyl-4-(4-trifluoromethyl-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-meth-
yl-imidazol-1-yl)-phenyl]-amine
##STR00154##
[0836] Obtained in 53% yield as light yellow solid. MS ISP (m/e):
454.3 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.45 (s, 1H), 7.77 (d, 1H), 7.75 and 7.70 (2 d, 2.times.2H),
7.62 (s, 1H), 7.22 (s, 1H), 7.16 (d, 1H), 7.05 (dd, 1H), 6.86 (s,
1H), 3.81 (s, 3H), 2.64 (q, 2H), 2.30 (s, 3H), 1.65 (t, 3H).
EXAMPLE 116
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-(3,4,5-trifluoro-phenyl)--
pyrimidin-2-yl]-amine
##STR00155##
[0838] Obtained in 7% yield as yellow solid. MS ISP (m/e): 412.2
[(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.55 (d, 1H), 7.78 (d, 1H), 7.73-7.78 (m, 2H), 7.66 (s, 1H),
7.32 (s, 1H), 7.22 (d, 1H), 7.12 (d, 1H), 7.09 (dd, 1H), 6.90 (s,
1H), 3.91 (s, 3H), 2.31 (s, 3H).
EXAMPLE 117
[4-(2,5-Dichloro-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-
-yl)-phenyl]-amine
##STR00156##
[0840] Obtained in 36% yield as light yellow solid. MS ISP (m/e):
426.1 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.55 (d, 1H), 7.92 (d, 1H), 7.73 (d, 1H), 7.63 (s, 1H), 7.45
(d, 1H), 7.37 (dd, 1H), 7.35 (s, 1H), 7.21 (d, 1H), 7.19 (d, 1H),
7.00 (dd, 1H), 6.88 (s, 1H), 3.81 (s, 3H), 2.30 (s, 3H).
EXAMPLE 118
[4-(3,4-Dichloro-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-
-yl)-phenyl]-amine
##STR00157##
[0842] Obtained in 18% yield as light yellow solid. MS ISP (m/e):
426.1 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.53 (d, 1H), 8.27 (d, 1H), 7.90 (d, 1H), 7.87 (dd, 1H), 7.66
(s, 1H), 7.58 (d, 1H), 7.33 (s, 1H), 7.21 (d, 1H), 7.18 (d, 1H),
7.03 (dd, 1H), 6.90 (s, 1H), 3.93 (s, 3H), 2.31 (s, 3H).
EXAMPLE 119
[4-(2,4-Dichloro-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-
-yl)-phenyl]-amine
##STR00158##
[0844] Obtained in 24% yield as light yellow solid. MS ISP (m/e):
426.0 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.53 (d, 1H), 7.79 (d, 1H), 7.64 (s, 1H), 7.63 (d, 1H), 7.54
(s, 1H), 7.38 (dd, 1H), 7.31 (s, 1H), 7.18 (d, 1H), 7.16 (d, 1H),
7.08 (dd, 1H), 6.88 (s, 1H), 3.84 (s, 3H), 2.30 (s, 3H).
EXAMPLE 120
[4-(4-Chloro-3-methyl-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imida-
zol-1-yl)-phenyl]-amine
##STR00159##
[0846] Obtained in 15% yield as light yellow solid. MS ISP (m/e):
406.3 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.50 (d, 1H), 7.97 (d, 1H), 7.86 (d, 1H), 7.84 (dd, 1H), 7.65
(s, 1H), 7.46 (d, 1H), 7.30 (s, 1H), 7.20 (d, 1H), 7.18 (d, 1H),
7.08 (dd, 1H), 6.89 (s, 1H), 3.90 (s, 3H), 2.47 (s, 3H), 2.31 (s,
3H).
EXAMPLE 121
[4-(4-Chloro-phenyl)-5-propyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imida-
zol-1-yl)-phenyl]-amine
##STR00160##
[0848] Obtained in 25% yield as off-white solid. MS ISP (m/e):
434.3 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.38 (s, 1H), 7.82 (d, 1H), 7.62 (s, 1H), 7.53 and 7.46 (2 d,
2.times.2H), 7.21 (s, 1H), 7.16 (d, 1H), 7.02 (dd, 1H), 6.86 (s,
1H), 3.81 (s, 3H), 2.59 (t, 2H), 2.30 (s, 3H), 1.59 (m, 2H), 0.86
(t, 3H).
EXAMPLE 122
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(5-methoxy-4-phenyl-pyrimidi-
n-2-yl)-amine
##STR00161##
[0850] Obtained in 23% yield as light yellow solid. MS ISP (m/e):
388.3 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.27 (s, 1H), 8.12 (m, 3H), 7.86 (d, 1H), 7.62 (s, 1H), 7.48
(m, 3H), 7.17 (d, 1H), 7.15 (s, 1H), 7.02 (dd, 1H), 6.87 (s, 1H),
3.91 (s, 3H), 3.86 (s, 3H), 2.30 (s, 3H).
EXAMPLE 123
[4-(3,5-Dimethyl-pyrazin-2-yl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imid-
azol-1-yl)-phenyl]-amine
##STR00162##
[0852] Obtained in 22% yield as light yellow solid. MS ISP (m/e):
388.3 [(M+H).sup.+].).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz):
.delta. (ppm)=8.61 (d, 1H), 8.45 (s, 1H), 7.63 (m, 2H), 7.34 (d,
1H), 7.15-7.20 (m, 2H), 6.88 (s, 1H), 6.80 (dd, 1H), 3.85 (s, 3H),
2.80 (s, 3H), 2.61 (s, 3H), 2.30 (s, 3H).
EXAMPLE 124
(4-Isopropyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-
-amine
##STR00163##
[0854] Obtained in 42% yield as yellow oil. MS ISP (m/e): 324.3
[(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.33 (d, 1H), 7.88 (d, 1H), 7.63 (s, 1H), 7.18 (s, 1H), 7.16
(d, 1H), 7.02 (dd, 1H), 6.88 (s, 1H), 6.68 (d, 1H), 3.88 (s, 3H),
2.92 (m, 1H), 2.30 (s, 3H), 1.32 (d, 6H).
EXAMPLE 125
(4-tert-Butyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl-
]-amine
##STR00164##
[0856] Obtained in 30% yield as light yellow solid. MS ISP (m/e):
338.3 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.38 (d, 1H), 8.40 (d, 1H), 7.63 (s, 1H), 7.18 (s, 1H), 7.17
(d, 1H), 7.02 (dd, 1H), 6.88 (s, 1H), 6.82 (d, 1H), 3.89 (s, 3H),
2.30 (s, 3H), 1.37 (s, 9H).
EXAMPLE 126
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-methoxymethyl-pyrimidin-2-
-yl)-amine
##STR00165##
[0858] Obtained in 29% yield as light yellow solid. MS ISP (m/e):
326.2 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.45 (d, 1H), 7.71 (d, 1H), 7.63 (s, 1H), 7.21 (s, 1H), 7.17
(d, 1H), 7.07 (dd, 1H), 6.92 (d, 1H), 6.87 (s, 1H), 4.46 (s, 2H),
3.87 (s, 3H), 3.51 (s, 3H), 2.30 (s, 3H).
EXAMPLE 127
Acetic acid
2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-ylmethyl
Ester
##STR00166##
[0860] Obtained in 11% yield as off-white solid. MS ISP (m/e):
354.2 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.45 (d, 1H), 7.66 (d, 1H), 7.63 (s, 1H), 7.23 (s, 1H), 7.17
(d, 1H), 7.11 (dd, 1H), 6.88 (s, 1H), 6.80 (d, 1H), 5.10 (s, 2H),
3.87 (s, 3H), 2.30 (s, 3H), 2.21 (s, 3H).
EXAMPLE 128
1-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-et-
hanol
##STR00167##
[0862] Obtained in 22% yield as light yellow solid. MS ISP (m/e):
326.2 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.43 (d, 1H), 7.64 (m, 2H), 7.24 (s, 1H), 7.19 (d, 1H), 7.09
(dd, 1H), 6.88 (s, 1H), 6.80 (d, 1H), 4.78 (q, 1H), 3.87 (s, 3H),
2.30 (s, 3H), 1.52 (d, 3H).
EXAMPLE 129
2-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-pr-
opan-2-ol
##STR00168##
[0864] Obtained in 23% yield as off-white solid. MS ISP (m/e):
340.2 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.44 (d, 1H), 7.64 (s, 1H), 7.63 (d, 1H), 7.22 (s, 1H), 7.19
(d, 1H), 7.07 (dd, 1H), 6.89 (s, 1H), 6.88 (d, 1H), 4.01 (s, 1H),
3.88 (s, 3H), 2.31 (s, 3H), 1.55 (s, 6H).
EXAMPLE 130
(4-Cyclopentylmethyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-
-phenyl]-amine
##STR00169##
[0866] Obtained in 15% yield as yellow oil. MS ISP (m/e): 364.2
[(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.32 (d, 1H), 7.80 (d, 1H), 7.63 (s, 1H), 7.18 (s, 1H), 7.17
(d, 1H), 7.05 (dd, 1H), 6.87 (s, 1H), 6.65 (d, 1H), 3.87 (s, 3H),
2.67 (d, 2H), 2.31 (s, 3H), 2.27-2.33 (m, 1H), 1.50-1.80 (m,
8H).
EXAMPLE 131
(4-Cyclopropyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-pheny-
l]-amine
##STR00170##
[0868] Obtained in 44% yield as light yellow solid. MS ISP (m/e):
322.2 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.22 (d, 1H), 7.81 (d, 1H), 7.62 (s, 1H), 7.15 (d, 1H), 7.10
(s, 1H), 6.94 (dd, 1H), 6.87 (s, 1H), 6.70 (d, 1H), 3.89 (s, 3H),
2.30 (s, 3H), 2.27-2.33 (m, 1H), 1.94 (m, 1H), 1.20 (m, 2H), 1.08
(m, 2H).
EXAMPLE 132
(4-Cyclopentyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-pheny-
l]-amine
##STR00171##
[0870] Obtained in 13% yield as light yellow solid. MS ISP (m/e):
350.4 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.30 (d, 1H), 7.82 (d, 1H), 7.63 (s, 1H), 7.17 (d, 1H), 7.15
(s, 1H), 7.03 (dd, 1H), 6.87 (s, 1H), 6.68 (d, 1H), 3.87 (s, 3H),
3.08 (m, 1H), 2.30 (s, 3H), 2.00-2.28 (m, 2H), 1.65-1.92 (m,
6H).
EXAMPLE 133
(4-Cyclohexyl-5-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-y-
l)-phenyl]-amine
##STR00172##
[0872] Obtained in 38% yield as light yellow solid. MS ISP (m/e):
378.3 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.13 (s, 1H), 7.93 (d, 1H), 7.62 (s, 1H), 7.15 (d, 1H), 7.08
(s, 1H), 6.94 (dd, 1H), 6.87 (s, 1H), 3.90 (s, 3H), 2.78 (m, 1H),
2.30 (s, 3H), 2.20 (s, 3H), 1.60-1.95 (m, 8H), 1.3-1.5 (m, 2H).
EXAMPLE 134
Ethyl
4-benzyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimi-
dine-5-carboxylate
##STR00173##
[0874] Obtained in 10% yield as light yellow solid. MS ISP (m/e):
444.3 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.99 (s, 1H), 7.63 (s, 1H), 7.59 (d, 1H), 7.42 (s, 1H),
7.20-7.35 (m, 5H), 7.13 (d, 1H), 7.06 (dd, 1H), 6.87 (s, 1H), 4.52
(s, 2H), 4.36 (q, 2H), 3.79 (s, 3H), 2.30 (s, 3H), 1.37 (t,
3H).
EXAMPLE 135
Ethyl
2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-4-(4-methyl-pen-
t-3-enyl)-pyrimidine-5-carboxylate
##STR00174##
[0876] Obtained in 8% yield as light yellow solid. MS ISP (m/e):
436.2 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.95 (s, 1H), 7.82 (d, 1H), 7.65 (s, 1H), 7.42 (s, 1H), 7.20
(d, 1H), 7.10 (dd, 1H), 6.89 (s, 1H), 5.22 (t, 1H), 4.36 (q, 2H),
3.88 (s, 3H), 3.16 (m, 2H), 2.45 (m, 2H), 2.30 (s, 3H), 1.68 and
1.59 (2 s, 2.times.3H).
EXAMPLE 136
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-(4-methyl-pent-3-enyl)-5--
phenyl-pyrimidin-2-yl]-amine
##STR00175##
[0878] Obtained in 17% yield as light yellow solid. .sup.1H NMR
(CDCl.sub.3, 300 MHz): .delta. (ppm)=8.27 (s, 1H), 7.84 (d, 1H),
7.64 (s, 1H), 7.15-7.50 (m, 6H), 7.20 (d, 1H), 7.12 (dd, 1H), 6.87
(s, 1H), 5.06 (t, 1H), 3.88 (s, 3H), 2.72 (m, 2H), 2.40 (m, 2H),
2.31 (s, 3H), 1.63 and 1.49 (2 s, 2.times.3H).
EXAMPLE 137
6-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-4H-
-benzo[1,4]oxazin-3-one
##STR00176##
[0880] Obtained in 20% yield as white solid. MS ISP (m/e): 429.2
[(M+H).sup.+]. .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta.
(ppm)=10.96 (s, 1H), 9.84 (s, 1H), 8.55 (d, 1H), 7.85 (d, 1H), 7.75
(dd, 1H), 7.74 (d, 1H), 7.68 (s, 1H), 7.33 (dd, 1H), 7.31 (s, 1H),
7.28 (d, 1H), 7.10 (d, 1H), 7.07 (s, 1H), 4.68 (s, 2H), 3.81 (s,
3H), 2.16 (s, 3H).
EXAMPLE 138
Cyclopropyl-[2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-4-(4-tri-
fluoromethyl-phenyl)-pyrimidin-5-yl]-acetonitrile
##STR00177##
[0881]
2-Cyclopropyl-4-oxo-4-(4-trifluoromethyl-phenyl)-butyronitrile
[0882] A solution of potassium cyanide (313 mg, 4.8 mmol) in water
(1 mL) was added at to a solution of
(E)-3-cyclopropyl-1-(4-trifluoromethyl-phenyl)-propenone (961 mg,
4.0 mmol) in a ethanol (8 mL) and acetic acid (0.26 mL). The
reaction mixture was stirred at for 6 days and then partitioned
between ethyl acetate and saturated sodium hydrogencarbonate
solution. The organic layer was washed with brine, dried over
sodium sulfate, and evaporated under reduced pressure. The residual
oil was subjected to column chromatography on silica gel using
heptane/0-15% ethyl acetate to give the title compound as white
solid (620 mg, 58%). Mp 91-93.degree. C.
b)
Cyclopropyl-[2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-4-(4--
trifluoromethyl-phenyl)-pyrimidin-5-yl]-acetonitrile
[0883] Using in analogous manner the procedure described in example
28a),
2-cyclopropyl-4-oxo-4-(4-trifluoromethyl-phenyl)-butyronitrile (170
mg, 0.5 mmol) was reacted with
tert.-butoxy-bis-(dimethylamino)-methane, and the resulting product
was subsequently reacted with
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate
operating in analogous manner as described in example 39b) to give
the title compound (46 mg, 24%). MS ISP (m/e): 505.3 [(M+H).sup.+].
.sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=8.81 (s, 1H), 7.82
(d, 2H), 7.60-7.75 (m, 4H), 7.39 (s, 1H), 7.20 (d, 1H), 7.12 (dd,
1H), 6.87 (s, 1H), 3.82 (s, 3H), 3.74 (d, 1H), 2.30 (s, 3H), 1.20
(m, 1H), 0.55-0.90 (m, 4H).
EXAMPLE 139
Ethyl
2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidine-4-ca-
rboxylate
##STR00178##
[0885] A mixture of
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate
(298 mg, 0.80 mmol), ethyl 4-dimethylamino-2-oxo-but-3-enoate (171
mg, 1.0 mmol) and potassium carbonate (69 mg, 0.5 mmol) in ethanol
(2 mL) was heated in a sealed tube in a microwave oven to
170.degree. C. for 0.5 h. The mixture was cooled, diluted with
ethyl acetate (30 mL), and then washed with saturated sodium
carbonate solution (10 mL) and with brine (10 mL). The organic
layer was dried over sodium sulfate and evaporated under reduced
pressure. The residual material was purified by chromatography on
silica gel using dichloromethane/0-20% methanol as eluent to give
the title compound (96 mg, 34%) as a pale-yellow solid. MS ISP
(m/e): 354.2 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz):
.delta. (ppm)=8.67 (d, 1H), 7.91 (d, 1H), 7.64 (s, 1H), 7.45 (s,
1H), 7.44 (d, 1H), 7.19 (d, 1H), 7.02 (dd, 1H), 6.88 (s, 1H), 4.47
(q, 2H), 3.91 (s, 3H), 2.30 (s, 3H), 1.44 (t, 3H).
EXAMPLE 140
[4-(2-Chloro-phenyl)-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imidazol-1-yl)-
-phenyl]-amine
##STR00179##
[0887] The title compound was prepared from
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate
(149 mg, 0.4 mmol) and
1-(2-chloro-phenyl)-3-dimethylamino-propenone (105 mg, 0.5 mmol)
using in analogous manner the procedure described in example 139.
Obtained as a white solid (49 mg, 31%). MS ISP (m/e): 392.1
[(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.53 (d, 1H), 7.85 (d, 1H), 7.68 (m, 1H), 7.63 (d, 1H), 7.51
(m, 1H), 7.40 (m, 2H), 7.34 (s, 1H), 7.17 (d, 1H), 7.16 (s, 1H),
7.06 (dd, 1H), 6.87 (s, 1H), 3.84 (s, 3H), 2.30 (s, 3H).
EXAMPLE 141
Ethyl
2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-5-methyl-pyrimi-
dine-4-carboxylate
##STR00180##
[0889] The title compound was prepared from
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate
(298 mg, 0.8 mmol) and ethyl
4-dimethylamino-3-methyl-2-oxo-but-3-enoate (185 mg, 1.0 mmol)
using in analogous manner the procedure described in example 139.
Obtained as a white solid (30 mg, 8%). MS ISP (m/e): 368.2
[(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.45 (s, 1H), 7.83 (d, 1H), 7.63 (s, 1H), 7.31 (s, 1H), 7.17
(d, 1H), 7.02 (dd, 1H), 6.87 (s, 1H), 4.46 (q, 2H), 3.89 (s, 3H),
2.41 (s, 3H), 2.30 (s, 3H), 1.44 (t, 3H).
EXAMPLE 142
(4,5-Dimethyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl-
]-amine
##STR00181##
[0891] The title compound was prepared from
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate
(149 mg, 0.4 mmol) and
1-(2-chloro-phenyl)-3-dimethylamino-propenone (64 mg, 0.5 mmol)
using in analogous manner the procedure described in example 139.
Obtained as a white solid (12 mg, 10%). MS ISP (m/e): 310.2
[(M+H).sup.+]. NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=8.14 (s,
1H), 7.75 (d, 1H), 7.62 (s, 1H), 7.15 (d, 1H), 7.05 (m, 2H), 6.86
(s, 1H), 3.88 (s, 3H), 2.41 (s, 3H), 2.30 (s, 3H), 2.18 (s,
3H).
EXAMPLE 143
(4-Ethyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-ami-
ne
##STR00182##
[0893] The title compound was prepared from
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate
(149 mg, 0.4 mmol) and 1-dimethylamino-pent-1-en-3-one using (64
mg, 0.5 mmol) using in analogous manner the procedure described in
example 139. Obtained as awhite solid (18 mg, 16%). MS ISP (m/e):
310.2 [(M+H).sup.+]. NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=8.33
(d, 1H), 7.81 (d, 1H), 7.63 (s, 1H), 7.25 (s, 1H), 7.15 (d, 1H),
7.07 (dd, 1H), 6.87 (s, 1H), 6.67 (d, 1H), 3.87 (s, 3H), 2.71 (q,
2H), 2.30 (s, 3H), 1.33 (t, 3H).
EXAMPLE 144
(4-tert-Butyl-6-trifluoromethyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imi-
dazol-1-yl)-phenyl]-amine
##STR00183##
[0895] A mixture of
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate
(224 mg, 0.60 mmol), crude 3-dimethylamino-1-pyridin-3-yl-propenone
(118 mg, 0.60 mmol) and triethylamine (0.50 mL, 3.60 mmol) in
ethanol (1.5 mL) was heated in a sealed tube in a microwave oven to
170.degree. C. for 0.5 h. The mixture was cooled, diluted with
ethyl acetate (30 mL), and then washed with saturated sodium
carbonate solution (5 mL) and with brine (5 mL). The organic layer
was dried over sodium sulfate and evaporated under reduced
pressure. The residual material was purified by chromatography on
silica gel using dichloromethane/0-10% methanol as eluent to give
the title compound (116 mg, 47%) as a white solid. MS ISP (m/e):
406.3 [(M+H).sup.+]. NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=8.00
(d, 1H), 7.67 (s, 1H), 7.39 (s, 1H), 7.18 (d, 1H), 7.11 (s, 1H),
6.97 (dd, 1H), 6.90 (s, 1H), 3.89 (s, 3H), 2.30 (s, 3H), 1.39 (s,
9H).
EXAMPLES 145-150
[0896] Using in analogous manner the procedure described in example
144, heptane-3,5-dione, 6-methyl-heptane-2,4-dione,
1-phenyl-butane-1,3-dione,
4,4,4-trifluoro-1-pyrazin-2-yl-butane-1,3-dione,
4,4,4-trifluoro-1-furan-2-yl-butane-1,3-dione, and
2-benzoyl-cyclohexanone were reacted with
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine
dinitrate, respectively, to afford the following compounds:
EXAMPLE 145
(4-Isobutyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-
-phenyl]-amine
##STR00184##
[0898] Obtained in 12% yield as light yellow solid. MS ISP (m/e):
352.3 [(M+H).sup.+]. NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=7.96
(d, 1H), 7.62 (s, 1H), 7.14 (d, 1H), 7.12 (s, 1H), 6.98 (dd, 1H),
6.87 (s, 1H), 6.51 (s, 1H), 3.87 (s, 3H), 2.49 (d, 2H), 2.40 (s,
3H), 2.30 (s, 3H), 1.25 (m, 1H), 0.97 (d, 6H).
EXAMPLE 146
(4,6-Diethyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-
-amine
##STR00185##
[0900] Obtained in 18% yield as light yellow solid. MS ISP (m/e):
338.2 [(M+H).sup.+]. NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=8.00
(d, 1H), 7.62 (s, 1H), 7.15 (d, 1H), 7.13 (s, 1H), 6.98 (dd, 1H),
6.87 (s, 1H), 6.55 (s, 1H), 3.88 (s, 3H), 2.68 (q, 2H), 2.30 (s,
3H), 1.32 (t, 3H).
EXAMPLE 147
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-methyl-6-phenyl-pyrimidin-
-2-yl)-amine
##STR00186##
[0902] Obtained in 11% yield as off-white solid. MS ISP (m/e):
372.2 [(M+H).sup.+]. NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=8.09
(m, 2H), 8.02 (d, 1H), 7.64 (s, 1H), 7.18 (d, 1H), 7.12 (s, 1H),
7.05 (dd, 1H), 6.89 (s, 1H), 3.90 (s, 3H), 2.51 (s, 3H), 2.31 (s,
3H).
EXAMPLE 148
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-pyrazin-2-yl-6-trifluorom-
ethyl-pyrimidin-2-yl)-amine
##STR00187##
[0904] Obtained in 4% yield as light yellow solid. MS ISP (m/e):
428.2 [(M+H).sup.+]. NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=9.68
(s, 1H), 8.77 and 8.73 (2 d, 2.times.1H), 8.14 (s, 1H), 7.92 (s,
1H), 7.64 (s, 1H), 7.24 (d, 1H), 7.09 (dd, 1H), 6.90 (s, 1H), 3.93
(s, 3H), 2.31 (s, 3H).
EXAMPLE 149
(4-Furan-2-yl-6-trifluoromethyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imi-
dazol-1-yl)-phenyl]-amine
##STR00188##
[0906] Obtained in 3% yield as light yellow solid. MS ISP (m/e):
416.3 [(M+H).sup.+]. NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=8.00
(s, 1H), 7.66 (s, 2H), 7.45 (s, 1H), 7.41 (s, 1H), 7.31 (d, 1H),
7.20 (d, 1H), 6.99 (dd, 1H), 6.64 (m, 1H), 3.91 (s, 3H), 2.31 (s,
3H).
EXAMPLE 150
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(4-phenyl-5,6,7,8-tetrahydro-
-quinazolin-2-yl)-amine
##STR00189##
[0908] Obtained in 61% yield as light yellow solid. MS ISP (m/e):
412.3 [(M+H).sup.+]. NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=8.04
(d, 1H), 7.62 (s, 1H), 7.61 (m, 2H), 7.46 (m, 3H), (s, 1H), 7.20
(s, 1H), 7.12 (d, 1H), 6.94 (dd, 1H), 6.86 (s, 1H), 3.81 (s, 3H),
2.88 and 2.70 (2 t, 2.times.2H), 2.30 (s, 3H), 1.91 and 1.76 (2 m,
2.times.2H).
EXAMPLE 151
Ethyl
2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimi-
dine-4-carboxylate
##STR00190##
[0910] A mixture of
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate
(371 mg, 1.0 mmol), ethyl 2,4-dioxo-pentanoate (158 mg, 1.0 mmol)
and potassium carbonate (69 mg, 0.5 mmol) in ethanol (2 mL) was
heated in a sealed tube in a microwave oven to 170.degree. C. for
0.5 h. The mixture was cooled, diluted with ethyl acetate (50 mL),
and then washed with water (20 mL) and with brine (20 mL). The
organic layer was dried over sodium sulfate and evaporated under
reduced pressure. The residual material was purified by
chromatography on silica gel using dichloromethane/0-10% methanol
as eluent to give the title compound (229 mg, 62%) as a yellow
solid. MS ISP (m/e): 368.2 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3,
300 MHz): .delta. (ppm)=8.04 (d, 1H), 7.64 (s, 1H), 7.40 (s, 1H),
7.34 (s, 1H), 7.17 (d, 1H), 6.98 (dd, 1H), 6.87 (s, 1H), 4.46 (q,
2H), 3.91 (s, 3H), 2.54 (s, 3H), 2.30 (s, 3H), 1.43 (t, 3H).
EXAMPLES 152-164
[0911] Using in analogous manner the procedure described in example
151, pentane-2,4-dione, 1,1,1,5,5,5-hexafluoro-pentane-2,4-dione,
2,6-dimethyl-heptane-3,5-dione,
1-(2-chloro-phenyl)-butane-1,3-dione, ethyl
2,4-dioxo-4-thiophen-2-yl-butyrate, ethyl 2,4-dioxo-hexanoate,
ethyl 5-methyl-2,4-dioxo-hexanoate, ethyl
5,5-dimethyl-2,4-dioxo-hexanoate, ethyl
4-cyclopropyl-2,4-dioxo-butyrate, ethyl
2,4-dioxo-4-pyridin-2-yl-butyrate, ethyl
2,4-dioxo-4-(4-trifluoromethyl-phenyl)-butyrate, and ethyl
5-(4-chloro-phenyl)-2,4-dioxo-pentanoate were reacted with
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine
dinitrate, respectively, to afford the following compounds:
EXAMPLE 152
(4,6-Dimethyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl-
]-amine
##STR00191##
[0913] Obtained in 20% yield as off-white solid. MS ISP (m/e):
310.2 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=7.89 (d, 1H), 7.62 (s, 1H), 7.15 (d, 1H), 7.12 (s, 1H), 7.03
(dd, 1H), 6.87 (s, 1H), 6.56 (s, 1H), 3.87 (s, 3H), 2.40 (s, 6H),
2.30 (s, 3H).
EXAMPLE 153
(4,6-Bis-trifluoromethyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-
-yl)-phenyl]-amine
##STR00192##
[0915] Obtained in 46% yield as yellow solid. MS ISP (m/e): 418.2
[(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)
7.93 (d, 1H), 7.77 (s, 1H), 7.67 (s, 1H), 7.35 (s, 1H), 7.23 (d,
1H), 6.97 (dd, 1H), 6.90 (s, 1H), 3.89 (s, 3H), 2.31 (s, 3H).
EXAMPLE 154
(4-Isopropyl-6-trifluoromethyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imid-
azol-1-yl)-phenyl]-amine
##STR00193##
[0917] Obtained in 52% yield as light yellow solid. MS ISP (m/e):
392.2 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.00 (d, 1H), 7.64 (s, 1H), 7.40 (s, 1H), 7.18 (d, 1H), 6.97
(s, 1H), 6.94 (dd, 1H), 6.88 (s, 1H), 3.89 (s, 3H), 3.01 (m, 1H),
2.30 (s, 3H), 1.34 (d, 6H).
EXAMPLE 155
(4,6-Diisopropyl-pyrimidin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phe-
nyl]-amine
##STR00194##
[0919] Obtained in 12% yield as off-white solid. MS ISP (m/e):
366.2 [(M+H).sup.+].).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz):
.delta. (ppm)=8.10 (d, 1H), 7.63 (s, 1H), 7.15 (s, 1H), 7.14 (d,
1H), 6.94 (dd, 1H), 6.88 (s, 1H), 6.55 (s, 1H), 3.89 (s, 3H), 2.88
(m, 2H), 2.30 (s, 3H), 1.30 (d, 12H).
EXAMPLE 156
[4-(2-Chloro-phenyl)-6-methyl-pyrimidin-2-yl]-[3-methoxy-4-(4-methyl-imida-
zol-1-yl)-phenyl]-amine
##STR00195##
[0921] Obtained in 8% yield as light yellow solid. MS ISP (m/e):
406.3 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=7.99 (d, 1H), 7.64 (m, 1H), 7.62 (s, 1H), 7.50 (m, 1H), 7.38
(m, 2H), 7.29 (s, 1H), 7.15 (d, 1H), 7.03 (s, 1H), 7.01 (dd, 1H),
6.86 (s, 1H), 3.89 (s, 3H), 2.52 (s, 3H), 2.30 (s, 3H).
EXAMPLE 157
Ethyl
2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-thiophen-2-yl-
-pyrimidine-4-carboxylate
##STR00196##
[0923] Obtained in 15% yield as light yellow solid. MS ISP (m/e):
436.1 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.05 (d, 1H), 7.87 (d, 1H), 7.77 (s, 1H), 7.66 (s, 1H), 7.59
(d, 1H), 7.51 (s, 1H), 7.20 (s, 1H), 7.20 (d, 1H), 7.15 (d, 1H),
7.03 (s, 1H), 6.98 (dd, 1H), 6.90 (s, 1H), 4.51 (q, 2H), 3.99 (s,
3H), 2.31 (s, 3H), 1.47 (t, 3H).
EXAMPLE 158
Ethyl
6-ethyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimid-
ine-4-carboxylate
##STR00197##
[0925] Obtained in 38% yield as light yellow solid. MS ISP (m/e):
382.4 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.06 (d, 1H), 7.63 (s, 1H), 7.43 (s, 1H), 7.35 (s, 1H), 7.17
(d, 1H), 6.96 (dd, 1H), 6.88 (s, 1H), 4.47 (q, 2H), 3.91 (s, 3H),
2.82 (q, 2H), 2.31 (s, 3H), 1.44 (t, 3H), 1.37 (t, 3H).
EXAMPLE 159
Ethyl
6-Isopropyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyr-
imidine-4-carboxylate
##STR00198##
[0927] Obtained in 49% yield as light yellow solid. MS ISP (m/e):
396.2 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.10 (d, 1H), 7.63 (s, 1H), 7.45 (s, 1H), 7.35 (s, 1H), 7.17
(d, 1H), 6.94 (dd, 1H), 6.88 (s, 1H), 4.47 (q, 2H), 3.91 (s, 3H),
3.03 (m, 1H), 2.30 (s, 3H), 1.44 (t, 3H), 1.35 (d, 6H).
EXAMPLE 160
Ethyl
6-tert-butyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-py-
rimidine-4-carboxylate
##STR00199##
[0929] Obtained in 24% yield as light yellow solid. MS ISP (m/e):
410.2 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.05 (d, 1H), 7.63 (s, 1H), 7.49 (s, 1H), 7.47 (s, 1H), 7.17
(d, 1H), 6.95 (dd, 1H), 6.88 (s, 1H), 4.48 (q, 2H), 3.91 (s, 3H),
2.30 (s, 3H), 1.44 (t, 3H), 1.40 (s, 9H).
EXAMPLE 161
Ethyl
6-cyclopropyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-p-
yrimidine-4-carboxylate
##STR00200##
[0931] Obtained in 23% yield as light yellow solid. MS ISP (m/e):
394.2 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=7.98 (d, 1H), 7.63 (s, 1H), 7.38 (s, 1H), 7.36 (s, 1H), 7.15
(d, 1H), 6.87 (m, 2H), 4.48 (q, 2H), 3.91 (s, 3H), 2.30 (s, 3H),
2.05 (m, 1H), 1.44 (t, 3H), 1.40 (s, 9H), 1.25 (m, 2H), 1.15 (m,
2H).
EXAMPLE 162
Ethyl
2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-pyridin-2-yl--
pyrimidine-4-carboxylate
##STR00201##
[0933] Obtained in 14% yield as light yellow solid. MS ISP (m/e):
431.3 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.78 (dd, 1H), 8.45 (s, 1H), 8.44 (d, 1H), 8.01 (d, 1H), 7.88
(td, 1H), 7.66 (s, 1H), 7.60 (s, 1H), 7.46 (dd, 1H), 7.22 (d, 1H),
7.08 (dd, 1H), 6.90 (s, 1H), 4.51 (q, 2H), 3.94 (s, 3H), 2.31 (s,
3H), 1.47 (t, 3H).
EXAMPLE 163
Ethyl
2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluorom-
ethyl-phenyl)-pyrimidine-4-carboxylate
##STR00202##
[0935] Obtained in 26% yield as light yellow solid. MS ISP (m/e):
498.2 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.26 (d, 2H), 8.01 (d, 1H), 7.92 (s, 1H), 7.79 (d, 2H), 7.66
(s, 1H), 7.59 (s, 1H), 7.22 (d, 1H), 7.07 (dd, 1H), 6.90 (s, 1H),
4.52 (q, 2H), 3.93 (s, 3H), 2.31 (s, 3H), 1.47 (t, 3H).
EXAMPLE 164
Ethyl
6-(4-chloro-benzyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylam-
ino]-pyrimidine-4-carboxylate
##STR00203##
[0937] Obtained in 33% yield as light yellow solid. MS ISP (m/e):
478.1 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=7.90 (s, 1H), 7.63 (s, 1H), 7.44 (s, 1H), 7.31 (d, 2H), 7.29
(s, 1H), 7.21 (d, 2H), 7.16 (d, 1H), 6.96 (dd, 1H), 6.87 (s, 1H),
4.45 (q, 2H), 3.83 (s, 3H), 2.30 (s, 3H), 1.42 (t, 3H).
EXAMPLE 165
2-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimidin-
-4-yl}-propan-2-ol
##STR00204##
[0939] To a solution of ethyl
2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-methyl-pyrimidine--
4-carboxylate (184 mg, 0.5 mmol) in tetrahydrofurane (10 mL) was
added at 0.degree. C. over 2 min a 3 M solution of
methylmagnesiumchloride in tetrahydrofurane (0.55 mL, 1.65 mmol).
The reaction mixture was stirred at 0.degree. C. for 15 min
followed by 1 h at. The mixture was poured on saturated sodium
carbonate solution (20 mL) and the product was extracted with ethyl
acetate (40 mL). The organic layer was washed with brine (20 mL),
dried over sodium sulfate and evaporated under reduced pressure.
The residual material was crystallized from dichloromethane/heptane
to give the title compound to give the title compound (105 mg, 59%)
as an off-white solid. MS ISP (m/e): 354.3 [(M+H).sup.+]. .sup.1H
NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=7.76 (d, 1H), 7.63 (s,
1H), 7.18 (d, 1H), 7.02 (dd, 1H), 6.88 (s, 1H), 6.75 (s, 1H), 4.04
(s, 1H), 3.88 (s, 3H), 2.47 (s, 3H), 2.30 (s, 3H), 1.53 (s,
6H).
EXAMPLE 166-173
[0940] Using in analogous manner the procedure described in example
165, the products of examples 158, 159, 161, 160, 157, 141, 162,
and 164 were reacted with methylmagnesium-chloride, respectively,
to give, after purification of the crude products by
crystallization from dichloromethane/heptane or by chromatography
on silica gel using dichloro-methane/0-10% methanol as eluent, the
following compounds:
EXAMPLE 166
2-{6-Ethyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin--
4-yl}-propan-2-ol
##STR00205##
[0942] Obtained in 35% yield as light yellow solid. MS ISP (m/e):
368.2 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=7.84 (d, 1H), 7.63 (s, 1H), 7.21 (s, 1H), 7.17 (d, 1H), 7.00
(dd, 1H), 6.88 (s, 1H), 6.74 (s, 1H), 4.10 (s, 1H), 3.88 (s, 3H),
2.43 (q, 2H), 2.30 (s, 3H), 1.54 (s, 6H), 1.34 (t, 3H).
EXAMPLE 167
2-{6-Isopropyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimi-
din-4-yl}-propan-2-ol
##STR00206##
[0944] Obtained in 49% yield as light yellow solid. MS ISP (m/e):
382.3 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=7.91 (d, 1H), 7.64 (s, 1H), 7.19 (s, 1H), 7.17 (d, 1H), 6.98
(dd, 1H), 6.88 (s, 1H), 6.74 (s, 1H), 4.18 (s, 1H), 3.89 (s, 3H),
2.94 (m, 1H), 2.30 (s, 3H), 1.54 (s, 6H), 1.33 (d, 6H).
EXAMPLE 168
2-{6-Cyclopropyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyri-
midin-4-yl}-propan-2-ol
##STR00207##
[0946] Obtained in 31% yield as light white solid. MS ISP (m/e):
380.3 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=7.84 (d, 1H), 7.65 (s, 1H), 7.16 (d, 1H), 7.12 (s, 1H), 6.90
(dd, 1H), 6.88 (s, 1H), 6.78 (s, 1H), 4.20 (s, 1H), 3.89 (s, 3H),
2.31 (s, 3H), 1.96 (m, 1H), 1.53 (s, 6H), 1.22 (m, 2H), 1.09 (m,
2H).
EXAMPLE 169
2-{6-tert-Butyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrim-
idin-4-yl}-propan-2-ol
##STR00208##
[0948] Obtained in 17% yield as light yellow solid. MS ISP (m/e):
396.3 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=7.94 (d, 1H), 7.64 (s, 1H), 7.19 (s, 1H), 7.17 (d, 1H), 6.98
(dd, 1H), 6.89 (s, 1H), 6.87 (s, 1H), 4.17 (s, 1H), 3.89 (s, 3H),
2.30 (s, 3H), 1.54 (s, 6H), 1.38 (s, 9H).
EXAMPLE 170
2-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-thiophen-2-yl-py-
rimidin-4-yl}-propan-2-ol
##STR00209##
[0950] Obtained in 62% yield as light yellow solid. MS ISP (m/e):
422.2 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=7.90 (d, 1H), 7.78 (d, 1H), 7.64 (s, 1H), 7.53 (d, 1H), 7.20
(d, 1H), 7.19 (s, 1H), 7.18 (m, 1H), 7.01 (dd, 1H), 6.90 (s, 1H),
4.00 (s, 1H), 3.96 (s, 3H), 2.31 (s, 3H), 1.58 (s, 6H).
EXAMPLE 171
2-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-5-methyl-pyrimidin-
-4-yl}-propan-2-ol
##STR00210##
[0952] Obtained in 54% yield as light yellow solid. MS ISP (m/e):
354.3 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.22 (s, 1H), 7.63 (s, 1H), 7.53 (d, 1H), 7.18 (d, 1H), 7.13
(s, 1H), 7.03 (dd, 1H), 6.87 (s, 1H), 5.30 (s, 1H), 3.87 (s, 3H),
2.37 (s, 3H), 2.31 (s, 3H), 1.59 (s, 6H).
EXAMPLE 172
2-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-pyridin-2-yl-pyr-
imidin-4-yl}-propan-2-ol
##STR00211##
[0954] Obtained in 82% yield as light yellow solid. MS ISP (m/e):
417.3 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.75 (dd, 1H), 8.44 (d, 1H), 7.94 (s, 1H), 7.87 (td, 1H),
7.77 (d, 1H), 7.66 (s, 1H), 7.43 (dd, 1H), 7.24 (d, 1H), 7.13 (dd,
1H), 6.91 (s, 1H), 4.29 (s, 1H), 3.91 (s, 3H), 2.31 (s, 3H), 1.63
(s, 6H).
EXAMPLE 173
2-{6-(4-Chloro-benzyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino-
]-pyrimidin-4-yl}-propan-2-ol
##STR00212##
[0956] Obtained in 47% yield as off-white solid. MS ISP (m/e):
464.2 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=7.67 (d, 1H), 7.62 (s, 1H), 7.30 (d, 2H), 7.22 (d, 2H), 7.15
(d, 1H), 6.99 (dd, 1H), 6.88 (s, 1H), 6.73 (s, 1H), 3.99 (s, 2H),
3.94 (br s, 1H), 3.78 (s, 3H), 2.30 (s, 3H), 1.51 (s, 6H).
EXAMPLE 174
2-[2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluorometh-
yl-phenyl)-pyrimidin-4-yl]-propan-2-ol
##STR00213##
[0958] To a solution of ethyl
2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromethyl-
-phenyl)-pyrimidine-4-carboxylate (597 mg, 1.2 mmol) in
tetrahydro-furane (25 mL) was added at 0.degree. C. over 2 min a 3
M solution of methylmagnesiumchloride in tetrahydrofurane (1.68 mL,
5.04 mmol). The reaction mixture was stirred at 0.degree. C. for 15
min followed by 1.5 h at. The mixture was poured on saturated
sodium carbonate solution (20 mL) and the product was extracted
with ethyl acetate (80 mL). The organic layer was washed with brine
(20 mL), dried over sodium sulfate and evaporated under reduced
pressure. The residual material was purified by chromatography on
silica gel using dichloromethane/0-10% methanol as eluent.
Following a more liopophilic by-product (54 mg, example 175) the
title compound was eluted and crystallized from
dichloromethane/diethyl ether to give a white solid (314 mg, 54%).
MS ISP (m/e): 484.4 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300
MHz): .delta. (ppm)=8.21 (d, 2H), 7.82 (d, 1H), 7.77 (d, 2H), 7.66
(s, 1H), 7.36 (s, 2H), 7.22 (d, 1H), 7.10 (dd, 1H), 6.90 (s, 1H),
3.90 (s, 3H), 3.84 (br s, 1H), 2.31 (s, 3H), 1.56 (s, 6H).
EXAMPLE 175
1-[2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluorometh-
yl-phenyl)-pyrimidin-4-yl]-ethanone
##STR00214##
[0960] Obtained as by-product in the preparation of example 174 in
10% yield as light yellow solid. MS ISP (m/e): 468.3 [(M+H).sup.+].
.sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=8.26 (d, 2H), 7.84
(s, 1H), 7.82 (d, 1H), 7.79 (d, 2H), 7.67 (s, 1H), 7.52 (s, 1H),
7.26 (m, 2H), 7.17 (dd, 1H), 6.91 (s, 1H), 3.92 (s, 3H), 2.76 (s,
3H), 2.32 (s, 3H).
EXAMPLE 176
3-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl}-pe-
ntan-3-ol
##STR00215##
[0962] To a solution of
2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidine-4-carboxy-
lic acid ethyl ester (46 mg, 0.13 mmol) in tetrahydrofurane (2.5
mL) was added at 0.degree. C. over 1 min a 1 M solution of
ethylmagnesiumbromide in tetrahydrofurane (0.43 mL, 0.43 mmol). The
reaction mixture was stirred at 0.degree. C. for 15 min followed by
1 h at. The mixture was poured on saturated sodium carbonate
solution (5 mL) and the mixture was extracted with ethyl acetate
(40 mL). The organic layer was washed with brine (20 mL), dried
over sodium sulfate and evaporated under reduced pressure. The
residual material was purified by chromatography on silica gel
using dichloromethane/0-10% methanol as eluent to give the title
compound (4 mg, 9%) as yellow oil. MS ISP (m/e): 368.2
[(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.42 (d, 1H), 7.66 (d, 1H), 7.65 (s, 1H), 7.39 (s, 1H), 7.20
(d, 1H), 7.06 (dd, 1H), 6.89 (s, 1H), 6.79 (d, 1H), 4.32 (br s,
1H), 3.88 (s, 3H), 2.31 (s, 3H), 2.35 (m, 4H), 0.76 (t, 6H).
EXAMPLE 177
1-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin-4-yl
##STR00216##
[0964] Obtained as by-product in the preparation of example 177 in
3% yield as white solid. MS ISP (m/e): 340.2 [(M+H).sup.+]. .sup.1H
NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=8.41 (d, 1H), 7.66 (s,
2H), 7.20 (s, 1H), 7.17 (d, 1H), 7.09 (dd, 1H), 6.88 (s, 1H), 6.78
(d, 1H), 4.60 (brt, 1H), 3.87 (s, 3H), 2.30 (s, 3H), 1.6-1.8 (m,
2H), 0.99 (t, 3H).
EXAMPLE 178
Dicyclopropyl-{2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimi-
din-4-yl}-methanol
##STR00217##
[0966] To a solution of
2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidine-4-carboxy-
lic acid ethyl ester (46 mg, 0.13 mmol) in tetrahydrofurane (2.5
mL) was added at 0.degree. C. over 1 min a 0.5 M solution of
cyclopropylmagnesiumbromide in tetrahydrofurane (1.02 mL, 0.51
mmol). The reaction mixture was stirred at 0.degree. C. for 15 min
followed by 1.5 h at. The mixture was poured on saturated sodium
carbonate solution (5 mL) and the mixture was extracted with ethyl
acetate (40 mL). The organic layer was washed with brine (20 mL),
dried over sodium sulfate and evaporated under reduced pressure.
The residual material was purified by chromatography on silica gel
using dichloromethane/0-10% methanol as eluent to give the title
compound as light yellow foam (44 mg, 88%). MS ISP (m/e): 392.3
[(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.45 (d, 1H), 7.64 (s, 1H), 7.56 (d, 1H), 7.23 (s, 1H), 7.19
(d, 1H), 7.08 (dd, 1H), 7.00 (d, 1H), 6.88 (s, 1H), 4.15 (s, 1H),
3.87 (s, 3H), 2.30 (s, 3H), 1.14 (m, 2H), 0.70, 0.50, 0.35, 0.25 (4
m, 4.times.2H).
EXAMPLE 179
2-[2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(3,4,5-trifluoro-
-phenyl)-pyrimidin-4-yl]-propan-2-ol
##STR00218##
[0967] a) Ethyl 2,4-dioxo-4-(3,4,5-trifluoro-phenyl)-butyrate
[0968] Potassium tert.-butoxide (1.12 g, 10.0 mmol) was added to a
solution of 1-(3,4,5-trifluoro-phenyl)-ethanone (1.74 g, 10.0 mmol)
and diethyl oxalate (1.49 mL, 11.0 mmol) in diethyl ether (20 mL)
cooled to 0.degree. C. The heterogenous mixture was stirred for 15
min at 0.degree. C. followed by 15 h at. The mixture was
partitioned between 3 N hydrochloric acid (20 mL) and diethyl ether
(50 mL). The organic layer was washed with brine (20 mL), dried
over sodium sulfate and evaporated under reduced pressure and the
residual oil was crystallized from diethyl ether/heptane to give
the title compound as a white solid.
2-[2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(3,4,5-trifluoro-
-phenyl)-pyrimidin-4-yl]-propan-2-ol
[0969] Ethyl 2,4-dioxo-4-(3,4,5-trifluoro-phenyl)-butyrate (274 mg,
1.0 mmol) was reacted with
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate
(298 mg, 0.80 mmol) in analogous manner as described in example
139, and the resulting product was subjected in analogous manner to
the procedure described in example 165 to give the title compound
light yellow solid (35 mg, 9%). MS ISP (m/e): 470.4 [(M+H).sup.+].
.sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=7.81 (m, 2H), 7.78
(d, 1H), 7.75 (s, 1H), 7.66 (s, 1H), 7.35 (s, 1H), 7.22 (d, 1H),
7.04 (dd, 1H), 6.90 (s, 1H), 3.91 (s, 3H), 3.76 (br s, 1H), 2.31
(s, 3H), 1.61 (s, 6H).
EXAMPLE 180
2-{6-(2,4-Dichloro-phenyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyla-
mino]-pyrimidin-4-yl}-propan-2-ol
##STR00219##
[0971] Ethyl 3-(2,4-dichloro-phenyl)-3-oxo-propionate (145 mg, 0.5
mmol) was subjected in analogous manner to the procedure described
in example 179b) to give the title compound as light yellow foam
(42 mg, 22%). MS ISP (m/e): 484.3 [(M+H).sup.+]. .sup.1H NMR
(CDCl.sub.3, 300 MHz): .delta. (ppm)=7.82 (d, 1H), 7.64 (d, 1H),
7.64 (s, 1H), 7.53 (d, 1H), 7.36 (dd, 1H), 7.33 (s, 1H), 7.23 (s,
1H), 7.18 (d, 1H), 7.04 (dd, 1H), 6.88 (s, 1H), 3.95 (br s, 1H),
3.84 (s, 3H), 2.30 (s, 3H), 1.59 (s, 6H).
EXAMPLE 181
2-{6-(4-Chloro-phenyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino-
]-pyrimidin-4-yl}-propan-2-ol
##STR00220##
[0973] Ethyl 3-(4-chloro-phenyl)-3-oxo-propionate (127 mg, 0.5
mmol) was subjected in analogous manner to the procedure described
in example 179b) to give the title compound as light yellow foam
(42 mg, 13%). MS ISP (m/e): 450.2 [(M+H).sup.+].).sup.+]. .sup.1H
NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=8.05 (d, 2H), 7.84 (d,
1H), 7.66 (s, 1H), 7.48 (d, 2H), 7.31 (s, 1H), 7.29 (s, 1H), 7.21
(d, 1H), 7.06 (dd, 1H), 6.89 (s, 1H), 3.94 (br s, 1H), 3.89 (s,
3H), 2.31 (s, 3H), 1.61 (s, 6H).
EXAMPLE 182
2-{6-(2-Chloro-phenyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino-
]-pyrimidin-4-yl}-propan-2-ol
##STR00221##
[0975] Ethyl 3-(2-chloro-phenyl)-3-oxo-propionate (127 mg, 0.5
mmol) was subjected in analogous manner to the procedure described
in example 179b) to give the title compound as light yellow foam
(33 mg, 18%). MS ISP (m/e): 450.2 [(M+H).sup.+]. .sup.1H NMR
(CDCl.sub.3, 300 MHz): .delta. (ppm)=7.88 (d, 1H), 7.66 (m, 1H),
7.64 (s, 1H), 7.52 (m, 1H), 7.41 (m, 2H), 7.34 (s, 1H), 7.25 (s,
1H), 7.18 (d, 1H), 7.04 (dd, 1H), 6.88 (s, 1H), 4.08 (br s, 1H),
3.84 (s, 3H), 2.30 (s, 3H), 1.60 (s, 6H).
EXAMPLE 183
2-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-5,6,7,8-tetrahydro-
-quinazolin-4-yl}-propan-2-ol
##STR00222##
[0977] Ethyl oxo-(2-oxo-cyclohexyl)-acetate (198 mg, 1.0 mmol) was
subjected in analogous manner to the procedure described in example
179b) to give the title compound as light yellow foam (15 mg, 5%).
MS ISP (m/e): 394.2 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300
MHz): .delta. (ppm)=7.67 (d, 1H), 7.63 (s, 1H), 7.45 (s, 1H), 7.13
(d, 1H), 7.00 (dd, 1H), 6.88 (s, 1H), 3.87 (s, 3H), 2.75-2.95 (m,
4H), 2.30 (s, 3H), 1.75-1.95 (m, 4H), 1.58 (s, 6H).
EXAMPLE 184
(4-Benzyl-6-methyl-pyrimidin-2-yl)-[3-fluoro-4-(4-methyl-imidazol-1-yl)-ph-
enyl]-amine
##STR00223##
[0979] The title compound was prepared from
4-benzyl-2-chloro-6-methyl-pyrimidine (100 mg, 0.46 mmol) and
3-fluoro-4-(4-methyl-imidazol-1-yl)-phenylamine (88 mg, 0.57 mmol)
using in analogous manner the procedure described in example 43b).
Column chromatography (15 g silica, dichloromethane+3.7% methanol
v/v) afforded the title compound (148 mg, 86%) as a white solid. MS
ISP (m/e): 374.4 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz):
.delta. (ppm)=7.98 (dd, 1H), 7.65 (s, 1H), 7.26 (m, 8H), 6.92 (s,
1H), 6.53 (s, 1H), 3.98 (s, 2H), 2.38 8s, 3H), 2.31 (s, 3H). Mp
155-158.degree. C.
EXAMPLE 185
(6-Ethoxy-pyridin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amin-
e
##STR00224##
[0981] A solution of
(6-chloro-pyridin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-ami-
ne (63 mg, 0.2 mmol) and 21% sodium ethanolate solution in ethanol
(112 uL, 0.3 mmol) was heated to 200.degree. C. for 30 minutes in a
microwave oven. The same amount of sodium ethanolate solution was
added and the reaction was again heated to 200.degree. C. for 30
minutes in a microwave oven. Water was added and the reaction was
extracted twice with ethyl acetate. The combined organic layers
were washed with brine, dried over sodium sulfate, filtered and the
solvent was evaporated under reduced pressure. The residue was
purified by column chromatography on silica gel using
dichloromethane/methanol (19:1 v/v) as eluent to yield the title
compound as a light brown solid (25 mg, 39%). MS ISP (m/e): 325.2
(100) [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=7.64 (s, 1H), 7.45 (t, 1H), 7.34 (s, 1H), 7.15 (d, 1H), 6.92
(d, 1H), 6.87 (s, 1H), 6.50 (s, 1H), 6.37 (d, 1H), 6.24 (d, 1H),
4.35 (q, 2H), 3.83 (s, 3H), 2.30 (s, 3H), 1.41 (t, 3H).
EXAMPLE 186
N-(4-Fluoro-phenyl)-N'-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-pyrid-
ine-2,6-diamine
##STR00225##
[0982] a)
(6-Chloro-pyridin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-ph-
enyl]-amine
[0983] Prepared in analogy to example 62 from
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and
2,6-dichloropyridine. The title compound was obtained as a yellow
solid (Yield=60%). MS ISP (m/e): 315.1 & 317.1 (100 & 37)
[(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=7.63 (s, 1H), 7.48 (t, 1H), 7.37 (s, 1H), 7.18 (d, 1H),
6.95-6.80 (m, 2H), 6.82 (d, 1H), 6.72 (d, 1H), 6.64 (s, 1H), 3.86
(s, 3H), 2.30 (s, 3H).
b)
N-(4-Fluoro-phenyl)-N'-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-py-
ridine-2,6-diamine
[0984] Prepared in analogy to example 62 from 4-fluoroaniline and
(6-chloro-pyridin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-ami-
ne. The title compound was obtained as a colorless foam
(Yield=17%). MS ISP (m/e): 390.4 (100) [(M+H).sup.+]. .sup.1H NMR
(DMSO-D.sub.6, 300 MHz): .delta. (ppm)=9.02 (s, 1H), 8.83 (s, 1H),
7.64 (d, 1H), 7.60-7.50 (m, 2H), 7.45-7.35 (m, 2H), 7.24 (dxd, 1H),
7.15 (d, 1H), 7.07 (t, 1H), 7.02 (s, 1H), 6.24 (qa, 1H), 3.59 (s,
3H), 2.15 (s, 3H).
EXAMPLE 187
N-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N'-(4-trifluoromethoxy-phe-
nyl)-pyridine-2,6-diamine
##STR00226##
[0986] Prepared in analogy to example 62 from
4-(trifluoromethoxy)aniline and
(6-chloro-pyridin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-
-amine. The title compound was obtained as a brownish solid
(Yield=10%). MS ISP (m/e): 456.3 (100) [(M+H).sup.+].
[0987] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=7.63 (s,
1H), 7.45-7.35 (m, 3H), 7.20-7.10 (m, 3H), 6.94 (dxd, 1H), 6.87 (s,
1H), 6.44 (s, 1H), 6.36 (s, 1H), 6.34 (dxd, 1H), 3.73 (s, 3H), 2.30
(s, 3H).
EXAMPLE 188
N-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N'-(3-trifluoromethoxy-phe-
nyl)-pyridine-2,6-diamine
##STR00227##
[0989] Prepared in analogy to example 62 from
3-(trifluoromethoxy)aniline and
(6-chloro-pyridin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-
-amine. The title compound was obtained as a brownish solid
(Yield=3%). MS ISP (m/e): 456.3 (100) [(M+H).sup.+].
[0990] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=7.63 (s,
1H), 7.45-7.35 (m, 3H), 7.20-7.10 (m, 2H), 6.96 (dxd, 1H),
6.90-6.80 (m 2H), 6.43 (s, 1H), 6.42 (s, 1H), 6.35 (dxd, 1H), 3.74
(s, 3H), 2.30 (s, 3H).
EXAMPLE 189
N-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N'-(4-pentafluorosulfanyl--
phenyl)-pyridine-2,6-diamine
##STR00228##
[0992] Prepared in analogy to example 62 from
4-aminosulfurpentafluoride and
(6-chloro-pyridin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-
-amine. The title compound was obtained as a colorless solid
(Yield=44%). MS ISP (m/e): 498.3 (100) [(M+H).sup.+].
[0993] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=7.70-7.60
(m, 3H), 7.55-7.40 (m, 3H), 7.20-7.10 (m, 2H), 6.57 (s, 1H), 6.48
(s, 1H), 6.42 (d, 1H), 6.37 (d, 1H), 3.72 (s, 3H), 2.30 (s,
3H).
EXAMPLE 190
N-[3-Methoxy-4-(4-methyl-imidazole-1-yl)-phenyl)]-N'-(3-sulfurpentafluorid-
e-phenyl)-pyridine-2,6-diamine
##STR00229##
[0995] Prepared in analogy to example 62 from
3-aminosulfurpentafluoride and
(6-chloro-pyridin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-
-amine. The title compound was obtained as a slightly orange solid
(Yield=30%). MS ISP (m/e): 498.1 (100) [(M+H).sup.+]. .sup.1H NMR
(CDCl.sub.3, 300 MHz): .delta. (ppm)=7.84 (s, 1H), 7.63 (s, 1H),
7.60-7.50 (m, 1H), 7.44 (t, 1H), 7.40-7.30 (m, 2H), 7.20-7.10 (m,
2H), 6.95 (dxd, 1H), 6.87 (s, 1H), 6.45 (s, 1H), 6.43 (s, 1H), 6.39
(d, 1H), 6.30 (d, 1H), 3.71 (s, 3H), 3.30 (s, 3H).
EXAMPLE 191
N-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N'-(3-trifluoromethyl-phen-
yl)-pyridine-2,6-diamine
##STR00230##
[0997] Prepared in analogy to example 62 from
3-trifluoromethylaniline and
(6-chloro-pyridin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-ami-
ne. The title compound was obtained as a brownish solid
(Yield=48%). MS ISP (m/e): 440.3 (100) [(M+H).sup.+]. .sup.1H NMR
(DMSO-D.sub.6, 300 MHz): .delta. (ppm)=9.24 (s, 1H), 9.13 (s, 1H),
7.93 (s, 1H), 7.82 (d, 1H), 7.65 (s, 1H), 7.55-7.40 (m, 2H), 7.36
(d, 1H), 7.25-7.10 (m, 3H), 7.00 (s, 1H), 6.32 (t, 2H), 3.54 (s,
3H), 2.15 (s, 3H).
EXAMPLE 192
N-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N'-(4-trifluoromethyl-phen-
yl)-pyridine-2,6-diamine
##STR00231##
[0999] Prepared in analogy to example 62 from
4-trifluoromethylaniline and
(6-chloro-pyridin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-ami-
ne. The title compound was obtained as a brownish solid
(Yield=18%). MS ISN (m/e): 438.4 (100) [(M-H).sup.-]. .sup.1H NMR
(CDCl.sub.3, 300 MHz): .delta. (ppm)=7.64 (s, 1H), 7.60-7.45 (m,
4H), 7.44 (d, 1H), 7.20-7.10 (m, 2H), 6.95 (dxd, 1H), 6.88 (s, 1H),
6.52 (s, 1H), 6.46 (s, 1H), 6.39 (t, 2H), 3.73 (s, 3H), 2.31 (s,
3H).
EXAMPLE 193
N-(3-Fluoro-phenyl)-N'-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-pyrid-
ine-2,6-diamine
##STR00232##
[1001] Prepared in analogy to example 62 from 3-fluoroaniline and
(6-chloro-pyridin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-ami-
ne. The title compound was obtained as a brownish solid
(Yield=24%). MS ISP (m/e): 390.3 (100) [(M+H).sup.+]. .sup.1H NMR
(DMSO-D.sub.6, 300 MHz): .delta. (ppm)=9.10 (s very broad, 2H),
7.70-7.50 (m, 2H), 7.45 (t, 2H), 7.39 (s, 1H), 7.30-7.10 (m, 4H),
7.02 (s, 1H), 6.63 (t broad, 1H), 6.30 (t, 2H), 3.62 (s, 3H), 2.14
(s broad, 3H).
EXAMPLE 194
N-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N'-methyl-N'-phenyl-pyridi-
ne-2,6-diamine
##STR00233##
[1003] Prepared in analogy to example 62 from N-methylaniline and
(6-chloro-pyridin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-ami-
ne. The title compound was obtained as a brownish solid
(Yield=16%). MS ISP (m/e): 386.2 (100) [(M+H).sup.+]. .sup.1H NMR
(DMSO-D.sub.6, 300 MHz): .delta. (ppm)=9.06 (s, 1H), 7.68 (d, 1H),
7.61 (s, 1H), 7.50-7.35 (m, 3H), 7.35-7.15 (m, 4H), 7.09 (1H), 6.99
(s, 1H), 6.19 (d, 1H), 5.95 (d, 1H), 3.70 (s, 3H), 3.44 (s, 3H),
2.14 (s, 3H).
EXAMPLE 195
N-Benzyl-N'-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-pyridine-2,6-dia-
mine
##STR00234##
[1005] Prepared in analogy to example 62 from benzylamine and
(6-chloro-pyridin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-ami-
ne. The title compound was obtained as a brown solid (Yield=11%).
MS ISP (m/e): 386.2 (100) [(M+H).sup.+]. .sup.1H NMR (DMSO-D.sub.6,
300 MHz): .delta. (ppm)=8.88 (s, 1H), 7.67 (d, 1H), 7.59 (d, 1H),
7.35-7.25 (m, 3H), 7.35-7.10 (m, 4H), 7.06 (d, 1H), 6.97 (d, 1H),
6.90 (t, 1H), 6.00 (d, 1H), 5.95 (d, 1H), 4.54 (d, 2H), 3.65 (s,
3H), 2.13 (s, 3H).
EXAMPLE 196
N-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N'-(4-trifluoromethoxy-phe-
nyl)-4-trifluoromethyl-pyridine-2,6-diamine
##STR00235##
[1006] a)
(6-Chloro-4-trifluoromethyl-pyridin-2-yl)-[3-methoxy-4-(4-methyl-
-imidazol-1-yl)-phenyl]-amine
[1007] Prepared in analogy to example 62 from
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and
2,6-dichloro-4-trifluoromethyl-pyridine. The title compound was
obtained as a yellowish solid (Yield=30%). MS ISP (m/e): 383.1 (39)
[(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=7.67 (d, 1H), 7.39 (d, 1H), 7.23 (d, 1H), 7.11 (s, 1H), 6.99
(s, 1H), 6.965-6.85 (m, 3H), 3.87 (s, 3H), 2.31 (s, 3H).
b)
N-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N'-(4-trifluoromethoxy--
phenyl)-4-trifluoromethyl-pyridine-2,6-diamine
[1008] Prepared in analogy to example 62 from
4-(trifluoromethoxy)aniline and
(6-chloro-4-trifluoromethyl-pyridin-2-yl)-[3-methoxy-4-(4-methyl-imid-
azol-1-yl)-phenyl]-amine. The title compound was obtained as a
yellowish solid (Yield=33%). MS ISP (m/e): 524.2 (100)
[(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=7.65 (d, 1H), 7.42 (d, 2H), 7.19 (d, 2H), 7.13 (d, 1H), 6.97
(dxd, 1H), 6.89 (s, 1H), 6.65 (s, 1H), 6.58 (s, 1H), 6.48 (s, 1H),
6.42 (s, 1H), 3.74 (s, 3H), 2.31 (s, 3H).
EXAMPLE 197
N-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N'-(3-trifluoromethoxy-phe-
nyl)-4-trifluoromethyl-pyridine-2,6-diamine
##STR00236##
[1010] Prepared in analogy to example 62 from
3-(trifluoromethoxy)aniline and
(6-chloro-4-trifluoromethyl-pyridin-2-yl)-[3-methoxy-4-(4-methyl-imid-
azol-1-yl)-phenyl]-amine. The title compound was obtained as a
yellowish solid (Yield=63%). MS ISP (m/e): 524.3 (100)
[(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=7.65 (d, 1H), 7.42 (s broad, 1H), 7.35-7.25 (m, 2H), 7.19 (d,
1H), 7.12 (d, 1H), 7.00 (dxd, 1H), 6.95-6.85 (m, 2H), 6.77 (d, 1H),
6.50 (s, 1H), 6.46 (s, 1H), 3.73 (s, 3H), 2.30 (s, 3H).
EXAMPLE 198
N-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-4-trifluoromethyl-N'-(4-tr-
ifluoromethyl-phenyl)-pyridine-2,6-diamine
##STR00237##
[1012] Prepared in analogy to example 62 from
4-trifluoromethylaniline and
(6-chloro-4-trifluoromethyl-pyridin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-
-1-yl)-phenyl]-amine. The title compound was obtained as a
yellowish solid (Yield=61%). MS ISP (m/e): 508.2 (100)
[(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=7.65 (d, 1H), 7.65-7.45 (AA'BB'-System, 4H), 7.21 (d, 1H),
7.13 (d, 1H), 6.98 (dxd, 1H), 6.90 (s, 1H), 6.83 (s, 1H), 6.75 (s,
1H), 6.54 (s, 1H), 6.50 (s, 1H), 3.72 (s, 3H), 2.31 (s, 3H).
EXAMPLE 199
N-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-4-trifluoromethyl-N'-(3-tr-
ifluoromethyl-phenyl)-pyridine-2,6-diamine
##STR00238##
[1014] Prepared in analogy to example 62 from
3-trifluoromethylaniline and
(6-chloro-4-trifluoromethyl-pyridin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-
-1-yl)-phenyl]-amine. The title compound was obtained as a
yellowish solid (Yield=60%). MS ISP (m/e): 508.2 (100)
[(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=7.74 (s, 1H), 7.65 (d, 1H), 7.60 (d, 1H), 7.43 (t, 1H), 7.30
(d, 1H), 7.18 (d, 1H), 7.11 (d, 1H), 7.00 (dxd, 1H), 6.89 (s, 1H),
6.87 (s, 1H), 6.82 (s, 1H), 6.51 (s, 1H), 6.44 (s, 1H9, 3.70 (s,
3H), 3.31 (s, 3H).
EXAMPLE 200
N-(4-Sulfurpentafluoride-phenyl)-N'-[3-methoxy-4-(4-methyl-imidazol-1-yl)--
phenyl]-4-trifluoromethyl-pyridine-2,6-diamine
##STR00239##
[1016] Prepared in analogy to example 62 from
4-aminosulfurpentafluoride and
(6-chloro-4-trifluoromethyl-pyridin-2-yl)-[3-methoxy-4-(4-methyl-imid-
azol-1-yl)-phenyl]-amine. The title compound was obtained as a
yellowish solid (Yield=43%). MS ISP (m/e): 566.2 (100)
[(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=7.69 (s, 1H), 7.66 (s, 2H), 7.52 (d, 2H), 7.20 (d, 1H), 7.13
(d, 1H), 7.10 (s, 1H), 6.97 (dxd, 1H), 6.90 (s, 1H), 6.87 (s, 1H),
6.56 (s, 1H), 6.51 (s, 1H), 3.71 (s, 3H), 2.31 (s, 3H).
EXAMPLE 201
N,N'-Bis-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-4-trifluoromethyl-p-
yridine-2,6-diamine
##STR00240##
[1018] Prepared in analogy to example 62 from
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and
(6-chloro-4-trifluoromethyl-pyridin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-
-1-yl)-phenyl]-amine. The title compound was obtained as a
yellowish solid (Yield=18%). MS ISP (m/e): 550.4 (100)
[(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=7.63 (d, 2H), 7.24 (d, 2H), 7.15 (d, 2H), 6.88 (s, 2H), 6.66
(s, 2H), 6.50 (s, 2H), 3.73 (s, 6H), 2.30 (, 6H).
EXAMPLE 202
[2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromethox-
y-phenylamino)-pyridin-4-yl]-methanol
##STR00241##
[1019] a)
4-(tert-Butyl-dimethyl-silanyloxymethyl)-2,6-dichloro-pyridine
[1020] A solution of 2,6-dichloropyridine-4-methanol (150 mg, 0.84
mmol), tert-butyl-chloro-dimethyl-silane (152 mg, 1.01 mmol) and
imidazol (143 mg, 2.01 mmol) in 1 mL of N,N-dimethylformamide was
stirred overnight at. The reaction mixture was concentrated in the
rotatory evaporator, water was added and the slurry extracted with
ethyl acetate. Chromatography on amino-modified silica gel (Merck
HPTLC Silica Gel 60 NH2F254S) using heptane/ethylacetate (gradient
0 to 50% ethyl acetate) gave the pure title compound as a colorless
solid (160 mg, 65%). MS ISP (m/e): 292.1 & 294.0 (100 & 97)
[(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=7.21 (s, 2H), 4.70 (s, 2H), 0.95 (s, 9H), 0.12 (6H).
b)
[4-(tert-Butyl-dimethyl-silanyloxymethyl)-6-chloro-pyridin-2-yl]-[3-met-
hoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine
[1021] Prepared in analogy to example 62 from
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine and
4-(tert-butyl-dimethyl-silanyloxymethyl)-2,6-dichloro-pyridine. The
title compound was obtained as a yellowish solid (Yield=31%).
.sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=7.64 (s, 1H), 7.36
(d, 1H), 7.17 (d, 1H), 6.95-6.85 (m, 2H), 6.75 (s, 1H), 6.73 (s,
1H), 6.68 (s broad, 1H), 4.65 (s, 2H), 3.86 (s, 3H), 2.30 (s, 3H),
0.94 (s, 9H), 0.11 (s, 6H).
c)
4-(tert-Butyl-dimethyl-silanyloxymethyl)-N-[3-methoxy-4-(4-methyl-imida-
zol-1-yl)-phenyl]-N'-(4-trifluoromethoxy-phenyl)-pyridine-2,6-diamine
[1022] Prepared in analogy to example 62 from
4-(trifluoromethoxy)aniline and
[4-(tert-butyl-dimethyl-silanyloxymethyl)-6-chloro-pyridin-2-yl]-[3-m-
ethoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine. The title compound
was obtained as a brownish gum (Yield=56%).
[1023] .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=7.63 (s,
1H), 7.38 (d, 2H), 7.20-7.10 (m, 4H), 6.96 (dxd, 1H), 6.87 (s, 1H),
6.42 (s, 1H), 6.35-6.25 (m, 3H), 4.62 (s, 2H), 3.74 (s, 3H), 2.30
(s, 3H), 0.93 (s, 9H), 0.10 (s, 6H).
d)
[2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromet-
hoxy-phenylamino)-pyridin-4-yl]-methanol
[1024]
4-(tert-Butyl-dimethyl-silanyloxymethyl)-N-[3-methoxy-4-(4-methyl-i-
midazol-1-yl)-phenyl]-N'-(4-trifluoromethoxy-phenyl)-pyridine-2,6-diamine
(50 mg, 0.083 mmol) was dissolved in 1 mL of tetrahydrofurane and
tetrabutyl ammonium fluoride (44 mg, 0.17 mmol) were added. The
mixture was stirred at for 2 hours, concentrated in the rotatory
evaporator and diluted with water. Extraction with ethyl acetate
and purification by chromatography on amino-modified silica gel
(Merck HPTLC Silica Gel 60 NH2F254S) using ethyl acetate/methanol
(gradient 0 to 2% methanol) gave the pure title compound as a
yellowish solid (5 mg, 10%). MS ISP (m/e): 486.2 (100)
[(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=7.58 (s, 1H), 7.41 (d, 2H), 7.19 (d, 1H), 7.20-7.05 (m, 3H),
6.97 (dxd, 1H), 6.83 (s, 1H), 6.78 (s broad, 1H), 6.67 (s broad,
1H), 6.40 (s, 1H), 6.33 (s, 1H), 4.59 (s, 2H), 3.67 (s, 3H), 2.28
(s, 3H).
EXAMPLE 203
{1-[4-(4-Benzyl-6-methyl-pyrimidin-2-ylamino)-phenyl]-1H-imidazol-4-yl}-me-
thanol
##STR00242##
[1026] A mixture of 4-benzyl-2-chloro-6-methyl-pyrimidine (86 mg,
0.39 mmol), 1-(4-amino-phenyl)-1H-imidazol-4-yl]-methanol (75 mg,
0.39 mmol, Europ. J. Med. Chem. 19 (3), 285-7 (1984), CAS
94128-93-5) and potassium carbonate (1.10 g, 7.86 mmol) in dioxane
(4 mL) and N,N-dimethylacetamide (1 mL) was degassed with nitrogen.
Palladium(II) acetate (3.6 mg, 0.016 mmol) and
2-(dicyclohexylphosphino)biphenyl (12 mg, 0.031 mmol) were added
and the reaction mixture was irradiated in a microwave oven at
200.degree. C. for 25 minutes.
[1-(4-Amino-phenyl)-1H-imidazol-4-yl]-methanol (43 mg, 0.19 mmol)
was added and the reaction mixture was irradiated in a microwave
oven at 200.degree. C. for another 25 minutes. The reaction mixture
was filtered; the filtrate was diluted with ethyl acetate, washed
with water and brine, dried with magnesium sulfate and concentrated
in vacuo. Purification by column chromatography on silica eluting
with dichloromethane/methanol (14:1 v/v) afforded the title
compound as a light yellow viscous oil (19 mg, 13%). MS ISP (m/e):
372.2 [(M+H).sup.+].
EXAMPLE 204
{1-[4-(4-Benzyl-6-methyl-pyrimidin-2-ylamino)-phenyl]-1H-imidazol-2-yl}-me-
thanol
##STR00243##
[1028] A mixture of 4-benzyl-2-chloro-6-methyl-pyrimidine (104 mg,
0.48 mmol), 1-(4-amino-phenyl)-1H-imidazol-2-yl]-methanol (90 mg,
0.48 mmol) and potassium carbonate (1.33 g, 9.5 mmol) in dioxane (4
mL) and N,N-dimethylacetamide (1 mL) was degassed with nitrogen.
Palladium(II) acetate (4.3 mg, 0.019 mmol) and
2-dicyclohexylphosphino)bi-phenyl (13.6 mg, 0.038 mmol) were added
and the reaction mixture was irradiated in a microwave oven at
200.degree. C. for 30 minutes.
[1-(4-Amino-phenyl)-1H-imidazol-4-yl]-methanol (43 mg, 0.19 mmol)
was added and the reaction mixture was irradiated in a microwave
oven at 200.degree. C. for another 25 minutes. The reaction mixture
was filtered; the filtrate was diluted with ethyl acetate, washed
with water and brine, dried with magnesium sulfate and concentrated
in vacuo. Purification by column chromatography on silica eluting
with dichloromethane/methanol (14:1 v/v) afforded the title
compound as a light yellow solid (93 mg, 52%). MS ISP (m/e): 372.2
[(M+H).sup.+]. Mp 95-98.degree. C.
EXAMPLE 205
(4-Benzyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(3-methyl-[1,2,4]triazol-1-
-yl)-phenyl]-amine
##STR00244##
[1029] a)
1-(2-Methoxy-4-nitro-phenyl)-3-methyl-1H-[1,2,4]triazole
[1030] A solution of 2-chloro-5-nitroanisole (1.0 g, 5.2 mmol),
3-methyl-1H-1,2,4-triazole (1.74 g, 20.9 mmol) and potassium
hydroxide (0.44 g, 7.8 mmol) in dimethyl sulfoxide (5 ML) was
heated to 80.degree. C. under an atmosphere of nitrogen for two
days. Water and 1M aqueous hydrogen chloride solution was added and
the reaction was stirred for 45 minutes. The precipitate was
filtered off, washed with water, dissolved in dichloromethane. The
aqueous layer was extracted twice with dichloromethane. The
combined organic layers were washed with water, dried over sodium
sulfate, filtered and the solvent was evaporated. The residue was
purified by reversed preparative HPLC using acetonitril/water (0.1%
formic acid) to yield the title compound as a yellow solid (77 mg,
6%). MS ISP (m/e): 235.2 (100) [(M+H).sup.+]. .sup.1H NMR
(CDCl.sub.3, 300 MHz): .delta. (ppm)=8.88 (s, 1H), 8.10 (d, 1H),
7.96-8.02 (m, 2H), 4.10 (s, 3H), 2.51 (s, 3H).
b) 3-Methoxy-4-(3-methyl-[1,2,4]-triazol-1-yl)-phenylamine
[1031] 1-(2-Methoxy-4-nitro-phenyl)-3-methyl-1H-[1,2,4]triazole (77
mg, 0.33 mmol) was dissolved in methanol (5 mL). The flask was
evacuated and flushed with nitrogen. This procedure was repeated
two times. 10% Palladium on charcoal (8 mg) was added. The reaction
was stirred at under an atmosphere of hydrogen over night, filtered
and the filtrate was evaporated under reduced pressure to yield the
title compound as a brown solid (67 mg, ca. 100%). MS ISP (m/e):
205.2 (100) [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz):
.delta. (ppm)=8.35 (s, 1H), 7.37 (d, 1H), 6.32-6.35 (m, 2H), 3.82
(s, 3H), 2.47 (s, 3H).
c)
(4-Benzyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(3-methyl-[1,2,4]triazo-
l-1-yl)-phenyl]-amine
[1032] Palladium(II) acetate (5.9 mg, 0.026 mmol) and
2-(dicyclohexylphosphino)biphenyl (19 mg, 0.052 mmol) were
dissolved under an atmosphere of nitrogen in dioxane (2 mL). The
reaction was stirred for 25 minutes at. Sodium tert.-butylate (48
mg, 0.49 mmol),
3-methoxy-4-(3-methyl-[1,2,4]triazol-1-yl)-phenylamine (67 mg, 0.33
mmol) dissolved in dioxane (1.5 mL) and
4-benzyl-2-chloro-6-methyl-pyrimidine (79 mg, 0.36 mmol) were
added. The reaction was heated three times for 30 minutes to
200.degree. C. in a microwave oven. Water was added and the
reaction was extracted twice with ethyl acetate. The combined
organic layers were dried over sodium sulfate, filtered and the
solvent was evaporated under reduced pressure. The residue was
purified by column chromatography on silica gel using
methylenechloride/methanol (19:1 v/v) as eluent to yield the title
compound as a yellow gum (38 mg, 30%). MS ISP (m/e): 387.3 (100)
[(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.49 (s, 1H), 7.97 (s, 1H), 7.56 (d, 1H), 7.26-7.33 (m, 5H),
6.98 (d, 1H), 6.51 (s, 1H), 3.97 (s, 2H), 3.83 (s, 3H), 2.48 (s,
3H), 2.37 (s, 3H).
EXAMPLE 206
(4-Benzyl-6-methyl-pyrimidin-2-yl)-[3-fluoro-4-(3-methyl-[1,2,4]triazol-1--
yl)-phenyl]-amine
##STR00245##
[1033] a)
1-(2-Fluoro-4-nitro-phenyl)-3-methyl-1H-[1,2,4]triazole
[1034] 3,4-Difluoronitrobenzene (514 mg, 3.23 mmol),
3-methyl-1H-1,2,4-triazole (325 mg, 3.72 mmol) and di-potassium
hydrogen phosphate trihydrate (1.49 g, 6.46 mmol) in 1 dimethyl
sulfoxide (5 mL) were stirred for 6 hours at 70.degree. C. The
mixture was concentrated in vacuo; the residue was diluted with
water and extracted three times with ethyl acetate. The combined
organic layers were washed four times with water, twice with brine,
dried over magnesium sulfate and evaporated. Column chromatography
(30 g silica, heptane/ethyl acetate 1:1 v/v) afforded the title
compound (261 mg, 36%) as white crystals MS ISP (m/e):
223.3[(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.72 (d, 1H), 8.20 (m, 3H), 2.52 (s, 3H). Mp 105-107.degree.
C.
b) 3-Fluoro-4-(3-methyl-[1,2,4]triazol-1-yl)-phenylamine
[1035] 1-(2-Fluoro-4-nitro-phenyl)-3-methyl-1H-[1,2,4]triazole (250
mg, 1.13 mmol) was dissolved in tetrahydrofurane (6 mL) and
triethylamine (5 mL) and stirred for 2 hours with 10% palladium on
carbon (55 mg) under 1.5 bar of hydrogen. The reaction mixture was
filtered and the solvent was removed under reduced pressure to
yield the title compound (159 mg, 73%) as a yellow solid MS ISP
(m/e): 193.3 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz):
.delta. (ppm)=8.31 (d, 1H), 7.45 (dd, 1H), 6.51 (m, 2H), 3.94 (s
broad, 2H), 2.48 (s, 3H). Mp 122-125.degree. C.
c)
(4-Benzyl-6-methyl-pyrimidin-2-yl)-[3-fluoro-4-(3-methyl-[1,2,4]-triazo-
l-1-yl)-phenyl]-amine
[1036] Palladium(II) acetate (5 mg, 0.022 mmol) and
2-(dicyclohexylphosphino)biphenyl (16 mg, 0.08 mmol) were stirred
in dioxane (1.5 mL) while nitrogene was bubbled through the
solution. A mixture of 4-benzyl-2-chloro-6-methyl-pyrimidine (120
mg, 0.55 mmol),
3-fluoro-4-(3-methyl-[1,2,4]triazol-1-yl)-phenylamine (105 mg, 0.55
mmol) and potassium carbonate (1.53 g, 10.9 mmol) in dioxane (5 mL)
and N,N-dimethylacetamide (1.5 mL) was degassed with nitrogen, the
above prepared catalyst solution was added and the reaction mixture
was irradiated in a microwave oven at 200.degree. C. for 20
minutes. The reaction mixture was partitioned between ethyl acetate
and water; the water layer was extracted twice with ethyl acetate
and the combined organic phases washed three times with water, once
with brine, dried with magnesium sulfate and the solvent was
removed in vacuo. The light brown solid was purified by trituration
in heptane/ethyl acetate (9:1 v/v, 6 mL) to afford the title
compound as a beige solid (140 mg, 68%). MS ISP (m/e): 375.2
[(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.43 (d, 1H), 8.98 (dd, 1H), 8.66 (dd, 1H), 7.30 (m, 5H),
7.18 (m, 2H), 6.54 (s, 1H), 3.98 (s, 2H), 2.50 (s, 3H), 2.38 (s,
3H). Mp 183-185.degree. C.
EXAMPLE 207
(4-Benzyl-6-methyl-pyrimidin-2-yl)-[3-fluoro-4-(5-methyl-[1,2,4]triazol-1--
yl)-phenyl]-amine
##STR00246##
[1037] a)
1-(2-Fluoro-4-nitro-phenyl)-5-methyl-1H-[1,2,4]triazole
[1038] 3,4-Difluoronitrobenzene (514 mg, 3.23 mmol),
3-methyl-1H-1,2,4-triazole (325 mg, 3.72 mmol) and di-potassium
hydrogen phosphate trihydrate (1.49 g, 6.46 mmol) in dimethyl
sulfoxide (1.5 mL) were stirred for 6 hours at 70.degree. C. The
mixture was concentrated in vacuo; the residue was diluted in water
and extracted three times with ethyl acetate. The combined organic
layers were washed four times with water, twice with brine, dried
with magnesium sulfate and evaporated. Column chromatography (30 g
silica, heptane/ethyl acetate 1:1 v/v) afforded the title compound
(160 mg, 22%) as white crystals MS ISP (m/e): 223.2[(M+H).sup.+].
.sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=8.22 (m, 2H), 8.04
(s, 1H), 7.74 (dd, 1H), 2.48 (d, 3H). Mp 56-58.degree. C.
b) 3-Fluoro-4-(5-methyl-[1,2,4]triazol-1-yl)-phenylamine
[1039] 1-(2-Fluoro-4-nitro-phenyl)-5-methyl-1H-[1,2,4]triazole (120
mg, 0.54 mmol) was dissolved in tetrahydrofurane (6 mL) and
triethylamine (10 mL) and stirred for 4 hours with 10% palladium on
carbon (50 mg) under 3 bar of hydrogen. The reaction mixture was
filtered and the solvent was removed in vacuo to yield the title
compound (78 mg, 75%) as a yellow solid. MS ISP (m/e): 193.3
[(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=7.93 (s, 1H), 7.16 (dd, 1H), 6.51 (m, 2H), 4.03 (s broad,
2H), 2.38 (s, 3H). Mp 106-108.degree. C.
c)
(4-Benzyl-6-methyl-pyrimidin-2-yl)-[3-fluoro-4-(5-methyl-[1,2,4]triazol-
-1-yl)-phenyl]-amine
[1040] The title compound was prepared from
4-benzyl-2-chloro-6-methyl-pyrimidine (86 mg, 0.54 mmol) and
3-fluoro-4-(5-methyl-[1,2,4]triazol-1-yl)-phenylamine (75 mg, 0.39
mmol) using in analogous manner the procedure described in example
206c). Column chromatography (15 g silica, dichloromethane+3.5%
methanol v/v) afforded the title compound as a light yellow waxy
solid (100 mg, 68%). .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.07 (dd, 1H), 7.97 (s, 1H), 7.27 (m, 7H), 6.56 (s, 1H), 4.00
(s, 2H), 2.42 (d, 3H), 2.39 (s, 3H). MS ISP (m/e): 375.2
[(M+H).sup.+]
EXAMPLE 208
(4-Benzyl-6-methyl-pyrimidin-2-yl)-[4-(2-methyl-oxazol-5-yl)-phenyl]-amine
##STR00247##
[1042] Palladium(II) acetate (9.3 mg, 0.041 mmol) and
2-(dicyclohexylphosphino)biphenyl (30 mg, 0.083 mmol) were stirred
in dioxane (1.5 mL) for 15 minutes at under an atmosphere of
nitrogen. Sodium tert.-butylate (76 mg, 0.78 mmol),
4-(2-methyl-oxazol-5-yl)phenylamine (90 mg, 0.52 mmol, CAS
89260-50-4) dissolved in dioxane (0.7 mL) and
4-benzyl-2-chloro-6-methyl-pyrimidine (124 mg, 0.57 mmol) were
added. The reaction was heated for 30 minutes to 200.degree. C. in
a microwave oven. Water was added and the reaction was extracted
twice with ethyl acetate. The combined organic layers were dried
over sodium sulfate, filtered and the solvent was evaporated under
reduced pressure. The residue was purified by column chromatography
on silica gel using dichloromethane and then
methylenechloride/methanol (19:1 v/v) as eluent to yield the title
compound as a yellow solid (112 mg, 61%). MS ISP (m/e): 357.2 (100)
[(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=7.69 (d, 2H), 7.53 (d, 2H), 7.26-7.35 (m, 4H), 7.11-7.12 (m,
2H), 6.45 (s, 1H), 3.97 (s, 2H), 2.52 (s, 3H), 2.36 (s, 3H).
EXAMPLE 209
(4-Benzyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(2-methyl-thiazol-5-yl)-ph-
enyl]-amine
##STR00248##
[1043] a) 5-(2-Methoxy-4-nitro-phenyl)-2-methyl-thiazole
[1044] In a microwave vial a mixture of 2-bromo-5-nitroanisole (800
mg, 3.38 mmol), potassium acetate (503 mg, 5.07 mmol) and
tetrakis(triphenylphosphine)-palladium(0) (197 mg, 0.17 mmol) in
N,N-dimethylacetamide (12 mL) were flushed with argon while
2-methylthiazole (1.71 g, 16.9 mmol) was added. The tube was sealed
and the mixture irradiated two times for 30 minutes at 160.degree.
C. The red-brown mixture was partitioned between ethyl acetate and
water. The water layer was re-extracted with ethyl acetate. The
combined organic phases were washed three times with water, once
with brine, dried with magnesium sulfate and evaporated to dryness.
Column chromatography (70 g silica, heptane/ethyl acetate 7:3 v/v)
afforded the title compound (360 mg, 42%) as a yellow solid. MS ISP
(m/e): 251.1 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz):
.delta. (ppm)=8.15 (s, 1H), 7.90 (dd, 1H), 7.84 (s, 1H), 7.72 (d,
1H), 4.05 (s, 3H), 2.76 (s, 3H). Mp 114-117.degree. C.
b) 3-Methoxy-4-(2-methyl-thiazol-5-yl)-phenylamine
[1045] A suspension of
5-(2-methoxy-4-nitro-phenyl)-2-methyl-thiazole (330 mg, 1.32 mmol)
and anhydrous stannous chloride (1.28 g, 6.6 mmol) in ethanol (21
mL) was stirred at reflux for one hour. The yellow solution was
evaporated and the residue dissolved in ethyl acetate. This
solution was washed twice with 2N aqueous sodium hydroxide
solution, with brine, dried with magnesium sulfate and evaporated
to dryness to afford the title compound (266 mg, 91%) as an orange
solid. MS ISP (m/e): 221.2 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3,
300 MHz): .delta. (ppm)=7.81 (s, 1H), 7.33 (d, 1H), 6.31 (m, 2H),
3.87 (s, 3H), 3.83 (m, 2H), 2.69 (s, 3H). Mp 125-129.degree. C.
c)
(4-Benzyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(2-methyl-thiazol-5-yl)-
-phenyl]-amine
[1046] The title compound was prepared from
4-benzyl-2-chloro-6-methyl-pyrimidine (130 mg, 0.59 mmol) and
3-methoxy-4-(2-methyl-thiazol-5-yl)-phenylamine (131 mg, 0.59 mmol)
using in analogous manner the procedure described in example 206c).
Column chromatography (20 g silica, heptane/ethyl acetate 1:1 v/v)
afforded the title compound as an off-white solid (165 mg, 69%). MS
ISP (m/e): 403.2 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz):
.delta. (ppm)=7.90 (s, 1H), 7.82 (s, 1H), 7.45 (d, 1H), 7.29 (m,
5H), 7.14 (s, 1H), 6.98 (dd, 1H), 6.48 (s, 1H), 3.97 (s, 2H), 3.87
(s, 3H), 2.71 (s, 3H), 2.37 (s, 3H). Mp 138-141.degree. C.
EXAMPLE 210
(4-Benzyl-6-methyl-pyrimidin-2-yl)-[4-(2,4-dimethyl-thiazol-5-yl)-3-methox-
y-phenyl]-amine
##STR00249##
[1047] 5-(2-Methoxy-4-nitro-phenyl)-2,4-dimethyl-thiazole
[1048] In a microwave vial a mixture of 2-bromo-5-nitroanisole (600
mg, 2.53 mmol), potassium acetate (377 mg, 3.80 mmol) and
tetrakis(triphenylphosphine)-palladium(0) (148 mg, 0.13 mmol) in
N,N-dimethylacetamide (8 mL) was flushed with nitrogen while
2,4-dimethylthiazole (1.47 g, 12.6 mmol) was added. The tube was
sealed and the mixture irradiated for 30 minutes at 170.degree. C.
The red-brown mixture was partitioned between ethyl acetate and
water. The aqueous layer was re-extracted with ethyl acetate. The
combined organic phases were washed with water, with brine, dried
with magnesium sulfate and the solvent was evaporated to dryness.
Column chromatography (40 g silica, heptane/ethyl acetate 7/3)
afforded the title compound (415 mg, 62%) as a yellow solid. MS ISP
(m/e): 265.1 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz):
.delta. (ppm)=7.90 (dd, 1H), 7.81 (d, 1H), 7.45 (d, 1H), 3.95 (s,
3H), 2.71 (s, 3H), 2.35 (s, 3H). Mp 123-125.degree. C.
b) 4-(2,4-Dimethyl-thiazol-5-yl)-3-methoxy-phenylamine
[1049] A suspension of
5-(2-methoxy-4-nitro-phenyl)-2,4-dimethyl-thiazole (415 mg, 1.57
mmol) and anhydrous stannous chloride (1.52 g, 7.85 mmol) in
ethanol (25 mL) was stirred at reflux for 3 hours. The yellow
solution was evaporated and the residue dissolved in ethyl acetate.
This solution was washed with 1N aqueous sodium hydroxide solution,
twice with water, with brine, dried with magnesium sulfate and the
solvent was evaporated to dryness. Column chromatography (50 g
silica, heptane/ethyl acetate 30-60% v/v) afforded the title
compound (276 mg, 75%) as a pale yellow solid. MS ISP (m/e): 235.2
[(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=7.04 (d, 1H), 6.31 (m, 2H), 3.80 (s broad, 2H), 3.78 (s, 3H),
2.66 (s, 3H), 2.29 (s, 3H). Mp 112-115.degree. C.
c)
(4-Benzyl-6-methyl-pyrimidin-2-yl)-[4-(2,4-dimethyl-thiazol-5-yl)-3-met-
hoxy-phenyl]-amine
[1050] The title compound was prepared from
4-benzyl-2-chloro-6-methyl-pyrimidine (130 mg, 0.59 mmol) and
4-(2,4-dimethyl-thiazol-5-yl)-3-methoxy-phenylamine (139 mg, 0.49
mmol) using in analogous manner the procedure described in example
206c). Column chromatography (20 g silica, dichloromethane/ethyl
acetate 1/1 v/v) afforded the title compound (193 mg, 78%) as a
light yellow waxy solid. MS ISP (m/e): 417.2 [(M+H).sup.+]. .sup.1H
NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=7.78 (d, 1H), 7.29 (m,
5H), 7.17 (d, 1H), 7.14 (s, 1H), 6.99 (dd, 1H), 6.48 (s, 1H), 3.97
(s, 2H), 3.78 (s, 3H), 2.67 (s, 3H), 2.37 (s, 3H), 2.32 (s,
3H).
EXAMPLE 211
(4-Benzyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(1-methyl-1H-pyrazol-4-yl)-
-phenyl]-amine
##STR00250##
[1051]
2-(2-Methoxy-4-nitro-phenyl)-4,4,5,5-tetramethyl-[1,3,2]dioxaborola-
ne
[1052] A mixture of 4-bromo-5-nitroanisole (5.0 g, 21.2 mmol),
bis(pinacolato)diboron (8.21 g, 31.7 mmol) and potassium acetate
(6.28 g, 63.3 mmol, dried on high vacuum at 100.degree. C.) in
dioxane (75 mL) was purged for 5 minutes with nitrogen.
Bis(triphenylphosphine)palladium(II) chloride (1.48 g, 2.11 mmol)
was added and the mixture was heated for 18 hours to 100.degree. C.
under nitrogen atmosphere. The mixture was diluted with ethyl
acetate, washed with water and brine, dried over magnesium sulfate
and the solvent was evaporated. Column chromatography (330 g
silica, heptane/ethyl acetate 5-60%) afforded the title compound
(3.46 g, 58%) as a light brown solid.
[1053] MS EI (m/e): 279 [(M.sup.+)]. .sup.1H NMR (CDCl.sub.3, 300
MHz): .delta. (ppm)=7.78 (s, 2H), 7.39 (s, 1H), 3.92 (s, 3H), 1.37
(s, 12H). Mp 75-78.degree. C.
b) 4-(2-Methoxy-4-nitro-phenyl)-1-methyl-1H-pyrazole
[1054] A solution of
2-(2-methoxy-4-nitro-phenyl)-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane
(635 mg, 1.79 mmol) and 1-methyl-4-iodo-1H-pyrazole (745 mg, 3.58
mmol) in ethanol (11 mL) and toluene (26 mL) was purged with argon
for 5 minutes. 1,1'-bis(diphenylphosphino)ferrocene palladium (II)
chloride (73.0 mg, 0.89 mmol) was added and the mixture was heated
to 80.degree. C., then 2M aqueous sodium carbonate solution (14 mL)
was added and stirring at 80.degree. C. was continued for further
24 hours. The mixture was diluted with ethyl acetate, washed with
water and brine, dried over magnesium sulfate and the solvent was
evaporated. Column chromatography (20 g silica, dichloromethane)
afforded the title compound (245 mg, 58%) as a yellow solid. MS ISP
(m/e): 234.0 [(M+H).sup.+]. .sup.1H NMR (DMSO, 300 MHz): .delta.
(ppm)=8.35 (s, 1H), 8.08 (s, 1H), 7.85 (m, 3H), 4.03 (s, 3H), 3.90
(s, 3H). Mp 132-134.degree. C.
c) 3-Methoxy-4-(1-methyl-1H-pyrazol-4-yl)-phenylamine
[1055] A mixture of
4-(2-methoxy-4-nitro-phenyl)-1-methyl-1H-pyrazole (240 mg, 1.03
mmol) and palladium on carbon 10% (55 mg, 0.052 mmol) in methanol
(15 mL) was stirred for 2 hours at under hydrogen atmosphere. The
mixture was filtrated and the solvent evaporated to afford the
title compound (210 mg, 100%) as a white solid. MS ISP (m/e):
204.3.0 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=7.76 (s, 1H), 7.70 (s, 1H), 7.28 (d, 1H), 6.32 (d, 2H), 3.91
(s, 3H), 3.85 (s, 3H), 3.68 (s broad, 2H). Mp 129-131.degree.
C.
d)
(4-Benzyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(1-methyl-1H-pyrazol-4--
yl)-phenyl]-amine
[1056] The title compound was prepared from
4-benzyl-2-chloro-6-methyl-pyrimidine (119 mg, 0.54 mmol) and
3-methoxy-4-(1-methyl-1H-pyrazol-4-yl)-phenylamine (100 mg, 0.49
mmol) using in analogous manner the procedure described in example
206c). Column chromatography (25 g silica, dichloromethane/ethyl
acetate 0-25% v/v) afforded the title compound (42 mg, 22%) as a
light yellow viscous oil. MS ISP (m/e): 386.2 [(M+H).sup.+].
.sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=7.82 (s, 1H), 7.76
(m, 2H), 7.39 (d, 1H), 7.29 (m, 5H), 7.08 (s, 1H), 6.98 (dd, 1H),
6.44 (s, 1H), 3.96 (s, 2H), 3.93 (s, 3H), 3.86 (s, 3H), 2.35 (s,
3H).
EXAMPLE 212
(4-Benzyl-6-methyl-pyrimidin-2-yl)-(4-pyridin-4-yl-phenyl)-amine
##STR00251##
[1058] Prepared in analogy to example 62 from
4-(pyridin-4-yl)aniline and 4-benzyl-2-chloro-6-methyl-pyrimidine
(example 43a). The title compound was obtained as a brownish oil
(Yield=31%). MS ISP (m/e): 353.1 (100) [(M+H).sup.+]. .sup.1H NMR
(DMSO-D.sub.6, 300 MHz): .delta. (ppm)=9.80 (s, 1H), 8.57 (d, 2H),
7.95 (d, 2H), 7.74 (d, 2H), 7.69 (d, 2H), 7.40-7.15 (m, 5H), 6.68
(s, 1H), 3.95 (s, 2H), 2.34 (s, 3H).
EXAMPLE 213
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(6-methyl-2-pyrrolidin-1-yl--
pyrimidin-4-yl)-amine
##STR00252##
[1060] The title compound was prepared from
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (61 mg, 0.30 mmol)
and 4-chloro-6-methyl-2-pyrrolidin-1-yl-pyrimidine (65 mg, 0.33
mmol, example 95a) in analogous manner as described in example 90.
The crude product was purified by stirring with diethyl ether. It
was obtained in 58% yield as a light brown solid.
[1061] MS ISP (m/e): 365.3 (100) [(M+H).sup.+]. .sup.1H NMR
(DMSO-D.sub.6, 300 MHz): .delta. (ppm)=9.30 (s, 1H), 8.06 (s, 1H),
7.65 (s, 1H), 7.21 (d, 1H), 7.15 (d, 1H), 7.02 (s, 1H), 5.91 (s,
1H), 3.81 (s, 3H), 3.50 (br m, 4H), 2.15 (s, 3H), 2.14 (s, 3H),
1.90 (br m, 4H).
EXAMPLE 214
[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-(6-methyl-2-piperidin-1-yl-p-
yrimidin-4-yl)-amine
##STR00253##
[1063] The title compound was prepared from
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (61 mg, 0.30 mmol)
and 4-chloro-6-methyl-2-piperidin-1-yl-pyrimidine (70 mg, 0.33
mmol, example 97a) in analogous manner as described in example 90.
The crude product was purified by stirring with diethyl ether. It
was obtained in 79% yield as a grey solid. MS ISP (m/e): 379.3
(100) [(M+H).sup.+]. .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta.
(ppm)=9.29 (s, 1H), 7.88 (s, 1H), 7.65 (s, 1H), 7.22 (d, 1H), 7.04
(d, 1H), 7.03 (s, 1H), 5.89 (s, 1H), 3.80 (s, 3H), 3.74 (m, 4H),
2.15 (s, 3H), 2.14 (s, 3H), 1.60 (m, 2H), 1.50 (m, 4H).
EXAMPLE 215
2-{5-Ethyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidin--
4-yl}-propan-2-ol
##STR00254##
[1065] A solution of ethyl 2-oxo-pentanoate (144 mg, 1.0 mmol) in
N,N-dimethylformamide diethyl acetal (0.68 mL) was heated to
100.degree. C. for 2 h. The mixture was evaporated under reduced
pressure and the remaining crude ethyl
3-[1-dimethylamino-methylidene]-2-oxo-hexanoate was reacted with
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate
(298 mg, 0.80 mmol) in analogous manner as described in example
139. The resulting ethyl
5-ethyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidine-4-
-carboxylate was subjected in analogous manner to the procedure
described in example 165 to give the title compound as a light
yellow solid (12 mg, 3%). MS ISP (m/e): 368.2 [(M+H).sup.+].
.sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=8.31 (s, 1H), 7.63
(s, 1H), 7.53 (d, 1H), 7.23 (s, 1H), 7.18 (d, 1H), 7.04 (dd, 1H),
6.87 (s, 1H), 5.44 (br s, 1H), 3.87 (s, 3H), 2.73 (q, 2H), 2.30 (s,
3H), 1.60 (s, 6H), 1.30 (t, 3H).
EXAMPLE 216
2-{5-Isopropyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimi-
din-4-yl}-propan-2-ol
##STR00255##
[1067] Ethyl
3-[1-dimethylamino-methylidene]-4-methyl-2-oxo-pentanoate (170 mg,
0.80 mmol) was reacted with
N-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine dinitrate
in analogous manner as described in example 139 and the resulting
ethyl
5-isopropyl-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidi-
ne-4-carboxylate was subjected in analogous manner to the procedure
described in example 165 to give the title compound as a light
yellow solid (10 mg, 4%). MS ISP (m/e): 382.3 [(M+H).sup.+].
.sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=8.45 (s, 1H), 7.64
(s, 1H), 7.53 (d, 1H), 7.25 (s, 1H), 7.18 (d, 1H), 7.04 (dd, 1H),
6.87 (s, 1H), 5.65 (br s, 1H), 3.87 (s, 3H), 3.31 (m, 1H), 2.30 (s,
3H), 1.61 (s, 6H), 1.28 (d, 6H).
EXAMPLE 217
Ethyl
2-[3-fluoro-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-isopropyl-pyri-
midine-4-carboxylate
##STR00256##
[1069] A mixture of
N-[3-fluoro-4-(4-methyl-imidazol-1-yl)-phenyl]-guanidine nitrate
(719 mg, 2.0 mmol), ethyl 5-methyl-2,4-dioxo-hexanoate (372 mg, 2.0
mmol) and potassium carbonate (138 mg, 1.0 mmol) in ethanol (5 mL)
was heated in a sealed tube in a microwave oven to 170.degree. C.
for 0.5 h. The mixture was cooled, diluted with ethyl acetate (50
mL), and then washed with water (20 mL) and with brine (20 mL). The
organic layer was dried over sodium sulfate and evaporated under
reduced pressure. The residual material was purified by
chromatography on silica gel using dichloromethane/0-10% methanol
as eluent to give the title compound (153 mg, 20%) as a light
yellow solid. MS ISP (m/e): 384.3 [(M+H).sup.+]. .sup.1H NMR
(CDCl.sub.3, 300 MHz): .delta. (ppm)=8.11 (dd, 1H), 7.68 (s, 1H),
7.47 (s, 1H), 7.38 (s, 1H), 7.25-7.30 (2H), 6.94 (s, 1H), 4.48 (q,
2H), 3.05 (m, 1H), 2.31 (s, 3H), 1.46 (t, 3H), 1.36 (d, 6H).
EXAMPLE 218
2-{2-[3-Fluoro-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-isopropyl-pyrimid-
in-4-yl}-propan-2-ol
##STR00257##
[1071] Using in analogous manner the procedure described in example
165, ethyl
2-[3-fluoro-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluorom-
ethyl-phenyl)-pyrimidine-4-carboxylate (115 mg, 0.3 mmol) was
reacted with methylmagnesiumchloride to give the title compound (66
mg, 59%) as a light yellow solid. MS ISP (m/e): 370.2
[(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=7.99 (dd, 1H), 7.64 (s, 1H), 7.25-7.35 (2H), 7.22 (s, 1H),
6.94 (s, 1H), 6.79 (s, 1H), 3.92 (br s, 1H), 2.95 (m, 1H), 2.31 (s,
3H), 1.54 (s, 6H), 1.33 (d, 6H).
EXAMPLE 219
Ethyl
2-[3-fluoro-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluorome-
thyl-phenyl)-pyrimidine-4-carboxylate
##STR00258##
[1073] Using in analogous manner the procedure described in example
217, but replacing ethyl 5-methyl-2,4-dioxo-hexanoate by
2,4-dioxo-4-(4-trifluoromethyl-phenyl)-butyric acid ethyl ester
(576 mg, 2.0 mmol), the title compound was obtained as light yellow
solid (128 mg, 13%). MS ISP (m/e): 486.2 [(M+H).sup.+]. .sup.1H NMR
(CDCl.sub.3, 300 MHz): .delta. (ppm)=8.25 (d, 2H), 8.08 (dd, 1H),
7.95 (s, 1H), 7.82 (d, 2H), 7.71 (s, 1H), 7.64 (s, 1H), 7.30-7.35
(2H), 6.96 (s, 1H), 4.54 (q, 2H), 2.31 (s, 3H), 1.50 (t, 3H).
EXAMPLE 220
2-[2-[3-Fluoro-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromethy-
l-phenyl)-pyrimidin-4-yl]-propan-2-ol
##STR00259##
[1075] Using in analogous manner the procedure described in example
165, ethyl
2-[3-fluoro-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluorom-
ethyl-phenyl)-pyrimidine-4-carboxylate (87 mg, 0.18 mmol) was
reacted with methylmagnesiumchloride to give the title compound (47
mg, 55%) as a light yellow solid. MS ISP (m/e): 472.2
[(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.19 (d, 2H), 7.97 (dd, 1H), 7.80 (d, 2H), 7.72 (br s, 1H),
7.42 (s, 2H), 7.28-7.32 (2H), 6.98 (s, 1H), 3.68 (br s, 1H), 2.32
(s, 3H), 1.63 (s, 6H).
EXAMPLE 221
2-{6-Dimethylamino-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-py-
rimidin-4-yl}-propan-2-ol
##STR00260##
[1076] a)
2-(2-Chloro-6-dimethylamino-pyrimidin-4-yl)-propan-2-ol
[1077] Using in analogous manner the procedure described in example
88b), but replacing ethyl
2-chloro-6-ethoxy-pyrimidine-4-carboxylate by methyl
2-chloro-6-dimethylamino-pyrimidine-4-carboxylate (645 mg, 3.0
mmol), the title compound was obtained as light yellow solid (504
mg, 78%). MS ISP (m/e): 216.2 [(M+H).sup.+].
b)
2-{6-Dimethylamino-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-
-pyrimidin-4-yl}-propan-2-ol
[1078] Using in analogous manner the procedure described in example
1e), 2-(2-chloro-6-dimethylamino-pyrimidin-4-yl)-propan-2-ol (65
mg, 0.3 mmol) was reacted with
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (61 mg, 0.3 mmol)
to give the title compound was obtained as light yellow foam (24
mg, 21%). MS ISP (m/e): 383.3 [(M+H).sup.+]. .sup.1H NMR
(CDCl.sub.3, 300 MHz): .delta. (ppm)=7.75 (d, 1H), 7.63 (s, 1H),
7.26 (s, 1H), 7.15 (d, 1H), 6.99 (dd, 1H), 6.87 (s, 1H), 6.01 (s,
1H), 4.38 (br s, 1H), 3.86 (s, 3H), 3.16 (s, 6H), 2.30 (s, 3H),
1.51 (s, 6H).
EXAMPLE 222
2-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-morpholin-4-yl-p-
yrimidin-4-yl}-propan-2-ol
##STR00261##
[1079] a)
2-(2-Chloro-6-moMholin-4-yl-pyrimidin-4-yl)-propan-2-ol
[1080] Using in analogous manner the procedure described in example
88b), but replacing ethyl
2-chloro-6-ethoxy-pyrimidine-4-carboxylate by methyl
2-chloro-6-morpholin-4-yl-pyrimidine-4-carboxylate (900 mg, 3.5
mmol), the title compound was obtained as light yellow solid (769
mg, 85%). MS ISP (m/e): 258.1 [(M+H).sup.+].
b)
2-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-morpholin-4-y-
l-pyrimidin-4-yl}-propan-2-ol
[1081] Using in analogous manner the procedure described in example
1e), 2-(2-chloro-6-morpholin-4-yl-pyrimidin-4-yl)-propan-2-ol (77
mg, 0.3 mmol) was reacted with
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (61 mg, 0.3 mmol)
to give the title compound was obtained as light yellow foam (62
mg, 49%). MS ISP (m/e): 425.2 [(M+H).sup.+].).sup.+]. .sup.1H NMR
(CDCl.sub.3, 300 MHz): .quadrature. (ppm)=7.82 (s, 2H), 7.16 (d,
1H), 6.98 (dd, 1H), 6.95 (s, 1H), 6.87 (s, 1H), 6.12 (s, 1H), 4.15
(br s, 1H), 3.81 (s, 3H), 3.78 and 3.65 (2 m, 2.times.4H), 3.16 (s,
6H), 2.30 (s, 3H), 1.51 (s, 6H).
EXAMPLE 223
1-{6-(1-Hydroxy-1-methyl-ethyl)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-ph-
enyamino]-pyrimidin-4-yl}-4-methyl-piperidin-4-ol
##STR00262##
[1082] a) Methyl
2-chloro-6-(4-hydroxy-4-methyl-piperidin-1-yl)-pyrimidine-4-carboxylate
[1083] A mixture of methyl 2,4-dichloropyrimidine-6-carboxylate
(1.66 g, 8.0 mmol), 4-methyl-piperidin-4-ol (1.21 g, 8 mmol) and
sodium carbonate (1.74 g, 16.0 mmol) in methanol (8 mL) was stirred
for 1 h at. The mixture was partitioned between ethyl acetate and
water, and the organic layer was subsequently washed with brine,
dried over sodium sulfate and evaporated under reduced pressure to
give crude title compound (1.70 g, 72%) as light yellow solid. MS
ISP (m/e): 286.1 [(M+H).sup.+].
b)
1-[2-Chloro-6-(1-hydroxy-1-methyl-ethyl)-pyrimidin-4-yl]-4-methyl-piper-
idin-4-ol
[1084] Using in analogous manner the procedure described in example
88b), but replacing ethyl
2-chloro-6-ethoxy-pyrimidine-4-carboxylate by methyl
2-chloro-6-(4-hydroxy-4-methyl-piperidin-1-yl)-pyrimidine-4-carboxylate
(1.71 g, 6.0 mmol), the title compound was obtained as light yellow
solid (0.38 g, 22%). MS ISP (m/e): 286.1 [(M+H).sup.+].
c)
2-{2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-pyrrolidin-1--
yl-pyrimidin-4-yl}-propan-2-ol
[1085] Using in analogous manner the procedure described in example
1e), 2-(2-chloro-6-morpholin-4-yl-pyrimidin-4-yl)-propan-2-ol (77
mg, 0.3 mmol) was reacted with
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (61 mg, 0.3 mmol)
to give the title compound was obtained as off-white foam (70 mg,
52%). MS ISP (m/e): 453.3 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3,
300 MHz): .delta. (ppm)=7.73 (d, 1H), 7.62 (s, 1H), 7.14 (d, 1H),
6.97 (s, 1), 6.92 (dd, 1H), 6.87 (s, 1H), 6.14 (s, 1H), 4.28 (br s,
1H), 4.10 (m, 3H), 3.85 (s, 3H), 3.47 (m, 2H), 2.30 (s, 3H),
1.55-1.70 (m, 4H), 1.51 (s, 6H), 1.32 (s, 3H).
EXAMPLE 224
2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromethyl--
phenyl)-pyrimidine-4-carboxylic acid dimethylamide
##STR00263##
[1086] a)
2-Chloro-6-(4-trifluoromethyl-phenyl)-pyrimidine-4-carboxylic
Acid
[1087] Pd(dppf)Cl.sub.2 (0.214 g, 0.02 mmol) was added to a mixture
of methyl 2,4-dichloropyrimidine-6-carboxylate (2.07 g, 10 mmol)
and 4-(trifluoromethyl)phenyl-boronic acid (1.90 g, 10 mmol) in DME
(100 mL) and sat. aq. NaHCO3 (20 mL), and the mixture was stirred
in an atmosphere of argon at 80.degree. C. for 3 h. The reaction
mixture was cooled to and added to ice water (100 mL). The mixture
was extracted with ethyl acetate (2.times.100 mL) and the organic
phase was extracted with saturated sodium carbonate solution (50
mL). The combined aqueous layers were acidified by the addition of
25% HCl (100 mL) and subsequently extracted with ethyl acetate
(2.times.100 mL). The organic phase was washed with brine, dried
over sodium sulfate, and the solvents were removed under reduced
pressure. The residual solid was recrystallized from ethyl
acetate/heptane to give the title compound (1.82 g, 60%) as light
red solid. MS ISN (m/e): 301.2 [(M-H).sup.-]. .sup.1H NMR
(CDCl.sub.3, 300 MHz): .delta. (ppm)=8.51 (s, 1H), 8.33 and 7.84 (2
d, 2.times.2H).
b) 2-Chloro-6-(4-trifluoromethyl-phenyl)-pyrimidine-4-carboxylic
Acid Dimethylamide
[1088] Oxalyl chloride (0.38 mL, 4.5 mmol) and
N,N-dimethylformamide (0.03 mL) were added to a suspension of
2-chloro-6-(4-trifluoromethyl-phenyl)-pyrimidine-4-carboxylic acid
(303 mg, 1.0 mmol) in dichloromethane (20 mL). The mixture was
stirred at for 3 h and then evaporated under reduced pressure. The
residue was dissolved in dichloro-methane (25 mL) and the solution
was stirred together with 60% aqueous dimethylamine (1.2 mL, 13.3
mmol) and saturated aqueous sodium hydrogencarbonate solution (8
mL) for 1 h at. The mixture was diluted with dichloromethane (25
mL), and the organic layer was washed with water and brine, dried
over sodium sulfate, and evaporated under reduced pressure. The
residual material was purified by chromatography on silica gel
using heptane/0-40% ethyl acetate as eluent to give the title
compound (215 mg, 65%) as a white solid. MS ISP (m/e): 330.2
[(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.24 (d, 2H), 7.99 (s, 1H), 7.80 d, 2H), 3.17 (s, 6H).
c)
2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluorometh-
ylphenyl)-pyrimidine-4-carboxylic Acid Dimethylamide
[1089] Using in analogous manner the procedure described in example
1e), 2-chloro-6-(4-trifluoromethyl-phenyl)-pyrimidine-4-carboxylic
acid dimethylamide (99 mg, 0.3 mmol) was reacted with
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (61 mg, 0.3 mmol)
to give the title compound as yellow solid (76 mg, 51%). MS ISP
(m/e): 497.4 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz):
.delta. (ppm)=8.21 (d, 2H), 7.77 (d, 2H), 7.74 (d, 1H), 7.66 (s,
1H), 7.45 (s, 1H), 7.41 (s, 1H), 7.23 (d, 1H), 7.18 (dd, 1H), 6.90
(s, 1H), 3.89 (s, 3H), 3.18 and 3.15 (2 s, 2.times.3H), 2.31 (s,
3H).
EXAMPLE 225
[2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromethyl-
-phenyl)-pyrimidin-4-yl]-morpholin-4-yl-methanone
##STR00264##
[1090] a)
[2-Chloro-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-morpholin-
-4-yl-methanone
[1091] Oxalyl chloride (0.38 mL, 4.5 mmol) and
N,N-dimethylformamide (0.03 mL) were added to a suspension of
2-chloro-6-(4-trifluoromethyl-phenyl)-pyrimidine-4-carboxylic acid
(303 mg, 1.0 mmol) in dichloromethane (20 mL). The mixture was
stirred at for 3 h and then evaporated under reduced pressure. The
residue was dissolved in dichloro-methane (25 mL) and the solution
was stirred together morpholine (0.174 mL, 2.0 mmol) and saturated
aqueous sodium hydrogencarbonate solution (8 mL) for 1 h at. The
mixture was diluted with dichloromethane (25 mL), and the organic
layer was washed with water and brine, dried over sodium sulfate,
and evaporated under reduced pressure. The residual material was
purified by chromatography on silica gel using heptane/0-40% ethyl
acetate as eluent to give the title compound (260 mg, 66%) as a
white solid. MS ISP (m/e): 372.2 [(M+H).sup.+]. .sup.1H NMR
(CDCl.sub.3, 300 MHz): .delta. (ppm)=8.25 (d, 2H), 8.04 (s, 1H),
7.80 d, 2H), 3.83 (br s, 4H), 3.74 (m, 4H).
b)
2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluorometh-
yl-phenyl)-pyrimidin-4-yl]-morpholin-4-yl-methanone
[1092] Using in analogous manner the procedure described in example
1e), 2-chloro-6-(4-trifluoromethyl-phenyl)-pyrimidine-4-carboxylic
acid dimethylamide (112 mg, 0.3 mmol) was reacted with
3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamine (61 mg, 0.3 mmol)
to give the title compound as yellow solid (42 mg, 27%). MS ISP
(m/e): 539.3 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz):
.delta. (ppm)=8.21 (d, 2H), 7.77 (d, 2H), 7.69 (d, 1H), 7.67 (s,
1H), 7.57 (s, 1H), 7.48 (s, 1H), 7.2-7.3 (2H), 6.91 (s, 1H), 3.88
(s, 3H), 3.83 and 3.69 (2 m, 2.times.4H), 2.31 (s, 3H).
EXAMPLE 226
1-[2-[3-Methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluorometh-
yl-phenyl)-pyrimidin-4-yl]-cyclopentanol
##STR00265##
[1094] A solution of ethyl
2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenylamino]-pyrimidine-4-carboxy-
late (99 mg, 0.2 mmol) in tetrahydrofurane (2 mL) was added at
0.degree. C. over 1 min to a 0.3 M solution of
butane-1,4-bis(magnesiumbromide) in tetrahydrofurane (1.6 mL, 0.49
mmol). The reaction mixture was stirred at 0.degree. C. for 10 min
followed by 2 h at. The mixture was poured on saturated ammonium
chloride solution (5 mL) and the mixture was extracted with ethyl
acetate (40 mL). The organic layer was washed with brine (20 mL),
dried over sodium sulfate and evaporated under reduced pressure.
The residual material was purified by chromatography on silica gel
using ethyl acetate as eluent to give the title compound (10 mg,
10%) as light yellow foam. MS ISP (m/e): 510.4 [(M+H).sup.+].
.sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=8.20 (d, 2H), 7.82
(d, 1H), 7.76 (d, 2H), 7.66 (s, 1H), 7.39 (s, 1H), 7.37 (s, 1H),
7.22 (d, 1H), 7.10 (dd, 1H), 6.90 (s, 1H), 3.89 (s, 3H), 2.31 (s,
3H), 1.85-2.25 (m, 4H).
EXAMPLE 227
2-[2-[4-(3-Methyl-[1,2,4]thiadiazol-5-yl)-phenylamino]-6-(4-trifluoromethy-
l-phenyl)-pyrimidin-4-yl]-propan-2-ol
##STR00266##
[1095] a) 4-(3-Methyl-[1,2,4]thiadiazol-5-yl)-phenylamine
[1096] To a suspension of
3-methyl-5-(4-nitro-phenyl)-[1,2,4]thiadiazole (422 mg, 1.9 mmol,
CAS 800408-77-9, Wilkins, D. J.; Bradley, P. A. Science of
Synthesis (2004), 13, 277-295.) in ethanol (19 mL) was added under
stirring tin(II)chloride (1.86 g, 9.54 mmol) and heated to
70.degree. C. for 4 hours. The mixture was poured on cold aqueous
saturated sodium hydrogen carbonate solution. The suspension was
stirred for 30 minutes and the solid was filtered off, washed with
water. The residue was heated two to three times with
tetrahydrofurane and filtered. The aqueous layer was extracted
twice with ethyl acetate. The combined organic layers were dried
over sodium sulfate and the solvent was evaporated under reduced
pressure. The residue was stirred with diethyl ether and the solid
was filtered off and washed with diethyl ether/heptane to yield the
title compound as a yellow solid (355 mg, 97%). MS ISP (m/e): 192.2
(100) [(M+H).sup.+]. .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta.
(ppm)=7.64 (d, 2H), 6.63 (d, 3H), 6.01 (BR s, 2H, NH2), 2.54 (s,
3H).
2-[2-[4-(3-Methyl-[1,2,4]thiadiazol-5-yl)-phenylamino]-6-(4-trifluoromethy-
l-phenyl)-pyrimidin-4-yl]-propan-2-ol
[1097] Palladium(II) acetate (3.6 mg, 0.016 mmol) and
2-(dicyclohexylphosphino)biphenyl (11 mg, 0.032 mmol) were stirred
in dioxane (1 mL) for 10 minutes at under an atmosphere of
nitrogen. Sodium tert.-butylate (29 mg, 0.3 mmol),
4-(3-methyl-[1,2,4-]thiadiazol-5-yl)-phenylamine (38 mg, 0.20 mmol)
and)
2-[2-chloro-6-(4-trifluoromethyl-phenyl)pyrimidine-4-yl]-propan-2-ol
(70 mg, 0.22 mmol) dissolved in dioxane (1 mL) were added. The
reaction was heated for 30 minutes to 130.degree. C. in a microwave
oven. Water was added and the reaction was extracted twice with
ethyl acetate. The combined organic layers were washed with brine,
dried over sodium sulfate, filtered and the solvent was evaporated
under reduced pressure. The residue was purified by column
chromatography on silica gel using heptane/ethyl acetate (1:1 v/v)
as eluent to yield the title compound as a yellow solid (26 mg,
28%). MS ISP (m/e): 472.2 (100) [(M+H).sup.+]. .sup.1H NMR
(CDCl.sub.3, 300 MHz): .delta. (ppm)=8.21 (d, 2H), 7.97 (d, 2H),
7.85 (d, 2H), 7.79 (d, 2H), 7.45 (br s, 1H, NH), 7.39 (s, 1H), 3.72
(s, 1H, OH), 2.73 (s, 3H), 1.62 (s, 6H).
EXAMPLE 228
(4-Benzyl-6-methyl-pyrimidin-2-yl)-[3-methoxy-4-(2-methyl-oxazol-5-yl)-phe-
nyl]-amine
##STR00267##
[1099] Palladium(II) acetate (5.4 mg, 0.024 mmol) and
2-(dicyclohexylphosphino)biphenyl (17 mg, 0.048 mmol) were stirred
in dioxane (3 mL) for 20 minutes at under an atmosphere of
nitrogen. Sodium tert.-butylate (44 mg, 0.45 mmol),
3-methoxy-4-(2-methyl-oxazol-5-yl)-phenylamine (61 mg, 0.30 mmol,
CAS 568556-28-5; E. J. Jwanowicz et. al. Bioorganic & Medicinal
Chemistry Letters, 13(12), 2059-2063; 2003) and
4-benzyl-2-chloro-6-methyl-pyrimidine (72 mg, 0.33 mmol) were
added. The reaction was heated for 30 minutes to 130.degree. C. in
a microwave oven. Water was added and the reaction was extracted
three times with ethyl acetate. The combined organic layers were
dried over sodium sulfate, filtered and the solvent was evaporated
under reduced pressure. The residue was purified by column
chromatography on silica gel using dichloromethane and then
methylenechloride/methanol (19:1 v/v) as eluent to yield the title
compound as a yellow solid (31 mg, 27%). MS ISP (m/e): 387.2 (100)
[(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=7.86 (s, 1H), 7.61 (d, 2H), 7.26-7.33 (m, 5H), 7.15 (br s,
1H), 6.98 (d, 1H), 6.48 (s, 1H), 3.97 (s, 2H), 3.90 (s, 3H), 2.51
(s, 3H), 2.37 (s, 3H).
EXAMPLE 229
2-{6-(4-Chloro-phenyl)-2-[4-(2-methyl-oxazol-5-yl)-phenylamino]-pyrimidin--
4-yl}-propan-2-ol
##STR00268##
[1100] a) 2-Chloro-6-(4-chloro-phenyl)-pyrimidine-4-carboxylic
acid
[1101] Using in analogous manner the procedure described in example
224a), but replacing 4-(trifluoromethyl)phenylboronic acid by
4-chlorophenylboronic acid (1.04 g, 5 mmol), the title compound was
obtained as light yellow solid (0.78 g, 58%). MS ISN (m/e): 267.2
[(M-H).sup.-].
b) Ethyl 2-chloro-6-(4-chloro-phenyl)-pyrimidine-4-carboxylate
[1102] To a solution of
2-chloro-6-(4-chloro-phenyl)-pyrimidine-4-carboxylic acid (1.35 g,
5.0 mmol) in ethanol (50 mL) was added diethyl ether (10 mL) which
had been saturated previously with hydrochloric acid gas at. The
reaction mixture was stirred for 24 h at. The solution was
evaporated under reduced pressure and the residual oil was
dissolved in ethyl acetate. The solution was washed with saturated
sodium hydrogencarbonate solution and with brine, dried over sodium
sulfate, and evaporated under reduced pressure. The residual
material was crystallized from ethyl acetate/heptane to give the
title compound (1.17 g, 78%) as light yellow solid. MS ISN (m/e):
297.1 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.31 (s, 1H), 8.13 and 7.53 (2 d, 2.times.2H), 4.53 (q, 2H),
1.47 (t, 3H).
c) 2-[2-Chloro-6-(4-chloro-phenyl)-pyrimidin-4-yl]-propan-2-ol
[1103] To a solution of ethyl
2-chloro-6-(4-chloro-phenyl)-pyrimidine-4-carboxylate (297 mg, 1.0
mmol) in tetrahydrofurane (6 mL) was added at--over 2 min a 3 M
solution of methylmagnesiumchloride in tetrahydrofurane (0.80 mL,
2.4 mmol). The reaction mixture was stirred at--for 30 min followed
by 2 h at. The mixture was poured on saturated ammonium chloride
solution (20 mL) and the product was extracted with ethyl acetate
(40 mL). The organic layer was washed with brine (20 mL), dried
over sodium sulfate and evaporated under reduced pressure. The
residual material was purified by chromatography on silica gel
using heptane/0-50% ethyl acetate as eluent to give after
crystallization from ethyl acetate/heptane the title compound (185
mg, 65%) as as white solid. MS ISP (m/e): 283.1 [(M+H).sup.+].
.sup.1H NMR (CDCl.sub.3, 300 MHz): .delta. (ppm)=8.07 (d, 2H), 7.80
(s, 1H), 7.49 (d, 2H), 3.16 (s, 1H), 1.62 (s, 6H).
d)
2-6{-(4-Chloro-phenyl)-2-[4-(2-methyl-oxazol-5-yl)-phenalamino]-pyrimid-
in-4-yl}-propan-2-ol
[1104] Using in analogous manner the procedure described in example
1e), 2-[2-chloro-6-(4-chloro-phenyl)-pyrimidin-4-yl]-propan-2-ol
(112 mg, 0.3 mmol) was reacted with
4-(2-methyl-oxazol-5-yl)-phenylamine (61 mg, 0.3 mmol) to give the
title compound as light yellow solid (28 mg, 22%). MS ISP (m/e):
421.1 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.04, 7.74, 7.63 and 7.50 (4 d, 4.times.2H), 7.20 (s, 1H),
7.23 (s, 1H), 7.15 (s, 1H), 4.01 (s, 1H), 2.53 (s, 3H), 1.61 (s,
6H).
EXAMPLE 230
2-{6-(4-Chloro-phenyl)-2-[4-(2-ethyl-oxazol-5-yl)-phenylamino]-pyrimidin-4-
-yl}-propan-2-ol
##STR00269##
[1106] Using in analogous manner the procedure described in example
229d), but replacing 4-(2-methyl-oxazol-5-yl)-phenylamine by
4-(2-ethyl-oxazol-5-yl)-phenylamine (57 mg, 0.2 mmol), the title
compound was obtained as light yellow solid (12 mg, 14%). MS ISP
(m/e): 435.2 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz):
.delta. (ppm)=8.04, 7.74, 7.64 and 7.50 (4 d, 4.times.2H), 7.17 (s,
1H), 4.01 (s, 1H), 2.86 (q, 2H), 1.60 (s, 6H), 1.40 (t, 3H).
EXAMPLE 231
2-[2-[4-(2-Methyl-oxazol-5-yl)-phenylamino]-6-(4-trifluoromethyl-phenyl)-p-
yrimidin-4-yl]-propan-2-ol
##STR00270##
[1107] a) Ethyl
2-chloro-6-(4-trifluoromethyl-phenyl)-pyrimidine-4-carboxylate
[1108] Using in analogous manner the procedure described in example
229b), but replacing
2-chloro-6-(4-chloro-phenyl)-pyrimidine-4-carboxylic acid by
2-chloro-6-(4-trifluoromethyl-phenyl)-pyrimidine-4-carboxylic acid
(1.89 g, 6.0 mmol), the title compound was obtained as light yellow
solid (1.83 g, 87%). MS ISP (m/e): 331.0 [(M+H).sup.+]. .sup.1H NMR
(CDCl.sub.3, 300 MHz): .delta. (ppm)=8.34 (s, 1H), 8.30 and 7.82 (2
d, 2.times.2H), 4.55 (q, 2H), 1.48 (t, 3H).
b)
2-[2-Chloro-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-propan-2-ol
[1109] Using in analogous manner the procedure described in example
229c), but replacing ethyl
2-chloro-6-(4-chloro-phenyl)-pyrimidine-4-carboxylate by ethyl
2-chloro-6-(4-trifluoromethyl-phenyl)-pyrimidine-4-carboxylate (661
mg, 2.0 mmol), the title compound was obtained as light yellow
solid (486 mg, 77%). .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.23 (d, 2H), 7.89 (s, 1H), 7.78 (d, 2H), 3.12 (s, 1H), 1.64
(s, 6H).
c)
2-[2-[4-(2-Methyl-oxazol-5-yl)-phenylamino]-6-(4-trifluoromethyl-phenyl-
)-pyrimidin-4-yl]-propan-2-ol
[1110] Using in analogous manner the procedure described in example
1e),
2-[2-chloro-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-propan-2-ol
(95 mg, 0.3 mmol) was reacted with
4-(2-methyl-oxazol-5-yl)-phenylamine (52 mg, 0.3 mmol) to give the
title compound as light yellow solid (29 mg, 21%). MS ISP (m/e):
455.2 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz): .delta.
(ppm)=8.20, 7.78, 7.75 and 7.63 (4 d, 4.times.2H), 7.31 (s, 2H),
7.16 (s, 1H), 3.93 (s, 1H), 2.53 (s, 3H), 1.61 (s, 6H).
EXAMPLE 232
2-[2-[4-(2,4-Dimethyl-oxazol-5-yl)-phenylamino]-6-(4-trifluoromethyl-pheny-
l)-pyrimidin-4-yl]-propan-2-ol
##STR00271##
[1112] Using in analogous manner the procedure described in example
1e),
2-[2-chloro-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-propan-2-ol
(95 mg, 0.3 mmol) was reacted with
4-(2,4-dimethyl-oxazol-5-yl)-phenylamine (56 mg, 0.3 mmol) to give
the title compound as light yellow solid (72 mg, 51%). MS ISP
(m/e): 469.2 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz):
.delta. (ppm)=8.20, 7.78, 7.75 and 7.63 (4 d, 4.times.2H), 7.31 (s,
2H), 3.93 (s, 1H), 2.53 (s, 3H), 1.61 (s, 6H).
EXAMPLE 233
2-[2-[3-Methoxy-4-(2-methyl-thiazol-5-yl)-phenylamino]-6-(4-trifluoromethy-
l-phenyl)-pyrimidin-4-yl]-propan-2-ol
##STR00272##
[1114] Using in analogous manner the procedure described in example
1e),
2-[2-chloro-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-propan-2-ol
(95 mg, 0.3 mmol) was reacted with
3-methoxy-4-(2-methyl-thiazol-5-yl)-phenylamine (66 mg, 0.3 mmol)
to give the title compound as light yellow solid (36 mg, 24%). MS
ISP (m/e): 501.1 [(M+H).sup.+]. .sup.1H NMR (CDCl.sub.3, 300 MHz):
.delta. (ppm)=8.21 (d, 2H), 7.98 (s, 1H), 7.77 (m, 3H), 7.54 (d,
1H), 7.34 (2 s, 2.times.1H), 7.10 (dd, 1H), 3.98 (s, 3H), 3.87 (s,
1H), 2.73 (s, 3H), 1.62 (s, 6H).
EXAMPLE 234
5-[4-(1-Hydroxy-1-methyl-ethyl)-6-(4-trifluoromethyl-phenyl)-pyrimidin-2-y-
lamino]-2-(4-methyl-imidazol-1-yl)-benzonitrile
##STR00273##
[1115] a) 2-(4-Methyl-imidazol-1-yl)-5-nitro-benzonitrile
[1116] A suspension of 831 mg (5 mmol) of
3-cyano-4-fluoronitrobenzene, of 0.82 g (10 mmol) 4-methylimidazol
and of 1.38 g (10 mmol) potassium carbonate in acetonitrile (10 mL)
was stirred for 60 h at 20.degree. C. The solvent was evaporated
and the residue was partitioned between ethyl acetate and 1N
aqueous sodium hydroxide solution. The aqueous layer was extracted
with ethyl acetate. The combined organic layers were washed with
brine, dried over sodium sulphate, and the solvent was evaporated
under reduced pressure. The crude product was crystallized from
ethanol/water yielding the title compound (0.65 g, 57%) as an
off-white solid. .sup.1H NMR (DMSO-D.sub.6, 250 MHz): .delta.
(ppm)=8.95 (s, 1H), 8.62 (d, 1H), 8.16 (s, 1H), 7.93 (d, 1H), 7.49
(s, 1H), 2.21 (s, 3H).
b) 5-Amino-2-(4-methyl-imidazol-1-yl)-benzonitrile
[1117] 0.65 g (2.84 mmol)
2-(4-methyl-imidazol-1-yl)-5-nitro-benzonitrile dissolved in ethyl
acetate (10 mL) were hydrogenated under an atmosphere of hydrogen
at 20.degree. C. for 5 h in the presence of 150 mg of 10% palladium
on charcoal. The catalyst was filtered off and washed with ethyl
acetate. The solvent of the filtrate was evaporated under reduced
pressure and dried to yield the title compound (0.45 g, 80%) as
yellow solid. MS ISP (m/e): 199.1 (100) [(M+H).sup.+]. .sup.1H NMR
(DMSO-D.sub.6, 250 MHz): .delta. (ppm)=7.72 (s, 1H), 7.23 (d, 1H),
7.10 (s, 1H), 6.96 (s, 1H), 6.91 (d, 1H), 2.15 (s, 3H).
c)
5-[4-(1-Hydroxy-1-methyl-ethyl)-6-(4-trifluoromethyl-phenyl)-pyrimidin--
2-ylamino]-2-(4-methyl-imidazol-1-yl)-benzonitrile
[1118] Using in analogous manner the procedure described in example
1e),
2-[2-chloro-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-propan-2-ol
(95 mg, 0.3 mmol) was reacted with
3-methoxy-4-(2-methyl-thiazol-5-yl)-phenylamine (59 mg, 0.3 mmol)
to give the title compound as light yellow solid (91 mg, 63%). MS
ISP (m/e): 479.1 [(M+H).sup.+]. .sup.1H NMR (DMSO-d.sub.6, 300
MHz): .delta. (ppm)=10.31 (s, 1H), 8.53 (d, 1H), 8.35 (d, 2H), 8.17
(dd, 1H), 7.94 (d, 2H), 7.92 (s, 1H), 7.78 (s, 1H), 7.61 (d, 1H),
7.28 (s, 1H), 5.52 (s, 1H), 2.19 (s, 3H), 1.54 (s, 6H).
EXAMPLE 235
2-[2-[3-Methyl-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluoromethy-
l-phenyl)-pyrimidin-4-yl]-propan-2-ol
##STR00274##
[1119] a) 4-Methyl-1-(2-methyl-4-nitro-phenyl)-1H-imidazole
[1120] A mixture of 2-chloro-5-nitro-toluene (2.0 g, 12 mmol), of
4-methylimidazole (1.0 g, 12 mmol) and of cesium carbonate (5.7 g,
17.5 mmol) in acetonitrile (20 mL) was refluxed for 15 h. The
reaction mixture was cooled, quenched by addition of water and
extracted with ethyl acetate. The organic layer was dried over
sodium sulfate and evaporated under reduced pressure and the crude
material was purified by column chromatography on silica gel using
ethyl acetate as eluent to yield the title compound (1.27 g, 50%)
as a slightly brownish solid. MS ISP (m/e): 218.3 (100)
[(M+H).sup.+].
b) 3-Methyl-4-(4-methyl-imidazol-1-yl)-phenylamine
[1121] A mixture of
4-methyl-1-(2-methyl-4-nitro-phenyl)-1H-imidazole (1.26 g, 5.8
mmol) and of stannous chloride dihydrate (6.81 g, 30.2 mmol) in
ethyl acetate (40 mL) and ethanol (20 mL) was stirred for 1 hour at
70.degree. C. The reaction mixture was quenched by addition of
water, neutralized with sodium hydrogen carbonate and extracted
with ethyl acetate. The organic layer was dried over sodium sulfate
and evaporated under reduced pressure to give the crude title
compound (1.08 g, 99%) as a yellowish gum. MS ISP (m/e): 188.4
(100) [(M+H).sup.+].
c)
2-[2-[3-Methyl-4-(4-methyl-imidazol-1-yl)-phenylamino]-6-(4-trifluorome-
thyl-phenyl)-pyrimidin-4-yl]-propan-2-ol
[1122] Using in analogous manner the procedure described in example
1e),
2-[2-chloro-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yl]-propan-2-ol
(95 mg, 0.3 mmol) was reacted with
3-methoxy-4-(2-methyl-thiazol-5-yl)-phenylamine (56 mg, 0.3 mmol)
to give the title compound as light yellow solid (38 mg, 27%). MS
ISP (m/e): 468.2 [(M+H).sup.+]. .sup.1H NMR (DMSO-d.sub.6, 300
MHz): .delta. (ppm)=9.88 (s, 1H), 8.35 (d, 2H), 7.96 (s, 1H), 7.95
(d, 2H), 7.74 (dd, 1H), 7.71 (s, 1H), 7.63 (s, 1H), 7.20 (d, 1H),
7.04 (s, 1H), 5.45 (s, 1H), 2.17 (s, 3H), 2.15 (s, 3H), 1.52 (s,
6H).
EXAMPLE 236
(4,6-Dimethyl-pyrimidin-2-yl)-[4-(2-methyl-pyridin-4-yl)-phenyl]-amine
##STR00275##
[1123] a) 4-(2-Methyl-pyridin-4-yl)-phenylamine
[1124] The title compound was prepared from
4-bromo-2-methylpyridine and
4-(4,4,5,5-tetramethyl-1,2,3-dioxaborolan-2-yl)aniline by the
method described in Organic Letters 8, 3421 (2006). Obtained as a
brownish solid (Yield=18%). MS ISP (m/e): 185.1 (100)
[(M+H).sup.+]. .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta.
(ppm)=9.80 (s, 1H), 8.57 (d, 2H), 7.95 (d, 2H), 7.74 8.34 (d, 1H),
7.51 (dxd, 2H), 7.43 (s, 1H), 7.35 (dxd, 1H), 6.65 (dxd, 2H), 5.48
(s, 2H), 2.46 (s, 3H).
b)
(4,6-Dimethyl-pyrimidin-2-yl)-[4-(2-methyl-pyridin-4-yl)-phenyl]-amine
[1125] The title compound was prepared in analogy to example 62
from 4-(2-methyl-pyridin-4-yl)-phenylamine and
2-chloro-4,6-dimethylpyrimidine. Obtained as a yellowish solid
(Yield=33%). MS ISP (m/e): 291.1 (100) [(M+H).sup.+]. .sup.1H NMR
(DMSO-D.sub.6, 300 MHz): .delta. (ppm)=9.73 (s, 1H), 8.43 (d, 1H),
7.97 (d, 2H), 7.73 (d, 2H), 7.55 (s, 1H); 7.47 (d, 1H), 6.67 (s,
1H), 2.50 (s, 3H hidden in DMSO-peak), 2.34 (s, 6H).
EXAMPLE 237
(4-Benzyl-6-methyl-pyrimidin-2-yl)-[4-(2-methyl-pyridin-4-yl)-phenyl]-amin-
e
##STR00276##
[1127] The title compound was prepared in analogy to example 62
from 4-(2-methyl-pyridin-4-yl)-phenylamine and
4-benzyl-2-chloro-6-methyl-pyrimidine (example 43a). Obtained as a
yellowish solid (Yield=48%). MS ISP (m/e): 367.1 (100)
[(M+H).sup.+]. .sup.1H NMR (DMSO-D.sub.6, 300 MHz): .delta.
(ppm)=9.77 (s, 1H), 8.45 (d, 1H), 7.93 (d, 2H), 7.71 (d, 2H), 7.55
(s, 1H), 7.47 (d, 1H), 7.35-7.20 (m, 5H), 6.67 (s, 1H), 3.95 (s,
2H), 2.51 (s, 3H), 2.33 (s, 3H).
EXAMPLE 238
N4-(5-tert-Butyl-2-methyl-2H-pyrazol-3-yl)-5-fluoro-N2-[3-methoxy-4-(4-met-
hyl-imidazol-1-yl)-phenyl]-pyrimidine-2,4-diamine
##STR00277##
[1129] Palladium(II) acetate (5.4 mg, 0.024 mmol) and
2-(dicyclohexylphosphino)biphenyl (17 mg, 0.048 mmol) were stirred
in dioxane (2.7 mL) for 10 minutes at 20.degree. C. under an
atmosphere of nitrogen. Sodium tert.-butoxide (44 mg, 0.45 mmol),
3-methoxy-4-(4-methyl-imidazole-1-yl)-phenylamine (61 mg, 0.30
mmol) and
(5-tert-butyl-2-methyl-2H-pyrazol-3-yl)-(2-chloro-5-fluoro-pyrimidin-4-yl-
)-amine (94 mg, 0.33 mmol, WO2008099210) were added. The reaction
was heated for 30 minutes to 200.degree. C. in a microwave oven.
Palladium(II) acetate (5.4 mg, 0.024 mmol),
2-(dicyclohexylphosphino)-biphenyl (17 mg, 0.048 mmol), sodium
carbonate (48 mg, 0.45 mmol),
(5-tert-butyl-2-methyl-2H-pyrazol-3-yl)-(2-chloro-5-fluoro-pyrimidin-4-yl-
)-amine (85 mg, 0.3 mmol) and dioxane (1 mL) were added. The
reaction was heated again for 30 minutes to 200.degree. C. in a
microwave oven. Water was added to the cooled reaction mixture and
the mixture was extracted with ethyl acetate. The organic layer was
dried over sodium sulfate and evaporated under reduced pressure.
The residue was purified by column chromatography on silica gel
using dichloromethane and then dichloromethane/methanol (19:1 v/v)
as eluent to yield the title compound as a yellow solid (41 mg,
30%). MS ISP (m/e): 451.2 (100) [(M+H).sup.+]. .sup.1H NMR
(CDCl.sub.3, 300 MHz): .delta. (ppm)=8.02 (s, 1H), 7.60 (s, 1H),
7.30 (s, 1H), 7.09 (d, 1H), 7.03 (m, 2H), 6.82 (s, 1H), 6.45 (br s,
1H, NH), 6.11 (s, 1H), 3.73 (s, 3H), 3.72 (s, 3H), 2.29 (s, 3H),
1.32 (s, 9H).
* * * * *